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Abstract 
 
Genome-wide association studies (GWAS) have recently shown their potential in the discovery of 
genetic factors associated with common diseases. Genetic association studies including GWAS 
can be used to explore the role of genetic variation underlying the associations between birth 
size, growth and metabolic phenotypes such as adiposity, lipid and glucose levels and 
hypertension. 
 
The aim of this thesis was to 1) review methods for genetic association analyses, 2) fit models for 
growth measurements, and to investigate prenatal predictors of early growth and associations 
between early growth and adult metabolic phenotypes, and 3) to examine genetic variation 
underlying birth size, postnatal growth and adult metabolic phenotypes. 
 
The primary study population comprised Northern Finland Birth Cohort 1966 (NFBC1966) 
members with DNA (N=5,753). Phenotypes included height/weight throughout childhood and 
adult metabolic phenotypes. Parametric growth curves were fitted to obtain peak growth velocities 
and timings of peaks and nadirs. These growth parameters were analysed in relation to birth and 
adult metabolic phenotypes and genetic variation. Meta-analyses of GWAS included samples 
with similar data.  
 
Shorter babies grew faster in length immediately after birth. Faster postnatal growth was 
associated with higher adult blood pressure and adiposity, independently of birth weight. Risk 
alleles at type 2 diabetes locus (ADCY5) were inversely associated with birth weight in a GWAS 
meta-analysis. Variants near BMI candidate genes LEPR and PCSK1 were associated with infant 
BMI. The established obesity locus (FTO) had a strong association with BMI after age 5 years. A 
GWAS meta-analysis of metabolic phenotypes suggested distinct pathways leading to the 
development of a metabolic syndrome. Adult height variants were associated with infant and/or 
pubertal height growth. The results suggest that foetal programming, growth acceleration and 
genetic susceptibility contribute to the associations between growth and metabolic phenotypes, 
and that some of the genetic effects are age-dependent. 
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1. Introduction 
 
This chapter gives a brief history of genetic studies until 2010 and outlines the challenges in the 
design and implementation of these studies. It gives an overview of the recent genome-wide 
association studies and their role in understanding the genetic architecture of common complex 
traits in humans and it identifies areas for future research. The purpose of this chapter is to give a 
historical context to the work presented in this thesis. It also outlines the structure of the thesis 
and its aims in brief. 
 
1.1. Discovery of monogenic traits 
 
Gregor Mendel (1822-1884) discovered the laws of inheritance which formed a basis for the 
earliest genetic studies. Rediscovery of these laws in the early 1900s increased understanding of 
the transmission of genes. Geneticists found out that some but not all traits and diseases are 
inherited according to Mendel‘s ratios as a result of single mutations. New methods and tools 
were needed to map the variants responsible for these monogenic traits, which are also called 
Mendelian traits (see definitions for key concepts in the Appendix, Table A.1) (1). 
 
The method of linkage analysis for mapping Mendelian traits was discovered by Sturtevant in 
1913 (1). It requires pedigree data to find genetic markers showing correlated segregation 
(linkage) with the trait of interest. Any such marker must lie near the causal variant in the 
genome, or at least in the same chromosome. In experimental genetics, positional cloning 
became an important way to discover pathways crucial in development and physiology. In 
humans, genetic mapping in families was initiated in the 1980s, and led to results such as the 
localisation of Huntington‘s disease in 1983 (1) which was the first mapped Mendelian disease. 
Subsequently, thousands of Mendelian disorders or diseases have been mapped (2). In addition, 
Mendelian subtypes of some common diseases (breast cancer, hypertension, diabetes) were 
mapped. At population level these subtypes are rare but these discoveries have sometimes shed 
light on the genetics of the more common forms of the disease or trait. An example of this is the 
recently identified association of variants near MC4R gene and obesity (3). 
 
1.2. Polygenic traits and association studies 
 
It was recognised already in the early 1900s that most human traits and diseases are polygenic, 
and both genes and the environment contribute towards them. A highly heritable trait which is 
normally distributed in a general population, such as height, must have a polygenic architecture – 
otherwise its distribution would be very different. Also, many complex diseases are expressions of 
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underlying continuous traits exceeding a certain threshold. For example, obesity and 
hypertension are defined by using pre-defined, clinically justified thresholds on body mass index 
(BMI) and systolic and diastolic blood pressure (SBP, DBP).  
 
The idea of mapping genes through comparing the prevalence of a genetic marker in affected 
and unaffected unrelated individuals emerged in the 1950s. The structure of DNA was discovered 
in 1953 and the very first association studies were also published around that time (1). However, 
it was only in the 1990s that this approach became widespread. Although association studies that 
used the candidate gene approach yielded some important findings - e.g. the association 
between the human leukocyte antigen (HLA) locus and autoimmune/infectious diseases, and the 
association between apolipoprotein E and Alzheimer‘s disease – the majority of published results 
from single studies could not be replicated. Several reasons were put forward to explain the 
inconsistent findings (4, 5). This approach requires prior information of potential biological 
candidate genes, and is based on the hypothesis that the genes selected on a biological basis 
confer a higher disease risk. The prior information may be inadequate which leads to small a 
priori probabilities for the selected genes to be disease-causing. Differences in study designs, 
e.g. different phenotype definitions, may have contributed to the inconsistent results produced 
using this approach. Inadequate sample sizes together with unreported multiple testing 
constituted the main problem and contributed to the high number of false positive and false 
negative results. Recommendations were made to set a more stringent criterion for interpreting 
association study results, to collect samples of thousands of cases and controls for these studies 
and to meta-analyse all existing data before making inferences (4).  
 
One of the first suggested strategies for finding gene-disease associations was linkage 
disequilibrium (LD) mapping. It utilises the high LD around the ancestral mutation (6). LD refers to 
the correlation structure between different loci in the same chromosome. The first application of 
this strategy found an association between an allele of a restriction fragment length polymorphism 
(RFLP) in the β-globin gene and the sickle-cell form of haemoglobin (7). After polymerase chain 
reaction (PCR) based assays became available and microsatellites replaced RFLPs, LD mapping 
became more feasible. However, linkage studies still dominated the field and the first genome-
wide studies used the linkage approach. Failure to replicate genome scans for common traits in 
families indicated a higher level of complexity of inheritance and a limited power of these studies. 
The first successful LD based genome-wide search for a disease gene was conducted in 1994 in 
a population isolate (8).  
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1.3. Genome-wide association studies (GWAS) 
 
To be sure of hitting the target, shoot first, and call whatever you hit the target. 
—Ashleigh Brilliant 
 
In 1996, a suggestion was made to catalogue all variants in the human genome to facilitate the 
hypothesis-free genome-wide association study (GWAS) approach (9), which surveys common 
genetic variation by probing a dense set of single nucleotide polymorphisms (SNPs) across the 
genome in a set of unrelated individuals. Instead of cataloguing all the variants, the SNP 
Consortium was launched in 1999 to create a dense map of SNPs for LD mapping. At this point 
the Human Genome Project (HGP) was already underway (formally launched in 1990). Its goal 
was to determine the human DNA sequence and identify the genes in DNA. After the completion 
of the HGP in April 2003, information from the entire human genome became available for 
researchers to study the relationship between genetic variation and the disease/health status in 
populations. Another major effort aiming to characterise haplotype patterns in the human 
genome, the International HapMap Project, was launched in 2003 (10). These efforts took several 
years to complete. In addition, considerable development in genotyping technology was required 
to facilitate genome-wide association studies. It was not until 2006 that everything was in place to 
launch the first GWAS. Meanwhile the candidate gene association approach dominated the field. 
Due to its limited success, high hopes were placed in better success of the GWAS approach. 
According to the common variant – common disease (CDCV) hypothesis, several common 
variants with small or modest effects contribute to common diseases (11). The scientific 
community widely supported this hypothesis (12, 13), and the GWAS approach was thought to be 
ideal for revealing the common variants behind common diseases.  
 
The challenge to capture the genetic basis of common diseases and traits from a vast amount of 
data and translate this information into beneficial public health interventions led to the 
establishment of many international networks, biobanks and consortia. The Human Genome 
Epidemiology Network (HuGENet) was set up as a global collaboration to investigate the role of 
human genome variation in population health and facilitate the dissemination and use of this 
information. Other initiatives included the Public Population Project in Genomics (P3G), the UK 
Biobank, and the Wellcome Trust Case Control Consortium (WTCCC). In addition, the value of 
large, well phenotyped population cohort studies was recognised at this point, particularly for the 
investigation of continuous traits. 
 
One of the major problems the GWAS approach faced stemmed from simultaneous testing of a 
large number of associations. There was a need to correct for multiple testing to avoid reporting 
too many false positive associations. Several suggestions were made to correct for multiple 
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testing. Calculation of empirical p-values through permutation was adopted as the gold standard 
method for doing this (14). However, since permutation would take a lot of computational time if 
applied to GWAS, most researchers adopted a quick and simple solution: using a much more 
stringent significance threshold than the conventional p < 0.05. Initially, a threshold of p < 5x10
-7
 
was commonly used. Today, the most commonly used genome-wide significance threshold is p < 
5x10
-8
, which is based on an estimated testing burden of a million independent tests genome-
wide in Europeans, achieved by a simulation study (15). This requirement inevitably implies the 
need for large sample sizes to reach an adequate statistical power to identify significant SNP - 
phenotype associations. In practice, the statistical power reached in a single study is rarely 
adequate. Thousands of case-control pairs are needed. Alternatively, continuous traits can be 
studied e.g. in population cohorts, but still a sample size of less than 5,000 will rarely be adequate 
even for well-defined and accurately measured phenotypes.  
 
Despite these challenges, the usefulness of the GWAS approach has become apparent in recent 
years (16). Studies on age-related macular degeneration were the first to be published with 
encouraging results (17). Other early findings using the GWAS approach include gene-
associations for Parkinson disease (18), oesophageal cancer (19) and rheumatoid arthritis (20). 
Multiple consistent SNP associations with cancers, diabetes and heart disease were revealed in 
2007 (see summary in Topol et al. (2007) (21)). Findings successfully replicated in several large 
cohorts include e.g. many risk loci for type 2 diabetes (T2D) (22), a risk loci for myocardial 
infarction (MI) and coronary heart disease (CHD) (23), a novel locus for schizophrenia (24), a 
number of new risk loci for breast cancer (25), and some new loci for bipolar disorder, rheumatoid 
arthritis, type 1 diabetes, coronary artery disease and Crohn‘s disease (26). Potential for 
identifying associations with quantitative traits such as BMI and height using this method has also 
been demonstrated (27-29). The first locus identified for BMI was in the fat mass and obesity 
associated (FTO) gene. It was initially discovered through its association with T2D but this 
association was later explained by BMI (27).
  
 
The GWAS approach turned out to be successful in finding associations between common 
variants of moderate effect sizes, and a multitude of diseases and traits (16). There is a 
continuously updated list online of published GWA studies and their main results (30). By the end 
of 2009, 658 genome-wide significant associations (p ≤ 5x10
-8
) had been published. Several 
review articles on associations identified for specific traits have been published but these reviews 
become outdated very quickly. For example, up to 18 loci had been identified for BMI and 
common obesity through GWAS by April 2009 (FTO, MC4R, TMEM18, NEGR1, SH2B1, 
KCTD15, GNPDA2, MTCH2, SEC16B, ETV5, DGKG, BDNF, BCDIN3D, FAIM2, BAT2, NPC1, 
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MAF, PTER) (31). By May 2010, the number of loci found to be associated with BMI had doubled 
(unpublished data from the Genetic Investigation of Anthropometric Traits (GIANT) Consortium). 
 
 
The requirement of large samples has necessitated replication and meta-analyses in large 
consortia (32, 33). In practice, replication is currently a requirement for a GWAS to get published. 
Replication and meta-analyses pose their own challenges since unified genotype and phenotype 
data are needed to combine results from several studies. Due to limited overlap between different 
genotyping platforms, it has become common practice to impute the non-overlapping SNPs using 
a common reference standard (HapMap) before analysing the data and combining the results 
(33). Unifying phenotype data is often more challenging due to differences between studies in 
phenotype definition, measurement technique, age of measurement, and frequency of 
measurements in longitudinal studies. It is also important to note that both allele frequencies and 
SNP-phenotype associations may be different in populations of different ancestry. Therefore it 
may be necessary to meta-analyse populations of different ancestry separately, or at least allow 
for heterogeneity in the analysis if it seems to be present. 
 
Recent GWA studies have only hit the tip of the iceberg, i.e. found and replicated associations 
between common variants and common diseases with large enough effects to be detected using 
stringent genome-wide significance thresholds. If the CDCV hypothesis holds, as simulation 
studies (34) and empirical evidence suggest, there are probably hundreds of more common 
variants with weaker effects yet to be discovered and replicated. The GWAS meta-analysis efforts 
are likely to continue worldwide in consortia of increasing size in order to discover the remaining 
common variants behind common diseases with increasingly smaller effect sizes. Although 
identifying variants with very small effect sizes may not be important from a public health point of 
view, some of these effects could still give important biological insights into the pathogenesis of 
common diseases. Published GWA studies can be used for derivation of ―statistical candidate 
genes‖ to study their overlapping or pleiotropic effects on other traits. For studies using such 
―candidates‖, relaxing the significance threshold can be justified due to a higher prior probability 
of the association. Estimated prior probabilities for associations with such candidates vary 
depending on the strength of evidence from literature. Therefore significance thresholds used in 
candidate gene studies vary considerably (typically they are included in the range: 0.0001 ≤ p ≤ 
0.05). 
 
1.4. Beyond common variation 
 
The common variants identified so far typically explain a modest proportion of the estimated 
heritability of a disease or trait. With increasing sample sizes, more common variants of similar or 
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smaller effects are expected to be discovered. However, part of the heritability may still remain 
unexplained. The search for the unexplained heritability is increasingly focusing on the study of 
low frequency variants with potentially substantial cumulative contribution to common disease 
susceptibility (Figure 1.1). Undertakings such as the 1000 Genomes Project 
(http://www.1000genomes.org) will aid in the study of low frequency variants with minor allele 
frequency (MAF) between 0.5% and 5% and intermediate effect size. Although detection of these 
kinds of variants requires different genotyping platforms and new statistical methodology which 
are still being developed (35), some evidence already exists of the contribution of low frequency 
and rare variants in common diseases (36). Other types of genetic variants, e.g. structural 
variants such as copy number variants (CNVs) are also under investigation, and have yielded 
some interesting findings (37). The genetic architecture of common diseases is likely to contain a 
combination of variants with different allele frequencies and structural variation in the genome 
(38). 
  
 
Figure 1.1. Identifiability of genetic variants by risk allele frequency and genetic effect size 
expressed by odds ratio. Most research interest lies between the dotted lines. The emphasis 
has moved from rare alleles in Mendelian disease to common variants in common disease, and is 
currently moving towards low frequency variants in common disease. Adapted from Manolio et al. 
2009 (39).   
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1.5. Refining identified signals 
 
After the variant-phenotype association has been identified, the finding needs to be refined. The 
associated variant is unlikely to be the causal variant. To get closer to the causal variant, fine 
mapping or resequencing the area of association is needed (32). In recent years, technological 
development has been rapid in this area. Resequencing the whole genome is expensive and the 
ability to conduct feasible genome-wide sequencing studies is still at least 10 years away. 
However, resequencing the signals identified in GWA studies is already feasible. Whole exome 
sequencing will probably be the first step forward. Statistical methods are currently being 
developed to minimise costs and maximise statistical power in the analysis of low frequency and 
rare variants in relation to common diseases.  
 
1.6. Translation of the findings 
 
Before the results from these studies can be translated into health benefits, the biology of the 
human genome needs to be better understood (40). As genes do not function independently, it is 
important to elucidate the genetic networks and protein pathways to understand phenotypic 
variation. Rather than studying genetic variants in isolation, studying gene expression and 
epigenetic changes can give insight into these processes. Research in pharmacogenomics and 
nutrigenomics could lead to development of personalised guidelines for medication and diet for 
each individual (41). Genetic tests are currently used to detect rare single-gene disorders. Testing 
for common multigenic diseases is becoming available but it still has several limitations. 
 
To date, GWAS have given some biological insights into common diseases. For example, for 
T2D, many variants related to beta-cell function have been identified, highlighting the importance 
of these pathways in T2D aetiology (42). Additionally, some pleiotropic genetic effects have been 
identified e.g. between T2D and diseases such as inflammatory bowel disease and prostate 
cancer (22). Accumulation of these types of findings should help identify shared pathways 
between diseases and in the course of time lead to novel treatment options (43). 
 
1.7. Summary 
  
Genome-wide association studies have succeeded in identifying a multitude of genetic variants 
for common, polygenic traits and diseases. Much work remains to be done in explaining the major 
part of heritability in common disease and revealing pleiotropic associations and links between 
genes, biological pathways and diseases. Early identification of groups at an increased risk of 
developing complex diseases of high public health importance, such as T2D and cardiovascular 
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disease (CVD), is essential. Large population cohorts with intermediate phenotypes (sometimes 
called endophenotypes) that are related to the risk of these diseases (e.g. adiposity measures, 
blood pressure, blood lipid and plasma glucose levels), together with genome-wide scan data are 
valuable in this investigation. Furthermore, longitudinal cohorts offer an opportunity to examine 
the genetic and environmental associations with these phenotypes more carefully by 
incorporating earlier measured phenotypes such as birth and growth measurements, which are 
known to be associated with metabolic phenotypes in adults. The inverse association between 
birth size and adult disease has been widely explored in the Developmental Origins of Health and 
Disease (DOHaD) framework. The mechanism of the association is largely unknown, although 
several hypotheses pointing to genetic or environmental factors or epigenetic modifications have 
been put forward (44-47). The availability of genome-wide data gives a good opportunity to 
investigate these hypotheses, including potential pleiotropic effects contributing to prenatal and 
postnatal growth and metabolic phenotypes.  
 
1.8. Structure of the thesis 
 
The initial plan of this PhD project was to study and apply new tools from modern statistical 
approaches to data mining in the analysis of GWA data. Chapter 1 and the first part of the 
literature review (2.1), which introduces genetic association studies and focuses on the 
challenges in GWAS and their meta-analyses, reflect the original aims of the project. The purpose 
of this review was to aid in the choice of genetic analysis approach for this PhD project (2.1.18). 
Over time, the project developed to encompass other focus areas, most importantly that of growth 
modelling. The second part of the literature review (2.2) focuses on growth modelling methods 
and gives a basis for the model choices in this PhD project.  
 
Besides methodological aspects, the genetic architecture of early growth and metabolic 
phenotypes are areas of interest in this thesis, and the rapidly growing literature in the field is 
reviewed (2.3 and 2.4). The overall scientific question about the role of genetics and other 
possible mechanisms in the association between early growth and adult metabolic phenotypes is 
outlined and discussed in the light of literature in the DOHaD framework in chapter 2.5. The 
scope and specific aims and study questions this thesis is set out to explore are presented in 
chapter 3.  
 
The Northern Finland Birth Cohort 1966 (NFBC1966) was chosen as the primary study population 
for this PhD project. The advantages of this cohort are prospective follow-up from before birth, the 
availability of a wide variety of data, including socio-economic and behavioural background 
variables, clinical examination data and dense growth measurements throughout childhood. 
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Candidate gene association studies were already ongoing at the start of this PhD project and they 
are reviewed in 2.6. The cohort itself is described in chapter 4.  
 
Since the methods partly overlap in several studies of this PhD project, they are presented in a 
single chapter to avoid unnecessary repetition (chapter 5). The selection of methods was based 
on the necessity to perform a GWAS while accounting for the longitudinal nature of phenotype 
data. Chapter 5 outlines methods for descriptive analyses (5.1) and describes how parametric 
growth models were fitted to growth data to obtain derived summary variables which characterise 
important aspects of growth and are readily usable in subsequent analyses (5.2). Methods for 
analysing associations between these derived growth parameters and other phenotypes (5.3) or 
genetic data (5.5) are presented. The preparation of genome-wide data (5.4) and methods used 
in GWAS and their meta-analyses (5.6) are also outlined. 
 
The analysis results from each separate study are presented and interpreted in the light of other 
studies from the same field (chapter 6). Growth data and the derived growth parameters and their 
correlations with anthropometric measures at birth and in adulthood are described (6.1 and 6.2). 
Associations between prenatal factors and infant height growth velocity, and associations 
between all growth parameters and adult anthropometric and metabolic phenotypes are 
presented (6.3). Relationships between candidate variants obtained from previous GWAS and 
derived growth parameters (6.4) are assessed. Finally, the GWAS results for adult metabolic and 
anthropometric traits, birth measures and growth parameters are presented (6.5). These include 
GWAS within the NFBC1966 as well as GWAS meta-analyses with other similar data sets. Most 
of the results from these studies have also been included in published papers or conference 
abstracts (List of papers, p. 19-23). 
 
Chapter 7 includes a general discussion of the methodology applied in this thesis (7.1). 
Furthermore, the contribution of the results to the DOHaD research is discussed (7.2). Strengths 
and limitations of this thesis are briefly discussed (7.3 and 7.4). The problem of unexplained 
heritability and new strategies for identifying genetic causes of complex diseases are outlined 
(7.5) and suggestions for future work are given (7.6). 
 
1.9. Aims of the study in brief 
  
1) to describe and evaluate the literature on (a) the analytic strategy and methods for genetic 
association analysis in population-based longitudinal studies, (b) growth modelling, (c) genetics of 
growth, (d) genetics of metabolic phenotypes, and (e) the DOHaD research, 
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2) to investigate maternal and environmental determinants of early growth and associations 
between early growth and metabolic phenotypes in adulthood in the longitudinal NFBC1966,  
 
3) to examine the genetic variation underlying birth size, postnatal growth and adult metabolic 
phenotypes in the NFBC1966 and other similar studies, and to explore possible mechanisms 
underlying the association between early growth and adult phenotypes in the DOHaD framework.  
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2. Literature review 
 
Let's remind ourselves that last year's fresh idea is today's cliche. 
—Austen Briggs 
 
 
The literature review introduces and discusses methodological aspects considered in this thesis, 
in particular the ones related to genome-wide association (GWA) analysis (2.1) and modelling of 
longitudinal growth data (2.2). In addition, current knowledge on the genetic architecture of early 
growth (2.3) and metabolic phenotypes (2.4) is outlined, and possible factors underlying the 
association between these two are discussed (2.5). Relevant publications up to the end of July 
2010 have been included. Finally, a summary is given of the genetic association studies 
conducted prior to the genome-wide era in the main study population of this thesis, the 
NFBC1966 (2.6).  
 
2.1. Genetic association studies with a focus on genome-wide association studies (GWAS) 
 
This chapter introduces the basic concepts of genetics and different types of genetic studies. 
Simple methods are outlined only for genetic association studies. The focus then moves onto 
GWAS and the challenges this approach poses; issues such as multiple testing, missing data, 
bias, confounding, population structure, interactions and statistical power are discussed in detail. 
Different possibilities for multi-marker analyses are outlined and software available for GWAS is 
reviewed. Problems related to meta-analysis and replication, as well as refinement of replicated 
signals are presented. Finally, interpretation of data and incorporation of functional information in 
genetic association studies are discussed. This chapter does not aim to give a systematic review 
of methodologies but to serve as an introduction to the challenges that researchers working in the 
field of GWAS are facing today. 
 
2.1.1. Introduction to gene mapping 
 
The human genome is the sequence of all genetic material in human chromosomes (see 
definitions for key concepts in Table A.1). Human cells contain 23 pairs of chromosomes each 
made up of a single DNA (deoxyribonucleic acid) molecule. In each of the pairs one chromosome 
is inherited from the mother and one from the father. The DNA sequence consists of four types of 
nucleotide bases (Figure 2.1): adenine (A), cytosine (C), guanine (G) and thymine (T). DNA is 
double-stranded so that A is bound with T and C with G between the strands. The number of 
these base pair letters is about three billion. The DNA spells out the exact ―instructions‖ required 
to create functioning human beings with their own unique traits. The DNA sequences of any two 
humans are 99.9% identical, leaving only 0.1% to express genetic variation. Genes are segments 
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of DNA that correspond to units of inheritance and they contain the information necessary to 
produce proteins (amino acid sequences). There are an estimated 20,000 to 25,000 genes in the 
human genome (48). Segments of DNA with protein-coding sequences in a gene are called 
exons. Non-coding segments that separate exons are called introns. A chromosomal location for 
an individual gene or DNA sequence is called locus (plural: loci). 
 
 
 
 
Figure 2.1. The structure of DNA. Source: U.S. National Library of Medicine, Genetics Home. 
Reference: http://ghr.nlm.nih.gov/handbook/illustrations/dnastructure.jpg.  
Copyright: http://www.nlm.nih.gov/copyright.html.  
 
Different DNA sequence variations at a given locus are called alleles. When a locus has at least 
two alternative alleles it is called polymorphic. Single nucleotide polymorphisms (SNPs) represent 
variation in a single nucleotide base. SNPs with two alleles with the less common allele (minor 
allele) prevalence of 1% or more in a population can be defined as common SNPs (11), although 
sometimes a 5% threshold is used instead. It is estimated that there are more than 10 million 
common SNPs (MAF ≥ 1%) in the human genome. Another important DNA sequence variant is a 
microsatellite which is a highly variable repeat of a short sequence. It has many alleles 
differentiated by the number of repeats involved (49). In addition, there are other variations in the 
human genome like minisatellites, some of which are highly polymorphic variable number of 
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tandem repeats (VNTRs). Structural alterations such as insertion-deletions, block substitutions 
and inversions of the DNA at particular locations on the chromosome form their own class of 
variation. A variant representing a structural change that has recently gained considerable 
interest is the copy number variant (CNV). These duplication or deletion events in the DNA 
sequence are a significant source of human genetic diversity. At least 12% of the genome 
contains CNVs. They are rarer than SNPs but affect much larger regions (>1kb) of DNA per event 
(50-52). Variants can be used in studying (mapping) genetic associations with diseases. The 
DNA sequence variants that can be linked to a trait or disease are often called genetic markers. 
However, genetic markers are usually not causative variants themselves but they have a strong 
statistical association (high LD) with the causative variant. This is because closely located 
variants are often inherited together. The measures of LD and their properties have have been 
reviewed previously (53, 54). 
 
The sequence of alleles in a single chromosome at a set of linked loci is called a haplotype. Short 
haplotypes often pass on between generations intact (without recombination) and therefore it is 
possible to base gene-disease analyses on haplotypes instead of single-locus genotypes (49). In 
the absence of parental DNA information (unphased data) haplotypes are not directly observed, 
but they can still be inferred from genotypes. This will introduce some ambiguity into the data 
(55). Analysis of measured or inferred haplotypes has also been found to be inefficient compared 
to the direct analysis of genotypes (56). When tagging strategies are used, the advantage of 
haplotypes over genotypes is diminished (57). On the other hand, there are methods for 
determining phased molecular haplotypes, and in certain situations this may be cost-effective 
(58). 
 
2.1.2. Types of genetic studies, design, costs and power 
 
The differences between linkage and association study designs are summarised in Table 2.1. 
Linkage studies use affected pairs of siblings (often called sib-pairs) or other groups of relatives 
to investigate the transmission of both disease and markers linked with causative variants across 
generations. They have the potential of identifying large causative regions, but due to a limited 
sample size often lack statistical power to reach conclusive evidence regarding complex disease 
markers (59). Therefore, association studies are often performed to follow up suggestive 
evidence from linkage studies. Association studies can either be conducted on related or 
unrelated individuals (60). 
 
Another way of classifying methods for genetic studies is to divide them into hypothesis-driven 
and hypothesis-free methods (61). Hypothesis-driven approaches such as candidate gene and 
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biological pathway analysis rely on prior evidence of functional genes and how they contribute to 
the development of disease. Genome-wide linkage and association studies can be classified as 
hypothesis-free methods since they are not driven by any prior assumptions. 
 
Table 2.1. Types of genetic studies. 
 
Study type Study design Approaches Time of findings in humans 
   Candidate gene Genome-wide 
Linkage study Related individuals 
- e.g. affected sib-
pairs, other groups 
of relatives (more 
than two affected 
siblings, extended 
pedigrees) 
Parametric 
linkage analysis 
Non-parametric 
linkage analysis 
Findings on 
Mendelian traits 
in the 1980s-. 
Preliminary 
findings on 
complex traits in 
the 1990s-. 
Association 
study 
Related individuals 
- e.g. pedigrees, 
case-parent triads, 
case-parent-
grandparent 
septets 
Populations 
- e.g. case-control 
and cohort designs 
Disease mapping 
-multi-stage / 
one-stage 
approach  
QTL mapping 
-trait-based / 
marker-based, 
multi-stage / one-
stage approach 
Findings on 
complex traits 
often without 
replication, 
mainly in the 
1990s-. 
Replicated 
findings on 
complex traits, 
2007-. 
 
Research has proceeded from studies of monogenic diseases to complex diseases and currently 
the GWAS are the main interest of the scientific community. To reduce costs and increase 
statistical power, multistage designs (62) were suggested for conducting them.  
 
Perhaps the most commonly used design in the early GWA studies was the two-stage design 
(63), in which a sub-sample of subjects was tested for a dense set of markers (stage 1), and then 
the rest of the sample was tested only on a subset of the markers which showed highest 
statistical association with the disease or trait (stage 2). The two-stage design could yield 
substantial cost savings over a one-stage design with the same number of tests and the same 
power (64). The downside was that disease markers which for some reason (e.g. lack of power 
due to limited sample or effect size or low minor allele frequency) did not show up at stage 1, 
were not detected at stage 2. Also, the design had to be taken into account when choosing 
statistical analysis methods for the data. An important issue was the optimisation of the spread of 
the costs in the two stages to obtain maximum power (65), (66). These estimates were affected 
by the difference between per-genotyping costs at each stage. Adding sampling and phenotyping 
costs into the equation (full optimisation) led to totally different optimal designs which favoured a 
higher sample proportion at stage 1 (67). As the costs in the second stage would have been 
 38 
higher than in the first stage, most investigators considered it more cost-effective to scan the 
whole genome in the whole population. However, advocates of the multistage design still argue 
for its cost-effectiveness, especially if more than two stages are used in an optimal way (68).  
 
In practice, conducting one-stage GWAS is much simpler, and also gives the advantage of 
studying multiple phenotypes in a cohort setting. Since the majority of studies today use one-
stage design and are part of large collaborative efforts, investigators have started using the term 
two-stage design in the context of GWA studies accompanied by replication. Here stage 1 means 
the discovery stage where one or more GWA data sets are analysed, and stage 2 means the 
replication stage where the most promising SNPs from stage 1 are analysed in additional data 
sets. 
 
Another technique to attempt cost reduction in the early GWAS was the use of pooled DNA 
samples. However, in the presence of sampling and measurement error this technique had a low 
power to detect modest effects (69). As the genotyping costs decreased, it became feasible to 
test a dense set of markers for entire cohorts of individuals without pooling the DNA samples. 
 
One way to increase the statistical power in GWAS that has recently been successful is the use 
of intermediate phenotypes. If several different intermediate phenotypes contribute to disease 
risk, then each of them should be influenced by a smaller set of genetic and environmental 
factors than the disease outcome itself (69). For instance, rather than studying a CVD outcome or 
metabolic syndrome (MetS), each intermediate risk factor (e.g. lipid levels and obesity) is studied 
separately (70). In this case it is often possible to study continuous instead of dichotomous 
phenotypes, which in itself may increase power if the phenotype is well-defined and does not 
contain too much measurement error. This is called quantitative trait loci (QTL) mapping.  
 
If the phenotype is longitudinal and repeatedly measured, it is sometimes called a dynamic 
complex trait (DCT). Instead of testing genetic associations with the trait at each measurement 
point, parameters estimated from a statistical model that determines the developmental trajectory 
of the trait can be tested for genetic effects (functional mapping), including epistatic effects and 
QTL-environment interactions as well as QTL-age interactions (71). This can help answer 
questions on the timing of the genetic effect on the DCT, which in turn may give insights into the 
biological pathways underlying the developmental changes. In addition, functional mapping has 
an increased statistical power to detect QTLs.  
 
An early suggested approach for GWA studies was to genotype only the tails of a phenotype 
distribution and to select the most promising genetic markers for typing in another population or in 
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those in the middle of the distribution. However, the cost-effectiveness of this trait-based (TB) 
approach (72) can be questioned and the statistical analysis of the resulting data poses additional 
challenges. Performance of the whole genome scan for the whole population instead allows the 
use of a marker-based (MB) approach in which the phenotype trait values are compared between 
different marker genotypes. This enables the study of multiple traits, which is a considerable 
advantage compared to the TB approach. Also, its power has been shown to be at least that of 
the TB approach (72). 
 
Finally, an optimal choice of tag-SNPs can improve the cost-effectiveness of a GWA study. The 
International Haplotype Map (HapMap) project recorded over a million single nucleotide 
polymorphisms (SNPs) and haplotypes throughout the genome in a diverse range of populations 
to produce a comprehensive map of human genetic variation (10). The HapMap reference is a 
valuable tool to guide SNP selection in the design of genetic association studies. The goal is to 
reduce redundancy while capturing all necessary information. An appropriate choice of tag-SNPs 
for GWAS utilises the LD structure in a cost-effective way: it is possible to reduce the number of 
SNPs genotyped (and thereby the costs) considerably without losing much power. Collecting 
large enough sample sizes rather than increasing genome coverage is therefore recommended 
(73).  
 
Genotyping platforms designed for GWAS utilise the LD structure of the genome to varying 
degrees. The method of SNP selection varies between platforms. For example, Illumina takes 
more advantage of the LD structure and HapMap tag-SNPs than Affymetrix. The performance of 
different chips has been compared across platforms and against a hypothetical ―complete chip‖ 
containing all HapMap SNPs in terms of statistical power, using a simulation approach (74). This 
study demonstrated, for example, a superior performance of Illumina 300K chip over Affymetrix 
500K chip for SNPs with MAF ≥ 0.1, but an inferior performance of Illumina 600K chip compared 
to Affymetrix 500K chip for lower frequency SNPs (MAF < 0.1). Comparison with the ―complete 
chip‖ revealed that increasing SNP density on a chip or imputing missing SNPs would be the 
most beneficial strategy regarding lower frequency variants. Anderson et al. (2008) argued that if 
finances are limited but sample size is not, the most powerful strategy in European populations 
would be to use the Illumina 300K chip on a large sample in conjunction with the imputation of 
untyped markers (75). However, it has to be noted that these calculations were based on 
genotyping costs in 2008. With declining genotyping costs, platforms covering one million SNPs 
are becoming more cost efficient.   
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2.1.3. Simple methods for population association studies 
 
The most commonly used methods for population association studies assume a case-control 
design. If genetic data on a whole cohort are available, the same methods for binary outcomes 
(disease / no disease) are applicable. One advantage of a cohort design is that it enables the 
study of continuous phenotypes. Methods for linkage and association studies in families such as 
TDT (transmission disequilibrium test) will not be considered here.  
 
Assumptions of the mode of inheritance are used in formulating a genetic model (see Table 1 in 
Lewis 2002 (76)). They are based on the fact that in the bi-allelic case (e.g. A and T) there are 
three different possible genotypes: you can either have 0, 1 or 2 causal alleles (AA, AT and TT, 
where T denotes the causal allele). The different possible modes of inheritance include dominant, 
recessive, additive, multiplicative and co-dominant (general) mode. In the dominant mode, having 
either one (AT) or two (TT) causal alleles, i.e. being either heterozygous or homozygous for T, 
has an equal effect on the trait or disease risk. In the recessive mode, only having two copies 
(TT) of the causal allele, i.e. only being homozygous for T, has an effect on the trait. If having two 
copies has double the effect (2n) compared to having only one copy (n) on a chosen scale of 
measurement, then the mode is additive. In the multiplicative mode, having two copies of the 
causal allele equals to the effect of having one copy squared (n
2
). The co-dominant mode does 
not involve any assumptions, i.e. the effect of having two copies has an arbitrarily different effect 
compared to having only one copy of the causal allele.  
 
If no genetic model is assumed (co-dominant, i.e. general mode) in the case-control design, 
independence between case-control status and genotype can be tested using the standard Chi-
Square test for 2x3 contingency table. It has to be noted that the Chi-Square approximation 
becomes less accurate with small cell counts and in this case exact tests are needed. The same 
can be applied to the dominant model after pooling genotypes AT and TT, and for the recessive 
model after pooling genotypes AA and AT. In the multiplicative model, the association between 
genotype and case-control status can be tested by breaking down the genotype and analysing 
allele counts instead. In this manner it is also possible to test the Hardy-Weinberg Equilibrium 
(HWE), which should hold for the controls. When the additive model is assumed, the number of 
causal alleles (0-1-2) is tested against case-control status. This can be done using the Cochran-
Armitage trend test. Alternatively, a logistic regression model for case-control status can be fitted 
using the genotype as an exposure variable. This is useful especially if other factors (genetic or 
environmental) are studied at the same time or if they need to be adjusted for (76). Similarly, in a 
cohort setting, a conventional regression model can be fitted between a normally distributed 
continuous phenotype and the genotype, and any relevant covariates can be adjusted for. More 
 41 
complex phenotypes, such as DCTs need to be analysed with specific methods, which may not 
be implemented in the standard statistical packages. Alternatively, a complex phenotype could be 
summarised into a simple phenotype, which could be analysed using conventional methods. 
 
2.1.4. Mendelian randomisation 
 
Mendelian randomisation, the random determination of a subject‘s genotype at conception, can 
be used to infer causality of environmentally modifiable exposures in observational studies. In 
observational epidemiology the cause-effect direction of the two associated variables is 
sometimes unclear (reverse causation), and there is a possibility that additional unobserved 
variables (confounders) are the underlying causes of the association (77). Randomised controlled 
trials (RCTs) account for unobserved confounding, but conducting them might be unethical or 
unfeasible, e.g. when studying the effects of smoking or alcohol consumption on disease risk. 
Mendelian randomisation can be used as a ―natural RCT‖ where a genotype that is known to 
affect the modifiable exposure is studied as an instrumental variable (Figure 2.2). If the genotype 
is also associated with the outcome of interest but only indirectly through the exposure (i.e. the 
association disappears after adjustment for the exposure), then the association between the 
exposure and the outcome can be declared causal. Mendelian randomisation is an appealing 
approach and there are many uses for it, including the study of intergenerational exposures (78). 
However, it relies on several assumptions on the instrumental variable itself and these should be 
examined before drawing conclusions. For example, a high LD with another genetic variant 
directly associated with the outcome, the presence of pleiotropic effects, population structure and 
nonrandom distribution of epigenetic changes may distort the inferences about causality (77, 79). 
Additionally, the usual distributional assumptions of the variables and assumptions on their 
relationships have to be satisfied in order to estimate the magnitude of the causal effect correctly 
(77). 
 
 
 
Figure 2.2. The use of an instrumental variable (genotype) in a Mendelian randomisation 
study. Adapted from Ogbuanu et al. (2009) (79)). 
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2.1.5. Use of population isolates for complex trait mapping 
 
The diversity in the human genome is largest and LD lowest in East Africa from where the human 
population originated (80). The diversity is smaller and LD higher in populations of European 
ancestry. Within Europe, LD is higher in the north than in the south (81). Population isolates have 
the smallest diversity and highest LD in the genome (82, 83).  
 
Mapping monogenic diseases in population isolates has been successful. This is partly due to a 
relatively high proportion of certain rare disease alleles in these populations. Although complex 
disease mapping does not directly benefit from this feature, population isolates often have other 
features that make research conditions ideal. Common culture, language and religion diminish 
the random variation caused by environmental factors. Some population isolates, e.g. Finland 
and Iceland, have uniform medical training and a standardised health-care system which 
facilitates standardising phenotype definitions. These countries, as well as other Nordic countries 
(Sweden, Norway and Denmark), have a well-established infrastructure, centralised demographic 
registries, healthcare and geneological records, which enable the linking of genetic, 
epidemiological and demographic information for research. In these countries following people up 
has been relatively easy due to aforementioned reasons and fairly low migration (82).  
 
Cryptic relatedness may be an issue which needs to be carefully addressed in the analysis of 
isolated populations (84, 85), and methods for correcting it in genetic association studies have 
been developed (86). Until recently, it was thought that population structure is virtually non-
existent in isolated populations. However, GWA data have now revealed previously unknown 
substructures in North European populations such as Finland (87, 88). Western and Eastern 
Finns seem to differ from each other considerably, and also a north-south gradient can be 
observed. Therefore, population substructure in GWA studies among Finns has to be taken into 
account to avoid potential bias in the genotype-phenotype association estimates. On the other 
hand, having a population substructure may help in the discovery of rare variants enriched in 
specific sub-populations (88). Studies in population sub-isolates are likely to become more 
popular as the research focus shifts from common variants towards rare variants. 
 
2.1.6. Choice of approach and type of genetic markers for analysis 
 
The main approaches for analysing GWA data can be divided to single-marker and multi-marker 
methods (classification according to Montana (2006) (89) is used here). In the first stage of the 
analysis it is common to analyse one marker at a time while controlling the number of false 
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positive associations (i.e. type I error). Although this method uses information from multiple 
markers, the focus is on the significance of a single marker. Afterwards, a joint analysis of the 
most promising SNPs may be performed in relation to a trait or a disease using multi-marker 
methods.  
 
Since sequencing the whole genome is still laborious and expensive, the choice of tag-SNPs has 
to be considered carefully. Part of the usefulness of the HapMap lies in the fact that it covers 
multiple populations, and therefore a study population might be adequately close to one of the 
populations in the HapMap in terms of the LD structure. For instance, it has been found that 
reference individuals from Utah, USA (CEU population (10)) can be used in selecting tag-SNPs 
for a study in a Finnish population (90). However, as the genotyping costs are continually 
decreasing, the advantage of high LD in population isolates and the use of tag-SNPs are 
decreasing in the future. At some point, sequencing the whole genome may become a realistic 
option. At that point, a high LD will rather be a nuisance than an advantage. 
 
Studying SNPs has been a common approach in genetic association studies. Other possibilities 
include e.g. the study of haplotypes or CNVs. Phased haplotypes can be inferred from unphased 
genotypes of unrelated individuals using different methods such as Hidden Markov Models 
(HMM). New methods and algorithms are being published and some of the software packages for 
this purpose are freely downloadable from the web (91-93). Recently, haplotype studies seem to 
have declined in popularity, although some reports can be found. For example, a genome-wide 
haplotype association study found a gene cluster as a risk locus for coronary artery disease (94). 
 
Studying CNVs has been suggested to complement SNP analyses (50). The first CNV map of the 
human genome was published in 2006 (95). Encourangingly, analyses on rare CNVs and disease 
have revealed associations with e.g. autism and schizophrenia (37). However, to facilitate further 
investigations of the associations between CNVs and disease, high resolution maps of common 
CNVs and technical advances in genotyping them are needed (96). Studies on the relationship 
between common CNVs and common disease have clearly indicated the need for development of 
new CNV-typing platforms (97). It seems that those CNVs that can be adequately genotyped with 
existing arrays are well tagged by SNPs, which can make an additional CNV analysis redundant. 
For example, a recent WTCCC study reported common CNV associations with Crohn‘s disease, 
rheumatoid arthritis and T1D, but each of these loci had already been identified in SNP studies. 
Furthermore, data preprocessing and quality control (QC) pose major challenges for CNV 
analysis. These analyses are susceptible to several artefacts causing false positive associations 
(e.g. dispersed duplications), some of which can even survive replication (97). New methods that 
facilitate large-scale studies on CNV-phenotype associations are currently being developed. For 
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example, cnvHap is a recently published algorithm with an improved CNV genotyping accuracy 
that integrates data from multiple platforms and pools results together across studies (98). 
 
2.1.7. Multiple testing 
 
A major factor that has contributed to spurious findings in genetic association studies is multiple 
testing (99). The hypothesis-free testing in GWA studies is particularly prone to this problem 
(100). The low pre-study odds for an association combined with hundreds of thousands or even 
millions of hypothesis tests means that a great majority of the identified associations will be false 
positive. For example, using a p-value threshold 0.05, a scan with 300,000 tests would produce 
15,000 statistically significant associations by chance alone. Instead of estimating the point-wise 
p-value (the probability that a test statistic exceeds a given threshold by chance), it is necessary 
to estimate the genome-wide significance threshold, i.e. the probability that one or more of the 
test statistics exceed this threshold by chance resulting in a type I error (Box 2 in Hoh & Ott 
(2003) (101)). More generally, this is called the family-wise error rate (FWER). The problem of 
multiple testing is obviously exacerbated by the inclusion of interactions.  
 
The simplest method to correct for multiple testing is called Bonferroni correction in which the 
threshold p-value for rejecting a null hypothesis is obtained by dividing the significance level by 
the number of tests, e.g. if alpha = 0.05 and n = 300,000, p = 1.67x10
-7
, and using this p-value as 
a genome-wide significance threshold. It assumes that the tests are independent which in genetic 
studies translates into an assumption that LD is nonexistent. In the presence of high LD this test 
obviously is very conservative (102). A modification which adjusts the procedure for pairwise LD 
has been suggested (103) but it fails to account for the genomic haplotype block structure. This 
procedure was evaluated in Salyakina et al. (2005) (104) which indicated that the resulting type I 
error rate varied depending on the LD and the method was conservative under haplotype block 
structure. Nicodemus et al. (2005) (102) found that it worked reasonably well in the presence of 
high LD but was conservative under moderate LD. They compared three LD block-based 
corrections with the aforementioned methods and they generally gave type I errors closer to the 
desired level (0.05).  
 
Several research groups have made efforts to establish a generally applicable genome-wide 
significance threshold, which not only considers the number of tests performed but also takes into 
account the LD structure of the genome appropriately. Risch and Merikangas (9) suggested a 
threshold as stringent as 5x10
-8
. The WTCCC (26) pointed out that the p-value threshold depends 
on the prior probability of the association. They gave a plausible estimate for prior odds of true 
association 1:100,000, used a less stringent threshold of 5x10
-7
 and still succeeded in replicating 
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ten out of eleven associations in other samples. Dudbridge and colleagues (105) determined a 
common significance threshold for any SNP by estimating genome-wide significance from the 
WTCCC controls using a Monod curve and discovered a threshold of 7.2x10
-8
. The currently 
commonly used threshold of p < 5x10
-8
, based on an estimated testing burden of a million 
independent tests genome-wide in Europeans was achieved by a simulation study (15). Various 
guideline thresholds of a similar order of magnitude were estimated for case-control GWA design, 
depending on the ancestry and size of the population, genetic model used and MAF of the SNPs 
(106). All these studies suggest that a threshold between 10
-7
 and 10
-8
 prevents effectively the 
reporting of chance findings and is therefore necessary, even though it may also prevent the 
discovery of true but weaker main effects. Literature on GWA studies indicates that most signals 
discovered at the p < 5x10
-8
 level have subsequently been replicated (107). 
 
An accurate but computationally intensive gold standard solution to the multiple testing problem is 
to evaluate the probability of an association being a chance finding empirically by permutation 
testing. In a case-control setting, this is done by shuffling the case-control status randomly and 
keeping other variables fixed. Similarly, when studying continuous traits, the phenotype values 
are shuffled. The same test statistics are obtained from all the permuted data sets and the ―best‖ 
results (those farthest from the null) are recorded. The test statistics from the actual data set are 
compared with the distribution of best test statistics from the permuted samples to obtain their 
statistical significance ((11) Box 2), which is called the empirical p-value. This procedure has the 
advantage of not requiring analyses to investigate theoreretical properties of test statistics ((101) 
Box 2). 
 
Although the permutation testing approach correctly accounts for the correlated structure of SNP 
data, it is very time-consuming and therefore it is impractical to apply to GWA studies with high 
genome coverage. Modifications to permutation testing have been suggested. In the combined-
evidence method (108), analytic distributions are fitted to the permutation samples. Re-use of the 
fitted parameters leads to approximately 40% savings in computation which implies significant 
time savings. This method is useful at the first stage of analysis for identifying a candidate set of 
markers for follow-up.  
 
To reduce the computational burden, various methods that utilise the multivariate normal (MVN) 
distribution assumption for test statistics over multiple markers have been suggested. A Monte 
Carlo approach can be applied in one-stage (109) or two-stage design GWAS (110). It can be 
used for searching multi-marker associations including interactions and haplotype effects in the 
presence of LD. Seaman and Muller-Myhsok (111) present a direct simulation approach (DSA) 
which applies to score statistic based tests. Conneely and Boehnke (14) report that their 
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alternative PACT (P Value Adjusted for Correlated Tests) method is as powerful as permutation 
testing and adjusts for correlation between hundreds of tests; hence the method is applicable on 
a candidate gene scale. The downside of these approaches is that they ignore correlations 
between markers from different LD blocks and are therefore less accurate on a genome-wide 
scale. Furthermore, the true null distribution tends to deviate from asymptotic distribution at the 
extreme tails, especially in the presence of low-frequency and rare variants (MAF<5%), which 
increases inaccuracy (112).  
 
Kimmel and Shamir (113) have developed a rapid association test (RAT) that uses importance 
sampling to decrease the amount of permutations and the decreasing LD along the chromosome 
to further speed up the permutation algorithm, resulting in considerably faster performance than 
the standard permutation testing procedure. However, this method requires phased haplotype 
data, which are rarely available. 
 
Lewinger et al. (2007) (114) suggest hierarchical Bayes prioritisation of a set of markers with a 
higher prior probability of association based on biological/evolutionary information or prior linkage 
or association data. Selection of hits for follow-up is based on ranked posterior expectations. 
When prior information is available, this is shown to be more effective in selecting true 
associations than traditional ranking of p-values. This method ignores the LD structure in the data 
which limits its efficiency. Roeder et al. (2007) (115) introduces a multiple testing procedure 
where weighting is based on groupings of tests. If this is done effectively keeping the number of 
groups small, power is improved if associations are clustered into certain groups.  
 
Recently, sliding window approaches have been suggested to correct for multiple testing in the 
presence of LD structure. Instead of estimating the genome-wide significance threshold, 
Moskvina and Schmidt (116) estimated the effective number of tests (Keff) based on pairwise 
correlations between the markers. Another approach called SLIDE (Sliding-window approach for 
Locally Inter-correlated markers with asymptotic Distribution Errors corrected) uses the 
conditional MVN distribution given all markers. This method accounts for most of the correlation 
due to local LD structure and scales the MVN to approximate the true distribution to correct for 
deviation in the tails. Its performance on a genome-wide scale exceeds that of most other 
approaches in terms of accuracy and computational time (112). RAT performs equally well in 
terms of accuracy but it is slower.  
 
Realistically, in the competitive world of GWAS where fast production of results is vital and 
analyses are often repeated several times under varying settings and for several phenotypes, an 
approach that takes more than a few hours of computational time is simply impractical. Most 
 47 
GWA studies have adopted the use of a single, stringent genome-wide significance threshold of p 
< 5x10
-8
 (107) which corresponds to an effective number of one million tests genome-wide at 
alpha=0.05. Since many large GWA data sets have become available and meta-analyses 
continue to dominate the field, this approach seems to be adequate and less interest is now 
focused on developing new methods for the correction of multiple testing in GWA studies. 
 
2.1.8. Missing data 
 
Sources of missing data 
 
There are several sources of missing data in genetic studies. Cohort studies in general are prone 
to unit non-response and loss to follow-up. Some attendees may refuse to give a blood sample 
especially if genetic information will be extracted. Therefore the study population may suffer from 
selection bias if the dropout or refusal is more common in certain population subgroups than 
others. However, the selection process is unlikely to be strongly related to disease gene 
distribution in the population due to Mendelian randomisation (2.1.4), and therefore this should 
not have a major effect on the results.  
 
Even after obtaining the blood samples, some missing data will be introduced into the genetic 
data as a result of an imperfect assay conversion rate (i.e. less than 100% of attempted markers 
generate genotypes) and an imperfect call rate for a converted marker (i.e. genotypes are called 
for less than 100% of the blood samples) (117). If random missing data can be assumed, this 
leads to a reduction of statistical power but does not introduce bias. However, failure to call may 
depend on the genotype. If this is the case, using only called samples leads to bias in genotype 
frequencies (118). Trying to reduce missing data by calling genotypes with a lower degree of 
certainty can produce erroneous genotypes, and this may lead to bias in the estimation of 
genotype-disease associations. An example of this is a differential bias in genotype scoring 
between cases and controls, which can cause false positive genotype-disease associations 
(118). Additionally, in the absence of parental data (in practice nearly always) haplotypes are 
missing. They may be inferred from genotype data e.g. using the Expectation-Maximisation (EM) 
algorithm or multiple imputation methods, accounting for the uncertainty in the estimated 
haplotypes (119, 120).  
 
Usually there are also some missing values in the environmental variables which are needed for 
adjustments and for investigating gene-environment interactions. This is called item non-
response and there are three mechanisms through which this can occur. If the probability of 
response is independent of both observed and missing data, the data are said to be missing 
completely at random (MCAR). This is very rarely the case but the most commonly used analysis 
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method which restricts the sample to individuals with complete data (complete case analysis) 
relies on this assumption. More commonly, after conditioning on the observed data, the 
probability of response is independent of missing data. The data are then said to be missing at 
random (MAR). In the worst case scenario, the probability of response depends on the missing 
data even after conditioning on all observed data (not missing at random, NMAR). Appropriate 
methods, e.g. multiple imputation method (121), should be used, especially in the case of non-
random item non-response. Even under MCAR, these methods could be applied to increase 
statistical power (122).  
 
Similarly, missing genotype values can be imputed when genotyping has failed for some reason. 
Imputation can be done using genotype information from other individuals in the sample and the 
LD between genotypes (120). Additionally, since GWAS are based on a selection of SNPs, i.e. 
the whole genome is not sequenced, the SNPs that are not genotyped using a certain panel can 
be perceived as missing data. Different panels use different SNPs based on different criteria of 
selection. For instance, Illumina‘s HumanHap300 BeadChip for genotyping of 317,000 tag-SNPs 
derived from HapMap and Affymetrix 500K array set for genotyping 500,000 quasi-random SNPs 
spread across the genome, have only 51,000 SNPs in common (123). The performance of 
different panels in terms of how well they capture common genetic variation in the HapMap 
reference samples are compared in Magi et al. (2007) (124). A comparison of studies that use 
different panels can be complicated. However, it is possible to impute (fill in) those genotypes that 
were genotyped in the HapMap project but not in the sample at hand. This procedure performed 
well e.g. in a Finnish sample when information from the HapMap CEU population was used as a 
basis for imputations (125). Currently the standard procedure is to meta-analyse several GWAS. 
Genotype imputation has become critically important since it enables the combining of data sets 
for meta-analysis (120). The HapMap has commonly been used as a reference panel for this 
purpose. 
 
Imputation methods for missing genotypes 
 
Various methods have been proposed for the imputation of untyped SNPs in GWAS. A method 
applied in the WTCCC study (2007) (26) is based on imputing missing genotypes using 120 
HapMap CEU haplotypes (10) and a HMM for each individual‘s genotype vector (126). The 
method uses information on all markers in LD with the missing SNP and weighs them so that the 
weight decreases with increasing genetic distance. Marginal probability is computed for each 
missing genotype. Imputation accuracy with this method is good (e.g. agreement with Illumina 
genotypes 98.4%, given a maximum posterior genotype probablility >0.95). Genotype-phenotype 
associations are then evaluated using Bayes factors either at a single SNP or within a region (the 
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latter deals with multiple comparisons in a natural way). The method can be extended to impute 
completely unobserved ‗hidden‘ SNPs, i.e. SNPs that are not included either in the set of sampled 
genotypes or the HapMap haplotypes. This extension requires phased genotype data and 
therefore a haplotype estimation step is needed (a version that directly handles genotype data is 
under development). The method also provides probability distributions for called genotypes 
which can be used to correct genotyping errors. The approach also extends to the situation where 
the incomplete data set consists of haplotypes instead of genotypes. Software called IMPUTE 
which implements this approach is freely available to download (126). This software has 
subsequently been updated to handle data from new reference panels such as the 1000 
Genomes Project (IMPUTE v2). It combines information across multiple reference panels, 
attaining a high accuracy for both common and rare SNPs (127). Instead of using analytical 
integration, phasing uncertainty is dealt with in the Markov Chain Monte Carlo (MCMC) 
framework in the updated version. 
 
Another method that has gained popularity infers haplotype information for each person using 
information from the coalescent theory, haplotype patterns and recombination in the population. It 
can be used for missing genotype imputation as well as haplotype inference. This method has 
been implemented in the MACH (MArkov Chain Haplotyping) software (128). Servin and 
Stephens (129) apply sampling-based algorithms PHASE and fastPHASE that use information on 
LD to impute missing genotypes. Imputations are then incorporated into the inference on 
genotype-phenotype associations for which they use a Bayesian regression approach. The 
approach is designed for quantitative trait data and association studies in candidate regions, but 
the same general framework can be used for discrete data and GWAS. Browning & Browning 
(130) have developed a software package called BEAGLE for haplotype phasing and missing 
data inference for GWA studies. The method is able to phase 3,000 individuals genotyped for 
490K markers in 3.1 days computing time with 99% masked allele imputation accuracy. 
Additionally, imputations can be performed using software initially developed for association 
mapping (e.g. PLINK, BIMBAM) (120). 
 
Published comparisons of the existing imputation methods are scarce. In a comparison of 
BEAGLE v3.0.1, IMPUTE v0.3.2, MACH v1.0.15 and PLINK v1.02, Nothnagel et al. (2009) (131) 
concluded that all these software are highly accurate in terms of genotype prediction but PLINK 
falling behind in imputation efficacy, measured by the number of SNPs for which imputation was 
actually performed. This paper recommended the use of BEAGLE or MACH based on user-
friendliness and smaller memory requirements. Howie et al. (2009) (127) have since compared 
IMPUTE v2 with IMPUTE v1.0, MACH v1.0.10 (typing error in the published paper stating 
v0.1.10), fastPHASE v1.3.2 and BEAGLE v3.0.2 under different scenarios. This study suggests 
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IMPUTE v2 yields 15-20% smaller error than the best of the competing methods and shows an 
improvement from its earlier version especially in terms of rare SNPs. Recently, Marchini and 
Howie (2010) (132) published a comprehensive review article on genotype imputation, in which 
they updated the earlier comparison of imputation methods and examined further their 
performance on a large reference panel of haplotypes (similar to what is being generated by the 
1000 Genomes Project). IMPUTE v2 turned out to be at least twice as fast as fastPHASE v1.4.0 
and BEAGLE v3.2 on a simulated data set. 
 
Even though imputation considerably improves power (126), there are limitations attached to it 
(133). Imputation based on HapMap may become inaccurate if it is done for a population other 
than European, Asian or West African. Although HapMap (Phase II) includes over 3 million SNPs 
(134), it has regions with large gaps in coverage. This can reduce imputation accuracy. HapMap 
data are biased towards SNPs of intermediate minor allele frequency and must be used with 
caution for uncommon SNPs or other types of population genetic testing (135). The 1000 
Genomes Project provides reference data for low-frequency and rare variants but these data may 
have more inherent uncertainty that needs to be taken into account in the imputation (132). 
Nevertheless, the advantages of imputation clearly outweigh its limitations and it has now 
become a standard procedure in genome-wide association studies. 
 
2.1.9. Bias and confounding 
 
Genetic association studies are not prone to confounding the same way that observational 
studies on environmental factors and disease risk are. This is due to Mendelian randomisation 
(2.1.4). However, different types of bias may affect power and distort conclusions. For example, 
there might be inaccuracies in the genotypes (miscalls), e.g. some heterozygotes miscalled as 
homozygotes. This may lead to deviation from HWE (57). If cases and controls are not drawn 
from the same population, their genotype frequencies differ systematically and this leads to 
selection bias (136). Some populations like the United States have a sub-structure due to 
population admixture which itself is due to a history of high intercontinental migration. This 
phenomenon is called population stratification, which means that there are sub-groups in the 
population that are on average more related to each other than to other members of the wider 
population. This may in some cases produce an increased number of false positive associations 
(57). Techniques such as genomic control, EIGENSTRAT or ancestry-informative-markers (AIMs) 
can be used to adjust for confounding caused by population sub-structure effects (136-138). 
Genetic association studies sometimes suffer from cryptic relatedness and this too can be 
addressed in the analysis (86). Another type of selection bias is causal bias, e.g. volunteer bias, 
which may be caused by personality traits partly explained by genetic factors. However, this 
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should be independent of most other (not personality related) loci (136). Publication bias occurs 
when statistically non-significant results remain unpublished, resulting in an inflated overall 
estimate of the association in a meta-analysis (139). Genetic association studies have suffered 
from this problem considerably due to the high number of polymorphisms in the human genome 
and the sheer volume of potential associations and studies on them. Language bias (most 
commonly a failure to include studies published in languages other than English) complicates this 
issue further (140). 
 
2.1.10. Interactions 
 
Genetic variants rarely work in isolation, independently of other variants or environmental factors. 
A major challenge is to unravel the gene-environment and gene-gene interactions (epistasis) that 
lead to increased disease susceptibility. Although taking into account interactions may help to 
discover new causal variants, low power and difficulties in giving meaningful biological 
explanations for the interactions remain major problems. The low statistical power to reveal these 
associations is due to the huge number of possible interactions. For example, if only pairwise 
gene-gene interactions for n SNPs are considered, the number of potential interactions in GWA 
data is over 1.5x10
6
 using 317,000 SNPs and restriction to within-gene interactions (N of genes = 
30,000; N of pairwise interactions within a gene = n(n-1)/2). When better genome coverage and 
more complicated epistasis and gene-environment interactions are added into the equation, this 
figure increases by many orders of magnitude. It is essential to collect samples that are well-
phenotyped and large enough to capture these effects (136). Techniques such as machine 
learning (141), random forests (142) and multifactor dimensionality reduction (143) have been 
suggested for studies with several SNPs and a high number of potential interactions. A 
combination of these techniques has been suggested as an optimal approach for investigating 
epistasis (144). Chapman & Clayton (145) suggest simultaneous testing of main effects and 
interactions using an ―omnibus‖ test they developed. Challenges, opportunities and possible 
designs for emerging gene-environment-wide interaction studies (GEWIS) have been reviewed in 
Khoury & Wacholder (2009) (146) and Thomas (2010) (147).  
 
2.1.11. Statistical power 
 
GWA scans in single studies are generally underpowered due to inadequate sample sizes (148). 
Possible solutions for case-control studies include strengthening the case sample by increasing 
sample size or ascertaining phenotype more carefully, strengthening the control sample, e.g. by 
releasing data in a public domain and forming combined data sets, or using other disease cases 
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as controls. The latter approach was used in the WTCCC (26) study but it has been seen as 
somewhat controversial. 
 
If there is no evidence from other studies for a given genotype-disease association or no 
biological reasons to suspect an association, then the prior probability for the association is very 
small. When the genome-wide significance threshold (p < 5x10
-8
) is applied to control the number 
of false positive findings, the sample size has to be large enough to attain adequate power to 
detect true associations. Otherwise only very strong effects will be found and moderate 
associations will be missed. Study sample size and power estimation are necessary in optimising 
design for GWA studies. This is not a straightforward process, since several parameters such as 
the extent of LD, MAF, the disease prevalence and the planned study design have to be taken 
into account (64, 149-151). For instance, it has been suggested that a coverage estimate based 
on standard LD measures such as r
2
 yields to inflated power estimates in GWA studies. An 
alternative ―cumulative r
2
 adjusted power‖ measure that integrates LD and tag-SNP information to 
obtain the overall power could be used to obtain more accurate estimates (152). Using this 
approach, Klein (2007) (153) computed the power as a function of sample size and genotype 
relative risk (GRR) using tag-SNPs from Affymetrix (100K and 500K) and Illumina (300K and 
550K) in the four HapMap populations. This study demonstrated how power depends not only on 
the sample size and effect size but also on the selected tag-SNPs. For example, over two 
thousand cases and an equal number of controls are needed to detect multiplicative associations 
of SNPs with MAF>5% and moderate effect size (GRR=1.5), with 80% statistical power, using the 
HapMap CEU population and Illumina 300K (i.e. 317K) chip (Figure 2.3). Significance threshold 
for this calculation (p = 1.6x10
-7
) was determined using Bonferroni correction 0.05/M (M=number 
of tag-SNPs with MAF>5% genotyped in the HapMap CEU population = 313,265). Han et al. 
(112) introduced a power estimation method called SLIP (Sliding-window approach for Locally 
Inter-correlated markers for Power estimation) in the MVN framework, and compared power 
estimates using different methods including standard simulation, null/alternative panel 
construction, best-tag Bonferroni (which Klein (2007) (153) used) and SLIP. They found that 
whilst the null/alternative panel construction and SLIP measured up to the gold standard 
simulation method, the best-tag Bonferroni underestimated power by up to 5%. 
 
Although imputation of untyped markers introduces a small genotyping error, it improves 
statistical power in GWAS given that no additional multiple testing penalty is added i.e. the 
significance threshold is kept unchanged. The additional power from imputation for Illumina 317K 
chip has been estimated to be about 4%, which is nevertheless smaller than the power gained by 
using Illumina 650K chip instead of 317K chip (about 13%) (154). 
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Figure 2.3. Statistical power for a genotypic association test as a function of sample size 
(including cases with equal number controls) and genotype relative risk (GRR) in the 
HapMap CEU population using Illumina 317K chip, under a multiplicative genetic model. 
Reproduction of the figure from Klein 2007 (153) permitted under the Creative Commons 
Attribution License 2.0.  
 
Both genetic and environmental variables as well as their interactions can be included in power 
calculations (155). Components that should be taken into account in determining the power 
include genotyping error, environmental error, sensitivity and specificity to detect the disease 
phenotype, and the statistical significance threshold. Very often, measurement errors are ignored 
in power calculations, and this leads to an underestimation of the required sample size. A 
calculation using the ESPRESSO software (155) illustrates this: 2,667 cases and 2,667 controls 
are needed to detect a genome-wide significant (p < 5x10
-8
) additive association of OR = 1.3 
between an accurately measured binary phenotype and a common, accurately measured SNP 
(MAF = 30%) with 80% statistical power. However, if the genotypes were measured with 99% 
sensitivity and specificity and the disease status was measured with 95% sensitivity and 99% 
specificity, 4,344 cases and 4,344 controls would be needed to reach the same statistical power. 
Lifestyle factors such as nutrition or smoking are typically less accurately measured than disease 
status, and therefore considerably larger sample sizes are needed for GWAS on such 
phenotypes. Also, much larger samples are needed to detect gene-gene and gene-environment 
interactions in GWAS. Power calculations for detecting gene-environment interactions in both 
candidate gene studies and GWAS have been presented in Thomas (2010) (147). These 
calculations suggest that in cases where MAF and exposure prevalence are both fairly low (10%), 
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tens of thousands of individuals are needed to detect moderate interaction odds ratios (IOR) of 
about 1.5. 
 
Analyses of continuous traits have the advantage of being better powered. Many clinically 
measured continuous phenotypes, such as BMI and height, are also reliably measured. Some 
power calculators such as Quanto and ESPRESSO have open access on the Internet (155, 156). 
However, implementation of power calculations for continuous traits with the inclusion of gene-
environment interactions, epistatic effects and different types of error has been slower.  
 
2.1.12. Multi-marker methods for genetic association studies 
 
Single-marker methods fail to take into account potential joint effects and interactions between 
multiple markers affecting the phenotype. Multi-marker approach may increase statistical power 
for identifying a gene-trait association, given considerable LD between the associated markers 
within a gene. Hoh and Ott (101) give a good historical review on multi-locus methods that have 
been applied to data with a limited number of markers, e.g. candidate gene data.  
 
Multi-marker methods can be applied either to genotype or haplotype data. The goal is to 
maximise the use of information from multiple loci without increasing the degrees of freedom too 
much, e.g. by classifying haplotypes into groups. If the genetic effects of different variants don‘t 
depend on whether they are in the same (cis) or different (trans) chromosome, then haplotype 
analysis does not have much advantage over genotype analysis (157). 
 
Early approaches of multi-marker methods include, for example, simultaneous search of all 
possible pairs of markers, one-by-one search of markers conditional on previously found 
significant markers, logistic regression model using stepwise model selection, neural networks, 
and approaches based on sums of single-marker statistics (101). Exhaustive searches easily run 
into multiple testing problems, as do logistic regression and neural networks which are also poor 
at handling large amounts of interactions. The use of sums of single-marker statistics leads to a 
loss of information (158).  
 
Data mining approaches suggested for genetic association studies include different classification, 
haplotype similarity and clustering and haplotype patterning techniques (159). Classification 
techniques cover, for example, combinatorial partitioning method (CPM), restricted partitioning 
method (RPM), recursive partitioning (RP) methods (including random forests), patterning and 
recursive partitioning (PRP), multifactor dimensionality reduction (MDR), symbolic discriminant 
analysis (SDA), association rules, the DICE algorithm, and support vector machines (SVM). Their 
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general aim is to find groups of variables (markers, haplotypes, and possibly environmental 
variables) that together predict the phenotype. Some of them (CPM, RPM and MDR) are based 
on data reduction which collapses the data to a lower dimensional space. Others (RP, SDA, 
SVM) attempt to discriminate groups by identifying patterns and using full dimensionality of the 
data. These non-parametric methods can for instance be used in detecting higher-order 
interactions without assuming marginal single-locus effects or any genetic model. The 
applicability of classification methods to genome-wide association studies is restricted to 
explorations in the follow-up stage(s) where the number of markers is limited. 
 
Bayesian methods make inferences of unknown parameters given the observed data. Inferences 
are drawn from the posterior distribution of the unknown parameter which can be calculated from 
its assumed prior distribution and the observed data likelihood. Methods such as MCMC can be 
used to draw random samples from the posterior distribution when it cannot be explicitly defined. 
 
Bayesian variable selection is an effective method of mapping QTL or binary traits in the 
presence of multiple correlated SNPs. The stochastic search variable selection method (SSVS; 
(160)) uses a mixture of two normal distributions for each regression coefficient in the model: both 
with zero mean, one with a small variance and one with a large variance. Those effects with high 
posterior probabilities of belonging to the distribution with the large variance are selected and 
others are excluded (161). In their linkage study, Oh et al. (162) applied it using the Haseman-
Elston method in finding markers linked to loci that determines change in cholesterol levels over 
time. The smart search it does over the whole model space was found to be powerful for finding 
even weak effects. 
 
Bayesian shrinkage estimation for QTL (161) is based on the idea of concentrating the prior 
distribution of the regression coefficients at zero. It assumes that most QTL have zero effect and 
only some have large effects. The name given to shrinkage methods comes from the fact that for 
a small effect the regression coefficient is ―shrunk‖ to zero (57). Hoggart et al. (163) developed a 
method that uses shrinkage priors to analyse all genotyped SNPs simultaneously genome-wide. 
This method is computationally efficient and is also suitable for fine mapping sequence or high 
density (e.g. imputed) SNP data from large regions. Compared to single-marker analysis, this 
approach has a higher statistical power and a reduced false discovery rate (FDR). 
 
Bayesian graphical models are suitable for mining genotype-phenotype associations on a 
genome-wide scale (164). MCMC is used for drawing from a posterior distribution of graphs, 
given the unphased genotype data, to make inferences on the strength of the associations. The 
joint distribution of markers and disease status is modelled as a discrete graphical model. Prior 
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information on the physical distance between the markers can be taken into account to restrict 
the network of dependencies. Reduction in the number of potential graphs, in turn, reduces 
computational complexity. Bayes factors (ratios of posterior to prior odds of association) are used 
to measure evidence in favour of association. The method is computationally efficient and can be 
extended, e.g. to handle missing data and interactions. Continuous variables have to be made 
discrete before they can be included in the analysis. Bayesian (belief) networks use a similar idea 
but are better suited for candidate gene studies (165), (166). 
 
In pathway-based approaches, multiple variants in the same molecular pathway in interacting or 
related genes are considered jointly with the help of prior biological information. They have 
recently been introduced to facilitate the interpretation of GWA data and to improve power of 
identifying disease susceptibility genes and even disease mechanisms (167). GWAS pathway 
analysis (GWASPA) integrates GWAS results with genes in a known pathway to test the pathway 
association with a trait or disease (168). Methodological development for GWASPA is still in its 
infancy. 
 
2.1.13. Meta-analysis and replication of genome-wide association signals 
 
We must all hang together, or assuredly we shall all hang separately. 
—Benjamin Franklin 
 
The lack of successful replication of the results has been a problem in genetic association 
studies. This can be explained by various reasons, e.g. low prior probabilities of association, high 
false positive result occurrence due to multiple testing, low statistical power, and publication bias 
(169). However, replication clearly increases the probability of a true positive finding (170). Meta-
analyses and systematic reviews are needed to help in the interpretation of the evidence from 
individual studies but they should be conducted with great care, taking into account the 
aforementioned and various other problems related to these studies (171, 172). Different 
scenarios of success and failure to find associations and replicate them in GWA studies are 
analysed comprehensively in a review article (100). 
 
Current GWA studies are mainly conducted in large consortia due to the practical requirement of 
large numbers to obtain adequate statistical power (see Figure 2.4 for a typical meta-analysis and 
replication work flow within a consortium). A common practice is to select a collection of data sets 
from individual studies that fulfill certain requirements related to study design and availability and 
quality of genotypic and phenotypic data. These are called discovery data sets. A uniform 
protocol on how to run the analyses within these data sets is then formed within the consortia. 
Due to commonplace restrictions in sharing genotype-phenotype data, it is customary to have a 
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data analysis team which consists of analysts from each study. Each analyst performs a GWA 
analysis for agreed phenotypes in their study and shares the results with the team. The results 
are pooled together in a meta-analysis, which are sometimes run in parallel by more than one 
analyst to ensure the reliability of the results. In the meta-analysis, studies are usually weighed by 
the precision of their effect estimates (inverse of the variance) (173). In general, larger studies 
have more weight than small studies. 
 
 
 
Figure 2.4. Typical meta-analysis and replication work flow within a consortium. Adapted 
from Zeggini & Ioannidis (2009) (33). 
  
Inverse-variance fixed-effects models (173) can be used for meta-analysis unless between-study 
heterogeneity is observed. They test the null hypothesis of no association in any of the study 
populations analysed. Random-effects models (173) which incorporate between-study variance in 
the estimation, are preferable in the presence of heterogeneity. Heterogeneity can be evaluated 
by using a number of different test statistics. They are reviewed in detail in Kavvoura & Ioannidis 
(2008) (174). Perhaps the most commonly used heterogeneity statistic is Cochran‘s Q statistic, 
which is the weighted sum of squared deviations of study-specific estimates from the overall 
estimate from the meta-analysis. Under the null hypothesis (i.e. when all studies evaluate the 
same effect), Q statistic follows Chi-square distribution with k-1 degrees of freedom (k=number of 
studies). This test has a low power to detect heterogeneity when the number of studies is low. 
Another statistic, I
2
, which is a function of the Q statistic and k (I
2
 = [Q–(k-1)]/Q x 100%), has the 
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advantage of being independent of the number of studies. It measures the proportion of variation 
across studies due to heterogeneity rather than chance (175). Sometimes a between-study 
variance, τ
2
, is reported and compared with the overall effect size, but this statistic has the 
disadvantage of being dependent on the effect size metric. The meta-analysis produces pooled 
inverse variance weighted estimates for the effect size (e.g. beta coefficients with SE from a 
regression analysis for a continuous phenotype) and p-values.  
 
Practical aspects and methods used in GWAS meta-analyses are discussed in detail in de 
Bakker et al. (2008) (176) and in Zeggini & Ioannidis (2009) (33). In addition to between-study 
heterogeneity, issues in the meta-analysis and replication that need to be addressed are different 
sources of bias, imputation of genetic data, quality and consistency of genetic and phenotypic 
data, analytical methods including phenotype transformations, genetic models and adjustments, 
inconsistencies in strand and build of the reference that individual studies use, and definition of 
the level of statistical significance required when several sequential meta-analyses are conducted 
as the data accumulate. 
 
The strongest (e.g. p < 5x10
-8
) and/or biologically most interesting signals are selected for 
replication in other data sets. Selection of SNPs for replication is a process where several 
aspects (e.g. p-value, prior information of disease associations in/near observed loci, 
heterogeneity, MAF, imputation quality) are taken into account. Usually the most strongly 
associated SNP (index SNP) from a selected locus is taken forward to replication, and 1-2 proxy 
SNPs in high LD with the index SNP are chosen. A proxy SNP can be used in the replication in 
case genotyping of the index SNP fails.  
 
Replication data sets should meet the same requirements as discovery data sets, except that 
they do not necessarily have to contain GWA data. However, extracted DNA should be readily 
available for de novo genotyping. In those replication data sets where GWA data are available, a 
quick in-silico replication can be done. The replication data sets are often meta-analysed 
separately to detect possible inflation of the association due to the winner’s curse in the discovery 
data sets. Discovery and replication data sets can then be meta-analysed together. 
 
2.1.14. Graphical illustration of GWAS and meta-analysis results 
 
Descriptive analyses of the GWAS data often include the inspection of quantile-quantile (Q-Q) 
and Manhattan plots for all the SNPs, and the examination of regional plots in the genomic 
regions around SNPs strongly associated with the phenotype. Additionally, forest plots 
(association estimates with 95% confidence intervals by study in meta-analysis) are produced for 
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promising signals to describe variation in effect sizes between studies. Forest plots are often 
used for visual inspection of heterogeneity, besides heterogeneity test statistics. Q-Q, Manhattan 
and forest plots are usually drawn only for meta-analysed data, although Q-Q plots may be 
produced additionally for each participating study.   
 
Observed p-values are plotted against expected p-values in -log10 scale in a Q-Q plot. If the 
observed p-value distribution does not deviate from the expected null distribution of p-values, all 
dots lie in or very close to the diagonal. This should be the case after true associations (dots 
clearly above the diagonal indicating a genotype-phenotype association) are removed from the 
plot. Residual deviations in the Q-Q plot may be a sign of poor quality data or uncorrected 
population stratification (176). Additionally, genomic inflation factor (λ) can be calculated to 
assess the extent of inflation and the excess false positive rate (137). The test statistics should be 
corrected for the observed inflation (176). This can be done in two steps: within-study correction 
prior to or during meta-analysis, and between-studies correction during meta-analysis.  
 
In a Manhattan plot, -log10(p-value) for each SNP is plotted against the genomic location of the 
SNP. Chromosomes are plotted next to each other, often with different colours. Peaks or 
―skyscrapers‖ in the Manhattan plot indicate clusters of SNPs with a high association p-value in 
the same region. These are often inspected more closely in a regional plot, which may also 
contain information about the recombination rate (the amount of LD) in that region. 
 
2.1.15. Fine mapping and resequencing 
 
The goal of fine mapping is to identify the causal variant underlying the observed genotype-
phenotype association. There are different methods of fine mapping signals. Exhaustive 
resequencing  of the region around the identified association in large population samples is 
becoming feasible with next-generation sequencing technologies (32), although this is still 
expensive. A cheap but still potentially adequate method is to use the existing GWA data and to 
impute untyped markers in the region using an appropriately dense reference panel such as the 
1000 Genomes Project. Functional information from, for example, gene expression studies can 
sometimes be used as a shortcut for the identification of a causal variant, without exhaustive 
resequencing efforts (107). 
 
Despite the recent technological advances, identifying the true causal variant is challenging (107). 
In the presence of high LD it is difficult to distinguish between the causal variant(s) and other 
highly correlated variants. There is also a possibility of multiple independent signals that are not 
evident at first glance. Furthermore, the causal variant can be a common, rare or a structural 
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variant, and it may represent coding or regulatory variation, and lie within or near the causative 
gene, or even further away from it, if there is a regulatory connection (32). 
 
Since LD patterns differ between populations of different ethnicities, fine mapping in a population 
of different ethnicity may be helpful in identifying the causal variant. For example, the fat mass 
and obesity associated (FTO) locus was fine mapped in African-derived populations (177). This 
study suggests that the SNPs originally associated with BMI (rs9939609 and rs1421085) are not 
the culprits as they are not associated with BMI in African-derived populations. Instead, two SNPs 
(rs3751812 and rs9941349) showed associations with BMI in these populations. These two 
variants had a similar effect on BMI, and the authors were unable to distinguish between them 
through conditional and haplotype analyses. This suggests neither of these two variants 
completely capture the FTO-association, and that these variants are strongly correlated with the 
unidentified causal variant. 
 
2.1.16. Interpretation of data: incorporating functional information 
 
Even if the causal variant was found, the finding would not be useful before its function and 
interaction with other genes and environmental factors on the trait or disease risk are understood. 
Integrative approaches in the field of systems biology, such as reconstruction of networks from 
data, can provide a context needed for data interpretation (178). This may help in finding 
pathways which in turn can lead to useful therapeutic interventions. 
 
In addition to genomics data, gene expression and metabolite data are included in studying the 
interactions and pathways. There may be several interacting networks (e.g. non-coding RNA, 
protein, transcriptional, and metabolite networks) that need to be modelled together. Causality 
can be expressed with directed networks. Differential connectivity is used as a statistical measure 
to identify differences between subgroups of the data (e.g. males vs. females, or subgroups with 
different phenotypic status). New understanding has been gained for instance on the factors 
underlying obesity, diabetes and atherosclerosis using this approach (179), but work is still very 
much in progress in this area. 
 
2.1.17. Selected software for GWAS and their meta-analysis  
 
Commonly used software packages were considered for the analyses performed in this PhD 
project. Most of them are freely available on the Internet. References and URL addresses to 
these packages are given in Table 2.2. Some of these packages are related to each other, e.g. 
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after imputation of untyped markers with IMPUTE, the data will be in the right format to be 
analysed using SNPTEST. 
 
Table 2.2. Selected software for genome-wide association studies (GWAS) and their meta-
analysis. 
 
Name Reference URL 
PLINK (180) http://pngu.mgh.harvard.edu/~purcell/plink/index.shtml 
GTOOL, 
IMPUTE, 
SNPTEST 
(126, 127) http://www.stats.ox.ac.uk/~marchini/software/gwas/gwas.html 
GenABEL (181) http://mga.bionet.nsc.ru/~yurii/ABEL/GenABEL/ 
SNPassoc (182) http://bioinfo.iconcologia.net/index.php?module=SNPassoc  
snpMatrix N/A http://bioconductor.org/packages/release/bioc/html/snpMatrix.html 
MaCH (128) http://www.sph.umich.edu/csg/abecasis/mach/ 
metaMapper N/A http://www1.imperial.ac.uk/medicine/people/l.coin/  
METAN (183) http://ideas.repec.org/c/boc/bocode/s456798.html  
METAL N/A http://www.sph.umich.edu/csg/abecasis/metal/  
 
2.1.18. Choice of genetic analysis approach for this PhD project 
 
The timing of this PhD project (2006-2010) coincided with the early years of the GWAS era. 
Therefore, in addition to continuing ongoing candidate gene analyses, the natural choice was a 
population-based GWAS on SNP data for investigating the genetic architecture of complex 
phenotypes. One stage marker-based approach was considered most economical, since it allows 
investigation of any number of phenotypes without additional genotyping costs. Imputation of 
missing genotypes was considered beneficial based on literature. Due to the requirement of large 
sample sizes in GWAS to obtain adequate statistical power, collaboration with other studies 
through consortia and meta-analysis of several GWAS was considered very important. Issues 
such as multiple testing and confounding need to be considered carefully in each sub-study 
included in this thesis. 
 
2.2. Growth modelling methods 
 
This chapter outlines the methods for modelling growth from birth to adulthood. To give an 
adequate background, phases and dimensions of growth and reasons for modelling growth are 
discussed briefly. Parametric and nonparametric growth modelling methods are compared. A 
selection of established parametric growth models are described in detail.  
 62 
 
2.2.1. Phases and dimensions of growth 
 
For the purpose of this thesis, only physical aspects of human growth are considered. Growth is 
defined as the increase of a body dimension in size over time (184). The endocrine system 
regulates the growth process so that different hormones and growth factors play a part in different 
phases of growth (185).  
 
For height growth, at least three different endocrine phases of growth have been recognised, with 
implications on the growth modelling techniques applied. These include infancy (~0-2 years), 
childhood (~2-9 years) and puberty (~9-17 years). Infant height growth is fast but rapidly 
decelerating, followed by almost constant childhood growth, leading to a pubertal height growth 
spurt and attainment of adult height. For some individuals, a visible mid-growth spurt occurs in 
the childhood phase (184). However, capturing it requires dense and accurate measurements in 
this age interval.  
 
Growth in weight and body mass are less regular processes, although weight growth follows 
similar phases as height growth. Since weight and height growth are highly correlated, attempts 
have been made to model growth indices that refer to body shape rather than size (186). Body 
mass index (BMI = weight [kg] / (height [m])
2
) has become a widely used measure of obesity in 
epidemiological research in both children and adults despite its limitations. Modelling BMI poses 
challenges due to its considerable change over time from birth to adulthood. For a typical child, 
BMI increases from birth until it reaches an infant adiposity peak (AP) at around 9 months. This is 
followed by decrease in BMI until it reaches its nadir, or adiposity rebound (AR), at about 6 years 
of age. After this, BMI typically increases until adulthood (and beyond) but individual variation is 
considerable. 
 
2.2.2. Reasons for modelling growth 
 
Growth can be used as an indicator of nutritional and health status in children (187), and is 
therefore monitored routinely in many societies. Availability of high-quality growth reference 
charts to facilitate comparisons between individuals and groups is essential. Deviation from a 
typical growth trajectory may indicate a particular health problem in an individual, and a regular 
follow-up with a help of a reference chart can aid in the early detection of these problems. Low 
birth weight indicating poor prenatal growth (often followed by faster than average catch-up 
growth) has been associated with a higher risk of CVD (188), although more studies are needed 
to assess the impact of postnatal growth patterns on CVD and its risk factors. Furthermore, 
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growth studies will add to the understanding of the biological and physiological processes 
underlying the changes in body size and shape over time. Studies on the genetic architecture of 
growth will help distinguish the hereditary component of these processes (189). 
 
From a statistical point of view, fitting growth curves has various advantages compared to the 
analysis of serial measurements over time in a cross-sectional manner. It allows the estimation of 
rate of change, e.g. height growth velocity over time in each individual, and the estimation of 
biologically meaningful parameters such as the timing of adiposity rebound. Curve fitting 
summarises a large amount of raw anthropometric data into a few constants or function 
parameters and thus serves as a data reduction technique. The resulting mean constant curve 
helps to describe typical growth in the sample. The growth curve also smooths out the 
fluctuations in the data caused by measurement error and other sources of variation. The 
individual growth curve gives an estimate of the variable of interest (e.g. height) at each time 
point between observed measurements, and in effect interpolates a value for all the ‗missing‘ 
measurements. (190)  
 
2.2.3. Biologically and non-biologically motivated growth models 
 
Growth curves can be fitted in a framework that follows a two level structure. Individual 
measurements are ‗nested‘ within each subject (level 1) and the study sample consists of several 
subjects (level 2). For example, one might want to study BMI measurements in a group of infants. 
Two main study questions arise from such data: 1) How does BMI change as a function of time 
(or age) within individuals (level 1); and 2) How do these changes vary across individuals, for 
example, is the change in BMI over time similar in males and females (level 2)? This multilevel 
model framework can also be called a hierarchical linear model, individual growth model, mixed 
effects model, or random coefficient model framework (191). Covariates such as sex can be 
included as fixed effects in the model. Variation between individuals may be allowed in the model 
intercept and slope, for example, by including these as random effects in the model. 
 
Table 2.3 gives an overview of growth modelling methods. Biologically motivated growth models 
are typically parametric, i.e. they assume a pre-determined functional form and have parameters 
that allow functional or biological interpretation. Although model constants may not be directly 
interpretable they can be used to derive biologically meaningful growth parameters. These 
functions do not often allow identification of short-term velocity shifts, e.g. mid-childhood growth 
spurt. 
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Linear mixed effects models estimate fixed effects at group level and random effects at individual 
level. Adding higher degree terms, e.g. age squared, into the model results in polynomial mixed 
effects models. These can be fitted in the same way as linear mixed effects models. If the 
functional form of the model is not linear in its constants, a nonlinear mixed effects model needs 
to be fitted. Assumptions on the normality of the residuals as well as the normality of random 
effects apply to linear and nonlinear mixed effects models (192). 
 
Cubic splines are curves that connect consecutive points smoothly by using a set of cubic 
equations (193). They may have a large number of parameters with no biological interpretation. 
However, the effective number of parameters can be controlled by specification of the roughness 
penalty. The number and position of transition points or ‗knots‘ on the spline is subjective and can 
affect the estimates (190). 
 
More complex methods that are not motivated by biological reasoning include Generalised Linear 
Latent and Mixed Models (GLLAMM) and Growth Mixture Models (GMM). Both involve latent 
variables of various types. GLLAMM form a class of multilevel latent variable models for 
responses of mixed type including continuous responses, counts, duration/survival data, 
dichotomous, ordered and unordered categorical responses and rankings. The latent variables 
(common factors or random effects) can be assumed to be discrete or to have a multivariate 
normal distribution. GMM are a generalisation of mixed effect models that allow the existence of 
heterogeneous subgroups with different patterns of growth. Parameters such as random intercept 
and slope reflect individual differences in growth and are treated as continuous latent variables. 
The variable that divides the population into subgroups is treated as a categorical latent variable. 
These models will not be explored in detail in this thesis. 
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Table 2.3. Growth modelling methods. 
 
Method Examples Software 
Biologically motivated 
models 
  
Linear mixed effects 
models (LMEM) 
Linear and polynomial or fractional polynomial mixed effects models; Reed models. Stata xtmixed, R lme, SAS 
PROC MIXED 
Non-linear mixed effects 
models (NLMEM) 
Jenss-Bayley curve from birth up to 8 years of age; JPA-2 model from birth to 
adulthood. 
R nlme, SAS PROC 
NLMIXED 
Non-biologically 
motivated models 
  
Linear mixed effects 
mixture models 
(LMEMM) 
Growth mixture models (GMM). Mplus 
Generalised Linear 
Latent and Mixed 
Models (GLLAMM) 
Multilevel generalised linear models or generalised linear mixed models; multilevel 
factor or latent trait models; item response models; latent class models; multilevel 
structural equation models.  
Stata gllamm 
Generalised additive 
models (GAM) 
Scatterplot smoothers. R smooth.spline, s, bs, ns, 
lo, poly, gam, lm 
Semi-parametric models Semi-parametric non-linear mixed effects models (SNM) (e.g. shape-invariant mixed 
effects models (SIMM)); penalised splines with random coefficients; linear mixed effect 
models fitted by placing one knot that splits the growth period into two linear parts 
(piecewise linear mixed effects models).  
R snm, lme, nlme, Stata 
xtmixed with mkspline. 
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Non-parametric non-biologically motivated growth models have been introduced to capture 
individual short-term variability in velocity within general trends (e.g. mid-childhood growth spurt) 
when frequent growth measurements are available. No pre-determined functional form is required 
and nonlinearities are inferred from data. Although these models are typically easy to fit, they are 
often unstable in the extremes of the data and do not tend to an asymptotic value (190). By 
comparison, parametric biologically motivated models may in some cases assume even too rigid 
a functional form on the growth data, which may result to systematic bias. It is also possible to fit 
a combination of parametric and non-parametric models, for example by using piece-wise linear 
mixed effects models interdispersed by knots. More sophisticated semi-parametric growth models 
include, for example, shape-invariant mixed effects models (SIMM).  
 
For the purpose of this study, parametric biologically motivated models seem to be preferable, 
since biological interpretation of derived growth parameters is considered highly important. 
Growth data need to be summarised in a way that increases our understanding of the biological 
growth process and facilitates the study of its relationship with genetic determinants as well as 
adult phenotypes. However, in the preliminary analyses a selection of various types of models will 
be fitted to explore differences in the results they produce. 
 
2.2.4. Parametric models specifically designed for linear growth 
 
Infant growth 
 
Two models for infant height and weight growth were suggested in the 1930s-1940s: a four-
parameter non-linear Jenss-Bayley model and a simpler, three-parameter Count model which is 
linear in its constants (190). 
 
Jenss-Bayley model has the form 
 
Y = A + Bt – exp(C + Dt), 
 
where 
t = postnatal age 
Y = height reached at age t 
and A, B, C and D the unknown function parameters. 
 
The Count model,  
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Y = A + Bt + Cln(t),  
 
can be written in a modified form that allows the inclusion of birth measurements: 
 
Y = A + Bt + C’ln(t+1). 
 
The first order Reed model, denoted as the Reed1 model (194), is a four-parameter extension of 
the three-parameter Count model and its functional form using a similar modification is 
 
Y = A + Bt + Cln(t+1) + D/(t+1). 
 
Of the function parameters of the Reed1 model, A is related to the baseline height at birth, B to 
the linear component of the growth velocity, C to the decrease in the growth velocity over time, 
and D to the inflection point that allows growth velocity to peak after birth rather than exactly at 
birth. The Reed1 model is linear in its constants. The second order Reed model, Reed2 model 
(194), has one more deceleration term (E) and its functional form is: 
 
Y = A + Bt + Cln(t+1) + D/(t+1) + E/(t+1)
2
. 
 
Alternative models for early growth include the infancy component from Karlberg‘s ICP (=infancy-
childhood-puberty) model (195), formulated as 
 
Y = A + B[1-exp(-Ct)], 
  
and Kouchi model (196): 
 
Y = A + Bt
C
. 
 
These models assume a normal distribution for the residuals, and homoscedasticity of the 
residuals over time. Different within-person covariance structures of observations can be 
explored, e.g. unstructured, first-order auto-regressive (AR(1)), or compound symmetry options 
can be tested. Most of these models fit fairly well to height data in infancy. They have also been 
applied to weight data even though weight growth exhibits a more irregular pattern especially in 
the first weeks of life. A useful comparison of all aforementioned models except the Jenss-Bayley 
model was reported using weight growth data from 95 rural Congolese infants aged 0-13 months 
(197). In this data set, the Reed1 model performed best, followed by Reed2 model and Karlberg‘s 
model, whereas fitting of the Count and Kouchi models led to systematic under- and 
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overestimation of weight. Although these results may not be directly generalised to Western 
populations e.g. due to differences in nourishment, which in turn affect growth velocities (197), 
they give a good grounding for further research in this area. 
  
Growth from birth to adulthood 
 
The identification of different phases of growth described earlier (2.2.1.) has influenced the 
development of parametric growth models from birth to adulthood. Researchers have been trying 
to find a mathematical formula that describes the typical growth pattern accurately. Due to the 
irregularity of weight growth, finding a parametric model for it from birth to adulthood may be 
unrealistic. The focus has been on finding a model for height growth covering the whole growth 
period. Most of these models date back to the 1970s and 1980s.  
 
One of the most well-known models is the ICP model (195), which splits growth into three 
components representing the three endocrine phases of growth. These components are additive 
and can also be studied separately. The functional form of the ICP model in infancy is 
exponential, in childhood quadratic and in puberty logistic. Each of these three submodels 
includes three parameters and they are fitted sequentially.  
 
Preece and Baines (198) introduced a five-parameter multiplicative exponential-logistic model 
(PB1 model) which fits better in adolescence than earlier in childhood (190). Measurements 
below the age of two years should not be included in the model at all. Bock, du Toit and Thissen 
(199) presented the eight-parameter triple generalised logistic BTT model. It allows for the 
contentious mid-growth spurt, which can be seen as a weakness because it can add unnecessary 
complexity into the model (190). One of the strengths of the model is that it can be fitted from 
birth to adulthood. Another model encapsulating the whole period of growth is the six-parameter 
Shohoji-Sasaki (SS) / Count-Gompertz model (200) and its seven-parameter modifications (201). 
This model resembles the ICP model in that it includes different components at different stages of 
growth. The Count model component representing infancy/childhood is replaced by the Jenss-
Bayley model in the modification by Cole (SSC model) (202). The limitation of the SS model and 
its extensions is that it is non-monotonic and starts declining after the age of 20 years. 
 
JPA-2 model by Jolicoeur, Pontier and Abidi (1992) (203) is an extension of a seven-parameter 
JPPS (Jolicoeur-Pontier-Pernin-Sempe) model which includes three components that match the 
endocrine periods of human height growth: infancy, childhood and puberty (204). The superiority 
of the JPPS model over PB1 and SSC models has been described from birth into adulthood 
(201). 
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The eight-parameter JPA-2 model can be written as  
 
Y = A[1 – [1+ ((t+E)/D1)
C1
 + ((t+E)/D2)
C2
 + ((t+E)/D3)
C3
]
-1
], where 
 
t = postnatal age 
Y = height reached at age t 
A = adult height 
E = estimated prenatal duration of growth 
D1, D2, D3 = time-scale factors 
C1, C2, C3 = dimensionless exponents 
All parameters are assumed to be non-negative.  
 
JPA-2 estimates the prenatal duration of growth (E), whereas JPPS fixes it at the average 
gestational age (E=0.75 years). This does not take into account individual variation in the 
gestational age or the presumed delay after conception before the start of the growth in stature 
(203). Therefore the extension from JPPS to JPA-2 improves the model fit in infancy. JPA-2 has 
been found to fit human growth data better than several other suggested models (201, 203). 
 
The first derivative of the JPA-2 model (and the other parametric growth models presented here) 
gives the height velocity curve, and the second derivative gives the acceleration curve. The 
individual growth parameters that can be estimated from the velocity and acceleration curves 
include peak height velocity (PHV) in infancy, PHV in puberty, age at height growth spurt take-off 
(ATO) and age at PHV in puberty (APHV). 
 
2.2.5. Summary of growth modelling methods 
 
For the purposes of modelling human growth, it is essential to understand the biological basis of 
the growth process and how growth can be divided into different phases. The first step in growth 
modelling is the visual inspection of growth data which gives an idea of the shape of the growth 
curve and possible irregularities in the growth process. Fitting a growth curve enables the 
estimation of growth rates and derivation of biologically meaningful summary statistics from the 
growth data, while smoothing out short-term fluctuations, some of which may be due to 
measurement error. Comparison of an individual growth curve with a curve based on population 
average is useful in clinical practice for identifying individuals with abnormal growth due to 
possible underlying health problems. 
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Growth curve fitting is usually done in the mixed effects, i.e. multilevel model framework where 
consecutive individual measurements (level 1) are considered across a sample of several 
individuals (level 2). The models fitted in this framework vary in their complexity (Table 2.3). For 
example, the Reed1 model is decomposed by splitting the function parameters into fixed and 
random parts for each person i: Ai = α + ai, Bi = β + bi, Ci = γ + ci, Di = δ + di. The model can then 
be written: 
 
Yij = α + ai + (β + bi)tij + (γ + ci)ln(tij+1) + (δ + di)/(tij+1). 
 
In this case, four random parameters (ai, bi, ci and di) will be estimated for each person i (level 2) 
to express deviation from the average population curve characterised by the fixed effects (α, β, γ 
and δ). For each individual, there are several measurements j (j = 1,…, ni) (level 2); tij = postnatal 
age of individual i at jth measurement and Yij = growth measurement of individual i at jth 
measurement point (at age tij).  
 
Parametric growth models impose a specific functional form on the growth and may therefore be 
considered rigid for certain growth processes. Nevertheless, if an adequately fitting parametric 
model can be identified, it will be easy to derive interpretable summary statistics from the fitted 
curves. Non-parametric models that do not assume any functional form can better capture short-
term variations in a data set with dense growth measurements, but it is more difficult to interpret 
the parameters from these models. For the purpose of this thesis, parametric models may be 
preferable due to the biological interpretability of the estimated parameters. However, both 
parametric and non-parametric models will initially be explored in a growth data set. Based on the 
literature review on suggested parametric models particularly for infant height and weight growth, 
a small selection of models will be evaluated against each other in a growth data set and the best 
of them will be selected for further analyses.   
 
2.3. Genetics of growth 
 
This chapter presents a summary of the current knowledge on the genetics of growth, with an 
emphasis on common genetic variation. A thorough review of single-gene mutations underlying 
rare disorders (e.g. severe obesity) is beyond the scope of this review. Genetic studies on adult 
anthropometric phenotypes have informed genetic studies on growth from birth until adulthood 
(2.3.1). Genetic association studies on birth size (2.3.2), height growth (2.3.3) and growth in body 
composition measured by BMI (2.3.4) are briefly outlined and summarised in (2.3.5) and Table 
2.4. Studies reported in the result section of this thesis are excluded from the review. 
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2.3.1. Genetic studies on adult anthropometric phenotypes 
 
The high heritability of height was recognised by the late 1800s. The regression analysis 
technique was developed in the context of predicting offspring height from the mid-parental height 
(29). Adult height is normally distributed and this suggests a complex genetic architecture 
underlying this trait. It is 80-90% heritable in populations of European origin (205-207) and easily 
measurable, and is therefore used as a model trait in genetic research on complex traits. Height 
has also shown associations with morbidity (e.g. CHD, cancer and T2D) in epidemiological 
studies (208-210). These associations may be partly explained by genetic factors although 
environmental factors also seem important.  
 
Until recently, the success in identifying common variants associated with adult height has been 
limited. Several mutations underlying monogenic disorders that lead to very short or tall adult 
stature have previously been identified (see e.g. (211-214)). These include the oestrogen 
receptor, the short stature homeobox (SHOX) gene, and the growth hormone 1 (GH1) gene. 
However, these do not explain the large variation in height in healthy individuals. Candidate gene 
studies failed to produce reproducible results on common height variants, but recent GWA 
studies with meta-analytic approaches have successfully identified several hundred variants 
associated with adult height (29). These variants tend to cluster within genomic loci and biological 
pathways (210, 215), e.g. skeletal development signaling, extracellular matrix, cell cycle or 
chromatin structure pathways. Many of the genes involved in the normal variation in height, e.g. 
HMGA2, GDF5, IHH and ACAN, also include rare variants that cause growth or skeletal 
development syndromes (210, 215). Some of the common height variants (e.g. GDF5 and CDK6) 
have pleiotropic effects on other phenotypes, such as osteoarthritis (in the opposite direction) and 
rheumatoid arthritis (in the same direction) (210). Longitudinal genetic studies on height growth 
from birth to adulthood would help in understanding how the common variants regulating adult 
height may operate at different critical stages of growth, such as infancy and puberty.  
 
In addition to height, genetic determinants of adult BMI have been studied using different 
approaches. The heritability estimates for adult BMI vary between 55-85% (216). Variants 
explaining rare monogenic disorders related to extreme forms of obesity have often been used to 
inform candidate gene studies on common, polygenic obesity or BMI as a continuous trait. This 
has provided some success, for example leptin and leptin receptor genes (LEP and LEPR) and 
melanocortin-4 receptor (MC4R) gene have now been implicated in both rare and common forms 
of obesity (3, 217). Interestingly, the variant for common obesity in the MC4R gene has also been 
associated with greater adult height (210), suggesting a potential pleiotropic effect. GWA studies 
 72 
have discovered many new previously unsuspected common variants related to adult BMI 
(reviewed in Loos (2009) and Walley et al. (2009) (31, 218)) (Table 2.4). A locus in the FTO gene 
was the first one to be identified (27, 219, 220), and this discovery immediately sparked 
investigations on the FTO effect on changes in BMI over childhood (2.3.4). 
 
2.3.2. Size at birth 
 
Based on twin studies, the heritability of birth weight is estimated to be around 40% (221-223). 
However, these estimates might not be directly applicable to data on singletons (224). Estimates 
from parent-offspring data have suggested somewhat lower heritability (25-31%) but they depend 
on assumptions such as random mating and absence of inter-generational cultural transmission 
on the paternal side (225, 226). The environmental determinants of birth weight have been 
studied extensively in several data sets including Finnish populations (227, 228) but the genetic 
associations on birth weight have been explored much less. Genetic determinants of birth size in 
general, including e.g. intra-uterine growth retardation, are reviewed in Dunger et al. (2007) (229). 
These include rare mutations in genes regulating foetal growth, such as insulin-like growth factor 
genes (IGF1, IGF2) (Table 2.4). Despite attempts to identify common genetic variation associated 
with birth weight by candidate gene and linkage studies, these loci are still largely undiscovered. 
Associations reported in small data sets with a minisatellite polymorphism in the insulin gene 
variable number tandem repeat (INS-VNTR) were not replicated in larger data sets including the 
NFBC1966 (230, 231). Similarly, interactions between polymorphisms in proliferator-activated 
receptor (PPAR) gamma and body size at birth on later disease outcomes such as insulin 
sensitivity, lipid metabolism and blood pressure (232-234) were not verified in larger data sets 
including the NFBC1966; two large studies found no associations between the polymorphisms in 
PPAR gamma and birth weight (235, 236). 
 
The importance of genetic factors acting independently of the intra-uterine environment is 
illustrated by correlations between paternal height or weight and offspring birth weight (227, 237, 
238). Genetic variants that are associated both with low birth weight and increased risk of type 2 
diabetes (CDKAL1 and HHEX-IDE) may account for some of the observed correlation between 
these phenotypes (45, 239, 240). These findings give an incentive for the search of more 
pleiotropic effects underlying the association between birth size and adult metabolic phenotypes.  
 
Birth weight may be influenced directly by foetal genotype, and also indirectly by maternal 
genotype operating through the intra-uterine environment. This is clearly illustrated by 
observations of mothers and offspring with rare, heterozygous glucokinase (GCK) mutations. By 
reducing insulin secretion, these mutations increase offspring birth weight by 600g when inherited 
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by the mother and reduce birth weight by 530g when inherited by the foetus (241). In another 
study, observed association between common variation in TCF7L2 foetal genotype and birth 
weight was driven by the effects of maternal TCF7L2 variation on the intrauterine environment 
rather than by a direct effect on foetal growth (242). However, many birth cohorts lack data on 
maternal genotype, which makes it impossible to disentangle the maternal and foetal genetic 
effects on birth weight. 
 
Large-scale meta-analysis of several GWAS should be performed to aid the identification of 
common polymorphisms underlying normal variation in birth weight. Ideally, at least some of the 
data sets would also have maternal genotypes available to help distinguish between maternal 
and foetal genetic effects on birth weight. 
 
2.3.3. Height growth 
 
Heritability estimates for early height growth are scarce. A study of 375 Swedish male twin pairs 
(243) estimated less than 50% heritability for birth length and height at age 1 year, but over 90% 
heritability for height between ages 2 and 18 years. This study also estimated 73% correlation 
between height at 2 and 18 years, and suggested that more than half of the genes affecting 
height operate from early life until adulthood, although some genetic factors start affecting height 
only in puberty. Another study of 2,701 Dutch twin pairs estimated a heritability of height at 2 
years of age to be 52% in females and 58% in males (244). Consistently, in a larger cohort of 
Dutch twin pairs (N=7,755 at age 3 years), heritability estimates for height at 3-12 years varied 
between 58% and 91% (224).   
 
Heritability estimates for pubertal height growth characteristics such as ATO, APHV and PHV at 
pubertal height growth spurt, and results from association studies on stature and height growth 
patterns prior to the GWAS era have been reviewed previously (245). Although generally high 
(mostly 60-90%), estimated heritabilities varied considerably between studies. Besides 
differences between study populations, this may also reflect differences between methods used 
to estimate the growth parameters from data. A later published study on 922 Finnish twin pairs 
used change in relative height between early and late adolescence as a marker of pubertal 
timing, and estimated its heritability to be 86% for females and 82% for males (246). 
 
The genetic findings for height growth summarised in Thomis & Towne (2006) (245) include 
associations between oestrogen receptor gene and timing of pubertal growth (247), and vitamin D 
receptor and height and bone mineral density in females (248). However, no reports on the 
replication of these findings could be found. Obvious candidate genes for height growth include 
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genes involved in the hormonal control of growth, like the GH1 gene, the growth hormone-
releasing hormone receptor (GHRHR) gene, and the IGF1 gene. These genes harbour rare 
variants associated with abnormal growth, but association studies focussing on common variation 
have yielded conflicting results (211). GWAS on large samples of children would be required to 
get a clearer idea of genetic variation affecting growth at different stages. The availability of GWA 
data on samples with dense height measurements throughout childhood has been limited. 
However, several longitudinal birth cohorts are currently in the process of obtaining GWA data. 
 
2.3.4. Growth in body mass index (BMI) 
 
Twin studies have estimated moderate-to-high, age-dependent heritability (~50-90%) of BMI, 
showing a decrease in heritability from infancy to around 5 years of age and subsequent increase 
in heritability from mid-childhood into adolescence (249). Studies of common genetic variation on 
changes in BMI over childhood are scarce. The variants identified for BMI levels in children using 
a candidate gene approach have been reviewed earlier (245). These include some findings that 
failed to replicate in subsequent studies, e.g. a polymorphism in the beta-3-adrenergic receptor 
(ADRB3) (250, 251). Other findings discussed in the same review, e.g. rare mutations in LEPR 
and MC4R genes on extreme childhood obesity (252, 253), are now well-established (254). In 
addition, common variants in proprotein convertase subtilisin/kexin type 1 (PCSK1) gene, which 
harbours mutations that cause monogenic obesity, have been associated with common obesity in 
both adults and children (255) (Table 2.4). 
 
Table 2.4. List of genes in/near loci associated with growth phenotypes. 
 
Phenotype Nearest gene to the identified locus References 
Adult height Several hundred genes, e.g. HMGA2, HMGA1, 
HHIP, IHH, PTCH1, DOT1L, CDK6, LIN28B, 
NOG, BMP2, GDF5 (UQCC), LCORL, SF3B4, 
DLEU7, SOCS2, ACAN, ADAMTSL3 
(29) 
Adult BMI Dozens of genes, e.g. FTO, CTNNBL1, TMEM18, 
BCDIN3D, SEC16B, ETV5,  BDNF, KCTD15, 
NEGR1, GNPDA2, SH2B1, MTCH2, MAF, NPC1, 
PTER, PCSK1; both rare and common variants: 
LEP, LEPR, MC4R 
(31, 218) 
Size at birth CDKAL1, HHEX-IDE, GCK, TCF7L2 (additionally 
rare variants, e.g. IGF1, IGF2, IGF1R) 
(45, 229, 239-
242) 
Height growth (rare variants, e.g. IGF1, GH1, GHRHR) (211) 
BMI growth FTO, MC4R, TMEM18, GNPDA2, KCTD15, 
NEGR1, BDNF, ETV5, PCSK1 (additionally rare 
variants: LEP, LEPR, MC4R) 
(27, 255, 256) 
 75 
 
In the GWAS era, the most studied common genetic effect has been the association between the 
FTO locus (rs9939609 or rs1421085) and BMI, initially discovered in adults and children over 7 
years of age (2.3.1; (27)). The association has been studied at a number of different ages, mostly 
in a cross-sectional manner. However, some studies have additionally used appropriate methods 
for repeated measurements. Many of these studies have replicated the association between the 
FTO locus and BMI from 7 years of age, and demonstrated a strengthening of the association 
towards adulthood (257-259). The association has been shown to weaken after 20 years of age 
(260). 
 
Haworth et al. (2008) simultaneously examined FTO associations with BMI and the heritability of 
BMI in a longitudinal twin collection with data at ages 4, 7, 10 and 11 years (258). This work 
demonstrates a differential association with age and that the heritability of BMI increased with age 
whilst the proportion of variance in BMI explained by a shared environment diminished. 
Consistent with BMI and adiposity related traits being determined by a complex interplay between 
genetic and environmental features, this suggests that, with age and individual autonomy, loci 
such as FTO may be able to exert a greater effect on BMI through growth and development. In 
addition, a Finnish twin study suggested an increase in the heritability of BMI throughout 
adolescent years (261), giving further support for this idea.  
 
Despite the published work on longitudinal differences in the associations between the FTO locus 
and BMI or related traits, lack of dense measurement points and power in studies of early life and 
periods of interest such as adiposity rebound make their interpretation difficult. Furthermore, 
studies on the FTO association on BMI changes in infancy are scarce. One study suggested that 
the association might already emerge by two weeks of age (262). Another study covering the first 
6 years of life did not find any associations in infancy but reported a statistically significant 
association from age 4 years onwards (263). To better assess different aspects of the relationship 
between the FTO locus and changes in BMI throughout infancy and childhood, a well-powered 
meta-analysis of several longitudinal studies would be needed. 
 
Similarly, other established loci for adult BMI (e.g. MC4R) could be studied for associations with 
BMI growth from birth until adulthood. At least one study has already explored a combination of 
adult BMI loci in relation to BMI changes over childhood (256). This study formed an ―obesity-risk-
allele score‖ using SNPs identified through GWAS mostly in adults that were individually 
associated with BMI in children (FTO, MC4R, TMEM18, GNPDA2, NEGR1, KCTD15, BDNF and 
ETV5). The genetic risk score was found to be associated with weight gain in early infancy (0-6 
weeks) and with BMI gain from birth up to 11 years of age. The association between the risk 
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score and BMI standard deviation score (SD score) was much stronger in childhood (3.5 – 11 
years) than in infancy (birth – 18 months).  
 
Novel loci for BMI or its changes in infancy or childhood could be discovered through meta-
analyses of GWAS. Phenotypes that summarise BMI growth trajectories will have to be defined 
and estimated from multiple data sets for these analyses. 
 
2.3.5. Summary of genetics of growth 
 
Anthropometric phenotypes have a strong genetic component, based on estimates from twin 
studies. Large-scale meta-analyses of GWAS on adult height and BMI have resulted in the 
discovery of a multitude of common variants underlying these traits. These studies have informed 
genetic studies on child growth. However, GWAS on height and BMI are rare in children and 
GWAS on other, more complex growth phenotypes, e.g. growth velocities or age at AR, are yet to 
be performed. Genetic associations with growth phenotypes in children have mostly been based 
on the candidate gene approach, and these studies have typically failed to identify robust 
phenotypic associations with common variants. GWAS on growth phenotypes in large samples of 
children will soon become possible as several longitudinal birth cohorts are in the process of 
obtaining GWA data. These studies will shed light on the genetic background of growth at 
different stages from birth through to adulthood. 
 
2.4. Genetics of metabolic phenotypes 
 
This chapter gives an overview of the genetic background of phenotypes that constitute the 
definition of the metabolic syndrome: waist circumference (WC), HDL cholesterol, triglyceride, 
fasting plasma glucose (FPG), SBP and DBP. It is based on studies (mostly GWAS) in multiple 
populations, and excludes the work presented in the result section of this thesis. 
 
Clustering of adverse metabolic traits known as the metabolic syndrome (MetS) is strongly 
associated with a higher risk of T2D and CVD (264). There are several, slightly different 
definitions for the MetS (265), which apply to adult populations. Perhaps the most commonly 
used MetS definition is the one based on the National Cholesterol Education Program's (NCEP's) 
clinical guidelines (266) which were subsequently updated (267). The NCEP MetS criteria is met 
if a person exceeds a threshold in three of the five components which are characterised by 
abdominal obesity (a large WC), a low level of HDL cholesterol, and elevated levels of FPG, 
triglyceride and BP (see details in 5.3.2).  
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Metabolic phenotypes have a genetic component but heritability estimates vary considerably. A 
review (268) gives heritability estimate ranges of 40-55% for abdominal obesity, 10-75% for FPG, 
25-60% for triglyceride, 30-80% for HDL cholesterol, and 10-70% for BP. Since there is little 
evidence for a single underlying heritable factor leading to the MetS cluster (268), it may not be 
appropriate to estimate the heritability of MetS itself. Furthermore, heritabilities of binary traits can 
be difficult to estimate correctly (269). Some examples of heritability estimates for MetS exist (see 
e.g. (270)) but they are scarce. The genetic architecture of metabolic phenotypes has been 
studied by examining either individual continuous traits (e.g. blood pressure levels), individual 
binary traits (e.g. hypertension), or the MetS as a binary trait. Due to the correlation between 
different MetS components, pleiotropic genetic effects can be expected. The genes in/near loci 
reported to be robustly associated with each metabolic phenotype are summarised in Table 2.5. 
 
Table 2.5. List of genes in/near loci associated with metabolic phenotypes. 
 
Phenotype Nearest gene to the identified locus References 
Waist circumference FTO, MC4R, NRXN3, TFAP2B, MSRA (27, 271-274) 
HDL cholesterol CETP, LPL, LIPC, LIPG, APOA1-APOC3-APOA4-
APOA5, MMAB, MVK, ABCA1, GALNT2, FADS1-
FADS2-FADS3, LCAT, TTC39B, HNF4A, PLTP, 
ANGPTL4 
(70, 275, 276) 
Triglyceride APOA1-APOC3-APOA4-APOA5, LPL, GCKR, 
TRIB1, MLXIPL, APOB, NCAN, CILP2, PBX4, 
ANGPTL3, FADS1-FADS2-FADS3, PLTP, XKR6-
AMAC1L2 
(70, 275, 276) 
Fasting glucose ENPP1, GCK, GCKR, G6PC2, MTNR1B, ADCY5, 
FADS1, IGF1, MADD, ADRA2A, CRY2,  GLIS3, 
SLC2A2, PROX1, C2CD4B, DGKB-TMEM195, 
SLC30AB, TCF7L2 
(277-284) 
Systolic blood pressure ATP2B, SH2B3, CYP17A1, PLEKHA7, MTHFR, 
PLCD3 
(285, 286) 
Diastolic blood pressure ATP2B, SH2B3, ATP2B1, CACNB2, CSK-ULK3, 
TBX3-TBX5, ULK4, FGF5, C10orf107, CYP1A2, 
ZNF652 
(285, 286) 
 
2.4.1. Waist circumference (WC) 
 
Of the obesity related phenotypes, BMI is more widely studied than WC (see 2.3.1). WC 
measurement gives a better estimate of the central abdominal fat, and is therefore a better 
indicator of metabolic risk than BMI. These two phenotypes have a high correlation and therefore 
genetic factors contributing to them are expected to overlap substantially. It has been shown that 
the obesity-associated FTO gene has an association with WC, but only to the extent that can be 
explained by its effect on BMI (27, 271). Many GWAS have not yet focussed on the WC 
phenotype (70) but one study reports an association between a common variant near the obesity-
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associated gene MC4R and both WC and insulin resistance (272). A meta-analysis of several 
GWAS (273) on WC found a novel locus within the neurexin 3 (NRXN3) gene, which had earlier 
been implicated in addiction and reward behaviour. However, the WC-associated variant was 
also associated with BMI, and its association with WC was attenuated after adjustment for BMI. 
Lindgren et al. (2009) found two loci near transcription factor AP-2 beta (TFAP2B) and 
methionine sulfoxide reductase A (MSRA) to be associated with WC in a meta-analysis of 
multiple GWAS (274). The TFAP2B association was only nominally significant (p = 0.02) after 
adjustment of BMI and thus seems to influence central adiposity largely through its effect on 
overall obesity. Although the MSRA locus was only weakly associated with BMI, adjustment of 
WC analysis for BMI reduced the association to non-significant (p = 0.11) (274).  
 
2.4.2. Lipids: HDL cholesterol and triglyceride 
 
Genetic factors for serious metabolic disturbances such as Mendelian dyslipidemias have been 
discovered many decades ago in humans and in mice. These include rare variants in 
apolipoproteins (APO) and lipoprotein lipase (LPL) genes. Subsequent GWAS have identified 
common genetic variants in these genes that are associated with common lipid phenotypes. The 
GWAS on lipid phenotypes including HDL and triglycerides have recently been reviewed (70, 
275, 276) (Table 2.5). Dozens of variants have been implicated for HDL and triglyceride so far, 
and some of these, including SNPs in LPL and LIPC genes, are associated with both traits. 
 
2.4.3. Fasting glucose 
 
Fasting plasma glucose (FPG) levels are used as one of the criteria for diabetes diagnosis (287). 
Individuals with FPG ≥ 7.0 mmol/l are considered to be diabetic. The threshold for impaired 
fasting glucose (IFG) is ≥ 5.5 mmol/l, and this threshold is used in the revised NCEP MetS 
definition for elevated fasting glucose (267). Due to this close relationship between glucose levels 
and T2D, overlapping genetic effects are expected. 
 
Before the GWAS era, a few genes implicated in glucose metabolism had been identified. One of 
these was the transmembrane glycoprotein ectonucleotide pyrophospatase phospodiesterase 1 
(ENPP1) gene (277-279) with a reported gene-environment interaction, although evidence for the 
interaction was rather weak (p = 0.03) (288). An interesting pleiotropic effect of common 
polymorphisms in the glucokinase (GCK) gene on both glucose metabolism and birth weight was 
identified in several populations using the candidate gene approach (280, 281). These studies are 
two rare examples of candidate gene studies that have yielded reproducible associations. 
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Meta-analyses of GWAS in large samples have have identified common variants in several new 
genes, e.g. G6PC2 (282) and MTNR1B (283). In the most recent study in a sample of over 
120,000 participants (including replication samples) nine new loci for fasting glucose were 
discovered (284) (Table 2.5).  
 
The genetic effects on glycaemic traits suggest that the overlap between genes associated with 
variation in normal fasting glucose levels and genes associated with T2D risk may not be as large 
as expected (289). However, variants in or near MTNR1B, GCK, DGKB-TMEM195, GCKR, 
ADCY5, SLC30AB, and TCF7L2 displayed a genome-wide significant association with both 
((284) analysis of replication data sets). For T2D, the predominant mechanism based on current 
evidence seems to be through beta-cell dysfunction rather than insulin resistance (289). Some 
genes implicated in the normal variation of fasting glucose (e.g. GCK, GCKR, G6PC2 and 
MTNR1B) are likely to have a role in glucose homeostasis (289). Many of them, e.g. ADCY5, 
FADS1, IGF1, GCK, GCKR, and G6PC2, are involved in signal transduction, the last three also in 
glucose transport and sensing, and some (MTNR1B and CRY2) in cicardian rhythm regulation 
(284).  
 
Generally, variants associated with fasting glucose levels do not seem to have marked 
associations with other MetS phenotypes. As exceptions, and rather surprisingly, the FADS1 
glucose raising allele was associated with higher HDL cholesterol and lower triglyceride, and the 
TCF7L2 glucose raising allele was associated with lower BMI (p-value range: 1.9x10
-6 
– 4.4x10
-4
) 
(284). 
 
2.4.4. Blood pressure (BP) 
 
Rare mutations in several genes contribute to large changes in BP (290). Before the GWAS era, 
attempts were made to identify common BP and hypertension variants by way of linkage and 
candidate gene association studies. These studies did not yield convincing, reproduciple 
associations (291). The first GWAS on essential hypertension using WTCCC case-control data 
(26) did not produce reproduciple associations either (292, 293).  
 
BP is a relatively inaccurate phenotype compared to other MetS components. It is variable during 
the day and even within a single clinical appointment; therefore it is often measured more than 
once. Due to the high level of random error in the measurement (which is reflected in the 
variability of heritability estimates (10-70%) (268)), larger samples need to be studied to obtain 
the same statistical power to discover associated variants. Therefore, meta-analyses of GWAS 
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and exchange of potentially associated SNPs between several large consortia were required to 
discover common variants reliably associated with BP. Over ten loci were identified in these 
studies for BP (Table 2.5) (285, 286). Two of them (ATP2B and SH2B3) were associated with 
both SBP and DBP. The typical effect size of these associations was about 1 mmHg per allele for 
SBP and 0.5 mmHg per allele for DBP. The total variation in the phenotype explained by each 
variant was about 0.05-0.10% (286), and together they explained about 1% of the phenotype 
variation, after adjustment for nongenetic determinants of BP (285). With increasing sample 
sizes, many more variants with equal or smaller effects are expected to be uncovered.        
 
2.4.5. Summary of genetics of metabolic phenotypes 
 
Meta-analyses of GWAS on WC are scarce and only a few loci with associated common SNPs 
have been identified to date. Most of these associations seem to operate through an effect on 
overall obesity/fat-mass. The GWAS on lipid phenotypes have been far more successful, and 
dozens of partly overlapping common variants have been identified for HDL cholesterol and 
triglyceride. Over ten replicated loci for fasting glucose have been identified through meta-
analyses of GWAS. In addition, a pleiotropic effect in the glucokinase (GCK) gene on glucose and 
birth weight was identified through the candidate gene approach. Common variants in over ten 
loci were found to be associated with BP through collaborative efforts in several large consortia. 
Rather than studying each metabolic phenotype in isolation, methods are needed to analyse 
them in conjunction on a genome-wide scale, appropriately taking into account their phenotypic 
interdepencencies. 
 
2.5. Developmental Origins of Health and Disease (DOHaD) 
 
This chapter explores possible mechanisms underlying the association between poor foetal 
growth and higher risk of adult disease and current evidence for these mechanisms. The 
availability of genome-wide data rich in phenotypic information will facilitate the examination of 
the plausibility of these mechanisms in conjunction with each other. 
 
The association between small size at birth and higher risk of adult disease, such as T2D and 
CVD, is well established (294). The foetal origins of adult disease hypothesis was first introduced 
by Barker (44) and in 1995 the British Medical Journal named it the ―Barker hypothesis‖ (295). It 
was later named Developmental Origins of Health and Disease (DOHaD) hypothesis (296) 
(Figure 2.5.). It can be placed within a wider framework of life course approaches to chronic 
disease epidemiology. In this framework, the DOHaD hypothesis has a close relationship with the 
critical period model that includes later life effect modifiers (297). 
 81 
 
2.5.1. Hypotheses explaining inverse association between birth size and adult disease 
 
There are two main hypotheses that have been put forward to explain the observed inverse 
association between small size at birth and adult disease: 1) foetal programming i.e. the thrifty 
phenotype hypothesis and 2) genetic susceptibility hypothesis, which proposes pleiotropic genetic 
effects for foetal and adult phenotypes (45). The idea of programming induced by foetal 
undernutrition was originally implied as an explanation behind the statistical associations between 
small size at birth and adult disease (44) and it is often included in the definition of the Barker or 
DOHaD hypothesis. The foetal programming hypothesis emphasises the environmental and the 
foetal insulin hypothesis the genetic influences behind the association between foetal growth and 
adult disease. The environmental effects may include maternal undernutrition and other maternal 
or placental abnormalities leading to foetal undernutrition, hormonal effects such as increased 
administration of natural glucocorticoids from the mother to the foetus during stress, and/or 
accelerated postnatal growth followed by restricted foetal growth. The foetal programming 
hypothesis proposes that the adaptive response of the foetus to the in utero environment at 
‗critical periods‘ of development leads to permanent changes in its body structure, physiology and 
metabolism (44). As an alternative mechanism, it has been suggested that pleiotropy may explain 
at least part of the association between the foetal and adult phenotype. In particular, the foetal 
insulin hypothesis proposes an insulin-resistant genotype which leads to both smaller size at birth 
and to an insulin-resistant phenotype in adulthood, increasing the risk of T2D and related 
diseases (45).  
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Figure 2.5. Developmental Origins of Health and Disease (DOHaD) hypothesis. Adapted 
from Ozanne & Constancia (2007) (298). 
 
2.5.2. Foetal undernutrition 
 
The hypothesis of foetal programming due to undernutrition postulates that the adverse 
conditions in the intrauterine environment cause the foetus to optimise the use of energy to 
guarantee its survival. This kind of adaptation, allowed by developmental plasticity (299), has 
short-term benefits (survival of the foetus) but detrimental permanent effects to the growth and 
function of the tissues, which later increase the risk of T2D and CVD (46, 300). However, 
maternal undernutrition is not common in Western societies (301) where most of the research on 
this topic has been done. In these countries, the function of placenta plays a more important role. 
However, the associations between absolute or relative measures of placental weight and T2D 
and CVD have been inconsistent (46). Pre-eclampsia as an extreme form of placental dysfunction 
seems to be associated to CVD in the mothers and a higher blood pressure in the offspring; 
however, the potential role of genetic factors in this association is unclear. In their review, Jaddoe 
and Witteman (46) conclude that there is no strong evidence for the foetal programming 
hypothesis by foetal undernutrition from the existing studies. 
  
2.5.3. Maternal stress and glucocorticoids 
 
An increasing problem among pregnant women especially in the Western socities is social stress 
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due to career demands, financial uncertainty and a low level of support from family (301). 
Glucocorticoids belong to steroid hormones and the most important one of them in humans is 
cortisol. Stress during pregnancy causes plasma glucocorticoid levels to rise in the mother. It is 
also known that administration of glucocorticoids during pregnancy leads to lower birth weight of 
the baby. The babies with decreased birth weight have increased cortisol levels throughout life, 
which may be explained by the programming of the function of the hypothalamic-pituitary adrenal 
axis (HPA), which is sensitive to glucocorticoids (302). In particular, placental 11β-hydroxysteroid 
dehydrogenase type 2 (11βHSD2) enzyme inhibits glucocorticoids by converting maternal cortisol 
to inactive cortisone. Reduced placental 11βHSD2 is associated with both lower birth weight and 
higher blood pressure in later life in the offspring (303). Studies in knockout mice support these 
findings (304). It has been suggested that the molecular mechanism that underlies the 
programming may include epigenetic changes which could be passed on to subsequent 
generations without further exposure (303). 
 
2.5.4. Epigenetic modifications  
 
In the recent years, increasing amount of research has focused on the role of epigenetics in 
DOHaD (47, 298). Epigenetic modifications, including DNA methylation and histone 
modifications, regulate gene activity without affecting the DNA sequence. For example, in 
mammals, parent of origin effects on gene expression and X-chromosome inactivation in females 
can be observed. The early foetal period after conception has been identified as a critical window 
for the establishment of DNA methylation patterns, and at a later stage, tissue-specific patterns of 
epigenetic modifications have been shown in organisms (47). There is an increasing body of 
evidence, mainly from animal models, suggesting that epigenetic changes due to early 
environmental factors have an important role in later disease susceptibility (see reviews of these 
studies in Ozanne and Constancia (2007) (298) and Gluckman et al. (2009) (47)). Imprinted 
genes, whose effect on gene expression is parent-specific, provide good candidates for the 
search for genes involved in developmental programming through epigenetic modifications. Some 
evidence already suggests the involvement of imprinted genes in growth and metabolism (298). 
  
2.5.5. Growth acceleration 
 
The growth acceleration hypothesis postulates that the foetal growth restriction relative to genetic 
growth potential could result in postnatal growth acceleration which is responsible for the higher 
risk of adult disease in later life (305). Since low birth-weight babies tend to have a relatively high 
postnatal growth rate, it can be difficult to separate the effects of foetal and postnatal growth on 
adult disease. To disentangle these effects, dense growth measurements throughout the 
 84 
postnatal life are needed, as well as complex statistical models which take into account the 
dependency between consecutive growth measurements in each individual (46). To date, there is 
evidence from numerous studies that not only small size at birth but also fast early postnatal 
growth is associated with later disease risk, such as an increased blood pressure and the 
metabolic syndrome (306, 307).  
 
2.5.6. Genetic susceptibility  
 
The foetal undernutrition, glucocorticoid and growth acceleration hypotheses all imply foetal or 
postnatal programming. The genetic susceptibility hypothesis has recently gained some support 
as an alternative hypothesis for the mechanism underlying the association between birth size and 
adult disease. The foetal insulin hypothesis, which specifically postulates a genotype producing 
small, thin babies and insulin-resistant adults, relies on the importance of foetal insulin secretion 
as a key factor in foetal growth particularly in the third trimester of pregnancy (45). The evidence 
for this hypothesis at the time it was presented came from studies on rare monogenic variants 
that were associated with both low birth weight and altered insulin secretion or resistance later in 
life. It remained to be seen if the same principle would work for more common, polygenic genetic 
factors and explain the association between birth size and abnormal insulin secretion/resistance 
in general population. Twin studies examining this hypothesis have overall been inconclusive and 
population-based genetic association studies conducted before the genome-wide era have 
produced conflicting results (46). However, recent studies have indicated that at least part of the 
association between low birth weight and T2D in particular may be explained by common genetic 
effects (239, 242). 
 
2.5.7. Synthesis and future research 
 
It is still unclear which of the mechanisms has the best explanatory power for the association 
between birth size and adult disease. It is likely that none of them is adequate in itself but several 
mechanisms operate simultaneously (45). The role of different mechanisms may vary between 
the adult disease phenotype studied. For example, it seems that the role of genetic factors in the 
association between birth weight and T2D is substantial, but so far the evidence for genetic 
influences in the association e.g. between birth weight and hypertension is scarce (294) (although 
this may partly be due to phenotype inaccuracy). Therefore, further studies on these mechanisms 
are warranted. It is important to design epidemiological studies in a way that allows the 
examination of these mechanisms in conjunction with each other. The ideal study design seems 
to be a prospective, population-based cohort study on a large number of subjects with a follow-up 
from pregnancy until adulthood (46). This requires a considerable commitment of time and money 
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in the form of genotyping and phenotyping efforts over the life-course. Recent research has 
proved the value of this study design, as well as the value of meta-analysis of several prospective 
cohorts, since a single cohort study can rarely reach conclusive evidence especially when genetic 
effects are studied on a genome-wide scale in conjunction with environmental effects. 
 
2.6. Candidate gene association studies in the Northern Finland Birth Cohort 1966 
 
This chapter gives a historical overview of genetic association studies carried out in the Northern 
Finland Birth Cohort 1966 (NFBC1966) before genome-wide data for this cohort became 
available in April 2008. These studies used the candidate gene approach. Variants were 
genotyped from a candidate gene selected on a biological basis (e.g. INS-VNTR, PPARG) or 
from a “statistical” candidate gene identified in a GWAS in another population (e.g. FTO) for the 
same trait (replication) or another, related trait (study of pleiotropic effects). The first genetic 
studies in the NFBC1966 were performed after blood sample collection in the clinical examination 
in 1997 (chapter 4). Studies described in this chapter that concern growth, adult metabolic 
phenotypes and hormonal disturbances include my personal contribution before or during the first 
18 months of my PhD project (see the list of papers at the beginning of this thesis). Studies at 
later stages of the PhD project are included in the result section (chapter 6) of this thesis. I have 
not been personally involved in the genetic studies on temperament and psychiatric disease.  
 
2.6.1. Temperament and psychiatric disease 
 
The first two biological candidate gene studies concentrated on the behaviour stemming from 
temperament and psychiatric disease. Type 4 dopamine receptor gene (DRD4) was found to be 
associated with the novelty seeking temperament trait so that the 2- and 5-repeat alleles were 
more common in those with extremely high novelty seeking scores compared to those with 
extremely low scores (308). This statistically significant (p = 0.007) result was based on a sample 
of 190 cohort members which at the time was considered large. An association between COMT 
polymorphism and suicidal behaviour in patients with schizophrenia was detected (309). The 
COMT L allele was associated with history of violent suicide attempts in N=94 Finnish and N=54 
US subjects. The association was statistically significant in men but not in women. 
 
2.6.2. Early growth, adult metabolic phenotypes and hormonal disturbances 
 
The majority of candidate gene studies in the NFBC1966 have focussed on the associations with 
early growth, adult metabolic phenotypes and hormonal disturbances such as polycystic ovarian 
syndrome (PCOS) symptoms and androgen levels (testosterone and free androgen index). 
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Candidate genes for these studies were selected based on biological clues and the variants were 
selected based on initial positive findings in small study samples which needed to be replicated in 
a larger sample.  
 
INS-VNTR 
 
The whole sample of NFBC1966 members who had DNA extracted (N=5646) was used to 
examine association between insulin gene variable number tandem repeat (INS-VNTR) and early 
growth (birth weight, birth length, ponderal index at birth, placental weight and head 
circumference at 1 year of age), but no convincing evidence of any association was found (230). 
Using the same sample, this polymorphism did not show associations with adult metabolic 
phenotypes (body mass index (BMI), waist-to-hip ratio (WHR), blood pressure, blood lipids, 
fasting insulin and glucose) either (310). INS-VNTR was further studied in relation to PCOS and 
testosterone levels in the sample of NFBC1966 females (N=1599) but no associations were 
found in this cohort or any other samples included in the study (311). 
 
CYP11A promoter variation 
 
A biological candidate for PCOS, CYP11A, was studied in relation to PCOS and androgen levels 
(312). The associations found in smaller samples were not confirmed in the NFBC1966 females 
(N=527 symptomatic cases and 1062 controls).  
 
PPARG and Kir6.2/KCNJ11 
 
Two variants known to be related to T2D, PPARG variant P12A (N=5332) and Kir6.2/KCNJ11 
variant E23K (N=5180), did not show associations with any early growth variables or adult 
anthropometric or metabolic variables in the NFBC1966 (236, 313). There was no evidence for 
associations between E23K and PCOS symptoms or androgen levels (N=550 symptomatic and 
1114 non-symptomatic NFBC1966 females). The UK sample included in the same study did not 
show any associations either (314). These studies provide evidence against shared genetic 
determinants of T2D and the growth and metabolic/hormonal traits studied. 
 
-238 and -308G/A TNF 
 
Well-studied -238 and -308G/A tumor necrosis factor (TNF) promoter variants (N=5433 and 5374, 
respectively) did not show any associations with early growth variables or adult metabolic 
phenotypes. They also failed to show consistent associations with metabolic phenotypes. There 
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was one nominally significant association for -238G/A variant (systolic blood pressure, SBP) and 
three for -308G/A variant (total cholesterol, HDL and glucose in males) in fully adjusted dominant 
models but these are probably spurious findings (315). 
 
Glucokinase -30 G/A variant 
 
No significant associations were observed for measures of early growth. Fasting glucose at age 
31 years was significantly associated with an increasing number of copies of the minor A allele (p 
= 0.003, adjusted additive model). When the individuals with fasting glucose levels >6mmol/l were 
excluded, the per-allele increase in glucose remained significant (p = 0.001). HOMA%B showed 
non-significant reductions with increasing copies of the A allele (p = 0.066). In conclusion, 
variation in the glucokinase promoter modifies adult fasting glucose levels, but associations with 
early growth measures such as birth weight remain unconfirmed. 
 
Variants of TCF7L2 
 
An established T2D gene, transcription factor 7-like 2 (TCF7L2), was not associated with PCOS 
or androgen levels in the symptomatic (N=540) and non-symptomatic (N=1083) NFBC1966 
females (316). Two variants of TCF7L2, rs7903146 and rs12255372, were studied. No 
associations were found either in the UK case/control data included in the same study. This study 
was powered to detect associations between the variants and PCOS and therefore provides 
evidence that T2D and PCOS have a distinct genetic architecture. 
 
Stearoyl-CoA desaturase (SCD) M224L variant 
 
The enzyme Stearoyl-CoA desaturase (SCD), hypothesised to be related to insulin sensitivity 
based on animal experiments, was found to be associated with BMI and HDL cholesterol in the 
Oxford Biobank sample. The same M224L variant was genotyped in the NFBC1966 (N=5262) but 
only few nominally significant associations with metabolic traits were observed (317). 
 
Mitochondrial position 16189  
 
There is evidence for rare mitochondrial mutations impairing glucose homeostasis and small 
studies have suggested contribution of common DNA variation at mt16189 in metabolic 
phenotypes. However, no significant (p < 0.01) associations between this variation and early 
growth or adult metabolic phenotypes were found in the NFBC1966 (N=5470; (318)). 
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As a whole, the aforementioned studies based on biological clues were not able to replicate some 
initial positive findings in smaller samples. Small candidate gene studies are known to be prone to 
produce spurious results and publication bias has aggravated the problem of assessing true 
associations in the past. The candidate gene studies in the NFBC1966 have generally been well-
powered to detect genetic main effects, although small effects could have been missed in these 
studies. The lack of replication may reflect the complexity of the genetic, environmental and 
lifestyle contributions in common disease traits. 
 
FTO gene 
 
A previously unsuspected variant (rs9939609) in the FTO gene which was detected by a GWAS 
in the Wellcome Trust Case Control Consortium study (26) in relation to T2D and BMI, showed a 
highly significant association with BMI in the NFBC1966 singletons at 31 years (N=4435, p = 
5x10
-5
) (27) and nominally significant association at age 14 years (N=4203, p = 0.04) (319). The 
associations with weight (N=4435, p = 2x10
-5
) and waist circumference (N=4425, p = 4x10
-5
) at 
age 31 years were highly significant but there was no association with height (N=4588, p = 0.32). 
The FTO variant was not associated with birth weight (N=4320, p = 0.42) or ponderal index at 
birth (N=4292, p = 0.14). The association with BMI at age 31 years translates into per allele 
OR=1.18 for overweight (BMI ≥ 25kg/m
2
) and OR=1.36 for obesity (BMI ≥ 30kg/m
2
). The 
association reflects specific increase in fat mass and has been observed from age 7 years 
upward in the other samples included in the study (27, 320).  
 
The FTO variant was studied in relation to growth measures at 6 and 12 months in the 
NFBC1966 (N=3849) but no associations were found (319). Results from the ALSPAC cohort 
included in the same study suggests that acceleration in weight gain attributed to this variant is 
likely to start between ages 4 and 7 years. In the NFBC1966, the timing of the start of the FTO 
effect will be studied more carefully in this thesis, as dense data on weight and height during 
childhood become available.  
 
In addition, the association between the FTO variant and other metabolic traits at age 31 years 
was studied in NFBC1966 singletons (N=4593), with and without adjustment for possible 
confounding factors (321). The variant was weakly associated with triglyceride and HDL 
cholesterol levels and this could be attributed to the between-genotype differences in BMI 
(correlation between phenotypes studied was accounted for). No association with fasting glucose 
was found. 
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The possible association between FTO variant and androgen levels was studied in 1000 
NFBC1966 females who did not have PCOS symptoms at age 31 years (322). No associations 
were found in this population or in the confirmed UK PCOS cases (N=324 with androgen 
measures available) included in the same study. In the UK population (N=463 cases and 1336 
controls), FTO was associated with PCOS but only when the analysis was not adjusted for BMI. 
Thus, the PCOS effect is probably mediated through the effects of FTO on adiposity. 
 
2.6.3. Summary of findings from genetic association studies in the NFBC1966 
 
In general, candidate gene studies in the NFBC1966 that were based on biological evidence and 
initial discoveries in small populations failed to replicate the genetic associations. This casts 
doubt on the associations originally discovered in much smaller data sets prior to larger studies 
such as the NFBC1966.  
 
On the other hand, a strong genetic association between FTO and adult BMI identified in a well-
powered GWAS was replicated in the NFBC1966. According to the initial explorations, no FTO-
BMI effect is seen during the first year of life in this cohort. Further work in this thesis will explore 
BMI growth throughout childhood and attempt to pinpoint the age when the FTO-BMI effect 
appears. FTO did not influence other metabolic traits (lipid or glucose levels) independently of 
BMI in the NFBC1966.  
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3. Scope and aims of the thesis 
 
If you don't know where you are going, you will probably end up somewhere else. 
—Laurence J. Peter 
 
After a series of initial successes in 2007, researchers are still discovering genetic factors of 
complex diseases and traits through genome-wide association (GWA) studies. Many current 
GWA studies lack longitudinal phenotypic information, which would enable the study of 
trajectories of phenotypic changes, not only the disease endpoints or phenotype levels at certain 
ages. Repeated measurements over time would make the study of interactions of genetic effects 
with age possible, illuminating the role of different or overlapping genetic influences at different 
ages or stages of development. Results from these studies might help in showing which biological 
pathways are important at certain ages. Therefore prospective population-based studies with 
longitudinal phenotype data are extremely valuable for GWA research. Diverse phenotypic 
information collected in the Northern Finland Birth Cohort 1966 (NFBC1966), including repeated 
early growth measurements, combined with genotype data, give an excellent opportunity to study 
the genetic background of complex traits. Collaboration with other studies is essential to ensure 
adequate statistical power to identify associations. This study focuses on growth phenotypes -  
birth size, peak height velocities (PHV) at sensitive ages of development (infancy and puberty), 
and the timing of adiposity rebound (AR) in childhood - and anthropometric and metabolic 
phenotypes (height, BMI, waist circumference, blood pressure, lipid and glucose measurements) 
in adulthood, which are influenced by growth and are also associated with later CVD risk. 
 
The first aim of this study is to describe and evaluate the analytic strategy and methods for 
genetic association analysis in population-based longitudinal studies through a literature review. 
In addition, growth modelling methods are reviewed, together with existing studies on the 
genetics of growth and metabolic outcomes and potential factors underlying the relationship 
between the two. 
 
Secondly, analyses on maternal and environmental determinants of early growth and analyses on 
the association between early growth and metabolic phenotypes in adulthood are described 
(Figure 3.1). Thirdly, genetic association analyses on early growth and later anthropometric and 
metabolic phenotypes are presented, ranging from candidate gene association analyses in a 
single study to meta-analyses of GWA studies. The aim is to explore possible mechanisms 
underlying the association between restricted foetal growth and adult phenotypes and disease 
risk, motivated by the Developmental Origins of Health and Disease (DOHaD) hypothesis. In 
particular, the design of this study is well suited for exploring the hypothesis that common genetic 
effects explain at least part of the association between the foetal, early growth and adult 
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phenotypes. However, to study disease endpoints such as T2D and CVD that are rare in young 
adults, supplementation by case-control studies in middle-aged or older populations would be 
needed. 
 
 
Figure 3.1. Outline of associations studied in this thesis. 
 
A selection of SNPs was genotyped for N=5,753 NFBC1966 members who gave a blood sample 
and an informed consent at age 31 years. GWA data were obtained for N=4,763 NFBC1966 
members using Illumina‘s HumanCNV370-Duo DNA Analysis BeadChip. These data were linked 
with the extensive phenotype data for the NFBC1966. The cohort was followed up with clinical 
examinations and questionnaires at birth and ages 1, 14 and 31 years. In addition, frequent 
height and weight measurements from childhood are available. The main outcomes of this study 
are growth: height, weight, body mass index (BMI) and derived phenotypes such as PHV in 
infancy and in puberty and timing of AR, and anthropometric and metabolic phenotypes at age 31 
years. To improve statistical power, other studies with adequately similar data are included in the 
GWA analyses by way of collaboration and large-scale meta-analysis. The main study questions 
are:  
 
1. What are the genetic factors associated with adult anthropometric and metabolic 
phenotypes? 
 
2. How do genetic variants identified for adult anthropometric and metabolic phenotypes 
influence growth throughout childhood? In particular, 
a. How do genetic factors of adult height influence height growth throughout 
childhood?  
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b. At what age does the FTO-BMI effect start emerging and how is this related to 
the timing of adiposity rebound? 
 
3. What are the genetic factors associated with size at birth and gestational age? 
 
4. What are the genetic determinants of longitudinal growth (height, weight, BMI growth) 
and derived phenotypes such as peak growth velocities, timing of infant adiposity peak 
(AP) and AR in childhood? 
 
5. What are the maternal and environmental determinants of early growth velocities? 
 
6. What is the association between the derived growth phenotypes and later anthropometric 
and metabolic phenotypes? 
 
7. Can overlapping or pleiotropic effects on growth measures and adult anthropometric or 
metabolic phenotypes be identified? How do these effects modify the association 
between growth and adult anthropometric and metabolic phenotypes? 
 
One way to start answering the questions on genetic factors of longitudinal growth is to fit 
biologically motivated growth curves to longitudinal growth measurement data, and to derive 
interpretable and biologically meaningful growth parameters (e.g. PHV and timing of AR) from 
these data. These parameters can then be used as outcomes in genetic association analyses. 
Results from these analyses are synthesised, interpreted and discussed in a wider context. In 
addition, future challenges in the field of genetic epidemiological studies, in particular in the 
DOHaD field, are discussed.  
 
There are restrictions to the scope of this thesis due to research priorities, data availability, 
choices based on literature, and space and time limits. Analyses using non-biologically motivated 
models for longitudinal growth analyses are not included in subsequent chapters of this thesis, 
since a priority was given to biologically motivated models due to their easier interpretability. The 
type of genetic variation examined in this thesis is common SNP data (MAF ≥ 0.01) since this 
type of data were available. Although a set of CNVs were included in the same chip, SNPs were 
considered a priority. Single marker methods and general or additive genetic models are applied 
due to requirements for simplicity, especially in a meta-analysis setting. Other alternative 
approaches such as Mendelian randomisation (2.1.4) are beyond the scope of this thesis. 
Sophisticated methods that aim to improve accuracy and reduce bias, such as correction for 
cryptic relatedness (2.1.5 and 2.1.9), are omitted due to time constraints. 
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4. Study material 
 
This chapter introduces the primary study population of this thesis, the Northern Finland Birth 
Cohort 1966 (NFBC1966). The inhabitation of Northern Finland is outlined (4.1), and the initial 
data collection and subsequent follow-ups of the NFBC1966 are described (4.2). Other data sets 
included in the meta-analyses presented in this thesis are only described in the related articles 
(4.3).  
 
4.1. Population background of the study subjects 
 
The study population of this thesis comprises individuals born in Northern Finland in 1966. The 
demographic history of Finland is characterised by immigration of a small number of founders, 
isolation, and population bottlenecks followed by rapid expansion of the population (82). Based 
on studies on the Y chromosome haplotype variation, the two main immigration waves occurred 
about 4,000 and 2,000 years ago (323). Before the 16
th
 century, only the coastal regions in the 
south and west of the country were inhabited. This is called the early settlement. Internal 
migration from South Savo in southeastern Finland to the interior of the country started in the 16
th
 
century by the order of the Swedish King Gustavus Vasa. This resulted in regional subisolates in 
the north and east of the country (82). This is called the late settlement. The study population of 
this thesis includes contemporary inhabitants born in both regions: early settlement (coastal 
region of Northern Finland from Ylivieska to Tornio) and late settlement (the non-coastal areas of 
Northern Finland). However, due to high internal migration rate around the time the study 
subjects were born, the birth location of their parents better reflects the population group of origin 
than their own birth location does. Currently there are six population groups inhabiting different 
areas of Northern Finland that are distinguishable based on historical information and spoken 
dialects: South Oulu, North Oulu and West Lapland arising from the early settlement, and Kainuu, 
Central Lapland and East Lapland arising from the late settlement (324). Recent studies utilising 
GWA data have confirmed population substructures within Finland (87, 88) that reflect the 
country‘s demographic history. As noted earlier, the study of this kind of data poses challenges 
but also unique opportunities in the field of genetic research.    
 
4.2. Data collection in the Northern Finland Birth Cohort 1966 (NFBC1966) 
 
4.2.1. Pregnancy and birth 
 
Women living in Finland‘s two northernmost provinces, Oulu and Lapland, with expected 
deliveries in 1966 (n=12,055) were recruited through maternity health centres. About 80% of the 
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women had their first visit by the 16
th
 gestational week. Questionnaires were administered 
between the 24
th
 and 28
th
 gestational weeks and the course of the pregnancies and data at birth 
were obtained from maternity records and transferred by midwives onto study forms. These 
pregnancies resulted in 12,068 births (13 women delivered twice). All live born (n=12,058) and 
stillborn (n=173) infants weighing 600 grams or more were included in the Northern Finland Birth 
Cohort 1966 (NFBC1966; total n=12,231 including 326 twins (325)). This unselected sample 
represents 96.3% of all births in the area. Nearly all of the cohort members are Finns (white 
Caucasians) and less than 1% of them are Gypsies and Lapps. Variables that will be considered 
in the analyses as confounders or intermediate phenotypes include maternal socio-economic 
status, age, smoking during pregnancy, pre-pregnancy height and weight, parity, gestational age, 
placental weight, child‘s sex, birth weight and birth length. The cohort has been followed up since 
pregnancy with clinical examinations and questionnaires covering health, lifestyle and socio-
economic indicators at 0, 1, 14 and 31 years of age. In addition, frequent height and weight 
measurements from childhood are available.  
 
4.2.2. Weight and height measurements in childhood and adolescence 
 
On average, 22 height and weight measurements per person were obtained from 0 years until 
adulthood (most observations between 0-16 years). At first instance the data were retrieved for 
those who had DNA extracted at age 31 years (maximum N=5,753). These were collected from 
original health clinic records. One quarter of the records requested had gone missing over the 
years or could not be obtained for other reasons. The final number of records amounted to 
N=4,311. The measurement times vary individually across the data. Individual growth curves will 
be fitted to these data and growth parameters derived from these models will be used as 
phenotypes in the genetic association analyses. 
 
4.2.3. Follow-up at age 31 years and genetic data 
 
The follow-up at 31 years in 1997 consisted of a postal questionnaire on health, lifestyle and 
socio-economic status to all alive and traced (n=11,541) and a clinical examination to those still 
living in Northern Finland and those who had moved into the capital area (n=8,463). The 
response rates were 75% (n=8,690) and 71% (n=6,007), respectively. The anthropometric and 
metabolic phenotypes investigated in detail in this thesis include height, BMI, WC, HDL 
cholesterol, triglyceride, glucose, SBP and DBP. BMI was calculated from weight and height 
measurements and WC was measured at a level midway between the lowest rib margin and the 
iliac crest. SBP and DBP were taken by trained nurses using a standard mercury 
sphygmomanometer after 15 minutes rest (326). Blood samples were drawn after overnight 
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fasting. Samples were stored
 
at –70ºC until analysed. Enzymatic assays of fasting
 
serum glucose, 
total cholesterol, HDL cholesterol and triglycerides were measured using
 
Hitachi 911 Clinical 
Chemistry Analyzer and commercial reagents (Boehringer
 
Mannheim, Germany) in the accredited 
laboratory of Oulu University
 
Hospital. These figures are restricted to those who also gave an 
informed consent allowing the use of their data within the Faculty of Medicine in the University of 
Oulu. The University of Oulu Ethics Committee approved the study. 
 
NFBC1966 members who gave a blood sample and an informed consent at 31 years and for 
whom DNA was extracted successfully (N=5,753) were eligible for genotyping. Illumina‘s 
HumanCNV370-Duo DNA Analysis BeadChip was used to obtain genome-wide data. It contains 
an informative set of tag SNPs derived from the HapMap European-derived (CEU) sample (10). 
In addition to over 318,000 SNPs on the HumanHap300-Duo Genotyping BeadChip, about 
52,000 markers to target approximately 14,000 copy number variant (CNV) regions are included, 
which gives a total of over 370K markers.  
 
Due to high genotyping costs in 2006, the original plan was to follow a two-stage case-cohort 
design and genotype a sample of 500 individuals (250 females and 250 males) representing the 
lowest and highest plasma triglyceride levels at age 31 years and 1500 randomly selected cohort 
members. It was then planned to select the most promising SNPs based on p-value and 
biological credibility to be genotyped in the remainder of the cohort. However, due to a reduction 
in genotyping costs in 2007, a decision was made to genotype the whole cohort for all the 
markers on the chip. The data were obtained in three stages. The first batch obtained at the end 
of November 2007 contained data for 1,842 cohort members and was used as a pilot study. The 
extremes of the triglyceride distribution were overrepresented in the pilot data. It was used mainly 
for quality control and training purposes, so that the analysts would be well-equipped and ready 
for analysis at the arrival of the rest of the data. A nearly final release of the data (N=4,763 after 
sample exclusions) was obtained in April 2008 and the analyses in this thesis are based on these 
data. The quality control and imputation of this release are described in chapter 5.4. The final 
data (N=5,402) were released at the end of 2009 and imputation was not yet done by the time 
analyses were finalised for this thesis. In addition, several SNPs were separately genotyped for 
candidate gene studies and for replication purposes using TaqMan® SNP genotyping assay 
(Applied Biosystems, Warrington, UK) according to the manufacturer‘s protocol. 
 
Anthropometric and metabolic phenotypes obtained at the clinical examination such as height, 
BMI, blood pressure and lipid and glucose measurements will be used as outcomes in the genetic 
association analyses and in the investigation between early growth and adult phenotypes. 
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4.3. Additional data included in comparative and meta-analyses 
 
Since the statistical power especially for GWA analyses in the NFBC1966 is limited, many 
analyses presented in this thesis have been performed as part of large consortia involving other 
data sets. Furthermore, comparisons of phenotype distributions and associations have been done 
with a younger cohort from the same area, the Northern Finland Birth Cohort 1985-1986 
(NFBC1986) (228). The NFBC1986 has also been used as a replication data set for genetic 
associations identified through GWAS, since it has a rich set of phenotypes and DNA available, 
although not genotyped genome-wide. The NFBC1986 or other data sets included in the meta-
analyses are not described in detail in this thesis. The description of these data sets can be found 
in the published papers listed at the beginning of this thesis. 
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5. Methods 
 
The methods for this thesis were selected keeping in mind the aim to perform a genome-wide 
analysis while accounting for the longitudinal nature of phenotype data. After conducting a very 
simple descriptive analysis (5.1), growth models were fitted to longitudinal growth data to obtain 
derived summary variables (5.2) which characterise important aspects of growth and can be used 
in subsequent analyses in a straightforward way. Methods for analysing associations between 
these derived growth parameters and other phenotypes (5.3) and candidate variants (5.5) are 
described. Additionally, preparation of genome-wide data (5.4) and methods used in GWAS and 
their meta-analyses (5.6) are outlined. 
 
5.1. Methods used in descriptive analysis of growth data 
 
To describe height, weight and BMI growth over time, data were initially split into pre-defined age 
intervals around ages 0 months, 6 months, 1 year and each subsequent year up to age 18 years. 
Since the body size changes faster in early childhood than later childhood, the age intervals were 
chosen to be narrow in infancy and gradually wider in childhood and adolescence. If a person had 
more than one measurement within the interval, only the earliest measurement in the data was 
included. Means and standard deviations (SD) of height, weight and BMI were calculated at each 
age interval. Additionally, adult measures at around age 31 years were calculated based on the 
clinical examination (or postal questionnaire if missing). Since males have a bigger body size 
than females at most ages, and growth velocities differ particularly during the years of puberty, 
the analysis was stratified by sex. In addition, differences between sexes at each age interval 
were examined by t-test. The analysis was restricted to singletons because multiple births are 
known to be related to smaller birth size and later growth velocities. The growth data were 
cleaned of impossible height and weight values at the project centre of Oulu before distribution to 
analysts. BMI outliers were checked subsequently by Ms. Marika Kaakinen in Oulu and myself in 
London. Additionally, measures indicating downward growth in height were removed from height 
analyses. Observations which did not fall into the pre-defined age intervals were omitted from the 
descriptive analyses. 
 
5.2. Growth modelling: application of parametric methods 
 
This chapter describes the process of model selection and model fitting for height, weight and 
BMI growth at different age periods from birth to adulthood in the NFBC1966. Some of the work 
described at the beginning of this chapter (5.2.1. and 5.2.2.) has been published previously in 
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Sovio et al. (2009) (327), and a manuscript of the latter part (5.2.3.) has been accepted for 
publication (Sovio* et al. PLoS Genet 2011 (in press)). 
  
5.2.1. Models for infant height and weight growth 
 
The five different growth models described in the article by Simondon et al. (1992) (197) and in 
the literature review (2.2.4.) were compared in terms of residual standard deviation (RSD) and 
Akaike Information Criterion (AIC) by fitting them to height growth data at 0-24 months in the 
NFBC1966. The models include the three-parameter Count, Karlberg and Kouchi models, the 
four-parameter Reed1 model, and the five-parameter Reed2 model. 
 
Growth curves were fitted separately for singleton males and females using nonlinear mixed 
effects models. All measurements taken at 0-24 months of age, including birth length, were 
included. Both fixed and random components were assumed for all parameters in the model. 
Estimates from Simondon et al. (197) were used as starting values for the model parameters in 
the NFBC1966 males, and the estimated parameter values in the NFBC1966 males were in turn 
used as starting values for the model parameters in the NFBC1966 females. The best-fitting 
curves for each individual were estimated by the maximum likelihood method. The nlme function 
in R program (version 2.4.1) was used to fit the models. It applies the nonlinear mixed effects 
model formulation and computational methods described in Lindstrom and Bates (192). 
 
Of the three-parameter models, the Count model had the smallest RSD and AIC and therefore 
the best fit for height growth at 0-24 months of age. However, the four-parameter Reed1 model 
showed a better fit than any of the three-parameter models in both genders in the NFBC1966, 
and a nearly equally good fit as the five-parameter Reed2 model (Table 5.1.).  
 
Table 5.1. Comparison of different parametric growth models for height growth at 0-2 
years of age in the NFBC1966. 
 
 Residual Standard Deviation [cm] Akaike Information Criterion 
Model Males Females Average Males Females Average 
Count 1.53 1.42 1.48 64849 63512 64181 
Karlberg 1.61 1.50 1.56 66082 64850 65466 
Kouchi 1.63 1.50 1.57 66242 64629 65436 
Reed1 1.44 1.34 1.39 63455 62142 62799 
Reed2 1.44 1.34 1.39 63332 62094 62713 
 
 99 
Since weight growth is a more irregular process than height growth, three-parameter models 
were considered too simplistic for it. Only a comparison between the best-fitting models for height 
growth (Reed1 and Reed2) is presented (Table 5.2.).  
 
Table 5.2. Comparison of different parametric growth models for weight growth at 0-2 
years of age in the NFBC1966. 
 
 Residual Standard Deviation [kg] Akaike Information Criterion  
Model Males Females Average Males Females Average 
Reed1 0.433 0.394 0.414 36108 30127 33117 
Reed2 0.432 0.394 0.413 36051 30126 33089 
 
The results were in line with those reported earlier from a population in a developing country 
(197). Since the advantage of the Reed2 model over the Reed1 model was negligibly small for 
both height and weight growth, the more parsimonious Reed1 model was chosen for further 
analyses of both traits in the NFBC1966 study subjects. 
 
All subjects with at least one height or weight measurement from birth to 24 months at least 0.1 
month (i.e. about 3 days) apart were included in the Reed1 model fitting (N=4,228 singletons). 
Although the models converged for the whole group, random effects for parameters B and C were 
estimated to be zero for those with only one measurement (typically birth length or birth weight). 
Having two measurements was still inadequate to capture the shape of the growth curve and 
therefore any further genetic association analyses are restricted to those with a minimum of three 
measurements per person.  
 
Growth velocity curves were obtained as the first derivatives of the height and weight growth 
curves. The growth parameters derived from the velocity curves for height were the maximum 
velocity, i.e. peak height velocity in infancy (PHV1), the minimum, i.e. lowest height velocity in 
infancy (LHV1), and the mean height velocity in infancy (MEANHV1). Due to high correlations 
between these three variables (0.81-0.99 in both sexes), only PHV1 was selected for further 
analyses. Similarly, for weight growth, estimated peak weight velocity in infancy (PWV1) was 
extracted for each person. Descriptive statistics of these parameters and their correlations with 
other derived growth parameters are presented in chapter 6.2.  
 
5.2.2. Models for height growth including pubertal growth 
 
Nonlinear mixed effects models were fitted to height growth from birth to adulthood using the 
same computational techniques and software as for infant growth. In addition, growth 
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acceleration curves were obtained as the second derivatives of the height growth curves. Velocity 
and acceleration curves were then used to draw biological parameters such as peak height 
velocity in puberty (PHV2) and puberty timing indicators: age at height growth spurt take-off 
(ATO) and age at PHV2. In addition, mean-constant curves that describe the average pattern of 
height growth velocity in the population were drawn for illustrative purposes, stratified by other 
factors, e.g. sex and a genotype of interest.  
 
To estimate the puberty parameters, JPPS and JPA-2 models (203, 204), described in detail in 
the literature review (2.2.4.), were fitted for the whole growth period from birth to adulthood (0-20 
years). Since the JPA-2 model had a better fit than the JPPS model based on the literature and 
also when the models were compared in the NFBC1966, it was selected for further analyses. Due 
to the high number of parameters in the JPA-2 model and sparseness of measurements after 
infancy in the data, the sample had to be restricted to study subjects with a minimum of 16 height 
measurements at 0-20 years at least 0.1 month (~3 days) apart to reach model convergence. 
 
PHV2 was derived from the individual height velocity curve. ATO and age at PHV2 were derived 
from the height acceleration curve estimated from the JPA-2 model. The maximum height growth 
velocity reached at 8-16 years in females and 9-17 years in males was defined as PHV2. The age 
windows were defined this way to accommodate the large individual variation in the timing of the 
height growth spurt, as well as the earlier timing of the spurt in females compared to males. ATO 
was defined to be the age ≥ 8 years in females and ≥ 9 years in males when the growth 
acceleration estimate first changed its sign from being negative to positive. Age at PHV2 was 
defined to be the age when the acceleration subsequently changed its sign from positive to 
negative. In summary, the growth parameters derived from the JPA-2 model were PHV1, PHV2, 
ATO and age at PHV2. Since PHV1 can be derived for a higher number of people from the 
Reed1 model with the added flexibility on the timing of early velocity peak, only genetic 
associations on puberty parameters are reported from the JPA-2 model. Descriptive statistics of 
these parameters and their correlations with growth parameters derived from other models are 
presented in chapter 6.2. 
 
5.2.3. Models for growth in body composition (BMI) 
 
Due to the considerable irregularity of the BMI growth process and the lack of pre-defined BMI 
curves in the literature, different methods and models were explored in the preliminary analysis. 
At first, a simple piece-wise linear mixed effects model (LMEM) was fitted in the data at the age of 
0-2 years. It included one knot which splits age into two different periods, and two linear LMEMs 
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on each side. This model enabled estimation of BMI growth velocity (slope) on each side of the 
knot. This work was done primarily by Dr. Nicholas Timpson at Bristol University.  
 
Subsequently, different LMEMs including quadratic and cubic age effects were explored by 
myself and Ms. Nicole Warrington at the University of Western Australia, Perth. At this point, the 
whole period of pre-pubertal BMI growth (0-13 years of age) was considered. However, due to 
the complex shape of the typical BMI curve, LMEMs did not fit adequately to the data. The data 
were split into infant and child growth periods, and cut-off points separating the two were 
evaluated at 1.0, 1.5 and 2.0 years of age. The LMEMs with linear, quadratic and cubic age 
effects had a better fit than the LMEMs without the cubic effect. Based on the AIC and RSD 
statistics and visual inspection of the curves, the best cut-off point turned out to be 1.5 years, 
although the differences were small. Also, as a biological justification, by this age the vast 
majority of children would have been weaned completely, although this cannot be confirmed due 
to the unavailability of breastfeeding data in the NFBC1966. Measurements taken in the first two 
weeks of life were excluded due to potential decrease in BMI in the first two weeks of life, which 
the chosen models would not have been able to accommodate appropriately. 
 
Before model fitting, age was centered. In the infant growth model at 0-1.5 years, the mid-point 
for age was 0.75 years (which is close to the average age at AP), and in the child growth model 
at >1.5-13 years, the mid-point for age was 7.25 years (on average shortly after AR). BMI 
distribution was skewed to the right and its skewness increased by age. Logarithmic 
transformation (log-transformation) of BMI slightly improved the model in childhood but not 
notably in infancy. Model fit was further evaluated by varying the inclusion of random effects for 
different model parameters. Initially, random effects for the intercept and linear component were 
included. This allows an individual baseline BMI and the rate of change in BMI for each individual. 
The addition of a random component to the quadratic or cubic parameter did not substantially 
improve the model and therefore they were not included. The first-order autoregressive 
correlation structure (AR(1)) was assumed, since it gave a lower AIC than compound symmetry 
structure in childhood. There were convergence problems using compound symmetry in infancy, 
whereas the model with AR(1) correlation structure converged and fitted well.   
 
The models were constructed for several different purposes. The first aim was to evaluate the 
association between a common variant (rs9939609) in the FTO gene in relation to infant and child 
BMI growth. The second aim was to derive age and BMI at AP and AR, whose associations with 
FTO would be examined. These growth parameters could also be used as outcomes in a GWAS. 
The models used in these studies and the derivation of the AP and AR parameters are described 
in detail in chapter 5.5.2.  
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5.3. Methods used in association analyses between different phenotypes  
 
This chapter presents the methods for the analysis of phenotypes from foetal life until adulthood. 
Derived growth parameters and their correlations with anthropometric measures at birth and at 
age 31 years are described in chapter 6.2 using simple methods: arithmetic means, standard 
deviations and Spearman’s correlation coefficients. Methods for more detailed analyses including 
regression model fitting are divided in two parts. The first part (5.3.1) describes methods for 
analysing the prenatal predictors of early growth, PHV1 in particular. This work has been 
submitted for publication (Das* et al. (under review in Pediatrics)). The second part (5.3.2) 
describes the methods for analysing associations between growth parameters and adult 
metabolic phenotypes. Some of this work has been described in Tzoulaki et al. (2010) (328). Both 
studies include a wide range of covariates either as predictors of the phenotype or for adjustment 
purposes. Item non-response results in a considerably reduced and potentially selected data set, 
and therefore imputation of missing data was applied in both studies to reduce bias and increase 
statistical power in the multivariate analyses. 
 
5.3.1. Prenatal predictors of infant height growth velocity  
 
The association between prenatal factors, birth length (BL) and PHV1 was studied in the 
NFBC1966. Similar data have been collected in the NFBC1986, and a comparative manuscript 
on the associations (Das* et al. (under review in Pediatrics), was written together with a PhD 
student, Ms. Shikta Das, who performed a pilot study for her MSc dissertation by exploring the 
determinants of PHV1 in the NFBC1986. My role in this project was to train her to use growth 
modelling methods, validate her growth analyses for the NFBC1986, and to perform association 
analyses for both cohorts. Prenatal factors were chosen based on literature (227) and availability 
in both cohorts. The initial variable selection based on literature was done by Ms. Shikta Das and 
Prof. Marjo-Riitta Järvelin. The selected prenatal factors included child‘s sex, gestational age 
(GA), birth length and birth BMI, mother‘s age, marital status, socio-economic status (SES), 
education, smoking at two months of pregnancy, previous deliveries, height, BMI and 
hypertensive complications during pregnancy, and father‘s SES (distributions are given in chapter 
6.3.1, Table 6.3). The relationship between BL and PHV1 was evaluated with and without 
adjustment for prenatal factors and the strength of the BL-PHV1 association was compared 
between the two cohorts. In this thesis I will only describe the findings in the NFBC1966. 
  
The average number of height measurements taken at 0-2 years of age was seven in the 
consented NFBC1966 population with growth data available (N=4,311). Reed1 model (chapter 
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2.2.4) was fitted for singletons (N=4,228) as described in chapter 5.2.1. The study population was 
restricted for the association analysis to singletons that had at least three height measurements 
at 0-2 years of age, since PHV1 estimation becomes unreliable with a low number of 
measurement (total N=3,783, including 1,891 males and 1,892 females). 
 
Representativeness of the samples included in the statistical analyses was examined in detail to 
reveal any potential bias due to dropout (i.e. unit non-response). The available cases approach 
was chosen for the descriptive and univariate regression analyses, since item non-response was 
low (≤ 8%) when analysed individually in relation to PHV1. For multiple regression analysis, the 
complete cases approach was first considered, and the extent of and background factors related 
to additional missing data due to item non-response in any of the included variables was 
examined. Finally, to minimise bias and preserve statistical power, missing values were imputed 
using the multiple imputation method (121) and multiple regression models were fitted to the 
imputed data to predict PHV1. In my previous research, based on simulations, I found the 
multiple imputation method a worthwhile approach even in the absence of bias, as a means of 
preserving statistical power (122). 
 
Representativeness 
 
I have previously analysed the representativeness of the NFBC1966 attendees of the clinical 
examination (N=6,007) by comparing register-based information on them with the remainder of 
the cohort alive at age 31 years who did not attend the clinical examination (N=5,630) (329). The 
attendees were fairly representative, except that a smaller proportion of them had only completed 
basic education by the age of 31 years (10% vs. 30% in the remainder of the cohort). For the 
present study, birth and maternal characteristics of those who were included in the analyses 
(N=3,783) and other eligible singletons who attended the clinical examination at age 31 years but 
whose health clinic records were missing or their PHV1 estimate was discarded due to a low 
number of measurements (N=2,094) were compared. The proportion of males was slightly higher 
in the included group (50% vs. 44%, which compensates for the reverse selection bias in the 
attendance of the clinical examination) and their mothers and fathers were less likely to be 
farmers (22% vs. 30% and 19% vs. 26%, respectively). Those included came more often from 
smaller families (p for trend < 0.0001) and their mothers were on average about 7 months 
younger (p = 0.0007) and slightly less likely to be obese or overweight (p for trend = 0.0031) than 
the mothers of those excluded. Maternal height, marital status, education, smoking at two months 
of pregnancy, gestational hypertension status, or the child‘s GA, BL or birth BMI did not differ 
between the included and excluded groups at p < 0.05 level. 
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Descriptive and univariate analysis on available cases 
 
PHV1 was skewed to the right and it was log-transformed for the association analyses. Therefore, 
results are reported as percentage difference per one unit change in the exposure variable. All 
analyses were stratified by sex. For descriptive purposes, means and standard deviations were 
calculated for continuous variables and percentage distributions for classified variables. The 
association between PHV1 and each covariate was studied by fitting a linear regression model 
using available cases. To take into account the uncertainty in the estimated PHV1 values, all 
regression models with PHV1 as an outcome were weighted by the number of observations from 
birth until age 2 years. In addition, the associations between each covariate and BL was analysed 
by univariate regression analysis. The purpose of these analyses was to assess the overlap 
between the predictors of BL and PHV1 and to evaluate the sources of confounding. 
Supplementary analyses (Table A.5) include descriptive statistics of PHV1 by sex-specific BL 
quintiles, and a univariate regression analysis between these quintiles and PHV1. For the interest 
of comparison, the association between sex-specific birth weight (BW) quintiles and PWV1 is also 
reported (Table A.6). Further analyses on BW and PWV1 association will be performed later. 
 
Item non-response and multiple regression analysis on complete cases 
 
The proportion of missing data (item non-response) varied between 0% and 10.5% per covariate. 
The full model including all covariates as predictors was initially fitted for complete cases, i.e. for 
those with complete data on all variables. However, the proportion of missing cases in the full 
model was as large as 25% (2,849 complete cases and 934 incomplete cases). Furthermore, 
some of the distributions of prenatal characteristics and birth variables differed between complete 
cases included in the full model and cases available for univariate analyses. The proportion of 
children of married (99% vs. 89%) and white collar (14% vs. 9%) mothers and white collar fathers 
(26% vs. 21%) was higher in complete cases than in incomplete cases. The proportion of children 
of mothers who had only completed primary education was lower in the complete cases than 
incomplete cases (63% vs. 73%). No differences at p < 0.05 level were seen in family size, 
maternal smoking, age, BMI or height, gestational hypertension status, or child‘s sex or birth 
characteristics between the two groups.  
 
Multiple imputation 
 
To recover statistical power and reduce selection bias due to item non-response in the full model, 
multiple imputations were performed for both cohorts using SAS (version 9.1.) PROC MI. In 
addition to the variables in the full model, BW was included in the imputation model since it is 
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measured in all individuals and correlates with many of the variables with missing values. The 
number of imputations (m=20) was based on the recommendations by Graham et al. (2007) (330) 
for a data set with the fraction of missing information of 10-30% and a low (<1%) tolerance for 
power falloff. Imputed data sets were analysed using multiple regression with SAS PROC REG, 
and results were pooled together for inference with SAS PROC MIANALYZE.  
 
A previous simulation study demonstrated how MI can reduce bias and increase statistical power 
when data are missing at random, and even when data are not missing at random (122). The 
same study also showed through a comparison between MI in SAS and STATA that different 
statistical techniques for MI yield similar results. 
 
5.3.2. Association between growth parameters and adult anthropometric and metabolic 
phenotypes  
 
Part of the work described in this chapter has been published in Tzoulaki et al. (2010) (328), 
using similar methods but different choices for variable transformations. The article includes only 
selected growth parameters (PHV1 and PWV1), selected metabolic outcomes (BMI, WC, HDL 
cholesterol, triglyceride, SBP and DBP) and MetS. To extend this analysis for this thesis, 
associations between a wider range of growth parameters covering infant, child and pubertal 
growth (PHV1, PWV1, BMI and age at AP and AR, PHV2 and age at PHV2) and a wider 
selection of adult metabolic outcomes were examined in the NFBC1966. The metabolic outcomes 
included BMI, WC, HDL, LDL and total cholesterol, triglyceride, glucose, insulin, SBP, DBP and 
MetS. They were obtained in the clinical examination at 31 years of age (see details in chapter 
4.2.3).  
 
MetS was defined by the National Cholesterol
 
Education Program's (NCEP's) clinical guidelines 
(266) which were subsequently updated to lower the glucose threshold from 110 to 100 mg/dl 
(6.1 mmol/l to 5.5 mmol/l). The lower cut point was considered more optimal in terms of predicting 
the future risk of diabetes (267). Thresholds were transformed to different units as in Jorgensen 
et al. (2004) (331) and they were: 
 
1) WC: ≥ 102 cm (males) and ≥ 88 cm (females), 
2) HDL: ≤ 1.04 mmol/l (males) and ≤ 1.29 mmol/l (females), 
3) Fasting triglyceride: ≥ 1.69 mmol/l, 
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4) Fasting glucose: ≥ 5.5 mmol/l or being on diabetes medication,  
5) BP: SBP ≥ 135 mmHg or DBP ≥ 85 mmHg or being on antihypertensive medication.  
 
Individuals who exceeded a threshold in at least three of the five MetS components were defined 
as MetS cases. Due to the possibility of missing data in one or more of the MetS components, the 
definition of case-control status varied according to the number of valid measures available as 
follows: 
 
Case if sum (WC, HDL, triglyceride, glucose, BP) ≥ 3, given at least 3 valid trait measurements; 
Control if sum (WC, HDL, triglyceride, glucose, BP) < 3, given 5 valid trait measurements;  
Control if sum (WC, HDL, triglyceride, glucose, BP) < 2, given 4 valid trait measurements;  
Control if sum (WC, HDL, triglyceride, glucose, BP) = 0, given 3 valid trait measurements.  
In any other case the case/control status was set as missing.  
 
The MetS case-control definition used in this thesis is based on these updated NCEP guidelines 
used in the SNP Typing for Association with Multiple Phenotypes from Existing Epidemiologic 
Data (STAMPEED) Consortium (chapter 5.6.1), which are well in line with the latest 
recommendations for MetS definition in adults (265). However, the already published results in 
Tzoulaki et al. (2010) (328) are based on the original NCEP guidelines (266), with the stricter 
glucose threshold and exclusion of all participants with any missing MetS components.  
 
Attendees of the clinical examination at age 31 years, who had at least three anthropometric 
measures available in the age window in question, were included in the analysis. Twins were 
excluded from the analyses (Table 5.3).  
 
Table 5.3. Maximum number of individuals included in the analysis for each growth 
parameter, age range at which the corresponding growth model was fitted, and the median 
number of measurements for each age range. 
 
 PHV1 PWV1 BMI and age 
at AP 
BMI and age 
at AR 
PHV2 and  
age at PHV2 
N 3,783 4,028 3,265 4,121 2,725  
Age (y) 0-2 0-2 0-1.5 1.5-13 8-16 (female) / 9-17 (male) 
Median 
N(meas) 
8 9 7 10 7 
 
PHV1 = peak height velocity in infancy, BMI = body mass index, PWV1 = peak weight velocity in infancy, AP = adiposity 
peak, AR = adiposity rebound, PHV2 = peak height velocity in puberty. 
 
Mothers
 
were classified as light smokers if they smoked 1-10 cigarettes
 
per day and as heavy 
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smokers if they smoked more than 10 cigarettes
 
per day at the second month of pregnancy. The 
social class of the family at birth was determined by the father‘s occupation and its prestige 
according to a social grouping established by the Helsinki Office of Statistics and frequently used 
for this purpose in Finland (332). 
 
Those who reported that they had failed to fast before the blood sample was taken were excluded 
from the glucose, insulin and triglyceride analyses. In addition, those on diabetes medication 
were excluded from the glucose and insulin analyses. The distributions of nearly all of the 
metabolic outcomes were skewed to the right. A logarithmic transformation was applied to all 
continuous outcomes presented in this thesis to ensure consistency in the presentation of the 
results. In the published article (328), only glucose and triglycerides were log-transformed as they 
were the most skewed variables, and descriptive statistics were presented
 
as median and 
interquartile range for logarithmically transformed variables, and percentages for categorical
 
variables. Association analyses were performed with and without imputation. Analyses between 
immediate postnatal growth (PHV1 and PWV1) and metabolic outcomes using non-imputed data 
have been published (328). In this thesis, analyses based on imputed data are presented. 
Multiple imputations for missing values in background factors were performed with SAS PROC MI 
in order to increase statistical power and reduce bias. The same number of imputations (m=20) 
was used as in chapter 5.3.1.  
 
Linear regression models were fitted to imputed data using PROC REG to
 
test associations 
between each growth parameter and each metabolic outcome at 31 years of age. Sequential 
models were fitted and adjusted for the following background factors: sex (model 1); additionally 
for maternal age, maternal height and weight before pregnancy, maternal smoking after 2 months 
of pregnancy, socioeconomic status at birth and GA (model 2); additionally for BW (model 3); and 
additionally for BMI at 31 years of age (model 4). The results from these four models for PHV1 
and PWV1 have been published (328). 
 
Since the published analyses (328) showed that associations between immediate postnatal 
growth and metabolic outcomes survive adjustment for birth weight (model 3), and that 
adjustment for BMI at 31 years (model 4) complicates the interpretation of the results, model 3 
was chosen as the starting model (model A) for the extended analysis on growth parameter 
associations with metabolic outcomes presented in this thesis. In addition, the analyses were 
repeated with further adjustments. The idea was to adjust height growth related analyses for 
weight growth and vice versa, and to adjust later growth analyses for earlier growth (childhood 
analyses for infant growth, and puberty analyses for childhood and infant growth). The further 
adjustments (model B) include 1) PHV1 analyses additionally adjusted for PWV1, 2) PWV1, age 
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at AP and BMI at AP additionally adjusted for PHV1, 3) age at AR and BMI at AR additionally 
adjusted for PHV1 and BMI at AP, and 4) age at PHV2 and PHV2 additionally adjusted for PHV1, 
BMI at AP and age at AR. The adjustment variables from infancy and childhood were chosen so 
as to avoid inclusion of strongly correlated variables in the same model.  
 
When age and BMI at AP had an adjusted association with the same metabolic outcome, a 
further analysis was performed where both growth parameters were included in the same model 
(model C). Similarly, analyses for age and BMI at AR, PHV2 and age at PHV2 were repeated with 
an additional adjustment for the other growth parameter estimated at the same time point (age at 
AR adjusted for BMI at AR and vice versa, and age at PHV2 adjusted for PHV2 and vice versa). 
Results from model C should be interpreted carefully, keeping in mind the inverse correlation 
between two closely related growth parameters.  
 
Effect sizes are presented as percentage changes in the outcome towards 2SD increase in the 
growth parameter. Logistic regression models were fitted with PROC LOGISTIC to test 
associations between the growth parameters and MetS with the adjustments described earlier. 
Additionally, linear regression models for metabolic outcomes and logistic regression for MetS 
were fitted to examine associations with birth weight with the same adjustments as model 2 (non-
imputed data only). Interaction terms were tested between growth measures
 
and sex or BMI and 
metabolic outcomes or MetS (non-imputed data only). To account for the random variation 
attached to the derived growth parameters, all association analyses were weighted by the 
number of measurements per person. A statistical significance threshold of p < 0.05 was used in 
Tzoulaki et al. (2010) (328), and no adjustments were made for multiple testing, since a set of 
predefined hypotheses were tested. However, in the analyses presented in this thesis, 
associations with 0.005 < p < 0.05 are considered only ―borderline significant‖ due to a high 
number of tests performed, to account for the possibility of false discoveries. Associations at p < 
0.005 significance level are given more weight in the interpretation of the results. Analysis results 
from imputed data were pooled together for inference with PROC MIANALYZE. Data were 
analysed by Dr. Ioanna Tzoulaki ((328), data without imputation) and myself (all analyses 
presented in this thesis, imputed data)
 
using SAS version 9.1. 
 
5.4. Preparation of genome-wide data 
 
Genome-wide data were extracted from the blood samples given at the clinical examination at 
age 31 years, as described in chapter 4.2.3. This chapter describes the steps for preparing the 
data for GWA analyses: quality control, principal component analysis and imputation. The 
preparation work was done by other researchers in various research units. My role was to 
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distribute the information and exclusion lists to analysts within Imperial College and collaborating 
units, and to arrange them access to the genotype data.    
 
5.4.1. Quality control 
 
The nearly final release of the genotype data used in this thesis includes N=4,763 individuals. 
The genotyping procedure and QC are presented in detail in Sabatti et al. (2009) (324). 
Altogether, genotyping was completed for N=4,936 individuals, of which N=173 were excluded for 
various reasons: consent withdrawal (N=14), sample duplicates (N=2), gender discrepancy 
(N=10), sample contamination (N=3), relatedness (N=51), and missing phenotype data (N=93). 
Of the related pairs that shared over 20% of the genome identical by descent (IBD), the 
individuals with more complete genotype data were selected for analysis. Genotyping 
completeness in the final data set was 99.7% on average (range 95.3-99.9%) and only 1.7% of 
individuals had ≤ 97.5% genotyping completeness (call rate).  
 
Genotyping was completed for 339,629 SNP markers, of which 3,345 were excluded due to lack 
of HWE (p < 10
-4
), 55 due to low call rate (< 95%) and 7,681 due to low MAF (< 1%), leaving 
N=329,091 SNPs to be analysed. The average SNP call rate was 99.7% and only for 1.6% of 
SNPs it was 95.0-97.5%. Quality control was performed by Dr. Chiara Sabatti, Dr. Susan Service 
and colleagues at the University of California, Los Angeles (UCLA), and by Ms. Marika Kaakinen 
(University of Oulu) and Dr. Inga Prokopenko at the University of Oxford. 
 
5.4.2. Principal component analysis 
 
After quality control the data comprised 329,091 genotyped SNPs in 4,763 individuals. A principal 
component (PC) analysis was performed on 60,000 of these SNPs selected in such a way that no 
two SNPs were in LD of r
2
 > 0.2 with any other selected SNP and the call rate was greater than 
99.9%. The thinning of SNPs prevented over-representation of genomic regions with high LD. PC 
analysis was performed using the eigen function in the R software package. Logistic regression 
models were fit in R using the glm function, and variable selection was performed using the step 
option within the glm function. The PC analysis was performed by Dr. Clive Hoggart at Imperial 
College London. The PCs from this analysis have been used in the genetic association analyses 
of this thesis to adjust for population structure, as appropriate. The selection of PCs has been 
described separately for each study in the method section. 
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5.4.3. Imputation of untyped variants 
 
After a sample QC at the University of Oxford, 4,762 individuals were included in the imputation 
(283). SNP QC was performed prior to imputation on the 339,629 genotyped SNPs. 7,553 SNPs 
with MAF < 1% and 3,282 SNPs with HWE < 10
-4
 were excluded. Also, 6,712 SNPs with call rate 
< 95% and 672 SNPs with call rate < 99% and MAF < 5% were excluded. The number of SNPs 
included in the imputation was 328,007. Imputation was performed using the IMPUTE software 
version 0.3.1 (126) in April 2008, applying information threshold (named ―proper_info‖ in the 
software) of > 0.4 and MAF threshold of > 1%. The HapMap Phase II panel of phased haplotypes 
for CEU samples was used as a reference for the imputation (134, 333). The NCBI build 35 
genetic map and SNP positions were used for the imputed SNPs. Imputation was performed only 
on the 22 autosomes, since imputation of the sex chromosomes was not yet possible with 
IMPUTE version 0.3.1 due to lack of reference data. X chromosome imputation has been 
available from IMPUTE version 0.5 but it is more complicated than autosome imputation (334). 
Since many collaborating studies have used the MACH software (where X chromosome 
imputation is not implemented), and the analyses are performed in large consortia with 
harmonised data, there has been no need to impute the X chromosome in the NFBC1966 either. 
Y chromosome imputation has not been implemented in IMPUTE or other imputation software. 
The imputed data consist of about 2.5 million SNPs, including both genotyped and imputed 
SNPs. Imputation was performed by Dr. Inga Prokopenko at the University of Oxford (see 
Supplementary Table 1 in Prokopenko et al. (2009) (283)). 
 
Since the sample QC resulted in slightly different exclusion lists in the UCLA (N=173) and the 
University of Oxford (N=174) with N=172 overlapping individuals, the combined exclusion list of 
N=175 has been used in further analyses, i.e. the analyses of imputed data presented in this 
thesis are based on the sample of N=4,761 individuals. In the QC of the final release of genotype 
data such discrepancies will be settled before imputation to ensure all published articles will be 
based on the same sample of individuals.  
 
5.5. Methods used in candidate gene analyses 
 
This chapter presents the methods applied in two candidate gene studies on longitudinal growth: 
one on height and the other on BMI growth. The candidate genes for these two studies were 
derived from published GWAS results on closely related traits. The methods described in chapter 
5.5.1 have already been published in Sovio et al. (2009) (327). I performed all growth modelling 
and genetic association analyses, and wrote the paper. Other authors gave their contributions 
especially for genotyping, interpretation of the results, and the discussion of the paper. The 
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methods described in chapter 5.5.2 form a part of a manuscript (Sovio* et al. PLoS Genet 2011 
(in press)). Since this is a multi-centre study, analyses were performed by multiple researchers, 
and results were meta-analysed centrally. Dr. Nicholas Timpson at the University of Bristol was in 
charge of the overall management of all studies involved, and collated and meta-analysed the 
cross-sectional (descriptive) results with Dr. Dennis Mook-Kanamori at the Erasmus Medical 
Center, Rotterdam. Additionally, Ms. Nicole Warrington at the University of Western Australia, Dr. 
Laurent Briollais at the University of Toronto and myself at Imperial College London were involved 
in developing longitudinal models for repeated BMI measurements throughout infancy and 
childhood, in the meta-analysis of the results from these models, and in the interpretation of the 
results. I co-ordinated the derivation of AP and AR related growth parameters from the 
longitudinal models, and meta-analysed these parameters with the help of Dr. Dennis Mook-
Kanamori. Prof. Tim Cole at University College London has contributed considerably in the 
revision of the submitted manuscript. However, these revisions could not be added into this thesis 
due to time constraints. 
 
5.5.1. Genetic determinants of height growth  
 
Forty-eight SNPs associated with adult height in other GWA studies (335-337) were studied in 
relation to height growth velocities in infancy and puberty in the NFBC1966. An additive model 
adjusted for sex, principal components and the exact measurement age was applied. A summary 
of the SNPs included is presented in Table 5.4. Genotyping was performed by Dr. Amanda 
Bennett at the University of Oxford, and detailed genotyping information is given in the publication 
(327). I performed all the statistical analyses for this publication myself. 
 
Principal component (PC) analysis was applied in the genome-wide scan sample of N=4,763 to 
characterise the genetic distances between persons within the sample. The correlation of the first 
20 PCs was analysed with birth length, adult height, PHV1, PHV2 and age at PHV2 by sex. In 
addition to first five PCs, the PCs that were associated with one or more of the growth outcomes 
in either sex (PCs 11, 13 and 15) were adjusted in all SNP association analyses to control for 
population structure (see the recommendation by Novembre and Stephens (338)). Additional 
adjustment for socio-economic status at birth (SES) did not change the results essentially and 
was not applied. Unpublished analyses on this cohort, performed by Dr. Clive Hoggart at Imperial 
College London, show that adjustment for PCs partly corrects for SES in the genome-wide 
analysis of adult height due to a correlation between SES and some of the PCs. Adjustment for 
PCs also corrects for parental geographic location. 
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Age at PHV2 was normally distributed but PHV1 and PHV2 were slightly skewed to the right and 
were log-transformed for the association analysis. Sex was adjusted in all SNP association 
analyses (sex-interactions explored and reported separately). All remaining twins were removed 
from the analyses, leaving N=4,682 for genetic analyses. Number was reduced further due to 
missing data in the phenotypes, e.g. for final height N=4,677 and for growth data maximum 
N=3,538 (Figure 5.1), which was further reduced depending on the minimum number of 
measurement points required for analysis at each age window, as explained in chapter 5.2.  
 
This study is hypothesis-based since it utilises prior information from GWA studies and can 
consequently be likened to candidate gene studies. Therefore, statistical significance was 
considered at p < 0.05 level for the SNP associations on adult height, PHV1 and PHV2 and the 
age-SNP interaction on PHV. Since we do not have similar prior information for the timing of 
height growth spurt, we only declare statistical significance at p < 0.0011 level for ATO and age at 
PHV2. This level is based on Bonferroni correction considering 44 independent signals. Previous 
GWA studies found no evidence for sex-SNP interactions on adult height, although sex is an 
important determinant of growth and adult height (335-337). We test sex-SNP interactions on 
each outcome but due to the absence of prior evidence for interactions use Bonferroni correction 
(p < 0.0011 level) for assessing their statistical significance.  
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Table 5.4. Summary of the height variants genotyped in the NFBC1966. 
 
SNP 
Original reference for 
SNP Gene abbreviation, name 
SNP 
location
0
 
Chromosomal 
Position
1
 
HapMap 
Alleles + 
strand 
HapMap 
MAF
2
 
NFBC1966 
MAF
2
 
HWE 
P GSR
5
 
rs11205277 
(336) SF3B4/SV2A, between splicing factor 3b, subunit 4, 
49kDa and synaptic vesicle glycoprotein 2A Between Chr1:146705945 A/G G_0.39 G_0.31 0.427 99.9 
rs6830062 
(336) LCORL, ligand dependent nuclear receptor 
corepressor-like 
 
Between Chr4:17693999 T/C C_0.16 C_0.093 0.560 99.9 
rs3116602 
(335) 
DLEU7, deleted in lymphocytic leukemia, 7 
 
Within Chr13:50009356 T/G G_0.18 G_0.30 0.033 93.8 
rs4713858 
(336) 
PPARD/ FANCE, between peroxisome proliferator-
activated receptor delta and Fanconi anemia, 
complementation group E 
 
 
Between Chr6:35510763 G/A A_0.16 A_0.11 0.832 100 
rs10946808 
(337) 
HIST1H1D, downstream of  histone cluster 1, H1d 
 
Between Chr6:26341366 A/G G_0.28 G_0.42 0.034 99.9 
rs6854783 
(335), also proxy for 
rs1812175 (336) and for 
rs1492820 (337) HHIP, hedgehog interacting protein 
 
 
Within Chr4:146000684 A/G G_0.45 G_0.35 0.936 95.1 
rs6060373 
(335), also proxy for 
rs6060369 (337) 
UQCC, ubiquinol-cytochrome c reductase complex 
chaperone  
 
Within Chr20:33377622 A/G G_0.36 G_0.43 0.936 97.7 
rs6724465 
(335) 
NHEJ1, nonhomologous end-joining factor 1 
 
Within Chr2:219769351 G/A A_0.16 A_0.08 0.682 89.0 
rs2814993 
(335) 
C6orf106, chromosome 6 open reading frame 106 
 
Within Chr6:34726871 G/A A_0.10 A_0.20 0.284 94.3 
rs6842303 
(336) LCORL, ligand dependent nuclear receptor 
corepressor-like 
 
Within Chr4:17530324 G/T T_0.33 T_0.283 0.832 99.9 
rs11107116 
(335) 
SOCS2, suppressor of cytokine signaling 2 
 
Within  Chr12:92480972 G/T T_0.20 T_0.25 0.445 94.6 
rs12459350 
Proxy for rs12986413 
(337) 
DOT1L, DOT1-like, histone H3 methyltransferase 
(S. cerevisiae) 
 
Within Chr19:2127586 A/G G_0.45 G_0.45 0.647 99.9 
rs4800148 
(336) 
CABLES1, Cdk5 and Abl enzyme substrate 1 
 
Within Chr18:18978326 A/G G_0.26 G_0.23 0.576 99.9 
rs2562785 
Proxy for rs2562784 (337) 
SH3GL3, SH3-domain GRB2-like 3 
 
Within  Chr15:82077025 G/T T_0.15 T_0.14 0.454 99.6 
rs4794665 
(336) C17orf67, upstream of chromosome 17 open 
reading frame 67 
 
Between Chr17:52205328 A/G G_0.48 A_0.48 0.977 99.9 
rs4549631 
(335) C6orf173, downstream of chromosome 6 open 
reading frame 173 
 
Between Chr6:127008001 T/C C_0.43 C_0.46 0.593 94.7 
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rs7846385 
(336) 
PXMP3/ PKIA, between peroxisomal membrane 
protein 3, 35kDa and protein kinase (cAMP-
dependent, catalytic) inhibitor alpha 
 
 
Between Chr8:78322734 T/C C_0.34 C_0.223 0.262 99.7 
rs1042725 
(335), also proxy for 
rs8756 (336), also (337) HMGA2, high mobility group AT-hook 2 
 
Within  Chr12:64644614 C/T T_0.42 T_0.50 0.526 97.9 
rs4533267 
(336) ADAMTS17, ADAM metallopeptidase with 
thrombospondin type 1 motif, 17 
 
Within Chr15:98603794 G/A A_0.28 A_0.24 0.001 99.9 
rs3731343 
Proxy for rs2040494 (337) 
CDK6, cyclin-dependent kinase 6 
 
Within Chr7:91918187 A/C C_0.49 A_0.49 0.910 99.9 
rs314277 
(337) 
LIN28B, lin-28 homolog B (C. elegans) 
 
Within Chr6:105514355 C/A A_0.13 A_0.17 0.267 98.6 
rs8041863 (335) ACAN, aggrecan 
 
Within Chr15:87160693 T/A A_0.49 A_0.373 0.650 98.1 
rs12735613 
(335) 
SPAG17, sperm associated antigen 17 
 
Within Chr1:118596015 G/A A_0.31 A_0.24 0.183 97.6 
rs10935120 
(335) 
CEP63, centrosomal protein 63kDa 
 
Within Chr3:135715790 G/A A_0.36 A_0.25 0.333 96.9 
rs10906982 
(335) 
ADAMTSL3, ADAMTS-like 3 
 
Within Chr15:82359162 T/A A_0.48 A_0.483 0.617 96.0 
rs10512248 
(335) 
PTCH1, patched homolog 1 (Drosophila) 
 
Within Chr9:95339258 T/G G_0.32 G_0.38 0.417 98.3 
rs6440003 
(335), also proxy for 
rs6763931 (336) and for 
rs724016 (337) ZBTB38, zinc finger and BTB domain containing 38 
 
 
Within Chr1:41199964 G/A A_0.48 A_0.46 0.062 94.0 
rs6686842 
(335) SCMH1, sex comb on midleg homolog 1 
(Drosophila) 
 
Within Chr1:41199964 C/T T_0.41 T_0.41 0.838 94.4 
rs3791675 
(335), also proxy for 
rs3791679 (336) 
EFEMP1, EGF-containing fibulin-like extracellular 
matrix protein 1 
 
Within Chr2:56022960 C/T T_0.28 T_0.24 0.221 97.9 
rs2282978 
(335), also (336) 
CDK6, cyclin-dependent kinase 6 
 
Within Chr7:91909061 T/C C_0.37 C_0.31 0.413 95.2 
rs9650315 
(335), also (337) CHCHD7, coiled-coil-helix-coiled-coil-helix domain 
containing 7 
 
Within Chr8:57318152 G/T T_0.13 T_0.13 0.198 95.1 
rs8007661 
Proxy for rs1390401 
(335), also (337) TRIP11, thyroid hormone receptor interactor 11 
 
Within Chr14:91529711 C/T T_0.30 T_0.48 0.249 95.9 
rs678962 
(336) 
DNM3, dynamin 3 
 
Within  Chr1:168921546 T/G G_0.16 G_0.233 0.937 99.9 
rs7153027 
(336) TRIP11/FBLN5, between thyroid hormone receptor 
interactor 11 and fibulin 5 
 
Between Chr14:91496975 A/C C_0.39 C_0.41 0.907 99.6 
rs3760318 
(336) ADAP2, upstream of ArfGAP with dual PH domains 
2 
 
Between Chr17:26271841 G/A A_0.36 A_0.40 0.393 99.9 
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rs757608 
 (336) 
TBX2, T-box 2 
 
Within Chr17:56852059 G/A A_0.30 A_0.26 0.001 99.6 
rs967417 
(336) 
BMP2, bone morphogenetic protein 2 
 
Within Chr20:6568893 G/A A_0.43 G_0.44 0.388 99.9 
rs12198986 
(336) 
BMP6, Upstream of bone morphogenetic protein 6  
 
Within Chr6:7665058 A/G A_0.50 A_0.47 0.460 99.8 
rs2844479 
(336) 
RDBP, (LST1) NCR3/AIF1, within RD RNA binding 
protein, between (leukocyte specific transcript 1), 
natural cytotoxicity triggering receptor 3 and 
allograft inflammatory factor 1
4
 
 
 
 
Between Chr6:31680935 A/C C_0.32 C_0.28 0.295 100 
rs3130050 
(336) RDBP/BAT3, between RD RNA binding protein and 
HLA-B associated transcript 3 
 
Between Chr6:31726740 A/G G_0.23 G_0.14 0.953 99.9 
rs185819 
(336) 
TNXB, tenascin XB 
 
Within Chr6:32158045 T/C C_0.43 T_0.483 0.364 99.9 
rs1776897 
(336) 
HMGA1, upstream of high mobility group AT-hook 1 
 
Within Chr6:34302989 T/G G_0.08 G_0.06 0.115 99.9 
rs6570507 
Proxy for rs4896582 (337) 
GPR126, G protein-coupled receptor 126 
 
Within Chr6:142721265 G/A A_0.25 A_0.26 0.325 99.9 
rs3748069 
(336), also proxy for 
rs4896582 (337) 
GPR126, downstream of G protein-coupled receptor 
126 
 
Between Chr6:142809326 A/G G_0.27 G_0.26 0.259 99.9 
rs798544 
(336) 
AMZ1/GNA12, between archaelysin family 
metallopeptidase 1 and guanine nucleotide binding 
protein (G protein) alpha 12 
 
 
Between Chr7:2536343 C/T T_0.28 T_0.37 1.000 99.9 
rs11765954 
(336) 
CDK6, cyclin-dependent kinase 6 
 
Within Chr7:91925346 T/C C_0.29 C_0.253 0.165 99.9 
rs10958476 
(336) 
PLAG1, pleiomorphic adenoma gene 1 
 
Within Chr8:57258362 T/C C_0.13 C_0.223 0.647 99.8 
rs4743034 
(336) 
ZNF462, zinc finger protein 462 
 
Within Chr9:106711908 G/A A_0.24 A_0.20 0.593 99.9 
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0
SNP location: Between genes / Within gene. 
1
Chromsomal positions are from the NCBI Build 35, produced by the 
International Human Genome Sequencing Consortium. 
2
Allele frequency is for the minor allele observed in the 
HapMap CEU population, or the NFBC1966 population, which differ in some instances. 
3
Genotyped on the negative 
strand. 
4
RDBP spans the region Chr6:31529510-32034664, within that region NCR3 and AIF1 are also encoded, LST1 
is also overlapping with RDBP and NCR3. 
5
GSR = genotyping success rate. Duplication was carried out for all 
genotyping carried out in-house, most duplication error rates were < 0.1% (rs807661 was 1.1%; however, the 
duplication plate had a low genotyping success rate overall). 
 
Association analysis of genetic variants and growth parameters 
 
Description of growth curve fitting and derivation of growth parameters from the fitted curves 
is described in chapter 5.2. The derived parameters from the Reed1 and JPA-2 models were 
used separately as outcomes in the SNP association analysis. Due to skewness, natural 
logarithmic transformation was used for PHV1 and PHV2. To account for the random variation 
attached to the derived growth parameters, the association analyses were weighted by the 
number of measurements per person within the age period in question (infancy: 0-24 months, 
puberty: 8-16 years for females, 9-17 years for males). A regression model assuming an 
additive genetic effect was fitted between each SNP and each growth parameter, adjusted for 
sex and PCs. Additionally, the same analyses were run with sex-SNP interaction included. 
Preliminary analyses showed that adjusting additionally for BL and GA does not essentially 
change the results, and this adjustment was not done. Results are reported per one allele 
increase in the genotype, the reference allele being the height decreasing allele in the 
previous GWA studies. SAS (version 9.1.3.) was used for all the association analyses of 
genetic variants and growth parameters.  
 
In addition, the interaction between SNP effects and age (infancy vs. puberty) on peak height 
velocity (PHV) was tested. This was necessary as, especially in the context of low power, 
finding that some SNPs are statistically significantly associated with PHV at one age and not 
the other does not automatically indicate different pattern of associations between these 
ages. Since PHV is much higher in infancy than in puberty, PHV Z-scores were calculated 
from the log-transformed PHV variables at each age to unify their scale. The data from 
infancy and puberty were combined into a single data set where most individuals had PHV 
values for both ages, i.e. two records per person, with the age indicator variable referring to 
the time when PHV was estimated (0=infancy, 1=puberty). A mixed model for repeated 
measures was chosen that takes into account the within-person correlation in the outcome 
values. The mixed model was fitted between each SNP and PHV Z-score without pre-defined 
covariance structure for the error matrix (type=unstructured), with SAS PROC MIXED (version 
9.1.3.). Age was included in the model as a binary variable (0=infancy, 1=puberty) and the 
age-SNP interaction was tested. The analysis was weighted by the number of measurement 
points at the age window in question (on average 7-8 measurements per person at both 
ages). The model was additionally adjusted for sex and PCs.  
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Power calculations 
 
Statistical power was 60% to detect a per allele effect size of 6.0% SD (0.24 cm/year) for 
PHV1, 6.6% SD (0.10 cm/year) for PHV2, and 4.9% SD (0.46 cm) for adult height, assuming 
a MAF of 0.31, which was the average among the 48 SNPs, additive genetic model and 
significance threshold p < 0.05. For comparison, statistical power was 80% to detect a per 
allele effect size of 7.6% SD (0.30 cm/year) for PHV1, 8.4% SD (0.13 cm/year) for PHV2, and 
6.2% SD (0.58 cm) for adult height with the same assumptions. Quanto (156) was used for 
the power calculations. 
 
 
 
Figure 5.1. Flow chart of genotyping strategy for the genetic association study on 
height growth in the NFBC1966. The left arm shows genotyping done separately for 19 
SNPs from Weedon et al., 2008 (335); the right arm shows the GWA route to identify further 
29 SNPs (336, 337). The maximum number in final analyses was 3,538 with both growth and 
genotype information.  
 
Representativeness 
 
The sub-sample that attended the clinical examination at age 31 years is adequately 
representative of the NFBC1966 in terms of gender and socio-economic indicators at birth 
and at age 31 years (329). Even better representativeness was observed when the sub-group 
with growth data and height SNP information (N=3,538) was compared with attendees of 
clinical examination who did not have this information available (N=2,469). In this comparison, 
males had data available slightly more often than females (61% vs. 57%). There were no 
differences regarding unemployment history or education (data available for 58-60% in all 
groups). There were small differences between social classes at birth (data available for 56-
62% in all groups). At age 31 years, other social classes had more often data available than 
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farmers (57-62% vs. 51%), but it has to be noted that this may be explained by random 
variation since the farmers group at age 31 years is small (N=214). 
 
5.5.2. Association between FTO polymorphism and longitudinal BMI growth 
 
To examine the association between FTO (rs9939609) genotype and changes in BMI from 
birth to 13 years of age, genetic data and longitudinal growth measurements from eight 
studies were used. This was a collaborative effort coordinated by Dr. Nicholas Timpson who 
contacted the cohorts, prepared descriptive analysis tables and provided data for all analyses 
from the ALSPAC study. I was involved in the planning stage and the longitudinal analysis 
decisions (modelling BMI growth in infancy and childhood, selecting the age window cut-offs), 
fitted the longitudinal models for NFBC1966 and GENR and provided data for longitudinal 
analyses from these cohorts, designed the adiposity peak (AP) and adiposity rebound (AR) 
analyses, combined results from different cohorts to AP and AR tables and meta-analysed the 
AP and AR results. Ms. Nicole Warrington analysed the RAINE, BGC and Uppsala cohorts 
longitudinally and performed some of the meta-analyses, Dr. Dennis Mook-Kanamori 
performed some of the meta-analyses and was actively involved in writing the manuscript 
based on this work (Sovio* et al. PLoS Genet 2011 (in press)). Several senior authors from 
different research units were involved in planning the study and writing the paper. 
 
The AR and AP analyses were originally performed only in the NFBC1966, and I wrote and 
presented an abstract on this work in the British Atherosclerosis Society‘s meeting in 2009 
(oral presentation) and in the American Society of Human Genetics 2009 meeting (poster 
presentation). I also drafted a separate manuscript on the AP and AR analyses in the 
NFBC1966. However, in the final stages of the work on several cohorts, the AP and AR 
analyses pioneered in the NFBC1966 were repeated in all other cohorts with data available, 
and the data from these analyses were included in the larger manuscript. 
 
Study subjects 
 
All subjects were children of white European ethnicity and, when multiple siblings were 
present in a specific cohort, only data from the oldest sibling were used for analyses. Multiple 
births were excluded from all analyses. All studies except the NFBC1966 are briefly described 
below: 
 
The Avon Longitudinal Study of Parents and Children (ALSPAC) is a prospective birth cohort 
in Bristol, UK, which recruited pregnant women with estimated delivery dates in 1991-1992 
(present analysis: 7,482 subjects). The Barry Caerphilly Growth Study (BCG) is a longitudinal 
study of infants born in the towns of Barry and Caerphilly in South Wales between 1972 and 
1974 (569 subjects). The Christ’s Hospital Cohort (CHC) is a retrospective follow-up study 
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comprised of former male students between the ages of 10 and 18 years of the Christ‘s 
Hospital born between 1927 and 1956 (812 subjects). As part of the Energy Balance Study 
(EBS), data were collected in 2002 and 2003 on pre-pubertal schoolchildren, ages 4 through 
to 10 years, from north-eastern Scotland, Dundee (2,604 subjects).The Generation R Study 
(GENR) is a prospective birth cohort from early foetal life onwards based in Rotterdam, the 
Netherlands. Subjects were born between 2002 and 2006 (2,851 subjects). The Raine Study 
(RAINE) is a prospective pregnancy cohort set up in 1989, which recruited pregnant women 
from Perth, Western Australia, to examine ultrasound imaging (1,106 subjects). The Uppsala 
Birth Cohort Multigeneration Study (UBC), is a multigenerational study based in Uppsala, 
Sweden, on children born between 1915 and 1929 (594 subjects). From the NFBC1966, 
3,707 subjects were available for the present analysis. 
 
In all studies, growth characteristics (weight and height) were measured during routine visits 
at community health centres or at the specific research centres. All subjects (or their 
parents/guardians) gave their informed consent and each study obtained ethical approval 
from the local ethical review board. Further details are presented in the Supplementary online 
material in Sovio* et al. PLoS Genet 2011 (in press). 
 
Genotyping and quality control 
 
Genotyping of the FTO rs9939609 was performed in all eight cohorts. DNA was isolated 
either from buccal swabs, blood or cord blood. Further details of the studies and of 
genotyping undertaken in them can be seen in the Supplementary online material in Sovio* et 
al. PLoS Genet 2011 (in press). 
 
Cross-sectional analyses 
 
Based on the ages at which the subjects visited the community health centres or the research 
centres in the various studies, growth characteristics were grouped into ten age strata: 0.01 to 
0.49 years (i.e. excluding birth); 0.50 to 1.49 years; 1.50 to 2.49 years; 2.50 to 3.49 years; 
3.50 to 4.49 years; 4.50 to 5.49 years; 5.50 to 6.99 years; 7.00 to 8.99 years; 9.00 to 10.99 
years; and 11.00 to 12.99 years. To ensure normality in each study, BMI was transformed 
using natural logarithmic transformation and stratum-specific Z-scores were created. All 
values with a Z-score above or below 3.0 were removed. Size at birth (birth weight and birth 
length), were not included in any of the analyses. 
 
To examine the effect of FTO genotype on BMI, defined as weight[kg]/(height[m])
2
, within 
each age stratum cross-sectionally, we used multiple linear regression. Study-specific effect 
estimates within each age-stratum were created assuming an additive genetic model. These 
models were adjusted for age, because age varied within each age-stratum, and sex as BMI 
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growth varies between sexes but previous work has shown no evidence for sex–FTO 
genotype interaction on BMI (27). As it has been previously shown that variation at rs9939609 
is not associated with either birth weight (BW) or gestational age (GA) (27), models were run 
without these covariates. Furthermore, the use of covariates (excluding sensitivity analysis) 
was restricted to sex and age since the distribution of genotypes is assumed to be unrelated 
to possible environmental confounders (339). To take into account known correlations 
between BMI and height at early ages, analyses were repeated in a further sensitivity analysis 
using weight/height
p
 (p ranging from 1.7 to 2.8) where we created stratum- and sex-specific p 
scores for each study (340). Basic analyses were performed in Stata version 11 (Stata corp.).  
 
Cross-sectional analysis results were meta-analysed within each stratum using an inverse 
variance method. A fixed effects model was applied if variance was homogeneous (all age 
strata under 9 years of age) and a random effects model if variance was heterogeneous (9-13 
years) using the Rmeta package in R (version 2.6.2). 
 
Longitudinal analyses 
 
BMI was modelled in two time windows (5.2.3) using the studies that contained the most data 
within these time windows (BCG, GENR, NFBC1966 and Uppsala in the 2 weeks to 18 
months window and ALSPAC, RAINE, NFBC1966 and Uppsala in the 18 months to 13 years 
window). In both time windows, analysis results for both intercept (baseline BMI) and slope 
(change in BMI over time) were meta-analysed (inverse variance) using a fixed effects model 
in the Rmeta package in R (version 2.6.2). 
 
Longitudinal analyses in infancy (2 weeks to 18 months). Linear mixed effects (LME) 
(341) models were fitted using sex, genotype, GA and their interactions with age as 
covariates, with random effects for intercept (baseline BMI) and slope (linear change in BMI 
over time). In addition to linear age effect, quadratic and cubic terms for age were included to 
account for nonlinearity of BMI change over time. The analysis was restricted to singletons 
with BMI measures from two weeks to 18 months of age. The model is written as: 
 
BMI (kg/m²) = β0 + β1 Age + β2 Age
2
 + β3 Age
3
 + β4 Sex + β5 Gest_age + 
β6 FTO TA genotype + β7 FTO AA genotype + β8 Age * Sex + β9 Age * FTO TA 
genotype + β10 Age * FTO AA genotype + β11 Age * Gest_age + u0 + u1 (Age) + ε, 
 
where βn (n = 0, ..., 11) are the fixed effects, um (m = 0, 1) are the individual level random 
effects and ε is the residual error. The age component was centered to nine months and GA 
(Gest_age) was centered to 40 weeks before fitting the model. Several sensitivity analyses 
were also performed to ensure that the inferences from the above model would not change if 
different parameters were incorporated. These included changing the upper limit of age from 
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18 months to 12 and 24 months, adjusting for BMI at birth, BW and duration of breast feeding 
in early life (where available), inclusion of BMI measurements from the first two weeks of life, 
and removing the adjustment for GA. 
 
Longitudinal analyses in childhood (beyond 18 months to 13 years). An extension to the 
LMEM based on multivariate skew-t distribution was applied to provide robustness against the 
normality assumptions of random effects and random error in the LMEM framework. This 
multivariate skew-t model (342, 343) assumes the random effects follow a multivariate skew-
normal distribution while the subject measurement errors follow a t distribution. Therefore, the 
overall distribution of the response follows a multivariate skew t distribution. In the skew-t 
LMEM, one has to estimate a skewness parameter for each component of the random effects 
and the degree of freedom of the t distribution for the error term, this latter parameter 
controlling the length and thickness of the distribution (kurtosis). The same covariates and 
random effects were chosen as in the infancy analysis, except that this analysis was not 
adjusted for GA. Age was centred at 7.25 years before fitting the model. Sensitivity analysis 
on the additional adjustment for the baseline BMI at 18 months of age was performed to 
ensure the stability of inferences. Additionally, a comparison was made between the skew-t 
model and a LMEM to determine the best fit for the data.  
 
Derivation of age and BMI at adiposity peak (AP) and adiposity rebound (AR). Age and 
BMI at AP and AR were derived from models similar to those described above. The same age 
thresholds (two weeks – 18 months and >18 months – 13 years) were used and multiple 
births excluded. The LMEM was chosen for this analysis since it gave nearly identical 
estimated values for the growth parameters as the skew-t model (correlation coefficients = 
0.93-0.99 in RAINE and Uppsala), but was more efficient. Logarithmic transformation 
improved the normality of the BMI distribution, particularly in childhood but also in infancy, 
and therefore the model was fitted for log-transformed BMI measurements. Linear, quadratic 
and cubic age effects and sex effect were included. Genotype effects were removed from 
these models since we wanted to estimate age and BMI at AP and AR independently and to 
then analyse their association with FTO. GA was not adjusted for in this infancy model 
(contrary to the model presented earlier), since its effect was minimal and the sample size 
would have decreased due to missing GA values in some of the cohorts. Sex interactions with 
linear and quadratic age effects were added in the childhood model since they both were 
statistically significant (p < 0.01) in ALSPAC and NFBC1966 after removing FTO from the 
model. Random terms for the intercept and slope were included in both models to allow 
individual departures from the common intercept and slope.  
 
The models are written as: 
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(1) Infancy model: 
ln(BMI (kg/m²)) = β0 + β1 Age + β2 Age
2
 + β3 Age
3
 + β4 Sex + u0 + u1 (Age) + ε 
 
(2) Childhood model: 
ln(BMI (kg/m²)) = β0 + β1 Age + β2 Age
2 
+ β3 Age
3
 + β4 Sex + β5 Age * Sex + β6 Age
2
 * 
Sex + u0 + u1 (Age) + ε 
 
For each participant, a predicted BMI at AP and AR (at a minimum resolution of every 0.05 
years in infancy and every 0.1 years in childhood) was calculated using the estimated fixed 
and random coefficients. Age at AP was defined as the age at maximum BMI between 0.25 
and 1.25 years and age at AR as the age at minimum BMI between 2.5 and 8.5 years. These 
cut-off points were chosen based on descriptive analysis of growth curves in the NFBC1966. 
The associations between FTO genotype and these growth parameters were analysed using 
general genetic models adjusted for sex. To account for uncertainty in the derived 
parameters, each person was weighted by the number of measurements within the age 
window in question in the association analyses. Persons who had fewer than three 
measurements per age window were excluded from the analyses, since capturing the 
complex relationship between age and BMI becomes impossible with fewer than three 
measurement points. Sensitivity analyses with GA as a further adjustment in the AP models 
made no substantive differences to the results (performed in the NFBC1966), and since this 
adjustment would have decreased numbers in some of the cohorts, it was omitted. Age at AP 
and age at AR were analysed without any transformation. The distribution of BMI at AP was 
slightly skewed to the right and BMI at AR more strongly skewed to the right. Therefore log-
transformation was used for BMI at AP and BMI at AR, and association results are reported 
as percentage differences in BMI between genotypes.  
 
In both time windows, association results between each growth parameter and FTO were 
meta-analysed (inverse variance) using a fixed effects model in the Rmeta package in R 
(version 2.6.2) and in parallel with the MetaAnalyst software (Beta 3.13). In case of 
heterogeneity, results from a random effects model were reported. 
 
5.6. Methods used in GWAS 
 
This chapter describes the methods applied in the GWA analyses on directly genotyped and 
imputed SNPs in the NFBC1966. Most of the described analyses within the NFBC1966 were 
performed in the context of a meta-analysis of several cohorts in a large consortium. My role 
varied between the studies so that in some of them (5.6.1 STAMPEED meta-analysis) I 
provided GWAS results from the NFBC1966 to the meta-analysis group, whereas in others I 
additionally performed the meta-analysis myself (5.6.2) and took the responsibility of co-
ordinating the GWAS and meta-analysis effort within the consortium (5.6.3). 
 123 
 
5.6.1. GWAS on adult anthropometric and metabolic phenotypes 
 
Analyses on directly genotyped data 
 
Preliminary analyses on metabolic traits were performed using the pilot data described in 
4.2.3. The data set was used solely for training purposes and quality control. At this point, 
BC/SNPmax system version 2.5.9 was installed at Imperial College and collaborating units at 
UCLA, University of Oulu and University of Oxford to facilitate whole genome data storage, 
management, analysis and data sharing between the units. I took the responsibility of the 
data management tasks at Imperial College. In addition to the genotype data, a 
representative selection (initial N=120) of several thousands of NFBC1966 phenotypes was 
imported into the BC/SNPmax system. QC of the pilot data was performed by a team at 
Imperial College (Dr. William Astle, Dr. Alexandra Lewin, and Dr. Lachlan Coin). The number 
of individuals included in the analysis after sample exclusions was 1,804. Since this data set 
was small and biased towards extreme triglyceride values, aiming for publication using this 
sample was not considered. I produced sex-stratified analyses on BMI with various selections 
of model adjustments, using PLINK versions 0.99 and 1.00 in December 2007 – January 
2008. These results were included in my MPhil to PhD upgrade presentation (29 January 
2008) although they were not performed in time to be included in the upgrade report itself.  
 
The first published analyses on the nearly final release of the NFBC1966 GWA data were 
performed before the imputation of SNPs using IMPUTE (324). These analyses are based on 
the 329,091 quality controlled, directly genotyped SNPs from 22 autosomes and the X 
chromosome in 4,763 individuals. The supplementary analysis using weighted haplotype 
association (WHAP) method for imputation is omitted from this thesis. Nine quantitative 
phenotypes measured at age 31 years were selected for the analysis: triglyceride, HDL 
cholesterol, LDL cholesterol, glucose, insulin, C-reactive protein (CRP), BMI, SBP and DBP. 
My contribution was mainly in data management at this stage. The final, published analyses 
were performed by the team in UCLA and the methods for these analyses are described in 
detail in Sabatti et al. (2009) (324).  
 
Analyses of height, body mass index and waist circumference on imputed data 
 
Subsequently, I performed analyses on a small selection of continuous traits using the 
imputed SNPs from IMPUTE (see details in 5.4.3). Height, BMI and WC at age 31 years were 
selected and analysis restricted to singletons to enable comparisons between GWAS on 
anthropometric traits at age 31 years with GWAS on early and childhood growth. In addition, 
the overlap between the BMI analysis results based on imputed data with those based solely 
on directly genotyped data were investigated. The same adjustments were made as in the 
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published paper (324), the only difference being the adjustment for population structure. The 
first two components from multidimensional scaling (MDS) analysis were adjusted for in the 
multivariate analyses of the paper, whereas the first three PCs (details in 5.4.2) were adjusted 
for in all my analyses. Similarly to the paper, my analyses were adjusted for sex, and BMI and 
WC analyses were also adjusted for oral contraceptive use and pregnancy status in females. 
Of the singleton females with imputed genotype data who attended the clinical examination at 
age 31 years, 8% (N=184) were pregnant. 54% (N=100) of the pregnant females did not have 
weight measured and 77% (N=144) of them did not have WC measured, and therefore were 
automatically excluded from the BMI and WC analyses. BMI and WC were log-transformed 
since their distributions were skewed to the right. Z-scores of the phenotypes ((value – mean) 
/ SD) were used as outcomes in the association analysis. Since for height the genomic 
inflation factor (Table A.1.) was clearly higher than for the other two phenotypes (1.09 for 
height vs. 1.03 for BMI and 1.01 for WC), height was re-analysed with an additional 
adjustment for PCs 4-15. The analyses were performed with SNPTEST software using linear 
regression, assuming an additive genetic model. SNPs with MAF ≤ 0.01 and/or imputation 
quality (proper_info) ≤ 0.4 were excluded from the results.  
 
Q-Q plots and Manhattan plots were obtained using R (version 2.7.0) scripts produced by Dr. 
Adailakavan Ramasamy at Imperial College London for all GWAS (including meta-analyses) 
presented in this thesis. The Q-Q plot script utilises the existing snpMatrix R package (Table 
2.2). 
 
STAMPEED Meta-analysis of GWAS on bivariate metabolic traits and metabolic syndrome 
 
A meta-analysis of GWAS on metabolic traits in a total sample of 22,161 participants from 
seven population/family studies was performed within the SNP Typing for Association with 
Multiple Phenotypes from Existing Epidemiologic Data (STAMPEED) Consortium MetS 
working group. The participating studies include ADVANCE (case and control samples), 
ARIC, CHS, FHS, GENOA, GeneSTAR, and NFBC1966, and they are described in detail in 
Kraja* et al. Diabetes 2011 (in press). My role in this collaboration was to perform the 
analyses within the NFBC1966, which included GWAS and several follow-up analyses after 
the meta-analysis. I did not perform any meta-analyses for this consortium.  
 
Ten bivariate combinations of the five components of MetS (high WC, low HDL cholesterol, 
high fasting triglyceride, high fasting glucose and high BP) were formed using the updated 
thresholds defined for the National Cholesterol Program ATP III (266, 267) (see the exact 
definition in chapter 5.3.2). In each bivariate combination, the individuals exceeding the 
threshold in both components were defined as cases and those exceeding the threshold in 
one or neither of the components were defined as controls. Those who had a missing value in 
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one or both of the components were excluded from the analysis of the bivariate combination 
in question.  
 
MetS was defined based on the same thresholds as the bivariate combinations. The definition 
of cases and controls varied according to the number of valid measures available as follows 
(see chapter 5.3.2): Individuals who exceeded the threshold in at least three of the MetS 
components (WC, HDL, triglyceride, glucose and BP) were defined as MetS cases. The 
minimum number of valid measures of MetS components for case definition was three. 
Individuals with less than three components exceeding the threshold who had valid measures 
in all five components were defined as MetS controls. In addition, individuals with less than 
two components exceeding the threshold who had valid measures in four of the components, 
and individuals with none of the components exceeding the threshold who had valid 
measures in three of the components, were defined as MetS controls. For all other individuals 
MetS was defined as missing and they were excluded from the MetS analyses.  
 
In each study about 2.5 million SNPs were imputed based on the HapMap haplotypes. In the 
NFBC1966, 2,378,857 SNPs were available for analysis after imputation. The maximum 
number of NFBC1966 individuals included in the analyses was 4,757. MetS per se and 10 
bivariate combinations of the five components of MetS were analysed as outcomes in GWAS. 
An additive genetic model was assumed for each of the eleven traits. Covariate adjustments 
varied between studies, e.g. due to differences in study design. For example, some of the 
studies had to adjust for study centre. All studies adjusted the analyses for sex, age and age
2
. 
This applied also to NFBC1966 despite the small variation in age at the time of the clinical 
examination (mean=31.1 years, SD=0.35 years). In addition, the first five PCs were adjusted 
for to account for population stratification. In the NFBC1966, a logistic regression model was 
fitted. Some studies had to take into account familial correlations in the data by fitting a 
Generalised Estimating Equations model instead (Kraja* et al. Diabetes 2011 (in press)). 
 
Each study provided GWA results for each of the 11 traits to the Data Coordinating Center 
(DCC - Division of Statistical Genomics, Washington University in Saint Louis, MO, USA) for 
the meta-analysis. SNPs with r
2
 < 0.3 (for studies that imputed using MACH), proper-info < 
0.4 (IMPUTE), or variance-ratio < 0.3 (BIMBAM), as well as those with study-specific MAF < 
5% were filtered out from meta-analysis. Only markers with an rs-name mapped to dbSNP 
build 36.3/130 were admitted in the analysis. As a result the following percentages of imputed 
markers were used in the meta-analyses: ADVANCE case 81.4%, ADVANCE control 81.2%, 
ARIC 85.2%, CHS 69.6%, FHS 85.5%, GeneSTAR 79.4%, GENOA 84.1% and NFBC1966 
86.1%. On average ~2 million SNPs remained for the meta-analysis.   
 
The DCC used markers from two studies of different genotyping platforms (ARIC - Affymetrix 
and GeneSTAR - Illumina), matching them with the dbSNP (Genome build 36.3/130) strand, 
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to create a ―template‖ of allele orientation. During the preparation of the data for meta-
analyses, strand alignments for each study were confirmed against this ―template.‖ After the 
alignment, a meta-analysis of the beta coefficients was conducted based on a random 
coefficients model as proposed by DerSimonian and Laird (344). The analyses were 
performed using SAS v. 9.2 Linux OS in combination with online SAS web tools developed at 
the DCC. To correct for multiple testing, the simpleM method was applied. It is an adjusted 
Bonferroni correction method based on PC analysis that takes into account LD among SNPs 
(345). As a result, a p-value of 9.7x10
-8
, which corresponds to a negative log10 p-value of 
7.01, was selected as the genome-wide significance threshold. 
 
The 42 most significantly associated SNPs (top SNPs) identified by the meta-analyses were 
tested in each study population for their association with each of the five dichotomised traits 
(WC, HDL cholesterol, triglyceride, glucose, and BP; cut points according to the MetS 
definition, chapter 5.3.2). The quantitative HDL cholesterol, triglyceride and/or SBP 
phenotypes for subjects using antihyperlipidemic and/or antihypertensive medications were 
corrected based on the estimated average effects of medications from clinical trials (346). The 
untreated triglyceride was estimated as triglyceride / (1 – 15.2 / 100); the untreated HDL 
cholesterol as HDL / (1 + 6.1 / 100); and the untreated SBP was estimated as SBP + 14.8 
mmHg. To test for pleiotropy with quantitative traits, i.e. a SNP having significant additive 
main effects on two different traits, the association for pairwise combinations of traits was 
assessed, while allowing for a residual correlation (due to all other effects besides the SNP in 
question). Linear mixed effect model association tests using the MIXED procedure of SAS v. 
9.2 were performed between two selected traits and a selected marker based on an additive 
genetic model. In studies with familial correlations, subjects were nested within pedigree and 
were considered statistically as repeated units. An unstructured variance-covariance matrix 
(in SAS language: type=un) was specified in the mixed model to account for the residual 
correlation among traits (not accounted for by the putative SNPs with pleiotropic effects). 
 
5.6.2. Meta-analysis of GWAS on birth weight and gestational age 
 
The meta-analysis of GWAS on birth weight (BW) and gestational age (GA) was an 
undertaking within the EGG (Early Growth Genetics) postnatal growth working group within 
the EAGLE (EArly Genetics & Lifecourse Epidemiology) Consortium (347). The NFBC1966 
was included in this study as a discovery cohort and the NFBC1986 as a replication cohort. 
My role was to perform all GWAS and all follow-up analyses on BW and GA phenotypes 
within the NFBC1966, part of the replication and follow-up analyses within the NFBC1986 
(work shared about 50%/50% with Ms. Marika Kaakinen at the University of Oulu), and the 
meta-analysis of BW (uniform), GA (uniform continuous and binary) using MetaMapper in 
parallel with Dr. Rachel Freathy, who performed the same analyses with METAN. In addition, 
I co-ordinated part of the additional data collection and produced tables (work shared with Dr. 
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Rachel Freathy, who did the majority of that work). I wrote parts of the manuscript and 
commented on the parts others wrote in Freathy* et al. (2010) (348).  
 
The protocols for these analyses were written by Dr. Rachel Freathy and shaped by 
comments from everyone involved in the meta-analysis. These protocols have been adapted 
to meta-analyses of GWAS on other phenotypes within the EGG postnatal working group with 
slight modifications (chapter 5.6.3).   
 
Methods for birth weight (BW) analyses 
 
Stage 1: GWAS meta-analysis of BW. Discovery samples, genotyping and imputation. 
Six population-based European studies with BW, GA and GWA data available at the 
beginning of May 2009 (combined N=10,623) were selected for a GWAS on BW: NFBC1966 
(N=4333); Netherlands Twin Register (NTR; N=414; singletons only); and sub-samples from 
the 1958 British Birth Cohort (B58C-WTCCC, N=1227; B58C-T1DGC, N=2037), Generation R 
(N=1194) and Avon Longitudinal Study of Parents And Children (ALSPAC; N=1418). The 
B58C-WTCCC and B58C-T1DGC were analysed separately because they were genotyped 
on different platforms at different times. However, there is no systematic phenotypic 
difference between these sub-samples. Informed consent was obtained from all study 
participants (or parental consent, as appropriate), and study protocols were approved by the 
local ethics committees. Genotypes were obtained using high-density SNP arrays, and then 
imputed for ~2.4 million HapMap SNPs (Phase II, release 21/22 (134, 333)). The basic 
characteristics, exclusions (e.g. samples of non-European ancestry), genotyping, quality 
control and imputation methods for each discovery sample are presented in Freathy* et al. 
(2010) (348) Supplementary Table 1. 
 
GWAS within discovery samples. Multiple and preterm births (GA <37 weeks) were 
excluded from the analysis. In the included samples, BW was transformed into a Z-score (= 
[value-mean]/SD) to allow comparison of the data from the various studies. The overall (as 
opposed to sex-stratified) mean and SD from each study were used to create Z-scores. 
 
The association between each SNP and BW was assessed in each study sample using linear 
regression of BW Z-score against genotype (additive model), with sex and GA as covariates. 
The analyses were performed with software designed for GWAS: SNPTEST (126, 349), 
MACH2QTL (350, 351) or PLINK (180, 352) (Freathy* et al. (2010) (348) Supplementary 
Table 1). Imputed genotypes were used only where directly-assayed genotypes were 
unavailable. In addition to this ―UNIFORM‖ analysis, a second analysis (the ―BEST‖ analysis) 
was performed, in which the genetic model, outcome transformation, stratifications and 
covariates were decided within each study. 
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Details of the GWAS software, any additional corrections for study-specific population 
structure in the UNIFORM analysis, and details of the BEST analysis are given in 
Supplementary Table 1 in Freathy* et al. (2010) (348). In the NFBC1966, the SNPTEST 
programme was used to perform GWA analyses. The first three principal components were 
adjusted for to correct for population structure, as recommended by the analysis team, 
although only the second principal component of the three was associated with BW. In the 
NFBC1966, the BEST analysis used a similar additive genetic model as the UNIFORM 
analysis, but it was stratified by sex and additionally adjusted for socio-economic status at 
birth (primarily based on data from the father) and maternal variables including education, 
smoking at two months of pregnancy, parity (i.e. the number of previous deliveries), age and 
desirability of pregnancy. A larger selection of potential variables for adjustment was initially 
considered based on previous studies on the determinants of BW (228), and the variables 
which remained associated with BW at p < 0.05 significance level in the NFBC1966 after 
adjusting for all other maternal/paternal variables were retained. Stratification by sex was 
made on the basis of known differences in foetal growth between sexes, some of which could 
be due to genetic differences. 
 
Meta-analysis of discovery samples. Data exchange was facilitated by the SIMBioMS 
platform (353). Prior to meta-analysis, SNPs with a minor allele frequency <1% and poorly-
imputed SNPs (proper_info ≤ 0.4 [SNPTEST]; r
2
 ≤ 0.3 [MACH2QTL]) were filtered. Results 
were carefully quality checked for formatting errors, incorrectly-applied filters, duplicate SNPs, 
and for the range (validity) of regression coefficients, standard errors and p-values. Meta-
analyses of the UNIFORM and BEST analyses were each run in parallel in two different study 
centres, and each meta-analysis was performed using two different software packages: 
METAL (http://www.sph.umich.edu/csg/abecasis/metal/index.html); and MetaMapper 
(software developed in-house at Imperial College London, UK). Genomic control (137) was 
applied twice at the meta-analysis stage: firstly, to adjust the statistics generated within each 
cohort (see Freathy* et al. (2010) (348) Supplementary Table 1 for individual study λ-values); 
and secondly, to adjust the overall meta-analysis statistics for any residual population 
stratification between the cohorts (λ=1.032). Cochran‘s Q statistic did not generally indicate 
heterogeneity between the data sets and therefore fixed effects models were considered 
adequate. The results from the UNIFORM analysis were meta-analysed using the inverse-
variance method, whereas for the BEST analysis a Z-score weighted method that allows for 
differences in the units of beta coefficients and standard errors was applied (176). SNPs that 
were available for less than half of the total expected sample were excluded. Final meta-
analysis results were obtained for 2,427,548 SNPs. Those SNPs that reached a p-value 
threshold of <10
-7
 in the UNIFORM analysis (N=10 SNPs, representing 2 distinct genomic 
regions on chromosome 3, separated by > 33Mb) were considered for further follow-up. The 
BEST analysis gave very similar results to the UNIFORM analysis. Therefore only UNIFORM 
results are reported.  
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Checking for independent association signals near to the top hits. To test for the 
presence of additional association signals around the most strongly associated SNP in each 
of the two regions (rs900400 and rs9883204), the UNIFORM association analysis on 
chromosome 3 was re-run in each discovery sample. This time, genotypes at rs900400 and 
rs9883204 were included as additional covariates. In cases where these SNPs were imputed, 
genotype dosage was calculated from the genotype probabilities and used in the model 
instead. The results were meta-analysed using the inverse-variance method. 
 
Stage 2: Follow-up of two lead signals in additional samples. Follow-up samples, 
genotyping and analysis. 17 study samples (combined N=30,098) were used to follow up 
the two lead signals from the GWA meta-analysis, represented by index SNPs rs900400 and 
rs9883204. The basic characteristics, genotyping and quality control details of these samples 
are presented in Supplementary Table 2 in Freathy et al. (2010) (348). 13 of the samples 
(combined N=27,591) were of European ancestry and were therefore used for replication of 
the BW associations. Associations were also examined in four further non-European or 
admixed study samples (combined N=2507). Informed consent was obtained from all study 
participants (or parental consent, as appropriate), and study protocols were approved by the 
local ethics committees. If the index SNP was unavailable, e.g. due to failed assay design, a 
closely correlated proxy was substituted (rs1482853 or rs900399 for rs900400 [HapMap r
2 
= 1 
and 0.96, respectively]; rs2877716 or rs6798189 for rs9883204 [HapMap r
2
 = 0.95 and 0.93, 
respectively]). In five of the replication studies, the index SNPs were imputed from genome-
wide genotype data (see Supplementary Table 2). In these cases, the study analysts either 
analysed directly genotyped proxy SNPs (Generation R study), or ―best-guess‖ genotype 
values with call rate ≥ 0.9 (CHOP study), or all imputed values using SNPTEST (LISA study: 
proper_info > 0.87), MACH2QTL (HBCS: r
2
 > 0.9) or GenABEL (ORCADES: r
2
 from MACH 
>0.9; http://mga.bionet.nsc.ru/~yurii/ABEL/GenABEL/). The UNIFORM BW analysis 
(described above) was performed within each study sample. Multiple births and deliveries 
before 37 weeks of gestation were excluded from this and all further analyses. The analysis 
was repeated in males and females separately to investigate possible differences in the 
associations between the sexes. This was carried out for both SNPs in all discovery and 
follow-up samples. 
 
Meta-analysis of replication samples, and overall meta-analyses. Fixed effects inverse 
variance meta-analyses of the UNIFORM results were performed as follows: (i) including all 
13 European replication samples; (ii) including all 19 discovery and replication samples of 
European descent, (iii) a sensitivity analysis, excluding the three studies without GA available; 
and (iv) including all 23 study samples, regardless of ethnic background (here, evidence for 
heterogeneity of effect sizes was tested using both fixed and random effects models). Sex-
stratified results from all European studies were meta-analysed. All meta-analyses were 
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performed in parallel at two different study centres, using different software packages (the 
METAN module, developed for Stata v.10 (183), MetaAnalyst Beta 3.13 (354), and rmeta in R 
v.2.7.0). The Cochran Q test and the I
2
 statistic (175) were used to assess evidence of 
between-study heterogeneity of effect sizes. 
 
Analysis of additional phenotypes: birth length (BL), birth head circumference (BHC) 
and ponderal index (PI). Where available, Z-scores ((value – mean) / SD) were created 
within each study for BL, BHC and PI (BW / BL
3
). Linear regression was used to assess the 
association between each of these outcomes and each of the two SNPs (rs900400 and 
rs9883204, or proxies), with sex and GA as covariates. Results across studies were 
combined using fixed effects inverse variance meta-analysis. BHC was not available in the 
NFBC1966. 
  
Analysis of smallness for gestational age (SGA). To examine the risk of SGA, sex- and 
GA-adjusted BW Z-scores (SDS) were created within 15 of the available European studies 
using Growth Analyser 3.0 (355). The reference was a cohort of 475,588 children born 
between 1977 and 1981 in Sweden (356). Subsequently, each study defined SGA as below 
the 10
th
 percentile of BW SDS within their study population. Logistic regression analyses were 
used to examine the associations of the two top hits with the odds of SGA. Analyses were 
repeated with a cut-off for SGA of below the 5
th
 percentile within each study. The results were 
combined across studies using fixed effects inverse variance meta-analysis. 
 
Combined allele score. To estimate the BW effect sizes attributable to the two loci in 
combination, an allele score was created using information from both SNPs. The idea was to 
use a score that would account for the different effect sizes of the two SNPs, while assuming 
an additive genetic model. Therefore a weighted score, rather than a simple allele count, was 
created. This allowed estimation of the differences in BW between individuals with different 
numbers of BW-lowering alleles at the two loci. Nine European replication samples (including 
the NFBC1986) in which GA was available (combined N=20,190) were chosen for this 
analysis. After verifying that the two SNPs were statistically independent, a weighted allele 
score was generated using the formula: 
 
2
1
2
1
/2
i
i
i
ijij wgws , 
where sj is the score for individual j, gij is the number of BW-lowering alleles (0,1, 2) for SNP i 
carried by individual j, and wi is the effect size for SNP i from the UNIFORM analysis within 
the cohort. Linear regression of BW (in grams) was performed against the allele score 
(additive model), with sex and GA as covariates. Beta coefficients from the nine studies were 
combined using fixed effects inverse variance meta-analysis. The weighted score was then 
rounded to the nearest integer, grouping scores ―0‖ and ―1‖ together. A linear regression 
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analysis of BW including the rounded allele score as indicator variables was performed, with 
sex and GA as covariates. The beta coefficients from the comparison of score 4 versus 0/1 in 
all nine studies were meta-analysed using the inverse variance, fixed effects method. 
 
Variance explained. To estimate the percentage of variation in BW that is explained by each 
of the associated loci, the adjusted-R
2
 value from the univariate linear regression of BW 
against genotype was obtained. A mean value from all European studies was then calculated, 
weighted by sample size. For comparison, the percentage of variation in BW explained by 
sex, GA, maternal age, parity, BMI and smoking during pregnancy, was also calculated. 
 
Analyses of potential confounders. To assess whether the associations observed between 
foetal genotype and BW were independent of maternal genotype, the mother-offspring pairs 
from the 4 studies with both maternal and foetal genotype available were used (ALSPAC, 
EFSOCH, Generation R (discovery and replication samples), and CLHNS; total N=8880 for 
rs900400; N=9127 for rs9883204). Within each study, the UNIFORM analysis of BW, with 
maternal genotype as an additional covariate was performed. For direct comparison, this was 
repeated without maternal genotype, using only subjects for whom maternal genotype was 
available. Two inverse variance meta-analyses (fixed effects) for each SNP were performed, 
combining regression coefficients for (i) foetal genotype, and (ii) foetal genotype adjusted for 
maternal genotype. 
 
To verify that the SNPs were not associated with maternal covariates of BW which could 
theoretically confound the observed associations with BW, linear or logistic regression was 
used to model the association between each covariate and genotype. The nine European 
replication cohorts with GA available were chosen for this analysis. Maternal age, weight, 
height and BMI (assessed during or before pregnancy) were analysed as continuous 
outcomes. Parity, maternal smoking during pregnancy, pregnancy-induced hypertension, pre-
eclampsia, gestational diabetes, induced labour and elective caesarean section were 
analysed as binary outcomes. Socio-economic variables, including maternal education and 
family income level were analysed as binary or continuous outcomes, depending on how the 
individual cohorts recorded the information. Where possible, results were meta-analysed from 
the individual cohorts to assess overall evidence of association. 
 
Methods for gestational age (GA) analyses 
 
The same studies as for BW were selected for the analysis of GA (total N=11,201 in the initial 
analysis in April-May 2009). Twins and babies born under 25 weeks of gestation were 
excluded. Also, the top 0.5% of GA distribution was excluded in each cohort. In the 
NFBC1966 this included babies with gestation over 44 weeks (N=21 born at 45 or 46 weeks). 
In addition, medically induced births were excluded where the information on this was 
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available. In the NFBC1966 this information was not available but in the 1960s medically 
induced births were rare and their effect on the results can be assumed minimal. GA in the 
NFBC1966 was based on estimation from the last menstrual period reported by the mother 
(weeks). On the contrary, in some of the younger cohorts such as Generation R, GA was 
based on ultrasound measurements (days). The ultrasound-based estimate is much more 
accurate than the estimate from the last menstrual period. 
 
GA was analysed in three different ways in the ―UNIFORM‖ analyses: 1) as a continuous 
variable using rank-based inverse-normal transformation, 2) in three categories: premature 
(<37 weeks), early (37 - <39 weeks) and on-time/late (>=39 weeks), and 3) as a binary 
variable: premature cases (<37 weeks) and controls (>=39 weeks). The association between 
each SNP and GA was assessed in each study using linear regression (analyses 1 and 2) or 
logistic regression (analysis 3) against genotype (additive model), with sex as a covariate. In 
addition, a ―BEST‖ analysis was performed, i.e. the genetic model, outcome transformation, 
stratifications and covariates were decided within each study. In the NFBC1966, SNPTEST 
was used for the GWA analyses and all the analyses were additionally adjusted for the first 
three principal components according to the recommendation by the study team, although 
they did not correlate with GA at p < 0.05 level. In the NFBC1966, the BEST analysis was 
otherwise similar to the UNIFORM analysis 1), except that the analysis was not adjusted for 
sex since there was no association between sex and GA. However, the BEST analysis was 
adjusted for socio-economic status at birth, mother‘s marital status and desirability of 
pregnancy. These variables were selected into the model using a similar protocol described 
earlier for the BW BEST analysis.  
 
5.6.3. Meta-analysis of GWAS on growth parameters  
 
The growth parameters selected for GWAS meta-analysis were peak height and weight 
velocities in infancy (PHV1 and PWV1), age at adiposity peak (AgeAP) and BMI at adiposity 
peak (BMIAP) in infancy, age at adiposity rebound (AgeAR) and BMI at adiposity rebound 
(BMIAR) in childhood. In the first instance (January 2010), GWAS results from Helsinki Birth 
Cohort Study (HBCS), NFBC1966, LISA and Generation R were available for the analyses in 
infancy (N=6,222-7,215). For childhood analyses data were available by mid-April 2010 from 
the HBCS, NFBC1966 and RAINE cohorts (N=6,051) (Table 5.4). 
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Table 5.4. Numbers in the growth parameter meta-analysis on GWAS. 
 
Study Birth 
years 
PHV1  PWV1 AgeAP BMIAP AgeAR BMIAR 
HBCS 1934-1944 1368 1449 1169 1169 1555 1555 
NFBC1966 1966 2977 3149 2585 2585 3459 3459 
RAINE 1989-1991 N/A N/A N/A N/A 1037 1037 
LISA 1998-1999 390 390 380 380 N/A N/A 
GENR 2002-2006 2198 2227 2088 2088 N/A N/A 
Total 1934-2006 6933 7215 6222 6222 6051 6051 
 
Cohort abbreviations: HBCS = Helsinki Birth Cohort Study, Finland; NFBC1966 = Northern Finland Birth Cohort 1966 
Study; RAINE = Raine Study, Perth, Australia; LISA = LISA Study, Germany (Munich, Leipzig, Wesel, Bad Honnef); 
GENR = Generation R Study, Rotterdam, The Netherlands. 
 
Exclusions 
 
Twins and individuals who had less than three growth measurements available within the age 
range in question were excluded from all analyses. In addition, premature babies (GA < 37 
weeks) were excluded from the infant growth parameter analyses (PHV1, PWV1, AgeAP, 
BMIAP).  
 
Peak height velocity (PHV1) and peak weight velocity (PWV1) in infancy 
 
In each cohort, PHV1 estimates for each person were derived using the Reed1 model (2.2.4, 
5.2.1, (327)). A cohort-specific Z-score of the transformed variable (ZLOGPHV1= [LOGPHV1 
- mean]/standard deviation) was used as an outcome in the GWAS. An additive model 
adjusted for sex, GA and population structure was fitted. PWV1 was obtained from Reed1 
weight growth curves in a similar manner and analysed in the same way as PHV1. The 
outcome was ZLOGPWV1= [LOGPWV1 - mean]/standard deviation. 
 
Age and BMI at adiposity peak (AP) in infancy were estimated as described earlier (5.2.3, 
5.5.2). Similarly to the PHV1 and PWV1 analyses, cohort-specific Z-scores of the derived 
variables were used as outcomes in the GWAS (ZAGEAP = [AGEAP – mean]/standard 
deviation and ZLOGBMIAP = [LOGBMIAP – mean]/standard deviation). An additive model 
adjusted for sex, GA and population structure was fitted for both variables.  
 
Age and BMI at adiposity rebound (AR) in childhood were estimated as described earlier 
(5.2.3, 5.5.2). Cohort-specific Z-scores of the derived variables were used as outcomes in the 
GWAS (ZAGEAR = [AGEAR – mean]/standard deviation and ZLOGBMIAR = [LOGBMIAR – 
mean]/standard deviation). An additive model adjusted for sex and population structure was 
fitted for both variables. Twins were excluded from the analysis. In addition, those who had 
less than three BMI measurements at > 1.5 - 13 years of age were excluded. Specification of 
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the growth models in R were given to the analysts to ensure the same models will be fitted in 
each cohort. 
 
The results from GWAS within each cohort were meta-analysed using metaMapper and 
METAL in a similar way as described in chapter 5.6.2. Poorly imputed (info < 0.3) and low-
frequency (MAF < 0.01) SNPs were not yet filtered out in the GWAS stage. However, 
performing a meta-analysis with metaMapper turned out to be impossible without removing 
poorly imputed SNPs, and therefore they were removed in the meta-analysis stage. In 
addition, SNPs with MAF < 0.001 were removed in the meta-analysis stage.  
 
Similarly to the BW analyses, genomic control (137) was applied twice at the meta-analysis 
stage: firstly, to adjust the statistics generated within each cohort; and secondly, to adjust the 
overall meta-analysis statistics. Primarily, fixed effects models were used. Cochran‘s Q 
statistic p-value for heterogeneity between the data sets was recorded and in case of 
heterogeneity (pQ < 0.05) the p-value from a random effects model was additionally reported. 
The results were meta-analysed using the inverse-variance method. After the meta-analysis, 
SNPs available in less than half of the cohorts and in less than half of the total sample size 
were excluded from the results, as well as SNPs which indicated very strong between-studies 
heterogeneity (pQ < 10
-5
) of association. All SNPs that reached a threshold of p < 10
-7
 were 
considered for further follow-up, as well as SNPs at p < 10
-5
 level which could be classified as 
biological candidates based on previous publications.  
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6. Results and study-specific discussions 
 
In this chapter, the analysis results from each separate study are presented and interpreted in 
the light of other studies from the same field. The results included in this thesis are discussed 
in the DOHaD framework in chapter 7.2. A description of growth data (6.1) is followed by a 
description of derived growth parameters and their correlations with anthropometric measures 
at birth and in adulthood (6.2). Associations between prenatal factors and infant height growth 
velocity, and associations between all growth parameters and adult anthropometric and 
metabolic phenotypes are presented (6.3). Relationships between candidate variants 
obtained from previous GWAS and derived growth parameters (6.4) are assessed. Finally, 
the GWAS results for adult metabolic and anthropometric traits, birth measures and growth 
parameters are presented (6.5). These include GWAS within the NFBC1966 as well as 
GWAS meta-analyses with other similar data sets. 
 
6.1. Descriptive analysis of growth data 
 
Figures 6.1 - 6.3 and Tables A.2 - A.4 describe the average height, weight and BMI in the 
NFBC1966 singletons by sex at pre-defined ages (see chapter 5.1). Males were on average 
115 g heavier and 0.8 cm longer than females at birth (p < 0.0001 for both differences) but 
both sexes had a similar BMI (p = 0.52) of 13.8 kg/m
2
. Growth was fastest during the first year 
of life when height increased by about 50% and weight nearly tripled. The height and weight 
figures (Figures 6.1 and 6.2) demonstrate the subsequent deceleration of growth in late 
infancy and constant childhood growth until the pubertal growth spurt, which occurs earlier in 
females than in males. 
 
 
Figure 6.1. Mean height in the NFBC1966 singletons by age and sex. 
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Sex differences in height were seen already in infancy. At 6 months of age (Table A.2) males 
were on average 1.9 cm taller than females, and the difference subsequently decreased so 
that males were about 1 cm taller than females between 3 and 10 years of age. Females 
caught up with males in height by the age of 11 years when their average height was about 
equal (p = 0.11). This reflects the earlier start of pubertal growth spurt in females. Females 
were still 1.3 cm taller than males at age 13 years (p = 0.0003) but at age 14 years males 
were already 1.6 cm taller than females (p < 0.0001). The average height at age 31 years was 
178 cm in males and 165 cm in females.  
 
At 6 months, males were on average 642 g heavier than females (Table A.3) and also their 
BMI was 0.42 kg/m
2
 higher (Table A.4, p < 0.0001 for both differences). The weight difference 
gradually declined and remained at about 400 g between 4 and 8 years of age (p < 0.01 at 
each age) and it was slightly smaller but statistically non-significant at ages 9 and 10. BMI 
was higher in males than in females from 6 months until 3 years of age (p < 0.05 at each age) 
but there were no sex differences in BMI at p < 0.05 level at 4 - 10 years of age. Females 
were heavier than males at 11-14 years of age (p < 0.05 at each age) but males were heavier 
from age 15 years onwards (p < 0.0001 at each age). The average weight at age 31 years 
was 80.0 kg in males and 65.7 kg in females. Females had a higher BMI than males at 11-16 
years of age (p < 0.05 at each age) but males had 0.47 kg/m
2
 and 0.98 kg/m
2
 higher BMI than 
females at ages 18 (p = 0.006) and 31 (p < 0.0001), respectively. The average BMI at age 31 
years was 25.2 kg/m
2
 in males and 24.2 kg/m
2
 in females.  
 
 
Figure 6.2. Mean weight in the NFBC1966 singletons by age and sex. 
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Figure 6.3. Mean body mass index (BMI) in the NFBC1966 singletons by age and sex. 
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years of age). Their height growth in puberty was slower than that of males (PHV 7.8 vs. 9.3 
cm/year) and they ended up nearly 14 cm shorter than males. Females had 1 kg/m
2
 lower 
BMI and 10 cm smaller waist circumference than males. 
 
Table 6.1. Growth measures and derived growth parameters from longitudinal data in 
the NFBC1966 by sex. Restricted to singletons with growth data (maximum N=4,228); mean 
(SD) given. 
 
Growth parameter or 
measurement 
Male (N=2,116) Female (N=2,112) Total (N=4,228) 
GA [weeks] 40.0 (1.9) 40.2 (1.8) 40.1 (1.9) 
BW [g] 3575 (519) 3458 (486) 3517 (506) 
BL [cm] 50.8 (2.1) 50.0 (2.0) 50.4 (2.1) 
PI [kg/m
3
] 27.2 (2.4) 27.5 (2.6) 27.4 (2.5) 
PHV1 [cm/year] 54.4 (3.2) 50.8 (3.8) 52.6 (4.0) 
PWV1 [kg/year] 13.7 (2.6) 12.1 (1.7) 12.9 (2.3) 
Age at AP [years] 0.74 (0.06) 0.75 (0.06) 0.75 (0.06) 
BMI at AP [kg/m
2
]  18.3 (1.1) 17.9 (1.1) 18.1 (1.1) 
Age at AR [years] 5.8 (0.9) 5.6 (1.0) 5.7 (0.9) 
BMI at AR [years] 15.4 (1.0) 15.3 (1.2) 15.4 (1.1) 
ATO [years] 11.2 (0.7) 9.3 (0.6) 10.3 (1.2) 
Age at PHV2 [years] 13.8 (0.8) 11.7 (0.7) 12.8 (1.3) 
PHV2 [cm/year] 9.3 (1.4) 7.8 (1.1) 8.6 (1.4) 
Height at 31 years [cm] 178.2 (6.4) 164.6 (6.2) 171.4 (9.3) 
Weight at 31 years [kg] 80.1 (12.6) 65.7 (13.3) 73.0 (14.8) 
BMI at 31 years [kg/m
2
] 25.2 (3.6) 24.2 (4.7) 24.7 (4.2) 
WC at 31 years [cm] 88.9 (9.8) 79.0 (12.1) 84.1 (12.0) 
 
GA = gestational age, BW = birth weight, BL = birth length, PI = Ponderal index = BW [kg] / BL [m]
3
, PHV1 = peak 
height velocity in infancy, PWV1 = peak weight velocity in infancy, AP = adiposity peak in infancy, BMI = body mass 
index, AR = adiposity rebound in childhood, ATO = age at pubertal height growth spurt take-off, PHV2 = peak height 
velocity in puberty, WC = waist circumference. 
 
Spearman correlation coefficients between derived growth parameters and selected growth 
measurements are reported by sex (Table 6.2). PHV1 had a weak inverse correlation (-0.05 
to -0.08) with BW and BL (0.0001 < p < 0.02 in both sexes), which is in line with the DOHaD 
growth acceleration hypothesis. A correlation of about 0.5 between PHV1 and PWV1 was 
observed. Higher PHV1 was associated with a slightly earlier age of AR and pubertal height 
growth spurt, and a slightly higher BMI at AR, PHV2 and adult waist circumference, but no 
correlation with adult BMI was observed. PHV1 had a correlation of about 0.45 with adult 
height. These associations were similar in males and females. 
 
In contrast to PHV1, PWV1 had a weak positive correlation with BW and BL in both sexes 
(Table 6.2). As expected, PWV1 had a high correlation of over 0.7 with BMI at AP, which 
suggests that weight growth in the first weeks of life is an important predictor of infant 
adiposity. The association between PWV1 and BMI tracked from infancy into childhood where 
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a correlation of about 0.5 was observed between PWV1 and BMI at AR. PWV1 also had a 
weak inverse correlation with age at AR. PWV1 had only negligible correlations with pubertal 
height growth spurt parameters (0.011 < p < 0.25). Surprisingly, the correlation between 
PWV1 and adult height was stronger (~0.30) than the correlation between PWV1 and adult 
BMI or waist circumference (0.12-0.14). The results were similar in both sexes. 
 
Higher PWV1 was also weakly correlated with a later AP (Table 6.2). Age at AP was also 
associated with slightly higher BMI at AP and at AR, but correlations with other growth 
measures and growth parameters were weak and most of them statistically non-significant. 
BMI at AP had a correlation of about 0.25 with BW and a correlation of 0.61 with BMI at AR in 
both sexes. There was still an observable, albeit weaker, correlation of 0.16-0.17 between 
BMI at AP and BMI at age 31 years.  
 
Higher age at AR correlated with a lower BMI at AR equally strongly as it correlated with 
lower BMI at age 31 years, correlations ranging from -0.45 to -0.53 (Table 6.2). The 
correlation between age at AR and waist circumference at age 31 years was -0.37 in both 
sexes. Later AR also had a correlation with later height growth spurt, correlation coefficients 
ranging from 0.25 to 0.39. BMI correlated with all weight and BMI related growth measures 
and growth parameters, most strongly with BMI at AP (correlation 0.61) and BMI at age 31 
years (correlation 0.44-0.45). Higher BMI at AR was also associated with an earlier pubertal 
height growth spurt in both sexes. 
 
Individuals with later pubertal height growth spurt had a lower growth velocity in puberty: the 
correlation between ATO or age at PHV2 and PHV2 varied between -0.59 and -0.86 (Table 
6.2). ATO and age at PHV2 were highly correlated with each other. The correlation was 0.97 
in males and 0.90 in females. 
 
In males, there were no correlations between the birth measures and any of the three growth 
parameters at puberty from the JPA-2 model (Table 6.2). In females, higher BW and BL were 
associated with slightly later pubertal height growth spurt (ATO and age at PHV2), coefficients 
0.07 - 0.11, p ≤ 0.011.  
 
As expected, PHV2 was positively correlated with adult height (p < 0.0001 in females and p = 
0.0005 in males). ATO was positively correlated with adult height in females (coefficient 0.10, 
p = 0.0001) but not in males (coefficient 0.007, p = 0.78), but age at PHV2 was not associated 
with adult height in either sex. Earlier pubertal height growth spurt (ATO and age at PHV2) 
was correlated with higher adult BMI in both sexes (coefficients between -0.10 and -0.18, p < 
0.0001 in all). The correlations with waist circumference were similar to the correlations with 
BMI in males and slightly weaker in females. 
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Table 6.2. Spearman correlation coefficients between derived growth parameters and selected growth measures at birth and at age 31 years in the 
NFBC1966 singletons with growth data (maximum N=4,228) by sex. Females on top right, males on bottom left.  
 
F (top) /  
M (bottom) 
BW BL PHV1 PWV1 Age at 
AP 
BMIAP Age at 
AR 
BMIAR ATO APHV2 PHV2 Height 
at 31 
BMI at 
31 
WC at 
31 
BW 1 0.76 -0.06 0.12 -0.07 0.25 -0.03 0.23 0.11 0.08 -0.03 0.27 0.06 0.07 
BL 0.78 1 -0.06 0.14 -0.02 0.12 0.02 0.11 0.10 0.07 -0.01 0.35 -0.01 0.03 
PHV1 -0.08 -0.05 1 0.54 0.03 0.04 -0.06 0.07 -0.06 -0.07 0.08 0.45 -0.02 0.08 
PWV1 0.11 0.15 0.50 1 0.23 0.75 -0.07 0.49 -0.05 -0.06 0.03 0.30 0.12 0.14 
Age at AP -0.06 -0.03 0.03 0.11 1 0.14 0.01 0.22 -0.03 -0.04 0.00 0.01 0.05 0.02 
BMIAP 0.26 0.12 0.01 0.73 0.08 1 -0.05 0.61 -0.02 -0.03 -0.01 0.03 0.17 0.12 
Age at AR -0.07 -0.06 -0.06 -0.06 0.01 -0.03 1 -0.53 0.27 0.39 -0.09 0.08 -0.49 -0.37 
BMIAR 0.21 0.11 0.08 0.45 0.22 0.61 -0.47 1 -0.14 -0.23 -0.03 -0.02 0.45 0.32 
ATO 0.03 0.01 -0.09 -0.06 -0.03 0.00 0.25 -0.14 1 0.90 -0.81 0.10 -0.10 -0.05 
APHV2 0.02 -0.01 -0.10 -0.06 -0.04 -0.01 0.31 -0.19 0.97 1 -0.59 0.04 -0.17 -0.13 
PHV2 -0.02 0.01 0.12 0.05 0.00 -0.04 -0.07 -0.01 -0.86 -0.75 1 0.14 -0.02 -0.01 
Height at 31 0.26 0.35 0.46 0.28 0.04 0.03 0.04 -0.01 0.01 -0.05 0.09 1 -0.11 0.08 
BMI at 31 0.05 0.04 0.00 0.12 0.06 0.16 -0.45 0.44 -0.14 -0.18 0.02 -0.04 1 0.84 
WC at 31 0.07 0.08 0.10 0.12 0.06 0.09 -0.37 0.32 -0.13 -0.18 0.04 0.18 0.87 1 
 
BW = birth weight, BL = birth length, PHV1 = peak height velocity in infancy, PWV1 = peak height velocity in infancy, AP = adiposity peak in infancy, BMI = body mass index, AR = adiposity rebound 
in childhood, ATO = age at pubertal height growth spurt take-off, PHV2 = peak height velocity in puberty, APHV2 = age at PHV2, BMI = body mass index, WC = waist circumference. Correlation 
coefficients >0.20 highlighted in bold. 
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6.3. Results from association analyses between different phenotypes with discussion 
 
This chapter presents and discusses the results from the analysis of phenotypes from foetal 
life until adulthood. The first part (6.3.1) describes the results of the analysis on prenatal 
predictors of early growth in the NFBC1966, focusing on the adjusted and unadjusted 
associations between birth length (BL) and peak height velocity in infancy (PHV1). This work 
has been submitted for publication (Das* et al. (under review in Pediatrics)). The submitted 
manuscript explores further how BL may mediate some of the associations between prenatal 
predictors and PHV1. It also compares the NFBC1966 and NFBC1986 in this respect. The 
second part of this chapter (6.3.2) describes the results from the analysis between growth 
parameters and adult metabolic phenotypes. These analyses are an extension to the work 
presented in Tzoulaki et al. (2010) (328). 
 
6.3.1. Prenatal predictors of infant height growth velocity 
 
Descriptive analysis 
 
The distributions of PHV1 and the covariates included in the analyses on the relationship 
between BL and PHV1 in the NFBC1966 singletons are presented in Table 6.3. Both prenatal 
and postnatal height growth indicators, BL and PHV1, were higher in males than in females 
but gestational age (GA) and birth BMI did not differ. As expected, maternal characteristics 
were similar in males and females. About a third of the children were born to nulliparous 
mothers. A vast majority (97%) of the mothers were married. Most of them had only 
completed primary education (65%) and belonged to the blue collar social class (64%). At two 
months of pregnancy, 13% of the mothers smoked. The mothers were on average 160 cm 
tall, and only 18% of them were overweight and 3% were obese. Elevated blood pressure, 
gestational hypertension and chronic hypertension were fairly common in the mothers (33% in 
total) but pre-eclampsia was rare (3% in total). 
 
Univariate analysis 
 
In the univariate analyses, a weak, inverse association between BL and PHV1 was observed 
(Table 6.4). For each cm increase in BL, PHV1 was on average 0.29% lower in males (p < 
0.0001) and 0.30% lower in females (p = 0.0005). In the lowest BL quintile, PHV1 was 0.7 
cm/year (1.4%) and 1.0 cm/year (1.7%) higher than in the highest BL quintile in males and 
females, respectively (Table A.5). For comparison, BW was positively associated with PWV1 
in both sexes (Table A.6). 
 
GA and birth BMI were associated inversely with PHV1 in both sexes (Table 6.4). Maternal 
age had an inverse association with PHV1 in males. Daughters of unmarried mothers had a 
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higher PHV1 than daughters of married mothers. Maternal education did not associate with 
child‘s PHV1. The children of farmers had a slightly lower PHV1 than children from other 
social classes. Maternal smoking at 2 months of pregnancy was not associated with PHV1. 
There was a clear trend towards a lower PHV1 by increasing number of previous deliveries in 
both sexes. Mother‘s height had a strong positive association with PHV1 and mother‘s BMI 
showed a slight inverse trend with PHV1 in both sexes. Mother‘s pre-eclampsia predicted 
higher PHV1 in males.  
 
Most covariates that were associated with PHV1 (birth BMI, GA, maternal age, smoking, 
parity and BMI) were associated in the opposite direction with BL, except maternal height, 
which was associated in the same direction with BL and PHV1 (data not shown). Some of 
these factors may confound the association between BL and PHV1. Therefore, they were 
adjusted in the subsequent analyses.  
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Table 6.3. Peak height velocity in infancy (PHV1) and covariate distributions in 
NFBC1966 singletons. Mean (SD) or % reported. 
 
  N All Males Females Missing N 
(%) 
Sex 3783 50.0 50.0 50.0 0 (0.0) 
PHV1 (cm/year) 3783 52.6 (4.0) 54.4 (3.3) 50.9 (3.9) 0 (0.0) 
Birth length (cm) 3754 50.4 (2.1) 50.8 (2.1) 50.0 (2.0) 29 (0.8) 
Birth BMI (kg/m
2
) 3754 13.8 (1.3) 13.8 (1.3) 13.8 (1.3) 29 (0.8) 
Underweight (< 5
th
 percentile) 188 5 5 5  
Ideal (5
th
 - < 85
th
 percentile) 3031 80 79 81  
Overweight (85
th
 - < 95
th
 percentile) 365 10 11 9  
Obese (≥ 95
th
 percentile) 170 4 5 4  
Gestational age (weeks) 3670 40.1 (1.9) 40.0 (1.9) 40.2 (1.8) 113 (3.0) 
Maternal age (years) 3776 27.9 (6.6) 28.1 (6.6) 27.8 (6.6) 7 (0.2) 
Maternal marital status 3778    5 (0.1) 
Married 3661 97 97 97  
Unmarried / Cohabiting 98 3 2 3  
Divorced / Widow 19 1 1 0  
Maternal SES 3721    62 (1.6) 
Social class I (white collar) 465 12 13 11  
Social class II (blue collar) 2424 64 64 64  
Social class III (farmer) 832 22 21 23  
Paternal SES  3647    136 (3.6) 
Social class I (white collar) 898 24 25 23  
Social class II (blue collar) 2053 54 53 55  
Social class III (farmer) 696 18 19 18  
Maternal education 3717    66 (1.8) 
Primary education 2444 65 64 65  
Vocational education 715 19 19 19  
Secondary education 440 12 12 11  
University degree 118 3 3 3  
Maternal smoking at 2 months of pregnancy 3700    83 (2.1) 
No 3195 84 85 84  
Smoker 505 13 13 13  
Previous deliveries 3775    8 (0.2) 
No previous deliveries 1272 34 35 33  
1 previous delivery 900 24 23 24  
2 previous deliveries 613 16 16 16  
3 previous deliveries 360 10 10 9  
More than 3 previous deliveries 630 17 16 17  
Maternal weight (kg) 3614 59.4 (8.8) 59.5 (8.7) 59.3 (9.0) 169 (4.5) 
Maternal height (cm) 3607 160 (5.4) 160 (5.3) 160 (5.5) 176 (4.7) 
Maternal BMI (kg/m
2
) 3474 23.1 (3.2) 23.1 (3.2) 23.1 (3.2) 309 (8.2) 
Underweight  (< 19 kg/m
2
) 192 5 5 5  
Ideal weight (19 - <25 kg/m
2
) 2518 67 67 66  
Overweight (25 - <30 kg/m
2
) 635 17 16 18  
Obese (≥ 30 kg/m
2
) 129 3 3 3  
Hypertensive complications in pregnancy 3386    397 (10.5) 
Gestational hypertension 318 8 8 9  
Pre-eclampsia 76 2 2 2  
Chronic hypertension 258 7 7 7  
Superimposed pre-eclampsia 35 1 1 1  
Normotensive 2083 55 56 54  
SBP elevated 313 8 8 9  
DBP elevated 303 8 8 8  
Total 3783   1891 1892   
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Table 6.4. Univariate associations between all predictors and peak height velocity in 
infancy (PHV1) in the NFBC1966. The estimates are given in percentage changes in PHV1 
by one unit increase in the continuous exposure variable or in percentage differences from 
the reference group in the categorical exposure variable. 
 
  Males Females 
  Beta 95% CI Beta 95% CI 
Birth length (cm) -0.29 -0.42 -0.16 -0.30 -0.46 -0.13 
Birth BMI (kg/m
2
)       
Underweight (< 5
th
 percentile) 2.63 1.39 3.89 1.35 -0.21 2.94 
Overweight (85
th
 - < 95
th
 percentile) -0.80 -1.70 0.10 -0.34 -1.52 0.86 
Obese (≥ 95
th
 percentile) -2.39 -3.70 -1.05 -2.16 -3.79 -0.50 
Gestational age (weeks) -0.28 -0.42 -0.13 -0.37 -0.56 -0.18 
Maternal age (years) -0.05 -0.10 -0.01 -0.05 -0.10 0.01 
Maternal marital status       
Unmarried / Cohabiting 0.87 -0.85 2.63 2.26 0.16 4.40 
Divorced / Widow -1.53 -5.16 2.23 -0.67 -5.53 4.43 
Maternal SES       
Social class II (blue collar) 0.00 -0.79 0.80 -0.17 -1.19 0.86 
Social class III (farmer) -1.31 -2.31 -0.31 -1.71 -2.95 -0.46 
Paternal SES       
Social class II (blue collar) 0.43 -0.21 1.07 -0.27 -1.07 0.53 
Social class III (farmer) -0.89 -1.80 0.02 -1.75 -2.88 -0.60 
Maternal education       
Vocational education 0.05 -0.67 0.77 0.60 -0.27 1.48 
Secondary education 0.39 -0.44 1.22 0.91 -0.13 1.96 
University degree 0.62 -0.86 2.12 1.17 -0.75 3.12 
Maternal smoking at 2 months of pregnancy       
Smoker -0.27 -1.05 0.53 0.20 -0.79 1.20 
Parity       
1 previous delivery -1.11 -1.81 -0.41 -0.70 -1.54 0.15 
2 previous deliveries -1.11 -1.92 -0.30 -1.09 -2.08 -0.08 
3 previous deliveries -1.61 -2.59 -0.62 -2.58 -3.83 -1.31 
more than 3 previous deliveries -2.69 -3.55 -1.82 -3.33 -4.37 -2.27 
        
Maternal height (cm) 0.26 0.21 0.31 0.38 0.32 0.44 
Maternal BMI (kg/m
2
)       
Underweight (< 19 kg/m
2
) 1.49 0.30 2.70 -0.46 -1.88 0.99 
Overweight (25 - <30 kg/m
2
) -0.59 -1.36 0.20 -0.88 -1.79 0.04 
Obese (≥ 30 kg/m
2
) -2.20 -3.91 -0.46 -2.42 -4.40 -0.39 
Hypertensive complications in pregnancy       
Gestational hypertension 0.81 -0.21 1.84 1.34 0.11 2.59 
Pre-eclampsia 3.50 1.51 5.54 1.96 -0.39 4.37 
Chronic hypertension 0.91 -0.28 2.11 -1.12 -2.55 0.34 
Superimposed pre-eclampsia 1.70 -1.71 5.22 1.85 -1.38 5.19 
SBP elevated 0.99 -0.09 2.10 0.36 -0.84 1.57 
DBP elevated 0.46 -0.56 1.50 0.60 -0.67 1.88 
 
Multiple regression analysis on imputed data and comparison with complete cases analysis 
 
After imputation and adjustment for all other covariates, the inverse association between BL 
and PHV1 persisted (Table 6.5). A 0.23% and a 0.44% lower PHV1 per 1 cm increase in BL 
was estimated in males (p = 0.0027) and females (p < 0.0001), respectively.  
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Table 6.5. Multiple regression between all predictors and peak height velocity (PHV1) in 
the NFBC1966 imputed data (m=20 imputations). The estimates are given in percentage 
changes in PHV1 by one unit increase in the continuous exposure variable or in percentage 
differences from the reference group in the categorical exposure variable. 
 
  Males Females 
  Beta 95% CI Beta 95% CI 
Birth length (cm) -0.23 -0.38 -0.08 -0.44 -0.62 -0.26 
Birth BMI (kg/m
2
)       
Underweight (< 5
th
 percentile) 1.54 0.27 2.82 -0.13 -1.72 1.49 
Overweight (85
th
 - < 95
th
 percentile) -0.62 -1.51 0.28 0.29 -0.87 1.46 
Obese (≥ 95
th
 percentile) -1.80 -3.11 -0.47 -1.54 -3.14 0.09 
Gestational age (weeks) -0.11 -0.27 0.05 -0.21 -0.40 -0.01 
Maternal age (years) 0.09 0.03 0.15 0.17 0.09 0.24 
Maternal marital status       
Unmarried / Cohabiting 0.05 -1.66 1.79 0.93 -1.13 3.04 
Divorced / Widow -1.24 -4.79 2.43 0.05 -4.71 5.04 
Maternal SES       
Social class II (blue collar) 0.10 -0.84 1.05 0.61 -0.59 1.82 
Social class III (farmer) -0.11 -1.55 1.36 1.02 -0.83 2.90 
Paternal SES       
Social class II (blue collar) 0.33 -0.34 1.01 -0.01 -0.86 0.84 
Social class III (farmer) -0.56 -1.86 0.75 -0.88 -2.55 0.81 
Maternal education       
Vocational education -0.41 -1.10 0.30 -0.05 -0.91 0.81 
Secondary education -0.28 -1.16 0.61 0.08 -1.01 1.19 
University degree -0.92 -2.56 0.74 -0.36 -2.48 1.80 
Maternal smoking at 2 months of pregnancy       
Smoker -0.67 -1.44 0.11 -0.18 -1.14 0.79 
Parity       
1 previous delivery -0.91 -1.64 -0.17 -0.72 -1.58 0.16 
2 previous deliveries -0.92 -1.82 -0.01 -1.50 -2.59 -0.40 
3 previous deliveries -1.41 -2.54 -0.28 -2.96 -4.34 -1.56 
more than 3 previous deliveries -2.47 -3.65 -1.27 -4.10 -5.48 -2.70 
        
Maternal height (cm) 0.28 0.22 0.33 0.40 0.34 0.47 
Maternal BMI (kg/m
2
)       
Underweight (< 19 kg/m
2
) 0.90 -0.26 2.06 -1.20 -2.53 0.15 
Overweight (25 - <30 kg/m
2
) -0.17 -0.98 0.64 -0.21 -1.13 0.72 
Obese (≥ 30 kg/m
2
) -1.61 -3.35 0.16 -0.55 -2.54 1.48 
Hypertensive complications in pregnancy       
Gestational hypertension 0.50 -0.47 1.48 0.67 -0.52 1.89 
Pre-eclampsia 2.56 0.60 4.55 1.73 -0.47 3.98 
Chronic hypertension 0.88 -0.31 2.09 -0.85 -2.28 0.59 
Superimposed pre-eclampsia 2.08 -1.23 5.51 0.69 -2.52 4.01 
SBP elevated 1.10 0.07 2.15 0.45 -0.69 1.61 
DBP elevated 0.23 -0.75 1.22 0.82 -0.37 2.03 
 
The benefit of using the multiple imputation technique was apparent in males. The complete 
cases analysis based on N=1,418 males estimated a weaker effect (0.17% lower PHV1 per 1 
cm increase in BL, p = 0.052, data not shown). This may be partly explained by a lower power 
to detect associations due to decreased sample size (which would produce a statistically less 
significant result even if the effect size remained the same), and partly by differences between 
complete cases and individuals with missing values (selection bias leading to a difference in 
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effect size). Since Missing Completely at Random (MCAR) assumption (121) rarely holds, 
complete cases analysis can be expected to suffer from selection bias at least to some 
extent. In the complete cases analysis in females (N=1,431), the association was about 20% 
stronger than in the analysis based on imputed data (0.53% lower PHV1 per 1 cm increase in 
BL, p < 0.0001) and this compensated for the decrease in statistical power. However, in 
females, regression estimates in general were not markedly different from the estimates 
based on regression using imputed data, nor was the variance notably different.  
 
Most of the associations between the covariates and PHV1 were weaker in the full analysis 
compared to the univariate analysis. Birth BMI remained significant only in males whereas GA 
remained significant only in females. Maternal age which was negatively or not at all 
associated with PHV1 in the univariate analysis became positively associated with PHV1 in 
both sexes in the full model. None of the parental socio-economic indicators, including 
maternal marital status and education, were associated with PHV1 in the full analysis. 
Maternal smoking did not significantly predict PHV1 in either sex in the full analysis. Maternal 
parity remained significantly inversely associated with PHV1 in the full model in both sexes. 
The strength of the positive association between maternal height and PHV1 remained similar 
after adjustment for the other covariates. Maternal BMI did not predict PHV1 in the full model. 
The association between maternal pre-eclampsia and higher PHV1 persisted in males. 
 
Discussion of prenatal predictors of infant height growth velocity  
 
This study of a sample of N=3,783 from the NFBC1966 found that BL was associated 
inversely with PHV1, and that this association was largely independent of other determinants 
of height growth and potential confounders. One of the strengths of this study is the 
availability of extensive background information and frequent growth measurements in 
infancy. The confounders that were taken into account included child‘s birth BMI, GA, 
maternal age, marital status, SES, education, smoking during pregnancy, parity, height, pre-
pregnancy BMI, gestational hypertension / pre-eclampsia, and paternal SES. Another 
strength and novelty of this study is the application of longitudinal growth models in 
determining individual peak growth velocities in a large, population-based birth cohort, and 
the use of these derived measures as outcomes in an epidemiological study. A limitation was 
that paternal height was not available and therefore could not be accounted for in the models. 
The limitations of the growth models that were used to derive PHV1 are discussed in chapter 
7.1.1 (see also discussion in Sovio et al. (2009) (327)). 
 
The association between rapid infant height and weight growth and adverse metabolic profile 
has been demonstrated in this cohort (328). Therefore, assessment of the determinants of 
rapid postnatal growth could be important for informing public health policies, e.g. on 
childhood obesity or other growth abnormalities.   
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Maternal height and parity had a consistent, strong association with PHV1, in both genders 
even after adjustments for other variables. The positive association between maternal height 
and PHV1 is likely to be genetically mediated (357). Ong et al. (2002) (358) have previously 
reported that maternal factors such as weight gain and smoking during pregnancy and parity 
are associated with a child‘s early postnatal growth realignment. They found that firstborn 
babies gained weight more rapidly during the first year of life than subsequently born babies. 
Furthermore, Eriksson et al. (2000) (359) found that faster growth from birth to age 7 years is 
associated with lower levels of crowding in the home, which may roughly correspond to lower 
parity. The present study suggests an effect of parity on immediate postnatal height growth in 
the same direction. A clear trend in both sexes towards slower height growth velocity with 
increasing parity was observed in the NFBC1966.  
 
Maternal pre-pregnancy BMI, which is associated with a larger size of offspring at birth (360), 
did not show any association with PHV1 after adjustments. The association between maternal 
age and PHV1 turned from zero/negative to positive after adjustment for other covariates, 
which suggests confounding of this association. Also, a positive association between pre-
eclampsia and PHV1 was observed. Intrauterine growth retardation (IUGR) is seen in pre-
eclampsia (361), hence rapid postnatal growth is likely to occur (362). 
 
To conclude, this study supports the hypothesis that shorter length at birth is associated with 
faster postnatal height growth, independently of confounding factors. Furthermore, several 
maternal factors such as height, pre-eclampsia and low parity were found to be associated 
with faster postnatal height growth. These results can be generalised in Western populations 
from a similar era but further studies are required to investigate if these associations hold in 
other settings.  
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6.3.2. Association between growth parameters and adult anthropometric and metabolic 
phenotypes 
 
Infant height, weight and BMI growth 
 
The results obtained for associations between immediate postnatal growth (estimated by 
PHV1 and PWV1) and metabolic outcomes on non-imputed data are described in Tzoulaki et 
al. 2010 (328) and are only very briefly summarised in this thesis. The main finding in this 
article was that both PHV1 and PWV1 were associated with a higher SBP (PHV1 also with a 
higher DBP) and a wider WC (PWV1 also with a higher BMI) at age 31 years, independently 
of BW. PHV1 but not PWV1 associations remained after a further adjustment for BMI at age 
31 years. In addition, for PWV1, a positive association with HDL and an inverse association 
with triglycerides appeared only after adjustment for BMI at age 31 years.  
 
The results from model A shown in Table 6.6 for PHV1 and PWV1 with metabolic outcomes 
on imputed data are only slightly different from the complete cases analysis results (328), and 
the interpretation remains as described earlier. This table also shows that age and BMI at AP 
were positively associated with BMI and WC at age 31 years, independently of BW. In 
particular, the association between BMI at AP and BMI at age 31 years was strong: 4.65% 
(95% CI: 3.50-5.81%) higher BMI at age 31 years by 2SD (2.19 kg/m
2
) higher BMI at AP. For 
an average sized adult (BMI = 24.7 kg/m
2
) this translates to 1.15 kg/m
2
 higher BMI per 2SD 
higher BMI at AP.  
 
Further adjustment (model B, Table 6.7) for PWV1 attenuated the PHV1-SBP association 
from 1.11% to 0.78% higher SBP per 2SD higher PHV1 (p-value attenuated from 0.0028 to 
0.078). Similarly, the weaker PHV1-DBP association was attenuated. Also, when the PWV1-
SBP analysis was adjusted for PHV1, the magnitude of the association was halved and it 
attenuated to non-significance (p-value from 0.013 to 0.25). It seems both PHV1 and PWV1 
are associated with a slightly increased SBP at 31 years, and their mutual correlation (about 
50%) explains the attenuation of these associations when both of them are included in the 
same model. Similarly, the PHV1-WC association was nearly halved after an adjustment for 
PWV1 (Table 6.7). However, PWV1-WC association weakened much less (from 2.39% to 
1.82%) after an adjustment for PHV1, which indicates that infant weight growth plays a more 
important role than height growth in terms of adult adiposity, and is a better predictor of adult 
WC. Furthermore, the PWV1-BMI association persisted and even strengthened after an 
adjustment for PHV1. On the contrary, an inverse PHV1-BMI association appeared after an 
adjustment for PWV1 (p = 0.0017). This suggests that babies that grow relatively fast in 
length compared to weight in the first few months of life become slimmer adults, measured by 
BMI. However, PHV1 did not confound the association between AP variables (age and BMI at 
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AP) and metabolic outcomes; the associations were very similar with and without adjustment 
for PHV1. When age at AP was further adjusted for BMI at AP (model C), its associations with 
BMI and WC at age 31 years diminished to non-significant (p = 0.087 and p = 0.16, 
respectively; data not shown). However the associations between BMI at AP and adult BMI 
and WC did not change after a further adjustment for age at AP (data not shown). 
 
For illustrative purposes, additional figures were produced for SBP and WC estimates, 
stratified by sex-specific tertiles of BW and infant growth velocities (PHV1 and PWV1) 
(Figures A.1-A.4). These analyses were performed without adjustments, using the non-
imputed data. Children in the lowest BW tertile that grew fastest immediately after birth in 
length or weight had on average the highest SBP at age 31 years, at about 127 mmHg 
(Figures A.1 and A.2). Within each BW tertile, children that grew fastest in length had the 
highest WC at age 31 years (Figure A.3). In the middle and high BW tertiles, the average WC 
in children who grew fastest in length was as high as 86 cm, whereas in children that grew 
slower it was about 83-84 cm. There was a clear trend towards a higher WC by increasing 
PWV1 in each BW tertile (Figure A.4), whereas BW tertile itself did not have a notable 
association with WC at age 31 years. 
 
Childhood BMI growth 
 
Later AR associated strongly with a better metabolic profile at age 31 years (model A, Table 
6.8, p < 0.0001 for all metabolic outcomes). BMI and insulin were about 14%, and WC and 
triglycerides about 10% lower per 2SD (1.86 years) higher age at AR. The odds of MetS were 
74% lower per 2SD higher age at AR. Since the MetS prevalence at age 31 years was fairly 
low – 9% according to the updated NCEP definition described in chapter 5.3.2 (5% according 
to the stricter definition used in Tzoulaki et al. (2010) (328)), the estimated odds ratio is 
approximately the same as the risk ratio. BMI at AR had weaker, positive associations with 
most metabolic outcomes (negative with HDL). Only for BMI at 31 years its association was 
equal or stronger than that of age at AR. BMI at AR was not associated with glucose or total 
cholesterol at age 31 years. 
   
The associations between age at AR and adult metabolic outcomes remained very similar 
after adjustments for PHV1 and BMI at AP (model B, Table 6.9). Interestingly, the 
associations between BMI at AR and metabolic outcomes strengthened considerably after 
these adjustments. For example, the non-significant (p = 0.15) association with glucose 
increased from 0.43% to 1.60% per 2SD (2.20 kg/m
2
) increase in BMI at AR (after adjustment 
p = 0.0003). Also, the association with insulin more than doubled in effect size (from 6% to 
13%). After the adjustment, OR for MetS was 3.43 (95% CI: 3.13, 3.75) per 2SD higher BMI 
at AR. These results suggest that the change in BMI between AP and AR is even more 
strongly associated with adult metabolic profile than the level of BMI at AR itself.  
 150 
 
When age and BMI at AR were both included in the same model, a slight attenuation of the 
association with metabolic outcomes was observed for age at AR (model C, Table 6.10). 
However, most associations remained highly significant. Only the associations with glucose, 
LDL and total cholesterol diminished into being borderline significant. However, since the 
associations were stronger with age at AR than with BMI at AR to start with and these two 
growth parameters are inversely correlated, the adjustment for age at AR attenuated the 
associations observed between BMI at AR and the metabolic outcomes (model C, Table 
6.10). Only the associations with BMI and WC at age 31 years remained highly significant, 
although their effect size was reduced to less than half. 
  
Pubertal growth 
 
Later age at PHV2 associated strongly with a better metabolic profile at age 31 years (model 
A, Table 6.8), except with SBP and glucose no associations were observed. The associations 
were strongest with insulin, triglycerides and BMI: these outcomes exhibited 9-12% lower 
levels per 2SD (2.65 years) higher age at PHV2. The odds of MetS were reduced by 75% by 
2SD increase in age at PHV2. Faster pubertal height growth measured by PHV2 (which is 
inversely correlated with age at PHV2) was associated with a slightly worse metabolic profile. 
PHV2 was associated with a higher DBP, a higher total and LDL cholesterol and a higher risk 
of MetS. 
 
The associations between age at PHV2 and metabolic outcomes attenuated considerably 
after an adjustment for PHV1, BMI at AP and age at AR (model B, Table 6.9). However, the 
inverse associations with DBP and MetS remained highly significant (p < 0.0001) and the 
positive association with HDL was still borderline significant (p = 0.0080) after the 
adjustments. The associations of PHV2 with LDL and total cholesterol were attenuated to 
borderline significant, but the associations of PHV2 with DBP and MetS were much less 
affected (model B, Table 6.9).  
 
Inclusion of age at PHV2 and PHV2 in the same model further attenuated the association of 
age at PHV2 with DBP and HDL cholesterol (model C, Table 6.10, p = 0.0099 and p = 0.088, 
respectively). However, the association between age at PHV2 and MetS strengthened (OR 
changed from 0.43 to 0.33). PHV2 did not show strong associations with any of the metabolic 
outcomes after the adjustment for age at PHV2.  
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Summary of associations between growth parameters and adult anthropometric and 
metabolic phenotypes 
 
Faster growth during infancy was associated with higher systolic and diastolic blood pressure, 
BMI, and waist circumference in adulthood. The majority of associations were independent of 
several potential confounders, including child‘s sex and BW, mother‘s age, height, pre-
pregnancy weight, smoking during pregnancy, GA, and father‘s socioeconomic status at birth. 
  
Age and BMI at AP were associated with adult adiposity but not with other metabolic 
phenotypes. Earlier timing of AR was a risk factor of an adverse metabolic profile in 
adulthood, independently of early growth or BMI at AR. Similarly, earlier timing of PHV2 was 
associated with an adverse metabolic profile, but this association was largely explained by 
pre-pubertal growth. 
.
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Table 6.6. Adjusted associations between infant growth parameters and metabolic phenotypes in the NFBC1966 singletons (model A*), missing 
covariates imputed (m=20 imputations). 
 
 PHV1 PWV1 Age at AP BMI at AP 
Phenotype at 31y % change (95% CI) p-value % change (95% CI) p-value % change (95% CI) p-value % change (95% CI) p-value 
SBP  1.11 (0.38, 1.85) 0.0028  0.91 (0.19, 1.62) 0.013  0.53 (-0.16, 1.22) 0.13  0.69 (-0.02, 1.41) 0.056 
DBP  1.14 (0.06, 2.22) 0.038  0.48 (-0.56, 1.53) 0.37  0.08 (-0.92, 1.09) 0.88  0.43 (-0.61, 1.47) 0.42 
BMI  0.21 (-0.94, 1.37) 0.72  3.05 (1.90, 4.21) <0.0001  1.58 (0.48, 2.68) 0.0046  4.65 (3.50, 5.81) <0.0001 
WC  2.26 (1.33, 3.20) <0.0001  2.39 (1.48, 3.31) <0.0001  0.96 (0.09, 1.83) 0.030  1.98 (1.09, 2.89) <0.0001 
INS  1.27 (-1.52, 4.15) 0.38 -1.55 (-4.20, 1.18) 0.26 -0.93 (-3.53, 1.74) 0.49 -3.03 (-5.66, -0.32) 0.029 
GLU -0.15 (-0.83, 0.53) 0.66 -0.63 (-1.30, 0.04) 0.064  0.44 (-0.21, 1.10) 0.19 -0.72 (-1.38, -0.05) 0.036 
Total-C -0.80 (-2.20, 0.62) 0.27  0.08 (-1.30, 1.47) 0.92 -0.10 (-1.43, 1.25) 0.88 -0.31 (-1.69, 1.08) 0.66 
HDL-C   0.76 (-0.86, 2.42) 0.36  0.30 (-1.29, 1.90) 0.71  0.33 (-1.20, 1.88) 0.67 -0.33 (-1.90, 1.27) 0.68 
LDL-C -1.33 (-3.41, 0.80) 0.22  0.67 (-1.40, 2.79) 0.53 -0.17 (-2.15, 1.86) 0.87  0.21 (-1.86, 2.33) 0.84 
TRIGLY -1.85 (-5.33, 1.76) 0.31 -1.23 (-4.67, 2.33) 0.49  0.36 (-3.03, 3.87) 0.84 -0.49 (-3.97, 3.12) 0.79 
Phenotype at 31y OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value 
MetS  0.90 (0.82, 0.98) 0.022  1.02 (0.94, 1.10) 0.70  1.05 (0.96, 1.16) 0.30 1.08 (0.98, 1.19) 0.11 
 
PHV1 = peak height velocity in infancy, PWV1 = peak height velocity in infancy, AP = adiposity peak in infancy, SBP = systolic blood pressure, DBP = diastolic blood pressure, BMI = body mass 
index, WC = waist circumference, INS = insulin, GLU = glucose, Total-C = total cholesterol, HDL-C = high-density lipoprotein cholesterol, LDL-C = low-density lipoprotein cholesterol, TRIGLY = 
triglyceride, MetS = metabolic syndrome. For continuous variables, % change and for MetS, OR with 95% confidence interval and p-value are given for 2SD increase in the growth parameter. 
Associations with p < 0.005 highlighted in bold. 
 
*Covariates adjusted for: father‘s SES, mother‘s age, height, weight, smoking at 2 months of pregnancy, gestational age, child‘s birth weight and sex.  
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Table 6.7. Further adjusted associations between infant growth parameters and metabolic phenotypes in the NFBC1966 singletons (model B*), 
missing covariates imputed (m=20 imputations). 
 
 PHV1 PWV1 Age at AP BMI at AP 
Phenotype at 31y % change (95% CI) p-value % change (95% CI) p-value % change (95% CI) p-value % change (95% CI) p-value 
SBP  0.78 (-0.09, 1.65) 0.078   0.48 (-0.33, 1.30) 0.25  0.49 (-0.20, 1.18) 0.17  0.63 (-0.08, 1.35) 0.080 
DBP  0.88 (-0.39, 2.17) 0.17  -0.14 (-1.32, 1.06) 0.82  0.04 (-0.96, 1.05) 0.93  0.38 (-0.66, 1.43) 0.48 
BMI  -2.16 (-3.48, -0.81) 0.0017  3.96 (2.64, 5.30) <0.0001  1.58 (0.49, 2.69) 0.0046  4.67 (3.52, 5.84) <0.0001 
WC  1.18 (0.09, 2.29) 0.033  1.82 (0.78, 2.87) 0.0005  0.88 (0.02, 1.75) 0.046  1.87 (0.98, 2.78) <0.0001 
INS  3.26 (-0.11, 6.73) 0.058 -2.69 (-5.68, 0.39) 0.086 -0.96 (-3.56, 1.71) 0.48 -3.08 (-5.72, -0.37) 0.026 
GLU  0.28 (-0.53, 1.10) 0.49 -0.67 (-1.43, 0.09) 0.084  0.45 (-0.21, 1.10) 0.18 -0.71 (-1.38, -0.04) 0.038 
Total-C -1.19 (-2.85, 0.49) 0.17  0.65 (-0.93, 2.26) 0.42 -0.07 (-1.41, 1.28) 0.91 -0.27 (-1.65, 1.12) 0.70 
HDL-C   0.76 (-1.17, 2.73) 0.44  -0.19 (-1.99, 1.65) 0.84  0.30 (-1.22, 1.86) 0.70 -0.37 (-1.94, 1.23) 0.65 
LDL-C -2.40 (-4.84, 0.10) 0.060  1.93 (-0.48, 4.39) 0.12 -0.12 (-2.10, 1.91) 0.91  0.29 (-1.79, 2.41) 0.79 
TRIGLY -1.59 (-5.71, 2.72) 0.46 -0.57 (-4.52, 3.54) 0.78  0.41 (-2.98, 3.93) 0.81 -0.41 (-3.90, 3.20) 0.82 
Phenotype at 31y OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value 
MetS  0.88 (0.79, 0.98) 0.023  1.06 (0.98, 1.15) 0.15  1.06 (0.96, 1.16) 0.25 1.09 (0.99, 1.20) 0.081 
  
PHV1 = peak height velocity in infancy, PWV1 = peak height velocity in infancy, AP = adiposity peak in infancy, SBP = systolic blood pressure, DBP = diastolic blood pressure, BMI = body mass 
index, WC = waist circumference, INS = insulin, GLU = glucose, Total-C = total cholesterol, HDL-C = high-density lipoprotein cholesterol, LDL-C = low-density lipoprotein cholesterol, TRIGLY = 
triglyceride, MetS = metabolic syndrome. For continuous variables, % change and for MetS, OR with 95% confidence interval and p-value are given for 2SD increase in the growth parameter. 
Associations with p < 0.005 highlighted in bold. 
 
*Covariates adjusted for: father‘s SES, mother‘s age, height, weight, smoking at 2 months of pregnancy, gestational age, child‘s birth weight and sex. Additionally, PWV1, Age at AP and BMI at AP 
analyses were adjusted for PHV1, and PHV1 analysis was adjusted for PWV1.  
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Table 6.8. Adjusted associations between child and pubertal growth parameters and metabolic phenotypes in the NFBC1966 singletons (model 
A*), missing covariates imputed (m=20 imputations). 
 
 Age at AR BMI at AR Age at PHV2 PHV2 
Phenotype at 31y % change (95% CI) p-value % change (95% CI) p-value % change (95% CI) p-value % change (95% CI) p-value 
SBP -2.44 (-3.02, -1.86) <0.0001  1.41 (0.78, 2.03) <0.0001 -1.08 (-2.30, 0.16) 0.089 -0.14 (-1.01, 0.73) 0.75 
DBP -3.62 (-4.47, -2.76) <0.0001  2.14 (1.21, 3.09) <0.0001 -5.69 (-7.42, -3.92) <0.0001  2.59 (1.26, 3.93) 0.0001 
BMI -14.5 (-15.2, -13.8) <0.0001  15.2 (14.2, 16.2) <0.0001 -9.06 (-10.9, -7.22) <0.0001  0.11 (-1.31, 1.55) 0.88 
WC -9.70 (-10.3, -9.06) <0.0001  8.56 (7.75, 9.38) <0.0001 -5.98 (-7.49, -4.45) <0.0001  0.55 (-0.59, 1.72) 0.35 
INS -14.0 (-15.9, -12.0) <0.0001  6.00 (3.51, 8.56) <0.0001 -11.6 (-15.8, -7.19) <0.0001  0.75 (-2.62, 4.24) 0.67 
GLU -1.24 (-1.81, -0.67) <0.0001  0.43 (-0.16, 1.04)   0.15 -0.60 (-1.84, 0.65)   0.35 -0.26 (-1.13, 0.61) 0.55 
Total-C -2.28 (-3.42, -1.12)   0.0001  0.81 (-0.40, 2.04)   0.19 -3.68 (-5.98, -1.32)   0.0024  2.70 (0.98, 4.45) 0.0020 
HDL-C   5.66 (4.23, 7.12) <0.0001 -4.13 (-5.47, -2.78) <0.0001  8.16 (5.11, 11.31) <0.0001 -1.98 (-3.93, 0.02) 0.052 
LDL-C -4.68 (-6.34, -2.99) <0.0001  2.95 (1.10, 4.84)   0.0017 -7.23 (-10.6, -3.77) <0.0001  4.12 (1.49, 6.82) 0.0020 
TRIGLY -10.2 (-12.9, -7.46) <0.0001  5.33 (2.11, 8.65)   0.0011 -10.1 (15.7, -4.23) <0.0001  5.23 (0.63, 10.0) 0.025 
Phenotype at 31y OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value 
MetS 0.26 (0.25, 0.28) <0.0001  2.20 (2.07, 2.34) <0.0001 0.25 (0.21, 0.29) <0.0001  1.35 (1.21, 1.51) <0.0001 
  
AR = adiposity rebound in childhood, PHV2 = peak height velocity in puberty, SBP = systolic blood pressure, DBP = diastolic blood pressure, BMI = body mass index, WC = waist circumference, 
INS = insulin, GLU = glucose, Total-C = total cholesterol, HDL-C = high-density lipoprotein cholesterol, LDL-C = low-density lipoprotein cholesterol, TRIGLY = triglyceride, MetS = metabolic 
syndrome. For continuous variables, % change and for MetS OR (95% CI) with p-value are given for 2SD increase in the growth parameter. Associations with p < 0.005 highlighted in bold. 
 
*Covariates adjusted for: father‘s SES, mother‘s age, height, weight, smoking at 2 months of pregnancy, gestational age, child‘s birth weight and sex. 
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Table 6.9. Further adjusted associations between child and pubertal growth parameters and metabolic phenotypes in the NFBC1966 singletons 
(model B*), missing covariates imputed (m=20 imputations). 
 
 Age at AR BMI at AR Age at PHV2 PHV2 
Phenotype at 31y % change (95% CI) p-value % change (95% CI) p-value % change (95% CI) p-value % change (95% CI) p-value 
SBP -2.06 (-2.72, -1.41) <0.0001  1.54 (0.66, 2.42) 0.0006  0.45 (-0.97, 1.88)   0.54 -0.44 (-1.35, 0.48)   0.35 
DBP -3.11 (-4.08, -2.14) <0.0001  3.02 (1.69, 4.36) <0.0001 -4.18 (-6.19, -2.12) <0.0001  2.22 (0.82, 3.63)   0.0018 
BMI -14.4 (-15.2, -13.6) <0.0001  20.3 (18.8, 21.8) <0.0001  0.51 (-1.42, 2.47)   0.61 -1.03 (-2.27, 0.22)   0.10 
WC -9.42 (-10.1, -8.71) <0.0001  11.6 (10.4, 12.8) <0.0001  1.09 (-0.60, 2.80)   0.21 -0.80 (-1.88, 0.29)   0.15 
INS -13.7 (-15.9, -11.5) <0.0001  13.2 (9.50, 17.1) <0.0001 -4.30 (-9.38, 1.07)   0.11 -0.40 (-3.87, 3.19)   0.82 
GLU -1.36 (-2.01, -0.71) <0.0001  1.60 (0.74, 2.47)   0.0003  0.34 (-1.10, 1.80)   0.64 -0.53 (-1.45, 0.41)   0.27 
Total-C -1.83 (-3.13, -0.51)   0.0067  1.54 (-0.20, 3.31)   0.083 -1.77 (-4.48, 1.02)   0.21  2.09 (0.25, 3.96)   0.026 
HDL-C   5.73 (4.13, 7.35) <0.0001 -5.71 (-7.55, -3.84) <0.0001  4.44 (1.14, 7.85)   0.0080 -1.52 (-3.56, 0.56)   0.15 
LDL-C -4.07 (-5.96, -2.14) <0.0001  4.19 (1.54, 6.91)   0.0018 -2.89 (-6.86, 1.24)   0.17  3.07 (0.32, 5.89)   0.029 
TRIGLY -10.0 (-13.0, -6.94) <0.0001  10.4 (5.63, 15.3) <0.0001 -3.94 (-10.7, 3.29)   0.28  4.10 (-0.70, 9.12)   0.095 
Phenotype at 31y OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value 
MetS  0.26 (0.24, 0.28) <0.0001  3.43 (3.13, 3.75) <0.0001  0.43 (0.35, 0.52) <0.0001  1.34 (1.19, 1.51) <0.0001 
 
AR = adiposity rebound in childhood, PHV2 = peak height velocity in puberty, SBP = systolic blood pressure, DBP = diastolic blood pressure, BMI = body mass index, WC = waist circumference, 
INS = insulin, GLU = glucose, Total-C = total cholesterol, HDL-C = high-density lipoprotein cholesterol, LDL-C = low-density lipoprotein cholesterol, TRIGLY = triglyceride, MetS = metabolic 
syndrome. For continuous variables, % change and for MetS OR (95% CI) with p-value are given for 2SD increase in the growth parameter. Associations with p < 0.005 highlighted in bold. 
 
*Covariates adjusted for: father‘s SES, mother‘s age, height, weight, smoking at 2 months of pregnancy, gestational age, child‘s birth weight, sex, PHV1 and BMI at AP. Additionally, pubertal growth 
parameters (PHV2 and age at PHV2) were adjusted for age at AR. 
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Table 6.10. Associations with extra adjustments between child and pubertal growth parameters and metabolic phenotypes in the NFBC1966 
singletons (model C*), missing covariates imputed (m=20 imputations). 
 
 Age at AR BMI at AR Age at PHV2 PHV2 
Phenotype at 31y % change (95% CI) p-value % change (95% CI) p-value % change (95% CI) p-value % change (95% CI) p-value 
SBP -2.23 (-3.09, -1.38) <0.0001 -0.35 (-1.47, 0.78)  0.54 -0.13 (-2.21, 1.99)   0.90 -0.52 (-1.91, 0.89) 0.47 
DBP -2.83 (-4.09, -1.55) <0.0001  0.60 (-1.08, 2.31)  0.49 -4.05 (-7.02, -0.99)   0.0099  0.12 (-1.97, 2.25) 0.91 
BMI -10.4 (-11.4, -9.29) <0.0001  9.82 (8.15, 11.5) <0.0001 -1.37 (-4.15, 1.50)   0.35 -1.70 (-3.57, 0.20) 0.080 
WC -7.31 (-8.25, -6.36) <0.0001  4.76 (3.39, 6.15) <0.0001  0.56 (-1.90, 3.09)   0.66 -0.47 (-2.11, 1.20) 0.58 
INS -13.6 (-16.5, -10.7) <0.0001  0.24 (-3.99, 4.65)  0.91 -9.79 (-16.8, -2.23)   0.012 -5.25 (-10.2, 0.00) 0.050 
GLU -0.99 (-1.84, -0.14)   0.023  0.76 (-0.35, 1.89)  0.18 -0.45 (-2.55, 1.70)   0.68 -0.72 (-2.14, 0.71) 0.32 
Total-C -1.84 (-3.53, -0.11)   0.037 -0.01 (-2.24, 2.26)  0.99  0.39 (-3.68, 4.64)   0.85  2.00 (-0.80, 4.88) 0.16 
HDL-C   4.60 (2.54, 6.70) <0.0001 -2.12 (-4.60, 0.42)  0.10  4.23 (-0.61, 9.31)   0.088 -0.18 (-3.32, 3.05) 0.91 
LDL-C -3.53 (-6.00, -1.00)   0.0066  1.12 (-2.21, 4.57)  0.51  0.71 (-5.32, 7.12)   0.82  3.37 (-0.83, 7.74) 0.12 
TRIGLY -9.22 (-13.2, -5.11) <0.0001  1.85 (-3.81, 7.85)  0.53 -0.01 (-10.2, 11.3)   0.998  3.73 (-3.49, 11.5) 0.32 
Phenotype at 31y OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value 
MetS  0.29 (0.26, 0.32) <0.0001  1.21 (1.07, 1.36)  0.0019  0.33 (0.24, 0.44) <0.0001  0.79 (0.66, 0.96) 0.017 
 
AR = adiposity rebound in childhood, PHV2 = peak height velocity in puberty, SBP = systolic blood pressure, DBP = diastolic blood pressure, BMI = body mass index, WC = waist circumference, 
INS = insulin, GLU = glucose, Total-C = total cholesterol, HDL-C = high-density lipoprotein cholesterol, LDL-C = low-density lipoprotein cholesterol, TRIGLY = triglyceride, MetS = metabolic 
syndrome. For continuous variables, % change and for MetS OR (95% CI) with p-value are given for 2SD increase in the growth parameter. Associations with p < 0.005 highlighted in bold. 
 
*Covariates adjusted for: father‘s SES, mother‘s age, height, weight, smoking at 2 months of pregnancy, gestational age, child‘s birth weight, sex, PHV1 and BMI at AP. Additionally, Age at AR 
analysis was adjusted for BMI at AR and vice versa, and pubertal growth parameters (PHV2 and age at PHV2) were adjusted for age at AR, and PHV2 analysis was adjusted for age at PHV2 and 
vice versa. 
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Discussion of growth parameters and adult anthropometric and metabolic phenotypes  
 
The association between weight gain in infancy and later obesity has been widely recognised 
(363). Baird et al. (2005) (364) published a systematic review of 10 studies on the relationship 
between weight gain in infancy (assessed in various ways) and subsequent obesity, 
measured as body weight or BMI. Relative risks for subsequent obesity ranged from 1.2 to 
5.7 among infants with rapid weight gain. However, in most of the articles reviewed, obesity 
was measured in childhood or adolescence, and few studies had repeated growth 
measurements over time. McCarthy et al. (2007) (365) reported variable, inconsistent 
associations between weight gain over the first five years of life and and adult adiposity in the 
Caerphilly Growth Study. These associations were influenced by the time window of 
measurements and the measure of adiposity used in adulthood, leading to inconclusive 
inferences. 
 
An early adiposity rebound (AR) has been found to be associated with a high or upward 
crossing BMI centile in childhood (366), and with increased BMI, hypertension and diabetes in 
adults (367, 368). Studies on the association between infant adiposity peak (AP) and later 
obesity or disease are scarce (186). This may be because BMI is a measure less commonly 
used in infants; another possibility is the lack of data with frequent height/weight 
measurements in infancy.  
 
Increased body fat has been repeatedly associated with an earlier puberty in females 
(measured by age at menarche), but in males increased body fat may delay the occurrence of 
pubertal changes (see a recent review article by Walvoord 2010 (369)). Studies measuring 
the timing of puberty by ATO or age at PHV2 are much harder to find, probably due to lack of 
frequent height measurements around puberty. Whether an early puberty is an independent 
risk factor of later obesity or an adverse metabolic profile is not clear, since few studies have 
adjusted their analyses for childhood BMI (369).  
 
In the NFBC1966, positive associations were identified between PWV1 and adiposity (BMI 
and WC) at age 31 years. PHV1 was also strongly associated with a greater WC, 
independently of BMI, despite the high correlation between WC and BMI. The associations of 
PWV1 and PHV1 with WC highlight the fact that early growth may influence later visceral 
obesity. This finding is of particular importance, since abdominal adipose tissue, an endocrine 
organ, secretes adipocytokines and other vasoactive substances and can influence the risk of 
developing metabolic traits (370). Furthermore, WC has recently been shown to be a powerful 
predictor of all-cause and CVD mortality, independently of BMI (371). 
 
PHV1 and PWV1 were inversely associated with SBP and DBP. A similar result for weight 
growth was also reported in the Barry Caerphilly Growth Study (372). Previous data from the 
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NFBC1966 and other cohorts suggest positive associations between weight gain from birth to 
age one year and higher SBP but not DBP (326). Interestingly, associations with PHV1 
retained statistical significance after several adjustments for potential confounders and were 
stronger and more consistent than associations with PWV1. BW displayed the well-described 
inverse association with adult SBP. This association was independent of PHV1 and PWV1, 
indicating an independent and probably distinct effect of these phenotypes on later BP levels. 
 
The NFBC1966 data show that both prenatal and postnatal growth patterns are associated 
with later metabolic phenotypes, contributing to later CVD risk. The mechanisms of these 
associations are largely unknown, although several hypotheses have been proposed (see 
chapter 2.5 for review). Rapid infant growth is often linked to the nutritional environment 
(373). Animal studies have shown that different nutritional exposures during early life are 
associated with obesity and a higher adult metabolic rate (374) as a result of tissue 
remodelling and changes in cell differentiation, organ growth, and cell signalling (373, 375, 
376). Postnatal nutritional excess, for example, leads to a chronic increase in leptin levels, 
which is further associated with obesity and blood pressure (377). Abnormal growth in the 
prenatal and postnatal environments is also associated with long-term effects on the elastin 
and collagen fibres in the arterial wall, which is further associated with hypertension (378). 
Finally, the observed associations might be a result of environmental plasticity, where the 
interplay between the genotype and conditions of growth and maturation can give rise to 
different phenotypes from the same genotype (379). Therefore, the postnatal environment 
could influence gene expression through epigenetic mechanisms, further influencing 
predisposition to obesity and high blood pressure later in adulthood, especially if genes 
modulating responses to later environmental challenge are affected. 
 
The NFBC1966 data support existing evidence that fast growth in the first months of life, as 
well as an early timing of adiposity rebound and pubertal height growth spurt, contribute to 
later obesity and an adverse metabolic profile, which are major risk factors for CVD and other 
chronic diseases (363, 372, 380). These results need to be considered in the context of other 
findings; for example, ischaemic heart disease (IHD) seems to be inversely associated with 
infant size and growth between three months and two years of age (381). Little is known 
about associations between growth patterns and other outcomes such as depression and 
cancer, which are responsible for substantial disease burden in adulthood (379, 381). A better 
understanding of mechanisms throughout the life course that contribute to an adverse 
metabolic profile, CVD risk, and other disease outcomes, could have important implications 
for chronic disease prevention. 
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6.4. Results from candidate gene analyses with discussion 
 
In this chapter, results from genetic association analyses on longitudinal growth are described 
and discussed. Candidate SNPs for the two studies presented were derived from published 
GWAS results on closely related traits. The results of the study on genetic determinants of 
height growth (6.4.1) have already been published in Sovio et al. (2009) (327). The results of 
the study on the association between FTO polymorphism and longitudinal BMI growth (6.4.2) 
are included in a submitted manuscript (Sovio* et al. PLoS Genet 2011 (in press)). My role in 
these studies has been explained in chapter 5.5.  
 
6.4.1. Genetic determinants of height growth  
 
The descriptive analysis of the growth outcomes presented in Table 1 in Sovio et al. (2009) 
(327) and Table 6.1 of this thesis differ slightly: in the former, the numbers were restricted to 
participants who had height SNP data available. Of the growth outcomes analysed in this 
study, males had a greater BL, PHV1 and PHV2, while females had about two years earlier 
pubertal height growth spurt, measured by ATO and age at PHV2. The correlations between 
derived growth parameters and birth measures, adult height and BMI have been described 
(without restriction to participants with height SNP data) in Table 6.2. Additionally, correlations 
between growth parameters and age at menarche were presented in females (see Text S1 
and Table S1 in Sovio et al. (2009) (327)). These correlations showed internal consistency. 
As expected, age at PHV2 had a strong correlation of r = 0.58 with age at menarche.  
 
Table 6.11 shows the associations between all SNPs, growth parameters and adult height 
from additive models per adult height increasing allele identified in three previous studies 
(335-337). To assess age-dependent effects of the variants on growth velocity, the p-value for 
interaction between the SNP and age (puberty vs. infancy) on PHV is shown. The interaction 
analyses formally tested the hypothesis that different genetic variants are involved in height 
growth regulation at different stages of life. Due to a high correlation between ATO and age at 
PHV2 (Table 6.2), genetic associations for ATO are omitted from Table 6.11 but the main 
results are reported in the text. All the analyses were adjusted for sex and principal 
components but not for socio-economic status (SES), BL or GA since the additional 
adjustment for these variables did not essentially change the results. Further information on 
these SNPs has been presented earlier (Table 5.4). To assess statistical significance, p < 
0.05 significance level is used for adult height, PHV1, PHV2 and the age-SNP interaction on 
PHV. For the age at PHV2 and ATO association analyses, and for sex-SNP interactions, a 
Bonferroni-corrected significance level of p < 0.0011 (see Chapter 5.5.1) was used, because 
of weaker a priori evidence for the existence of the associations. 
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Based on LD in the NFBC1966, the 48 SNPs analysed represent 44 independent signals in 
43 loci (detailed description is found in Sovio et al. (2009) (327) in Materials and Methods: 
Genotyping of SNPs). Twenty-four of the 44 signals (corresponding to 26 of the 48 SNPs) 
associated (p < 0.05) with adult height (Table 6.11). All of them had the same direction of 
effect as identified in the three previous GWA studies. 
 
Seven SNPs in or adjacent to the genes SF3B4/SV2A, LCORL, UQCC, DLEU7, HHIP and 
HIST1H1D showed an association (p < 0.05) with PHV1 (Table 6.11). All these SNPs except 
rs6854783 in HHIP were also associated with adult height in our study. All the SNP-PHV1 
associations were in the same direction as SNP associations with adult height in the previous 
GWA studies and in the current study. 
  
Five SNPs in or adjacent to the genes SF3B4/SV2A, SOCS2, C17orf67, CABLES1 and 
DOT1L were associated at p < 0.05 significance level with PHV2 (Table 6.11). Of these, three 
(related to SF3B4/SV2A, SOCS2 and C17orf67) associated with adult height in our sample. 
All five associated in the same direction as with adult height in the previous studies and in our 
study. Two of the five (related to SOCS2, CABLES1) and two additional SNPs (related to 
CDK6, C6orf106) associated with timing of pubertal growth spurt (ATO and/or age at PHV2) 
at p < 0.05 (data not shown in Table 6.11, see Sovio et al. (2009) (327) Table 2). However, 
because a similar prior evidence for association with the timing of height growth spurt (as for 
height velocities) did not exist, even the strongest association with age at PHV2 (C6orf106, p 
= 0.0057) could not be declared statistically significant after a Bonferroni correction. 
 
Only SNP rs11205277 upstream of SF3B4/SV2A showed significant evidence for an 
association with both PHV1 and PHV2. SNP rs6830062 in LCORL had a similar effect size on 
PHV1 (beta 0.74%, 95% CI 0.19 to 1.21%) and PHV2 (0.88%, -0.44 to 2.17%) as had SNP 
rs6842303 in the same gene (PHV1 beta 0.38%, 0.01 to 0.76%, PHV2 beta 0.30%, -0.58 to 
1.19%). The associations in LCORL were statistically significant for PHV1, but not PHV2, 
which may reflect inadequate power to detect association with PHV2 - the standard error in 
the PHV2 analysis was considerably larger than in the PHV1 analysis. 
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Table 6.11. Associations between SNPs and adult height and peak height velocities in 
infancy (PHV1) and puberty (PHV2).  
 
  Adult height [cm] PHV1 [%] PHV2 [%] Int
2
 
Gene SNP rs, allele
1
 Beta (SE(Beta)), p Beta (SE(Beta)), p Beta (SE(Beta)), p p 
SF3B4/SV2A rs11205277, G 0.43 (0.14), 0.0019 0.75 (0.18), 3x10
-5
 0.90 (0.43), 0.036 0.19 
LCORL
3
 rs6830062, T 0.73 (0.22), 0.0010 0.74 (0.28), 0.0087 0.88 (0.67), 0.19
 
 0.38 
DLEU7 rs3116602, T 0.55 (0.15), 0.0003 0.60 (0.20), 0.0023 0.31 (0.47), 0.51 0.12 
PPARD/ 
FANCE 
rs4713858, G 0.17 (0.21), 0.41 0.45 (0.27), 0.091 0.01 (0.63), 0.99 0.16 
HIST1H1D rs10946808, A 0.49 (0.13), 0.0002 0.44 (0.17), 0.0093 -0.45 (0.40), 0.26 0.0093 
HHIP rs6854783, A 0.20 (0.14), 0.16 0.41 (0.18), 0.025 -0.33 (0.43), 0.44 0.045 
UQCC rs6060373, G 0.69 (0.13), 2x10
-7
 0.41 (0.17), 0.016 0.75 (0.41), 0.069 0.53 
NHEJ1 rs6724465, G 0.51 (0.26), 0.053 0.40 (0.34), 0.24 0.88 (0.80), 0.26 0.92 
C6orf106 rs2814993, A 0.80 (0.17), 2x10
-6
 -0.39 (0.23), 0.086 0.08 (0.52), 0.88 0.19 
LCORL
3
 rs6842303, T 0.39 (0.15), 0.67 0.38 (0.19), 0.044 0.30 (0.45), 0.51  0.46 
SOCS2 rs11107116, T 0.47 (0.16), 0.0029 -0.16 (0.21), 0.43 1.60 (0.48), 0.0009 0.0030 
DOT1L rs12459350, G 0.20 (0.13), 0.13 0.09 (0.17), 0.59 1.26 (0.41), 0.0021 0.047 
CABLES1 rs4800148, A 0.24 (0.15), 0.12 0.38 (0.20), 0.056 0.96 (0.47), 0.040 0.75 
SH3GL3
3
 rs2562785, T 0.07 (0.19), 0.44 -0.07 (0.25), 0.79 -0.92 (0.59), 0.11 0.27 
C17orf67 rs4794665, A 0.34 (0.13), 0.0094 0.21 (0.17), 0.22 0.82 (0.41), 0.046 0.56 
C6orf173 rs4549631, C 0.18 (0.14), 0.19 0.17 (0.18), 0.34 0.71 (0.41), 0.085 0.69 
PXMP3/ PKIA rs7846385, C -0.09 (0.16), 0.56 -0.06 (0.21), 0.76 0.40 (0.49), 0.41 0.40 
HMGA2 rs1042725, C 0.47 (0.13), 0.0005 0.13 (0.18), 0.48 -0.25 (0.42), 0.54 0.28 
ADAMTS17 rs4533267, A 0.24 (0.15), 0.12 0.37 (0.20), 0.072 -0.44 (0.48), 0.36 0.068 
CDK6
3
 rs3731343, C 0.29 (0.13), 0.028 0.22 (0.17), 0.20 -0.69 (0.40), 0.084 0.029 
LIN28B rs314277, A 0.45 (0.17), 0.0084 0.06 (0.23), 0.81 0.33 (0.53), 0.53 0.97 
ACAN rs8041863, A 0.24 (0.14), 0.081 -0.01 (0.18), 0.96 0.20 (0.43), 0.64 0.68 
SPAG17 rs12735613, G 0.41 (0.16), 0.0083 0.15 (0.20), 0.46 0.51 (0.48), 0.28 0.85 
CEP63 rs10935120, G -0.03 (0.15), 0.84 -0.22 (0.20), 0.27 0.30 (0.46), 0.52 0.25 
ADAMTSL3
3
 rs10906982, A 0.34 (0.14), 0.013 -0.09 (0.18), 0.62 -0.18 (0.42), 0.66 0.96 
PTCH1 rs10512248, G 0.11 (0.14), 0.42 0.00 (0.18), 0.98 0.28 (0.42), 0.51 0.54 
ZBTB38 rs6440003, A 0.61 (0.14), 7x10
-6
 0.30 (0.18), 0.094 0.33 (0.42), 0.43 0.69 
SCMH1 rs6686842, T 0.16 (0.14), 0.25 -0.12 (0.18), 0.51 -0.13 (0.42), 0.76 0.97 
EFEMP1 rs3791675, C 0.16 (0.16), 0.31 0.09 (0.20), 0.67 -0.23 (0.48), 0.63 0.53 
CDK6
3
 rs2282978, C 0.31 (0.15), 0.038 0.19 (0.20), 0.34 0.00 (0.46), 0.999 0.48 
CHCHD7 rs9650315, G 0.57 (0.21), 0.0056 0.15 (0.28), 0.59 -0.06 (0.66), 0.93 0.81 
TRIP11
3
 rs8007661, C  0.01 (0.14), 0.94 0.06 (0.18), 0.76 0.57 (0.43), 0.18 0.48 
DNM3 rs678962, G 0.31 (0.15), 0.045 -0.15 (0.21), 0.47 -0.20 (0.49), 0.68 0.69 
TRIP11/FBLN5
3
 rs7153027, A 0.15 (0.13), 0.26 0.18 (0.17), 0.30 0.30 (0.40), 0.45 0.83 
ADAP2 rs3760318, G 0.37 (0.13), 0.0046 -0.10 (0.17), 0.56 -0.27 (0.40), 0.51 0.80 
TBX2  rs757608, A 0.32 (0.15), 0.036 0.12 (0.20), 0.55 -0.06 (0.47), 0.90 0.60 
BMP2 rs967417, G 0.41 (0.13), 0.0017 0.24 (0.17), 0.16 0.05 (0.40), 0.90 0.49 
BMP6 rs12198986, A 0.15 (0.13), 0.26 0.13 (0.17), 0.43
 
 -0.23 (0.39), 0.56 0.46 
RDBP, (LST1) 
NCR3/AIF1
3
 
rs2844479, A 0.17 (0.15), 0.24 0.27 (0.19), 0.15 -0.01 (0.45), 0.98 0.46 
RDBP/BAT3
3
 rs3130050, G 0.62 (0.19), 0.0011 -0.02 (0.24), 0.95 -0.64 (0.57), 0.26 0.55 
TNXB rs185819, C -0.05 (0.13), 0.72 -0.11 (0.17), 0.72 0.12 (0.40), 0.77 0.52 
HMGA1 rs1776897, G 0.42 (0.28), 0.14 -0.11 (0.37), 0.77 0.19 (0.84), 0.82
 
 0.84 
GPR126
3
                   rs6570507, G 0.55 (0.15), 0.0002 0.13 (0.19), 0.51 0.56 (0.46), 0.22 0.61 
GPR126
3
 rs3748069, A 0.55 (0.15), 0.0002
 
 0.22 (0.19), 0.26 0.68 (0.46), 0.14 0.69 
AMZ1/GNA12 rs798544, C 0.27 (0.14), 0.046 0.03 (0.18), 0.85 0.26 (0.42), 0.54 0.86 
CDK6
3
 rs11765954, C 0.23 (0.15), 0.14 0.27 (0.20), 0.18 0.62 (0.47), 0.19 0.97 
PLAG1 rs10958476, C -0.21 (0.16), 0.19 -0.21 (0.21), 0.32 -0.52 (0.49), 0.28 0.90 
ZNF462 rs4743034, A 0.52 (0.16), 0.0016 0.26 (0.21), 0.22 -0.14 (0.51), 0.78 0.15 
 
All analyses are adjusted for sex and principal components. Results are sorted by effect sizes: ten largest for PHV1 
at the top followed by remainder of ten largest for PHV2, followed by the remaining SNPs in arbitrary order. The 
SNPs with associations at p < 0.05 significance level are highlighted for adult height, PHV1 and PHV2. Beta is 
expressed as the change in PHV1 and PHV2 [%] per one adult height increasing allele.
 1
Height increasing allele 
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identified in GWAS (using the HapMap B35 + strand as the reference strand). The sign of adult height beta shows if 
the direction of effect was the same as in the three GWAS (+=same, -=different).
 2
Interaction p-value between SNP 
and age (puberty vs. infancy) on PHV, values at p < 0.05 are highlighted in italics and values at p < 0.01 in bold.
 
3
Genes with more than one SNP or SNPs close together in different genes. r
2
 between SNPs: LCORL 0.03, 
SH3GL3/ADAMTSL3 0.12, RDBP, (LST1) NCR3/AIF1 / RDBP/BAT3 0.06 (all SNPs counted as separate signals); 
CDK6 r
2
 0.32-0.78, TRIP11/FBLN5 r
2 
0.72 and GPR126 r
2
 0.97 (counted as one signal per gene). 
 
Interaction between SNP and age on PHV was detected for four SNPs that had a main effect 
(p < 0.05) on PHV1 and/or PHV2 (Table 6.11). For SNPs rs6854783 in HHIP and rs10946808 
in HIST1H1D adult height increasing alleles increased PHV1 but not PHV2 (p = 0.045 and 
0.0093). SNPs rs11107116 (in SOCS2, see Figure 6.4 for velocity by genotype, sex and age), 
and rs12459350 (DOT1L), showed an effect on PHV in puberty but not in infancy (p = 0.0030 
and 0.047). Given the strong biological argument for differential effects at different ages (382), 
the SOCS2 and HIST1H1D interactions were considered as suggestive and also a possible 
biological explanation for the SOCS2 interaction was found. The HHIP and DOT1L 
interactions are borderline significant (just below p < 0.05) but for the former there is also a 
possible biological explanation. 
 
 
 
Figure 6.4. Mean-constant curves for height growth velocity between ages 8-16y, 
estimated from the JPA-2 model, by sex and rs11107116 genotype (SOCS2 gene). Adult 
height increasing allele (T) is associated with higher PHV2 and earlier timing of pubertal 
height growth spurt. 
 
The interaction between sex and SNP effects on growth was investigated due to differences 
in growth parameters between sexes (see Table 6.1). No statistically significant sex-SNP 
interactions were observed on any of the outcomes after Bonferroni correction (at p < 0.0011 
level). The smallest p-value was observed for SNP rs2814933 (C6orf106) which could be 
associated with timing of pubertal growth spurt in males (age at PHV2 beta = 0.16 years) 
while in females there is no effect (age at PHV2 beta = -0.003 years; sex interaction p = 
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0.003). Due to only few interactions that were not significant after Bonferroni correction, the 
results are shown as sex-adjusted for all SNPs in Table 6.11. 
 
Discussion of the genetic determinants of height growth 
 
The majority of signals associated with growth parameters in this study lie close to genes that 
are involved in recognised growth and development pathways, or have a potential role in 
growth through an effect on gene expression or regulation (e.g. cell proliferation, bone 
formation and growth hormone signalling pathways). In the analysis between confirmed adult 
height SNPs and peak height growth velocities at different ages, an age-SNP interaction 
(rs11107116, p = 0.0030) was identified, suggesting an effect in puberty but not in infancy. 
Together with a meaningful biological explanation, this gives suggestive evidence for an age-
specific SNP effect in the SOCS2 (Suppressors of cytokine signalling 2) gene, which is a 
negative regulator of cytokine and cytokine hormone signalling via JAK/STAT pathways. One 
of its functions is to influence growth and development through effects on growth 
hormone/IGF-1 signalling (383). Oestrogen has been shown to induce SOCS2 expression in 
vitro, with a subsequent decrease in JAK-STAT signalling in response to growth hormone 
(384). This potential role for SOCS2 in the interplay between steroid hormones and growth, 
could explain the association observed between SOCS2 variation and growth velocity during 
puberty. The lack of association in early infancy could be explained by the fact that height 
growth is not yet dependent on growth hormone at that age (382).  
 
Also, a possible biological explanation for the age-SNP interaction (rs6854783, p = 0.045) in 
HHIP (Hedgehog interacting protein) was found, suggesting an effect on growth velocity in 
infancy but not in puberty. HHIP is a component of the hedgehog signal transduction pathway 
involved in embryogenesis and development (385). This pathway influences the transcription 
of many target genes and is important for development of many tissues and organs. It is 
important in early embryogenesis and cell proliferation, including limb and central nervous 
system development (385, 386). Therefore it seems plausible that variants in HHIP would 
only play a role in early infancy but not in puberty. However, since the HHIP interaction does 
not appear to be very strong in these data, this result needs replication. In the meta-analysis 
of GWAS (chapter 6.5.3), PHV1 but not PHV2 was studied, and therefore no attempt could be 
made to replicate the interaction in this setting.  
 
To summarise, these results show that nearly half of the genetic variants associated with 
adult height in this sample had a detectable (statistically significant) effect on PHV1 or PHV2. 
The power to detect an effect size of 0.46 cm per allele with adult height was only 60% at 
level p < 0.05 using MAF = 0.31 (average MAF among the 48 SNPs) and an additive genetic 
model. This contributes to the fact that almost half of the signals were not replicated (the 
known height variants tested typically have a 0.2–0.6 cm per allele effect size). The statistical 
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power was slightly lower to identify similar effect sizes for PHV1 and PHV2. Only one variant 
associated statistically significantly with both PHV1 and PHV2. Suggestive evidence that the 
associations of some of the variants may be age-dependent was found. This study is the first 
population-based genetic study of longitudinal height growth, and provides an insight into how 
height in humans may be regulated by its genetic determinants during different periods of 
growth. 
 
6.4.2. Association between FTO polymorphism and longitudinal BMI growth  
 
Cross-sectional results 
 
Table 6.12 describes the stratum and study-specific subject characteristics. It illustrates that 
overall, the variation in BMI between age strata was larger than between-study variation 
within a given age stratum. Unlike the NFBC1966, many other cohorts had data available only 
at selected ages. Around adiposity rebound (4.5 - 7 years of age), the NFBC1966 comprised 
over half of the study population. 
 
Table 6.12. Numbers and characteristics of subjects by cohort and age strata. Values 
represent means and standard errors. 
 
Age Stratum 
(years) 
Cohort N Age (years) Weight (kg) Height (cm) BMI (kg/m
2
) Males (%) 
0.00 - 0.49*  ALSPAC 6512 0.15 (3.6*10
-4
) 5.05 (0.01) 57.67 (0.03) 15.16 (0.02) 50.9 
 BCG 567 0.24 (1.3*10
-3
) 6.08 (0.03) 60.50 (0.10) 16.61 (0.06) 54.0 
 GENR 2545 0.16 (1.6*10
-3
) 5.30 (0.02) 57.88 (0.07) 15.80 (0.03) 50.5 
 NFBC1966 2954 0.26 (1.4*10
-3
) 6.15 (0.02) 61.61 (0.06) 16.20 (0.03) 49.4 
 UBC 569 0.25 (1.0*10
-3
) 6.13 (0.03) 61.30 (0.10) 16.32 (0.06) 51.1 
 Stratum total 13185      
0.50 - 1.49  ALSPAC 6402 0.80 (1.41*10
-3
) 9.27 (0.01) 72.65 (0.04) 17.53 (0.02) 50.7 
 BCG 566 1.00 (1.5*10
-3
) 10.30 (0.05) 74.87 (0.11) 18.38 (0.07) 54.1 
 GENR 2760 0.94 (2.3*10
-3
) 9.67 (0.02) 74.69 (0.06) 17.33 (0.02) 50.6 
 NFBC1966 3461 0.99 (1.8*10
-3
) 10.14 (0.02) 75.52 (0.05) 17.78 (0.03) 49.3 
 RAINE 1012 1.14 (2.9*10
-3
) 10.25 (0.04) 77.48 (0.09) 17.08 (0.04) 52.2 
 UBC 571 1.00 (3.0*10
-3
) 10.11 (0.05) 75.92 (0.12) 17.54 (0.06) 51.3 
 Stratum total 14811      
1.50 - 2.49  ALSPAC 4622 1.72 (3.0*10
-3
) 11.96 (0.02) 84.13 (0.06) 16.88 (0.02) 51.2 
 BCG 548 1.99 (5.7*10
-3
) 12.72 (0.06) 85.52 (0.14) 17.39 (0.06) 54.2 
 GENR 2395 2.02 (4.0*10
-3
) 12.69 (0.03) 87.69 (0.08) 16.50 (0.03) 50.3 
 NFBC1966 2585 1.98 (3.1*10
-3
) 11.87 (0.02) 84.03 (0.06) 16.81 (0.02) 49.6 
 RAINE 326 2.14 (6.7*10
-3
) 12.88 (0.08) 89.91 (0.20) 15.94 (0.07) 50.3 
 UBC 483 1.81 (1.2*10
-2
) 12.49 (0.07) 85.97 (0.17) 16.90 (0.06) 52.6 
 Stratum total 10990      
2.50 - 3.49  ALSPAC 735 2.59 (7.1*10
-4
) 13.95 (0.06) 91.56 (0.12) 16.61 (0.05) 51.6 
 BCG 548 3.01 (4.8*10
-3
) 14.65 (0.07) 94.08 (0.16) 16.55 (0.06) 53.3 
 GENR 787 2.60 (3.0*10
-3
) 13.97 (0.06) 92.97 (0.13) 16.16 (0.04) 50.6 
 NFBC1966 2159 3.02 (4.1*10
-3
) 14.33 (0.04) 94.48 (0.09) 16.06 (0.03) 48.3 
 RAINE 733 3.09 (3.4*10
-3
) 14.98 (0.07) 96.36 (0.14) 16.13 (0.05) 50.6 
 UBC 503 3.03 (4.5*10
-2
) 15.43 (0.08) 96.75 (0.17) 16.49 (0.06) 51.1 
 Stratum total 5474      
3.50 - 4.49  ALSPAC 4794 3.72 (2.8*10
-3
) 16.44 (0.03) 100.44 (0.06) 16.26 (0.02) 50.7 
 BCG 547 4.01 (5.6*10
-3
) 16.75 (0.08) 101.13 (0.17) 16.38 (0.05) 53.6 
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 NFBC1966 2122 4.02 (4.2*10
-3
) 16.23 (0.04) 101.71 (0.09) 15.69 (0.03) 46.9 
 UBC 525 4.04 (4.2*10
-3
) 17.65 (0.09) 104.53 (0.19) 16.15 (0.06) 51.6 
 Stratum total 8023      
4.50 - 5.49  ALSPAC 679 5.17 (2.3*10
-3
) 19.46 (0.09) 110.27 (0.17) 15.96 (0.05) 51.5 
 BCG 560 5.00 (3.2*10
-3
) 18.71 (0.09) 107.32 (0.18) 16.24 (0.06) 53.6 
 NFBC1966 1901 5.02 (4.5*10
-3
) 18.11 (0.05) 108.37 (0.11) 15.42 (0.03) 46.3 
 UBC 151 5.13 (2.6*10
-2
) 20.08 (0.26) 111.83 (0.42) 16.05 (0.13) 51.0 
 Stratum total 3299      
5.50 - 6.99  EBS 714 6.44 (1.4*10
-2
) 23.39 (0.14) 118.75 (0.20) 16.59 (0.06) 50.3 
 NFBC1966 2759 6.34 (6.6*10
-3
) 20.86 (0.06) 116.62 (0.10) 15.33 (0.03) 48.9 
 RAINE 984 5.90 (5.7*10
-3
) 21.16 (0.09) 116.00 (0.15) 15.73 (0.05) 52.2 
 UBC 500 6.02 (2.2*10
-2
) 22.19 (0.15) 118.14 (0.26) 15.90 (0.07) 50.4 
 Stratum total 4957      
7.00 - 8.99  ALSPAC 5549 7.83 (6.3*10
-3
) 26.72 (0.06) 127.49 (0.08)  16.35 (0.03) 50.8 
 EBS 1350 8.02 (1.6*10
-2
) 27.97 (0.14) 127.90 (0.17) 17.09 (0.06) 49.2 
 NFBC1966 3261 7.82 (6.7*10
-3
) 24.33 (0.06) 124.60 (0.10) 15.68 (0.03) 50.2 
 RAINE 986 8.10 (1.0*10
-2
) 27.82 (0.16) 129.34 (0.18) 16.63 (0.07) 52.0 
 UBC 510 7.84 (2.3*10
-2
) 27.23 (0.23) 129.14 (0.28) 16.29 (0.09) 51.6 
 Stratum total 11694      
9.00 - 10.99 ALSPAC 5159 9.94 (4.6*10
-3
) 34.63 (0.10) 139.73 (0.09) 17.63 (0.04) 49.9 
 CHC 545 10.26 (1.4*10
-2
) 33.19 (0.17) 138.72 (0.23) 17.25 (0.06) 100 
 NFBC1966 2602 10.06 (8.2*10
-3
) 31.43 (0.11) 137.43 (0.13) 16.64 (0.04) 50.6 
 RAINE 945 10.57 (4.6*10
-3
) 37.87 (0.26) 143.68 (0.21) 18.34 (0.10) 52.4 
 UBC 510 10.51 (2.0*10
-2
) 35.36 (0.31) 142.22 (0.30) 17.48 (0.11) 51.6 
 Stratum total 9798      
11.00 - 13.00  ALSPAC 4635 11.75 (3.3*10
-3
) 43.26 (0.14) 150.63 (0.11) 18.94 (0.05) 49.3 
 CHC 811 12.01 (3.9*10
-3
) 38.67 (0.17) 146.63 (0.21) 17.99 (0.05) 100 
 NFBC1966 3389 11.88 (6.2*10
-3
) 37.99 (0.12) 147.32 (0.13) 17.50 (0.04) 50.3 
 UBC 339 12.03 (2.7*10
-2
) 43.47 (0.49) 153.46 (0.44) 18.45 (0.15) 52.2 
 Stratum total 9203      
 
* Birth weight and length were excluded from analyses. Subjects are all singletons of Caucasian ethnicity with FTO 
(rs9939609) genotype and weight/height information available. No siblings have been included. 
 
Figure 6.5 shows the results of meta-analyses of the association between each additional 
minor allele (A) at rs9939609 and BMI at different age strata. From age 5.5 years, the minor 
allele (A) was associated with a higher BMI, though this association was not statistically 
significant in the age stratum 11 to 13 years due to a relatively low sample size in this 
stratum. The mean effect ranged from 0.26 kg/m
2
 per one A-allele increase at age 5.50-6.99 
years to 0.53 kg/m
2
 at age 9.00-10.99 years. In contrast to this, each minor allele was 
associated with a lower BMI before the age of 2.5 years. The mean effect size ranged from -
0.13 kg/m
2
 per one A-allele increase at age 0.50-1.49 years to -0.09 kg/m
2
 at age 1.50-2.49 
years. Between the ages of 2.5 and 5.5 years, no cross-sectional association was observed 
between rs9939609 genotype and BMI. Justifying the use of a random effects model, 
maximum heterogeneity in this meta-analysis was high and reflected in an I
2
 value of 70% 
(95% CI: 22, 88). Similar results (not shown) were found for analyses regarding 
weight/height
p
.  
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Figure 6.5. Summary of the association between rs9939609 minor allele (A) and body 
mass index (BMI) [kg/m
2
] by age. Mean effect with a 95% confidence interval is given. 
 
The pattern of observed mean BMI at different ages in the NFBC1966 (the cohort with most 
dense data from birth to 13 years of age) is described in Figure 6.6. Although the BMI growth 
pattern is given for each rs9939609 genotype, the figure is presented here to illustrate the 
BMI trajectory and its inflection points which are further explored in relation to rs9939609 
genotypes in the longitudinal analyses using appropriate methods for repeated measurement 
data.   
 
 
Figure 6.6. Pattern of observed mean body mass index (BMI) at 0-13 years in the 
NFBC1966 by the rs9939609 genotype. A=minor allele, i.e. the allele associated with 
increased adiposity. 
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Longitudinal results 
 
Derived from longitudinal infancy analysis, the rs9939609 minor allele (A) was associated with 
a lower estimated mean BMI at the centre point of 9 months of age; difference in BMI 
between genotypes AA (two risk alleles) and TT was -0.11 kg/m² (95% CI: -0.20, -0.03), p = 
0.007 (Table 6.13). In contrast, in the childhood analysis, the risk allele was associated with a 
higher BMI at the centre point of 7.25 years; difference in BMI between genotypes AA and TT 
was 0.13 kg/m² (95% CI: 0.07, 0.20), p = 9 x 10
-5
. Heterogeneity in these analyses was low 
and I
2
 statistics did not exceed 0% in either case. 
 
The rate of change in BMI was associated with variation at rs9939609 locus in childhood but 
not in infancy. BMI increased faster in those with two minor (A) alleles compared to the 
reference (TT) group. This equated to a difference of 0.039 kg/m²/year (95% CI: 0.028, 0.051) 
around age 7.25 years, p = 7 x 10
-12
 (Table 6.14). In these analyses, values for heterogeneity 
were larger (I
2
 from 30-65%) and again warranted use of random effects models. Sensitivity 
analyses indicated that the inferences for the intercept and slope terms of rs9939609 
genotype (main effect and interaction with time) were not notably affected by the inclusion of 
additional covariates (outlined in the method section) or by moving the cut-off point between 
the two age windows from 18 to 12 or to 24 months of age.  
 
There was weak evidence for a lower BMI at AP in the carriers of two minor alleles (AA) of 
rs9939609 compared to the reference group (TT): -0.401% (95% CI: -0.741, -0.060), p = 0.02 
(Table 6.15). In contrast, by the age of AR, this effect showed evidence for inversion with 
carriers of two minor alleles (AA) having higher BMI at AR than those in the reference group 
(TT): 0.933 % (95% CI: 0.224, 1.642), p = 0.01. Whilst there was no evidence for genotypic 
association with age at AP in the meta-analysis, there was evidence for an earlier AR in the 
carriers of two minor alleles (AA) compared to the reference group (TT): -0.273 years (95% 
CI: -0.358, -0.188), p = 4 x 10
-10
. Among AP and AR analyses, there was evidence for 
heterogeneity between the cohorts only when age at AR was compared between carriers of 
one minor allele (TA) and the reference group (TT) (I
2
 = 72% (95% CI: 21%, 90%)), and when 
BMI at AR was compared between carriers of two minor alleles (AA) and the reference group 
(TT) (I
2
 = 69% (95% CI: 12%, 89%)). For consistency, random effects models were used for 
comparisons regarding meta-analyses on age and on BMI at AR. 
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Table 6.13. Differences in body mass index by rs9939609 genotype. Reference group: 
genotype TT. 
 
Genotype Study 
Difference in BMI (kg/m
2
) 
0 to 1.5 years 1.5 to 13 years 
TA 
ALSPAC N/A 0.053 (0.036), p = 0.1 
BCG 0.008 (0.119), p = 0.9 N/A 
GENR -0.061 (0.043), p = 0.2 N/A 
RAINE N/A 0.129 (0.088), p = 0.1 
NFBC1966 0.021 (0.052), p = 0.7 0.050 (0.041), p = 0.2 
UBC -0.136 (0.106), p = 0.2 -0.098 (0.115), p = 0.4 
Meta-analysis 
-0.035 (95% CI: -0.094, 0.025), 
p = 0.3 
0.051 (95% CI: 0.002, 0.100),  
p = 0.04 
AA 
ALSPAC N/A 0.147 (0.048), p = 0.002 
BCG -0.322 (0.165), p = 0.05 N/A 
GENR -0.130 (0.060), p = 0.03 N/A 
RAINE N/A 0.226 (0.129), p = 0.08 
NFBC1966 -0.048 (0.071), p = 0.5 0.113 (0.055), p = 0.04 
UBC -0.130 (0.142), p = 0.4 0.012 (0.155), p = 0.9 
Meta-analysis 
-0.113 (95% CI: -0.196, -0.031),  
p = 0.007 
0.133 (95% CI: 0.066, 0.199),  
p = 9 x 10
-5
 
 
Values are regression coefficients (95% confidence interval) and represent differences in BMI (kg/m
2
) at centre points 
of age: 0.75 years in infancy and 7.25 years in childhood. Heterogeneity was not detected in the meta-analyses. N/A 
denotes insufficient data for longitudinal analysis. 
 
Table 6.14. Differences in body mass index growth rate by rs9939609 genotype. 
Reference group: genotype TT. 
 
Genotype Study 
Difference in BMI per year (kg/m
2
) 
0 to 1.5 years 1.5 to 13 years 
TA 
ALSPAC N/A 0.030 (0.007), p = 3.4 x 10
-6
 
BCG -0.097 (0.127), p  =0.5 N/A 
GENR 0.015 (0.053), p = 0.8 N/A 
RAINE N/A 0.028 (0.016), p = 0.08 
NFBC1966 0.132 (0.066), p = 0.04 0.003 (0.006), p = 0.6 
UBC 0.190 (0.109), p = 0.08 0.003 (0.017), p = 0.9 
Meta-analysis 
0.062 (95% CI: -0.010, 0.134) 
p = 0.092 
0.016 (95% CI: 0.008, 0.024),  
p = 1 x 10
-4
 
AA 
ALSPAC N/A 0.058 (0.009), p = 2 x 10
-11
 
BCG -0.205 (0.177), p = 0.3 N/A 
GENR 0.065 (0.074), p = 0.4 N/A 
RAINE N/A 0.027 (0.026), p = 0.3    
NFBC1966 0.098 (0.090), p = 0.3 0.026 (0.009), p = 0.003 
UBC -0.162 (0.146), p = 0.3 0.016 ( 0.023), p = 0.5 
Meta-analysis 
0.026 (95% CI: -0.074, 0.125) 
p = 0.6 
0.039 (95% CI 0.028, 0.051),  
p = 7 x 10
-12
 
 
Values are regression coefficients (95% confidence interval) and represent differences in BMI per year (kg/m
2
 per 
year) at centre points of age: 0.75 years in infancy and 7.25 years in childhood. In these longitudinal analyses, values 
for heterogeneity were I
2
 from 30-65%. N/A denotes insufficient data for longitudinal analysis. 
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Table 6.15. Differences in age and body mass index (BMI) at adiposity peak (AP) and 
adiposity rebound (AR) between rs9939609 genotype groups with 95% confidence 
interval (95% CI). Reference group: genotype TT. 
 
Genotype Study Age difference at AP [weeks] % difference of BMI at AP 
 BCG -0.050 (-0.228, 0.129), p = 0.6 0.062 (-0.852, 0.985), p = 0.9 
 GENR 0.003 (-0.176, 0.181), p = 0.98 -0.226 (-0.563, 0.113), p = 0.2 
TA NFBC1966 -0.054 (-0.306, 0.199), p = 0.7 0.113 (-0.384, 0.613), p = 0.7 
 UBC 0.176 (0.009, 0.343), p = 0.04 -0.495 (-1.111, 0.126), p = 0.1 
 Meta-analysis  0.035 (-0.059, 0.128), p = 0.5 -0.164 (-0.411, 0.082), p = 0.2 
 BCG  -0.078 (-0.328, 0.172), p = 0.5 -1.368 (-2.627, -0.092), p = 0.04 
 GENR  -0.019 (-0.270, 0.233), p = 0.9 -0.505 (-0.977, -0.030), p = 0.04 
AA NFBC1966 0.273 (-0.069, 0.615), p = 0.1 -0.260 (-0.930, 0.415), p = 0.5 
 UBC  -0.131 (-0.355, 0.093), p = 0.3 0.103 (-0.725, 0.938), p = 0.8  
 Meta-analysis -0.030 (-0.159, 0.099), p = 0.7  -0.401 (-0.741, -0.060), p = 0.02 
Genotype  Age difference at AR [years] %difference of BMI at AR 
 ALSPAC -0.181 (-0.253, -0.109), p = 8 x 10
-7
 0.621 (0.157, 1.088), p = 0.009 
 RAINE -0.257 (-0.405, -0.110), p = 7 x 10
-4
 0.414 (0.073, 0.756), p = 0.02 
TA NFBC1966 -0.067 (-0.137, 0.003), p = 0.06 0.518 (-0.010, 1.050), p = 0.06 
 UBC 0.051 (-0.207, 0.309), p = 0.7 -0.141 (-1.480, 1.216), p = 0.8 
 Meta-analysis -0.134 (-0.234, -0.034), p = 0.009 0.473 (0.234, 0.713), p = 1 x 10
-4
 
 ALSPAC -0.354 (-0.452, -0.256), p = 2 x 10
-12
 1.256 (0.620, 1.896), p = 1 x 10
-4
 
 RAINE -0.241 (-0.451, -0.030), p = 0.03 0.313 (-0.172, 0.799), p = 0.2 
AA NFBC1966 -0.224 (-0.319, -0.129), p = 4 x 10
-6
 1.584 (0.860, 2.314), p = 2 x 10
-5
 
 UBC -0.138 (-0.484, 0.208), p = 0.4 0.266 (-1.534, 2.099), p = 0.8 
 Meta-analysis -0.273 (-0.358, -0.188), p = 4 x 10
-10
  0.933 (0.224, 1.642), p = 0.01 
 
Age and BMI at AP and AR have been estimated from the LMEM for all cohorts. Meta-analysis results for AP and AR 
parameters are based on fixed and random effects models, respectively. Heterogeneity was present when age at AR 
was compared between TA and the reference group TT (I
2
 72% (95% CI: 21%, 90%)) and when BMI at AR was 
compared between AA and the reference group TT (I
2
 69% (95% CI: 12%, 89%)). 
 
Discussion of the effect of the FTO variant (rs9939609) on BMI growth throughout childhood 
 
The finding that the FTO variant rs9939609 associates with BMI in the expected direction only 
from age 5.5 years is in line with the studies on the biology of this locus. It has been 
suggested that FTO operates by influencing appetite and the amount of food consumed (387, 
388). Therefore it is logical to assume that until children gain autonomy over their dietary 
intake the FTO effect will not be realised. The inverse association between rs9939609 and 
BMI in infancy is harder to explain (more details in Sovio* et al. PLoS Genet 2011 (in press)). 
This effect is of borderline significance, p = 0.007-0.02 depending on the measure. If real, the 
magnitude of this effect is in any case small, about 0.1 kg/m
2
 difference in BMI between the 
two heterozygote groups, and probably not of clinical importance. However, even small 
effects can bring biologically interesting insights, and therefore further research to this 
question is warranted. 
 
The strengths of this study were the large sample size which ensured a high statistical power, 
the availability of longitudinal measurements, and the versatile use of methods to analyse 
growth curves and to extract interpretable growth parameters for meta-analysis.   
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There are also some limitations to this study. Firstly, the binning of sample contributions and 
definition of analytic windows in longitudinal data may not be optimal. There are still age 
groups for which we have limited sample size and this is reflected in the sampling error 
associated with these periods of growth and development. However, considerable effort was 
made and sensitivity analyses were performed to choose the most reasonable age windows 
and to maximise data usage over childhood.  
 
Secondly, possible complication to the patterns of association seen between common 
variation at the FTO gene and BMI relates to the interplay between maternal and offspring 
genotypes. Whilst not formally tested here and not within the bounds this study, the 
observation that mothers with greater BMI have, on average, offspring with greater 
birthweight may be relevant in our interpretation of results (see e.g. (389)). Owing to the 
correlation between maternal and foetal genotype, individuals carrying minor (A) adiposity 
raising alleles at rs9939609 will be more likely to have mothers harbouring the same variants. 
One may hypothesise that, on average, the elevation of adiposity in these mothers may 
translate to increased levels of birthweight or differential growth and development in early 
ages as shown observationally (390, 391). Whilst this pattern fits with childhood patterns 
shown here, this would counteract the inverse association between minor (A) alleles at 
rs9939609 and BMI at very young ages (i.e. reduce the observed negative association 
between rs9939609 and BMI in infancy). Confirmation of this would require large collections 
with both maternal and offspring genotypes. 
 
Lastly, the use of BMI as an assessment of adiposity at early ages has been disputed (392, 
393), although BMI is still commonly used. Therefore sensitivity analyses were performed 
using the derived measure weight/height
p
 (340) to account for this limitation and found that 
results were largely consistent with BMI (weight/height
2
). For this reason and for consistency 
with later ages in childhood, we adopted the use of BMI throughout. 
 
To conclude, this study demonstrated a weak inverse association between the adult adiposity 
associated FTO variant rs9939609 (minor allele A) and BMI before the age of 2.5 years. 
Beyond the age of 5.5 years, anticipated patterns of association between this variant and BMI 
gradually emerged and became stronger: in a cross-section, minor allele carriers showed 
greater levels of BMI. When assessed longitudinally, they exhibited steeper rates of BMI 
increase throughout childhood. This study also showed that the minor allele A is associated 
with a lower BMI at AP, a higher BMI at AR and an earlier timing of AR. These observations 
might help develop understanding to the biological mechanisms underlying the association 
between common variation at this locus and adiposity related traits. Further, specific, 
analyses will be required to confirm the associations between variation at rs9939609 and 
 171 
adiposity (especially at very young ages) and to investigate the clinical implications of 
associations between common genetic variation and both BMI at AP and the timing of AR. 
 
6.5. Results from GWAS with discussion 
 
This chapter presents and discusses GWAS results, including stand-alone analyses in the 
NFBC1966 as well as GWAS meta-analyses conducted in large consortia. Analyses of adult 
anhropometric and metabolic phenotypes (6.5.1), birth weight and gestational age (6.5.2), 
and growth parameters (6.5.3) are presented. Discussion of the results is either integrated 
with the results in each sub-study (chapters 6.5.1 and 6.5.3), or placed after the results 
(6.5.2). My role in each of these analyses is explained in chapter 5.6. 
 
6.5.1. GWAS on adult anthropometric and metabolic phenotypes 
 
Summary of analyses on directly genotyped NFBC1966 data  
 
In the GWAS, the additive effect of each directly genotyped SNP on the nine metabolic traits 
at age 31 years was tested, adjusted for sex, use of oral contraceptives and pregnancy status 
(324). The traits included triglyceride, HDL cholesterol, LDL cholesterol, glucose, insulin, 
CRP, BMI, SBP and DBP. Altogether 21 associations in 20 genome regions at p < 5x10
-7
 
significance level were identified for five of these traits: four for triglyceride, five for HDL and 
six for LDL cholesterol, three for CRP, and three for glucose  (Table 2 in Sabatti et al. (2009) 
(324)). One third of these observations were novel. Further adjustment for BMI unveiled two 
more associations, one for LDL cholesterol and one for insulin.  
 
Many of the nine novel associations identified in Sabatti et al. (2009) (324) highlight genes 
with metabolic functions: HDL association with NR1H3 (LXRA), LDL with androgen receptor 
(ARe) and FADS1-FADS2, glucose with MTNR1B, and insulin with PANK1. NR1H3 is a 
transcriptional regulator of cholesterol metabolism. The low-frequency variant in intron 6 of 
ARe (MAF = 0.017) encodes a transcription factor controlling androgen levels which in turn 
are associated with sex-specific dyslipidemias. FADS1-FADS2 encode desaturates which 
have demonstrated associations with fatty acids in serum phospholipids. MTNR1B is 
transcribed in human islets and rodent insulinoma cell lines, and the translated receptor is 
thought to mediate the inhibitory effect of melatonin on insulin secretion. PANK1 encodes 
panthothenate kinase which is involved in glucose metabolism according to chemical 
knockout studies in mice. References to these studies can be found in Sabatti et al. (2009) 
(324).  
 
The identified associations persisted after adjustment for other relevant variables: smoking 
and alcohol consumption at age 31 years, birth BMI, and the first two components from the 
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MDS analysis representing the geographical origins of the subject. Furthermore, most 
previously reported associations with six of these traits (triglyceride, LDL and HDL 
cholesterol, CRP, glucose and BMI) were replicated in the NFBC1966 (Table 3 in Sabatti et 
al. (2009) (324)). Gene-environment interaction analyses were underpowered and the 
suggestive findings from them require validation in other samples. 
 
Analyses of height, body mass index and waist circumference using imputed NFBC1966 data 
 
The quantile-quantile (Q-Q) plot for BMI at age 31 years (Figure 6.7) did not show a notable 
departure of observed p-values from the expected p-value at any point of the scale, which 
means that there was no indication of population structure (λ=1.030) or genome-wide 
significant association signals. The top SNP (rs12329227) in chromosome 2 reached a p-
value 7.15 x 10
-7
 (see also Figure 6.8). This is in line with the result in Sabatti et al. 2009 
(324) which found a slightly weaker peak in the same region. This signal is in protein coding 
LOC100128572 gene but no references to biological functions could be found. However, a 
nearly genome-wide significant peak in chromosome 6 observed in Sabatti et al. 2009 (324) 
could not be identified in the analysis of imputed data.  
 
Associations between the known BMI variants in the FTO and MC4R genes and BMI at age 
31 years were of similar statistical significance to the associations reported in Sabatti et al. 
(2009) (324). The directly genotyped FTO SNP rs3751812, which could potentially be causal 
(177), was associated with BMI in the present analysis at p = 2.9x10
-4
, while in Sabatti et al. 
2009 (324) it reached a p-value of 2.4x10
-4
. The effect of the FTO SNP rs9939609 (imputed) 
in this analysis, 0.08 (95% CI 0.03-0.12) SD higher BMI per one additional A allele, was 
similar to the effect reported in Frayling et al. 2007 (27) using the directly genotyped SNP 
(0.09 (95% CI 0.04, 0.13), respectively). 
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Figure 6.7. Q-Q plot for body mass index (BMI) at age 31 years in the NFBC1966 
singletons, from a GWAS on imputed data. 
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Figure 6.8. Manhattan plot for body mass index (BMI) at age 31 years in the NFBC1966 
singletons, from a GWAS on imputed data. 
 
Similarly to BMI, the Q-Q plot did not indicate an effect of population structure for WC either 
(Figure 6.9; λ = 1.011), but there was a slight departure from the expected p-values at about 
3.5-5.5 in the log10 scale (p = 3x10
-4
 to 3x10
-6
). There were no genome-wide significant 
associations for WC. The top SNP in chromosome 8 (rs7814326) reached a p-value 5.94x10
-7
 
(Figure 6.10). There was a cluster of ten SNPs with p < 3.5x10
-5
 in that region. These SNPs 
lie within the Cub and Sushi Multiple Domains 1 (CSMD1) gene which is a potential 
suppressor of squamous cell carcinomas (394). Variants in this gene have been associated 
with MetS and BMI in the Framingham Heart Study (395), but these particular variants were 
not associated with WC in the NFBC1966 (e.g. for rs1997137 p = 0.96). Since this signal has 
not been discovered in larger studies on WC (e.g. within the GIANT Consortium), its role in 
adult adiposity is probably negligible.  
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Figure 6.9. Q-Q plot for waist circumference (WC) at age 31 years in the NFBC1966 
singletons, from a GWAS on imputed data. 
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Figure 6.10. Manhattan plot for waist circumference (WC) at age 31 years in the 
NFBC1966 singletons, from a GWAS on imputed data. 
 
The Q-Q plot for adult height (Figure 6.11) looked very different from the Q-Q plots for adult 
BMI and WC. A strong evidence for population structure for height was observed (λ = 1.094) 
as well as a nearly genome-wide significant association in chromosome 20. The top SNP 
(rs4911494) in the recombination interval containing GDF5 and UQCC had a p-value of 
6.67x10
-8
 (Figure 6.12). There were three other nearly genome-wide significant signals for 
height: rs2814982 within C6orf106 in chromosome 6, rs6476520 within RECK in chromosome 
9, and rs1291374 within ACAN in chromosome 15 (5x10
-8
 < p < 5x10
-7
). All these signals 
except RECK have been identified earlier in other GWAS (335, 337, 396) and they were 
tested for adult height and height growth in Sovio et al. (2009) (327) (results in Table 6.11 of 
this thesis). The RECK gene is known to be involved in cancer progression (397). Since this 
signal has not been observed in larger GWAS meta-analyses, it is unlikely to play a marked 
role in human height.  
 
A further adjustment of the height analysis for PCs 4-15 did not reduce population 
stratification markedly (λ = 1.085). The stratification may be partly due to cryptic relatedness 
that would require different methods for adjustment. These methods are beyond the scope of 
this thesis but should be considered in future research on height (and possibly other 
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phenotypes) in this cohort. The reason why population structure is clearly shown in height but 
not in BMI or WC phenotypes may be due to the higher heritability of height and its 
associations with socio-economic factors that vary geographically within Finland (unpublished 
work by Dr. Clive Hoggart at Imperial College London). 
 
 
 
Figure 6.11. Q-Q plot for height at age 31 years in the NFBC1966 singletons, from a 
GWAS on imputed data. 
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Figure 6.12. Manhattan plot for height at age 31 years in the NFBC1966 singletons, 
from a GWAS on imputed data. 
 
STAMPEED Meta-analysis of GWAS on bivariate metabolic traits and metabolic syndrome 
 
In the NFBC1966, both GWA data and metabolic traits at 31 years of age were available for 
N=4,757 individuals. The study populations showed large variation in the prevalence of MetS 
from 9% in the NFBC1966 to 55% in GENOA (Table 6.16). The average age of subjects 
among the 7 studies ranged from 31 years in the NFBC1966 to 73 years in the CHS. Of the 5 
MetS components, triglyceride (TG) and HDL cholesterol (HDLC) had the highest average 
correlation of all combinations (Kraja* et al. Diabetes 2011 (in press)).  
 
SNPs from 15 independent loci had a genome-wide significant association (defined in chapter 
5.6.1 as p < 9.7x10
-8
) with at least one of the 11 traits studied (Table 6.17). Three of these loci 
that mapped within APOA cluster in chromosome 11 were associated with MetS per se: 
rs2075290 in ZNF259 (zinc finger protein 259), rs2266788 in APOA5 (apolipoprotein A-V), 
and rs10790162 in BUD13 (BUD13 homolog). The variants in this cluster were also 
associated with the TG-BP, TG-GLUC, HDLC-TG, and WC-TG combinations.  
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Table 6.16. Characteristics of participants included in genome-wide association analyses (% or mean±SD).  
 
Sample Characteristic  ADVANCE 
contr (≤311) 
ADVANCE 
case (≤275) 
ARIC 
(≤8,127) 
CHS 
(≤3,262) 
FHS 
(≤2,432) 
GeneSTAR 
(≤1,789) 
GENOA 
(≤1,208) 
NFBC1966 
(≤4,757) 
% Females 59 59 53 61 55 52 55 52 
% Diabetic* 2.5 27 8 12 5 9 10 1 
% Smoking† 32.8 63.3 25 11 29 23 14 30 
Age (years) - Males 40±3 42±4 55±6 73±6 50±13 47±13 56±11 31±0.4 
- Females 48±5 52±4 54±6 72±5 51±13 47±13 55±11 31±0.3 
Body mass index (kg/m
2
) - Males 27±5 31±6 27±4 26±4 28±4 29±5 30±5 25±4 
- Females 26±6 31±8 27±6 26±5 27±6 29±7 31±7 24±5 
Waist circumference (cm) - Males 93±12 102±14 100±10 98±10 100±12 101±14 104±12 89±10 
- Females 79±13 94±19 93±15 90±14 94±16 94±17 96±17 79±12 
HDL cholesterol (mg/dl) – Males 44±11 40±10 43±12  48±13 43±11  45±13  45±13 55±13 
- Females 62±14 51±16 57±17 60±16 56±15 57±15 57±17 66±15 
Triglycerides (mg/dl) – Males 151±224 184±165 147±100  138±78 163±113  160±97 194±107 119±75 
- Females 97±69 162±145 128±81 141±74 138±87 133±79 188±102 94±52 
Fasting glucose (mg/dl) – Males 86±11 104±43 107±27 111±31 102±29 99±27 103±32 93±11 
- Females 88±11 95±18 102±28 105±27 95±22 92±21 96±27 88±11 
SBP (mm Hg) – Males 117±11 114±12 120±16  135±21 119±15  126±16  134±17 130±13 
- Females 109±13 118±20 117±18 135±21 114±18 121±17 132±17 120±12 
DBP (mm Hg) - Males 78±10 73±10 74±10 72±11 72±9 80±11 81±10 80±11 
- Females 70±9 70±10 70±10 69±11 67±10 76±10 77±9 75±11 
% Anti-hyperlipidemic Meds. use 4 81 3 4 10 15 17 0 
% Anti-hypertensive Meds. use 7 84 20 35 3 22 65 0.6 
% Anti-glycemic Meds. use‡ 1.3 24 3.2 5 0.2 4.3 6.9 0.6 
MetS prevalence (%) 13.7 55.2 37.3 41.7 29.7 34.3 55.4 9.1 
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*Definition of Diabetic: fasting blood glucose > 126 mg/dl or anti-glycemic medication use; †Smoking: current 
smoking; ‡Anti-glycemic Meds. use: Oral hypoglycemic agents or insulin. Where available, data have been split by 
sex. 
 
Variant rs295 in LPL (lipoprotein lipase) and rs173539 near CETP (cholesteryl ester transfer 
protein, plasma) were associated with MetS per se. Variants in LPL were also associated with 
BP-HDLC (rs1441756), TG-BP (rs15285), TG-GLUC (rs2197089), HDLC-TG (rs13702), and 
HDLC-WC (rs301). Variants in/near CETP were also associated with BP-HDLC (rs3764261), 
HDLC-GLUC (rs9939224), HDLC-TG (rs173539), and HDLC-WC (rs173539) (Table 6.17). 
 
The GCKR cluster of genes is biologically interesting for MetS, although in the present study 
these genes did not have a genome-wide significant association with MetS per se. This 
cluster includes GCKR (glucokinase (hexokinase 4) regulator), ZNF512 (zinc finger protein 
512), CCDC121 (coiled-coil domain containing 121), and C2orf16 (chromosome 2 open 
reading frame 16). Variants in these genes were significantly associated with WC-TG 
(rs780093, rs13022873, rs3749147), and TG-BP (rs1919128) (Table 6.17).   
 
Additional variants significantly associated with other binary traits but not with MetS per se. 
These include, for example, variants rs2043085 and rs10468017 near LIPC (lipase hepatic) 
for HDLC-GLUC and WC-HDLC, respectively; rs569805 in ABCB11 (ATP-binding cassette, 
sub-family B (MDR/TAP), member 11) for HDLC-GLUC; rs2954026 and rs2954033 near 
TRIB1 (tribbles homolog 1 (Drosophila)) for HDLC-TG and TG-BP, respectively; and 
rs2206277 in TFAP2B (transcription factor AP-2 beta (activating enhancer binding protein 2 
beta) for WC-GLUC (Table 6.17). 
 
Two SNPs between LOC100128354 (similar to small nuclear ribonucleoprotein polypeptide 
G) and MTNR1B (melatonin receptor 1B) were significantly associated with BP-GLUC and 
HDLC-GLUC (rs1387153), and with TG-GLUC (rs10830956). In addition, rs439401 in 
LOC100129500 (protein coding hypothetical LOC100129500) was significantly associated 
with HDLC-TG, and rs9987289 near LOC100129150 (protein coding LP5624) was 
significantly associated with HDLC-TG and HDLC-WC (Table 6.17).    
 
Top SNPs (N=29), identified from the analysis of the 11 traits, were further tested for 
association with each of the individual dichotomised traits: WC, HDLC, TG, GLUC and BP. 
None of the SNPs demonstrated nominally significant (p < 0.05) associations with 3 or more 
traits. However, several variants associated with 2 traits: rs2266788 of APOA5, rs2075290 of 
ZNF259, rs11820589 of BUD13, and rs13702 of LPL associated with TG and HDLC and 
rs780093 of GCKR with TG and GLUC. The top SNPs were also subjected to a formal test of 
pleiotropy using the respective quantitative traits. Several SNPs showed pleiotropic effects on 
TG and HDLC (rs13702, rs295 and rs301 in LPL, rs2954026 near TRIB1, rs10790162 in 
BUD13, rs2075290 in ZNF259, rs2266788 in APOA5, and rs439401 in LOC100129500). 
Additional pleiotropic associations (for quantitative WC and GLUC, WC and HDL, TG and 
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GLUC, WC and GLUC and SBP and HDLC) were present in ARIC, the study with the largest 
sample, and a few in GeneSTAR and GENOA. In the NFBC1966, no additional pleiotropic 
associations were identified.  
 
Finally, 11 of 16 top hits exhibited association p-values with MetS at nominal significance 
level (p < 0.05) (Table 6.18). These SNPs together, averaged across studies, explained the 
following proportion of the total variance of each trait: TG 9.0%, HDLC 5.8%, GLUC 3.6%, 
WC 2.3% and SBP 1.4%.  
 
According to the KEGG database (398), accessed in July 2010, LPL and APOA5 are 
classified in hsa03320 (PPAR signaling) pathway, and LIP and LIPC are classified in 
hsa00561 (Glycerolipid metabolism) pathway. In addition, LPL is classified in hsa05010 
(Alzheimer‘s disease) and LIPC is classified in hsa01100 (Metabolic pathways). MTNR1B is a 
member of hsa04080 (Neuroactive ligand receptor interaction) and ABCB11 is a member of 
hsa02010 (ABC transporters) pathway. The rest of the reported genes are not currently 
classified in any pathways. 
 
To summarise, this study identified genetic variants in APOA cluster (APOA5, ZNF259, 
BUD13), LPL and CETP that associated with MetS and with binary bivariate combinations of 
metabolic traits. According to the results, pleiotropic genetic effects on components of MetS 
may partly explain the correlated architecture of MetS. None of the variants identified in this 
study associated simultaneously with all 5 MetS traits, suggesting the involvement of more 
than one pathway in MetS. The present study examined additive genetic effects from 
common variants on MetS traits. Future studies on low-frequency and rare variants, gene 
expression studies, and studies on gene-environment and gene-gene interactions will clarify 
MetS etiology further. 
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Table 6.17. The most significant results from STAMPEED meta-analyses.     
Obs Trait rs(ch:pos(bp);gene(/near)) Meta-
β 
Meta- 
SE 
Meta 
p-value 
Homogeneity 
p-value 
Coded 
allele 
Genotype 
1 MetS rs295;8:19860518;LPL 0.17 0.03 1.7x10
-9
 0.47 A A/C 
2 MetS rs2266788;11:116165896;APOA5 0.26 0.04 1.9x10
-9
 0.66 C C/T 
3 MetS rs2075290;11:116158506;ZNF259 0.26 0.04 2.1x10
-9
 0.64 C C/T 
4 MetS rs10790162;11:116144314;BUD13 0.25 0.04 5.4x10
-9
 0.44 A A/G 
5 MetS rs173539;16:55545545;(CETP) 0.16 0.03 9.1x10
-9
 0.41 C C/T 
6 BP-GLUC rs1387153;11:92313476;(LOC100128354) -0.19 0.03 8.1x10
-9
 0.48 C C/T 
7 BP-HDLC rs3764261;16:55550825;(CETP) 0.29 0.04 3.3x10
-13
 0.43 G G/T 
8 BP-HDLC rs1441756;8:19912666;(LPL) -0.18 0.03 2.7x10
-8
 0.43 G G/T 
9 HDLC-GLUC rs9939224;16:55560233;CETP -0.31 0.05 6.9x10
-12
 0.46 G G/T 
10 HDLC-GLUC rs1387153;11:92313476;(LOC100128354) -0.21 0.03 2.4x10
-9
 0.49 C C/T 
11 HDLC-GLUC rs2043085;15:56468246;(LIPC) -0.17 0.03 1.3x10
-8
 0.83 A A/G 
12 HDLC-GLUC rs569805;2:169491126;ABCB11 0.16 0.03 8.5x10
-8
 0.46 A A/T 
13 TG-BP rs15285;8:19868947;LPL -0.27 0.04 1.3x10
-10
 0.65 A A/G 
14 TG-BP rs780093;2:27596107;GCKR 0.18 0.03 3.0x10
-10
 0.70 A A/G 
15 TG-BP rs11823543;11:116154345;ZNF259 0.35 0.06 2.5x10
-9
 1.00 A A/G 
16 TG-BP rs11825181;11:116131468;BUD13 0.32 0.05 3.0x10
-9
 0.98 A A/G 
17 TG-BP rs2954033;8:126562928;(TRIB1) 0.17 0.03 8.5x10
-9
 0.55 A A/G 
18 TG-BP rs2266788;11:116165896;APOA5 0.37 0.07 3.5x10
-8
 0.18 C C/T 
19 TG-GLUC rs10830956;11:92320661;(LOC100128354) -0.20 0.03 4.8x10
-11
 0.67 C C/T 
20 TG-GLUC rs2197089;8:19870653;(LPL) 0.18 0.03 1.6x10
-9
 1.00 C C/T 
21 TG-GLUC rs11820589;11:116139072;BUD13 0.32 0.06 5.5x10
-9
 0.83 A A/G 
22 TG-GLUC rs12286037;11:116157417;ZNF259 -0.32 0.06 1.1x10
-8
 0.86 C C/T 
23 HDLC-TG rs13702;8:19868772;LPL 0.29 0.03 1.0x10
-16
 0.67 A A/G 
24 HDLC-TG rs173539;16:55545545;(CETP) 0.26 0.03 4.5x10
-16
 0.61 C C/T 
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Table 6.17 (cont.) The most significant results from STAMPEED meta-analyses.     
Obs Trait rs(ch:pos(bps);gene(/near)) Meta- 
β 
Meta- 
SE 
Meta- 
p-value 
Homogeneity 
p-value 
Coded 
allele 
Genotype 
25 HDLC-TG rs10790162;11:116144314;BUD13 0.38 0.05 2.8x10
-15
 0.44 A A/G 
26 HDLC-TG rs2075290;11:116158506;ZNF259 0.39 0.05 1.5x10
-14
 0.39 C C/T 
27 HDLC-TG rs2266788;11:116165896;APOA5 0.39 0.05 4.6x10
-13
 0.36 C C/T 
28 HDLC-TG rs2954026;8:126553708;(TRIB1) -0.16 0.03 7.9x10
-9
 0.46 G G/T 
29 HDLC-TG rs439401;19:50106291;LOC100129500 0.24 0.04 1.0x10
-8
 0.44 C C/T 
30 HDLC-TG rs9987289;8:9220768;(LOC100129150) 0.25 0.04 1.1x10
-8
 0.54 A A/G 
31 HDLC-WC rs173539;16:55545545;(CETP) 0.29 0.03 1.0x10
-16
 0.65 C C/T 
32 HDLC-WC rs301;8:19861214;LPL -0.22 0.03 3.2x10
-11
 0.58 C C/T 
33 HDLC-WC rs9987289;8:9220768;(LOC100129150) 0.24 0.04 3.7x10
-8
 0.58 A A/G 
34 HDLC-WC rs10468017;15:56465804;(LIPC) 0.16 0.03 5.5x10
-8
 0.47 C C/T 
35 WC-GLUC rs2206277;6:50906485;TFAP2B 0.17 0.03 1.3x10
-7
 0.75 A A/G 
36 WC-TG rs2075290;11:116158506;ZNF259 0.41 0.05 1.1x10
-16
 0.94 C C/T 
37 WC-TG rs2266788;11:116165896;APOA5 0.41 0.05 2.2x10
-16
 0.92 A A/G 
38 WC-TG rs10790162;11:116144314;BUD13 0.39 0.05 6.6x10
-16
 0.79 A A/G 
39 WC-TG rs780093;2:27596107;GCKR 0.19 0.03 1.9x10
-12
 0.64 A A/G 
40 WC-TG rs3749147;2:27705422;CCDC121 -0.18 0.03 1.4x10
-9
 0.79 C C/T 
41 WC-TG rs1919128;2:27655263;C2orf16 -0.18 0.03 2.0x10
-9
 0.82 A A/G 
42 WC-TG rs13022873;2:27669014;ZNF512 -0.17 0.03 5.0x10
-9
 0.47 A A/C 
 
rs - rs name; ch - chromosome number; pos - position in base pairs; gene - gene name; (/near) gene name is shown in parenthesis when an SNP is near a 
gene‘s location; Meta-β – meta-analysis beta coefficient; Meta-SE – meta-analysis beta coefficients standard error; Homogeneity – a p-value from a test of 
homogeneity of beta-coefficients which has a high bound and equal to one when all beta coefficients included in the beta-meta-analysis are very similar, and 
is significant (less than 0.05) when coefficients among studies differ drastically; Coded - the allele which was considered as coded allele for combining data of 
different studies accounting for beta coefficient direction. 
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Table 6.18. Meta-analysis of 16 top SNPs (1 per gene) for their association with MetS.    
Gene SNP Chromo-
some 
Position 
(bps) 
Meta-β Meta-
SE 
Chi-square 
statistic 
p-value Homogeneity 
p-value 
#samples 
GCKR rs780093 2 27596107 0.042 0.030 1.94 0.16 0.222        8 
C2orf16 rs1919128 2 27655263 -0.055 0.035 2.51         0.11 0.186  8 
ZNF512 rs13022873 2 27669014 -0.054 0.036 2.24 0.13 0.154 8 
CCDC121 rs3749147 2 27705422 -0.050 0.039 1.62 0.20 0.110 8 
ABCB11 rs569805 2 169491126 0.059 0.024 5.91 0.015 0.411 8 
TFAP2B rs2206277 6 50906485 0.134 0.046 8.57 0.0034 0.073 6 
LOC100129150 rs9987289 8 9220768 0.186 0.038 23.83 1.1x10
-6
 0.703 8 
LPL rs13702 8 19868772 0.152 0.029 27.45 1.6x10
-7
 0.343 8 
TRIB1 rs2954026 8 126562928 -0.084 0.035 5.74 0.017 0.132 8 
LIPC rs2043085 15 56468246 -0.059 0.023 6.40 0.011 0.734 8 
LOC100128354 rs10830956 11 92320661 -0.070 0.031 5.03 0.025 0.254 8 
BUD13 rs10790162 11 116144314 0.243 0.060 16.65 4.5x10
-5
 0.172 8 
ZNF259 rs2075290 11 116158506 0.259 0.059 19.52 1.0 x10
-5
 0.196 7 
APOA5 rs2266788 11 116165896 0.265 0.044 36.07 1.9 x10
-9
 0.663 6 
CETP rs9939224 16 55560233 -0.168 0.036 21.84 3.0 x10
-6
 0.810 8 
LOC100129500 rs439401 19 50106291 0.053 0.056 0.89 0.35 0.071 6 
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6.5.2. Meta-analysis of GWAS on birth weight (BW) and gestational age (GA) 
 
SNPs at two independent loci on chromosome 3 were associated with BW (p < 5x10
-8
) in the 
discovery data sets (N = 10,623; Figures 6.13 and 6.14). The first locus was at 3q25, between 
CCNL1 and LEKR1; and the second, at 3q21 in ADCY5 (Figure 1 in Freathy* et al. (2010) 
(348)).  
 
 
 
Figure 6.13. Manhattan plot for birth weight (adjusted for sex and gestational age) from 
the meta-analysis of GWAS on N = 10,623 singletons from European ancestry. 
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Figure 6.14. Q-Q plot for birth weight (adjusted for sex and gestational age) from the 
meta-analysis of GWAS on N = 10,623 singletons from European ancestry. 
 
To replicate these associations, the most strongly associated SNP from each locus (rs900400 
from 3q25; rs9883204 from 3q21), or a closely-correlated proxy (HapMap r
2 
= 0.927 - 0.963), 
were genotyped in 13 further samples of European descent (N=27,591; Supplementary Table 
2 in Freathy* et al. (2010) (348)). Robust evidence of association was seen for both signals in 
these replication samples (Figures 6.15 and 6.16; p = 3x10
-26
 and 3x10
-9
, respectively). 
Combining all discovery and replication samples, each additional C-allele of SNP rs900400 
(frequency 32 - 47%) was associated with a 0.086 SD lower BW (95% CI: 0.073 - 0.100; p = 
2x10
-35
), while each C-allele of SNP rs9883204 (frequency 71 - 83%) was associated with a 
0.063 SD lower BW (95% CI: 0.047 - 0.079; p = 7x10
-15
; Table 6.19). These SD changes 
equate approximately to differences of 40 g and 30 g per allele, respectively (median study 
SD = 484 g). Analysis conditional on the index SNPs, rs900400 and rs9883204 did not 
produce any evidence for additional independent signals at either of the loci. 
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Figure 6.15. Forest plot of the association between birth weight and SNP rs900400 at 
3q25. If the index SNP was unavailable, a closely correlated proxy (HapMap r
2
 > 0.9) was 
used. Adapted from Freathy* et al. (2010) (348). 
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Figure 6.16. Forest plot of the association between birth weight and SNP rs9883204 at 
3q21. If the index SNP was unavailable, a closely correlated proxy (HapMap r
2
 > 0.9) was 
used. Adapted from Freathy* et al. (2010) (348). 
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Table 6.19. Associations between novel birth weight loci and anthropometric traits at birth. 
 
Phenotype Locus 3q25, nearest genes: CCNL1, LEKR1
a 
Locus 3q21, ADCY5
b 
 N Effect 95% CI p-value
c 
N Effect 95% CI p-value
c 
Birth weight Z-score
d 
37,745 -0.086 -0.100, -0.073 2x10
-35 
38,214 -0.063 -0.079, -0.047 7 x10
-15 
Birth length Z-score 21,512 -0.028 -0.046, -0.010 0.002 21,782 -0.044 -0.066, -0.022 4 x10
-5 
Birth head circumference Z-score 17,349 -0.024 -0.044, -0.004 0.017 17,693 -0.025 -0.048, -0.004 0.030 
Ponderal index
e
 Z-score 21,515 -0.094 -0.113, -0.074 5x10
-21 
21,785 -0.032 -0.055, -0.009 0.006 
Odds ratio for SGA < 10th 
percentile
f 30,370 1.16 1.10, 1.23 1x10
-7 
30,778 1.09 1.02, 1.16 0.009 
 
Results are from inverse variance, fixed-effects meta-analysis of all 19 study samples of European ancestry. The effect allele for each SNP is labelled on the positive strand according 
to HapMap. The effect is the change in phenotype Z-score per allele from linear regression, adjusted for sex and gestational age, assuming an additive genetic model. If the index SNP 
was unavailable, this was substituted with a closely correlated (HapMap r
2
 > 0.9) proxy (rs1482853 or rs900399 for rs900400; rs2877716 or rs6798189 for rs9883204). There was no 
evidence of between-study heterogeneity of effect-size estimates (all p > 0.18; I
2
 < 26%). 
a
Index SNP rs900400, effect allele C (40% frequency in HapMap CEU; range 32–47% in the 
European study samples); nearest genes to the 3q25 signal are CCNL1 and LEKR1. 
b
Index SNP rs9883204, effect allele C (73% frequency in HapMap CEU; range 71–83% in the 
European study samples); nearest gene to the 3q21 signal is ADCY5. 
c
The p-value for the birth weight meta-analysis includes the double–genomic control correction of the discovery 
meta-analysis. 
d
Excluding the three studies that were unable to adjust for gestational age, the β (s.e.m.), N and p-values in the birth weight analysis were –0.089 (0.008), N = 31,510, p 
= 7×10
–32
 (3q25); –0.068 (0.009), N = 31,901, p = 8×10
–15
 (3q21). 
e
Ponderal index = (birth weight) / (birth length
3
).
 f
Smallness for gestational age (SGA) < 5
th
 percentile, OR (p-value): 
rs900400 = 1.11 (0.004); rs9883204 = 1.04 (0.41). 
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We found no evidence of heterogeneity between the studies examined (p > 0.5; I
2 
= 0%) 
(175), despite differences in mean BW (reflecting secular and population differences in BW 
distribution; Table 6.20), and the associations with BW were similar in males and females (p > 
0.05 for difference in effect sizes). Gestational age was not available as a covariate in three of 
our replication studies (combined N=6235; Supplementary Table 2 in Freathy* et al. (2010) 
(348)), but these studies did not introduce detectable heterogeneity, and their removal from 
the meta-analysis changed the results very little (Figures 6.15 and 6.16 and Table 6.19 
footnote). The effects of the two SNPs on BW were also assessed in a limited number of non-
European or admixed samples from 2 studies (N=1415 Filipino subjects from the Cebu 
Longitudinal Health and Nutrition Survey, and N=298-448 Black, Moroccan and Turkish 
subjects from Generation R; see Supplementary Tables 2 and 3 in Freathy* et al. (2010) 
(348)). There was no difference in the effect sizes observed relative to the European studies 
(p > 0.5), but power to detect association was limited. Further well-powered studies will be 
needed to investigate these associations in non-Europeans.  
 
Maternal and foetal genotypes are correlated due to segregation. In a previous study, an 
observed association between foetal TCF7L2 genotype and BW was driven by the effects of 
maternal TCF7L2 variation on the intra-uterine environment, rather than by a direct effect on 
foetal growth (242). To distinguish between these two mechanisms, we tested whether the 
novel BW associations were independent of maternal genotype. We genotyped both SNPs in 
all available maternal DNAs (N=9127; 5 study samples). Meta-analysis of associations 
between BW and foetal genotype, conditional on maternal genotype, yielded results which 
were very similar to the original associations at both loci (Supplementary Table 4 in Freathy* 
et al. (2010) (348)), showing that these are direct foetal effects. As expected, there was no 
association between foetal genotype and various covariates of BW that were not included in 
our main analysis (maternal smoking, BMI, parity, education, age; all p > 0.05; data not 
shown).  
 
BW may be influenced by skeletal growth or fat mass. In the available samples, we analysed 
the association between each locus and birth length (BL), birth head circumference (BHC) 
and ponderal index (PI) (Table 6.19 and Freathy* et al. (2010) Supplementary Figures 2-4 
(348)). The association with PI, relative to the BL and BHC associations, was particularly 
strong for the rs900400 SNP (0.094 SD (95% CI: 0.074-0.113) per C-allele; p = 5x10
-21
), 
suggesting a greater association with fat mass than skeletal growth. For the rs9883204 SNP, 
the measures showed more proportionate associations (Table 6.19). We investigated 
associations between the two signals and adult height and BMI using published GWA meta-
analyses from the GIANT consortium (335, 399). Only the rs900400 signal was captured in 
the published height data at r
2 
> 0.8 (since that study only included direct genotypes from the 
Affymetrix Genechip 500k), and there was no association with height (p = 0.64; N=9818). 
There was no association with adult BMI for either locus (N ≈ 32,500, p > 0.1). This is 
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consistent with the weak observational association between BW and adult BMI (400), 
indicating that they are largely governed by different processes. 
 
Although BW is a continuous trait, standard clinical cut-offs are used to identify neonates who 
are small for gestational age (SGA) and who may require further observation. We therefore 
assessed whether each SNP increased the odds of SGA < 10
th
 percentile. Both loci were 
associated with SGA: odds ratios (OR) 1.16 (95% CI: 1.10 - 1.23) (p = 1x10
-7
) and 1.09 (1.02-
1.16) (p = 0.009) per C-allele of rs900400 and rs9883204, respectively (Table 6.19; 
Supplementary Figure 5 in Freathy* et al. (2010) (348)).  
 
Meta-analyses of GWAS on the three GA phenotypes described in the methods (chapter 
5.6.2; N=11,201) did not produce any genome-wide significant (p < 5x10
-8
) associations or 
any biologically interesting weaker associations that would have justified a follow-up in other 
data sets. Considering the failure to identify associations along with space limitations of this 
thesis, the results from meta-analyses of GWAS on GA are omitted. The lack of observed 
associations may be partly due to inaccuracy of the phenotype in cohorts (including the 
NFBC1966) where GA was estimated from the last menstrual period before pregnancy. 
Furthermore, maternal genotype might be a more important determinant of GA than the 
genotype of the child.  
 
For both BW and GA, extended meta-analyses in larger samples of individuals started in 
November 2009 and reached replication stage in June 2010. Due to time and space 
constraints, these analyses cannot be included in this thesis, although I was actively involved 
in this work in the discovery stage. 
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Table 6.20. Mean birth weight (SD) by genotype and individual association results by study. 
  
Study type Study 
Year(s) 
of birth 
Total 
N
a 
% 
male 
Locus 3q25, nearest genes: CCNL1, LEKR1
b 
Locus 3q21, ADCY5
b 
TT CT CC 
P 
value
c 
TT CT CC 
p- 
value
c Mean BW 
in g (SD) 
Mean BW 
in g (SD) 
Mean BW 
in g (SD) 
Mean BW 
in g (SD) 
Mean BW 
in g (SD) 
Mean BW 
in g (SD) 
Discovery 
NTR 1923-86 414 37.9 3470 (652) 3401 (615) 3329 (646) 0.08 3500 (720) 3402 (604) 3359 (633) 0.09 
B58C-WTCCC 1958 1227 50.4 3367 (444) 3337 (455) 3364 (454) 0.77 3459 (457) 3357 (456) 3336 (455) 0.05 
B58C-T1DGC 1958 2037 49.2 3399 (468) 3339 (464) 3308 (461) 1x10
-3 
3396 (463) 3375 (484) 3341 (463) 0.07 
NFBC1966 1966 4333 48.1 3567 (458) 3519 (458) 3503 (458) 5x10
-4 
3630 (459) 3559 (459) 3529 (459) 4x10
-3 
ALSPAC (D) 1991-2 1418 48.8 3486 (481) 3419 (482) 3374 (467) 2x10
-3 
3451 (458) 3462 (465) 3405 (514) 0.03 
Generation R 
(D) 
2002-6 1194 53.1 3633 (435) 3562 (447) 3492 (448) 1x10
-4 
3655 (449) 3593 (444) 3549 (456) 0.01 
Replication 
ORCADES 1920-88 328 43.3 3635 (599) 3615 (594) 3487 (602) 0.12 3542 (612) 3670 (605) 3566 (595) 0.74 
HBCS 1934-44 1566 42.7 3462 (436) 3434 (438) 3403 (430) 0.06 3391 (426) 3479 (434) 3431 (418) 0.33 
B58C (R) 1958 2550 51.6 3407 (454) 3341 (451) 3308 (456) 7x10
-5
 3338 (457) 3387 (448) 3340 (477) 0.14 
NFBC1986 1985-6 5008 49.1 3656 (440) 3607 (440) 3591 (440) 4x10
-5
 3674 (441) 3646 (441) 3620 (441) 0.03 
CHOP 
1987-
2009 
5149 53.3 3384 (634) 3333 (646) 3318 (628) 5x10
-3 
3389 (641) 3357 (647) 3341 (609) 0.19 
RAINE 1989-92 988 52.4 3507 (428) 3432 (417) 3384 (429) 1x10
-3 
3472 (426) 3489 (431) 3427 (425) 0.06 
ALSPAC (R) 1991-2 5695 54.6 3303 (547) 3259 (568) 3229 (493) 3x10
-6
 3305 (464) 3288 (580) 3257 (626) 3x10
-3 
GENDAI 1994-6 758 45.5 3401 (530) 3215 (528) 3235 (529) 1x10
-3 
3291 (539) 3286 (539) 3260 (539) 0.53 
PIAMA 1996-7 1789 51.3 3629 (438) 3575 (443) 3512 (427) 9x10
-5
 3619 (441) 3607 (425) 3554 (430) 0.01 
LISA 1998-9 387 56.9 3476 (366) 3454 (363) 3368 (363) 0.07 3532 (365) 3429 (366) 3443 (367) 0.84 
PROJECT 
VIVA 
1999-
2003 
300 50.0 3711 (406) 3646 (411) 3594 (407) 0.08 3698 (412) 3703 (402) 3625 (408) 0.15 
Generation R 
(R) 
2002-6 1885 50.3 3558 (435) 3527 (423) 3481 (413) 6x10
-3 
3615 (433) 3534 (435) 3518 (430) 0.04 
EFSOCH 2003-4 719 53.1 3556 (427) 3509 (432) 3504 (431) 0.20 3660 (433) 3513 (435) 3503 (432) 0.07 
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All birth weight (BW) values are adjusted for sex and gestational age. 
a
Study N in the birth weight association analysis for 
rs900400 genotype. Total numbers of European discovery and replication samples, respectively, were N=10623 and 
N=27122 for rs900400; N=10623 and N=27591 for rs9883204. 
b
If the index SNP was unavailable, this was substituted 
with a closely-correlated (HapMap r
2
>0.9) proxy (rs1482853 or rs900399 for rs900400 at 3q25; rs2877716 or rs6798189 
for rs9883204 at 3q21).  
c
P-value is from linear regression of birth weight Z-score against SNP (additive model), with sex 
and gestational age as covariates. All study samples were of European descent. Key to study names: NTR, Netherlands 
Twin Register;  B58C-WTCCC, British 1958 Birth Cohort – Wellcome Trust Case Control Consortium subset; B58C-
T1DGC, British 1958 Birth Cohort – Type 1 Diabetes Genetics Consortium subset;  NFBC1966, Northern Finland Birth 
Cohort 1966; ALSPAC (D), Avon Longitudinal Study of Parents and Children Discovery subset; Generation R (D), 
Generation R Discovery subset; ORCADES, Orkney Complex Disease Study; HBCS, Helsinki Birth Cohort Study; B58C 
(R), British 1958 Birth Cohort Replication subset; NFBC1986, Northern Finland Birth Cohort 1986; CHOP, Children‘s 
Hospital Of Philadelphia;  RAINE, The Raine Study; ALSPAC (R), Avon Longitudinal Study of Parents and Children 
Replication subset; GENDAI, GENe and Diet Attica Investigation; PIAMA, Prevention and Incidence of Asthma and Mite 
Allergy; LISA, Lifestyle – Immune System – Allergy; Project Viva, The Project Viva Cohort; Generation R (R), Generation 
R Replication subset; EFSOCH, Exeter Family Study Of Childhood Health. 
 
Discussion of the meta-analysis of GWAS on birth weight (BW) 
 
The BW signal marked by rs900400 maps approximately 35 kb 3′ to the LEKR1 locus (encoding 
leucine, glutamate and lysine rich 1) and 67 kb 3′ to CCNL1 (encoding cyclin L1). Neither gene 
has previously been implicated in foetal growth. The CCNL1 protein may be involved in pre-
mRNA splicing and RNA processing and associates with cyclindependent kinases (401). A non-
coding RNA of unknown function, 682 bp from rs900400 (AK311218, Human March 2006 
Assembly 18), overlaps with the signal. No evidence for association was found at a genome-wide 
significance level (p < 5x10
-8
) between the 3q25 BW signal and mRNA expression in 
lymphocytes, using the publicly available ‗mRNA by SNP Browser 1.0‘ (402). There was no 
association between rs900400 or rs900399 and T2D or related adult glycemic traits in the recent 
GWA meta-analysis from the Meta-Analyses of Glucose and Insulin-related traits Consortium 
(MAGIC) (p > 0.1) (284). A range of approaches (including re-sequencing and functional studies) 
will be required to establish which gene—CCNL1, LEKR1 or another transcript—mediates the 
effect on foetal growth. 
 
The second BW locus at 3q21 (index SNP rs9883204) maps within ADCY5, encoding adenylyl 
cyclase 5. ADCY5 belongs to the family of enzymes responsible for the synthesis of cyclic 
adenosine monophosphate (cAMP) (403-405). Allele A of rs11708067, which is in LD with the 
BW–lowering C allele of rs9883204 (r
2
 = 0.75), was associated with a higher risk of T2D (OR = 
1.12 (95% CI 1.04–1.15); p = 9.9x10
−21
; 40,655 cases / 87,022 controls), higher fasting glucose 
(0.027 mmol/l (95% CI 0.021–0.033); p = 7.1x10
−22
; N=118,475) and reduced values of the 
Homeostatic Model Assessment (HOMA)-derived indices of beta-cell function (HOMA%B; p = 
7.1x10
-12
; N=94,212) (284), suggesting that it may influence insulin secretion. Foetal insulin is a 
key foetal growth factor, and these metabolic associations suggest that one mechanism 
explaining the ADCY5–BW association might be a direct effect of the foetal risk allele on foetal 
growth via reduced insulin secretion, consistent with the foetal insulin hypothesis (45).  
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However, our previous studies suggest that an association between foetal genotype and BW is 
not characteristic of all T2D–associated loci. For example, susceptibility variants at CDKN2A–
CDKN2B, IGF2BP2 and SLC30A8 and at TCF7L2 were not associated with BW in previous 
studies of n > 15,000, after adjusting for maternal genotype (239, 242). To test this more 
comprehensively, we examined the associations between BW and all published T2D–associated 
(N=24) and fasting glucose–associated (N=16) loci in our discovery GWA meta-analysis 
(N=10,623) (283, 284, 406). Only ADCY5 and CDKAL1 variants (the latter in line with previous 
reports (239, 240)) showed evidence for association at p < 0.01 significance level (Supplementary 
Table 5 in Freathy* et al. (2010) (348)). One explanation for the variable effects of different T2D 
susceptibility loci on BW is that they may influence beta-cell function at different stages of life, 
with ADCY5 having a more marked prenatal effect than the other loci. However, other 
mechanisms could be partially or wholly responsible for the ADCY5–BW association, including 
the regulation of placental glucose transporter expression (407), vitamin B2 uptake in the 
placenta (408), and the architecture and permeability of the materno-foetal placental barrier 
(409).  
 
The associations at 3q25 and 3q21 explained 0.3% and 0.1% of the variance in BW, respectively. 
Given that estimates of the foetal genetic contribution to BW from twin and family studies are 
generally between 10% and 40% (226, 410), the proportion of heritability explained may be up to 
ten times greater. The variance explained by the first locus is comparable to that of maternal age 
(0.5%). We used a weighted risk allele score to estimate the differences in BW attributable to 
combinations of BW–lowering alleles at both loci. The 9% of Europeans with four BW–lowering 
alleles were, on average, 113 g (95% CI 89–137 g) lighter at birth than the 24% with zero or one 
allele (p for trend = 7x10
−30
). For comparison, this effect on BW is similar to the impact of a 
mother smoking 4–5 cigarettes per day and is approximately one third of the impact of the severe 
malnutrition of the Dutch Famine of 1944–1945, during which pregnant women consumed, on 
average, < 1,000 calories per day (411).  
 
To conclude, previously unknown, robust associations between foetal genotype and BW at loci 
near CCNL1 and at ADCY5 were identified. The causal mechanisms are not yet known, but the 
ADCY5 locus has pleiotropic effects on glucose regulation and adult T2D. This strongly suggests 
that the widely described association between lower BW and higher T2D risk has a genetic 
component, distinct from the proposed role of programming by maternal nutrition. Further 
understanding of these associations will illuminate the biological pathways important for foetal 
growth and its relationship with adult diseases. 
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6.5.3. Meta-analysis of GWAS on growth parameters 
 
Infancy 
 
Indicators of immediate postnatal growth velocity, PHV1 (Figure 6.17) and PWV1 (Figure 6.18), 
did not show associations at p < 10
-7
 level or biologically plausible associations at p < 10
-5
 level 
with any SNP. However, there was one potentially interesting association with PWV1 at p = 
5.9x10
-5
 significance level, which warranted selection for replication although it did not fulfil the 
pre-defined criteria for follow-up (post-hoc decision of the meta-analysis group). This was a SNP 
near the transmembrane protein 18 (TMEM18) gene, which is in high LD (r
2 
= 0.85) with the 
published BMI-associated SNP rs6548238 (399). The published SNP had a slightly weaker 
association with PWV1 in our meta-analysis (p = 1.6x10
-4
) than the top SNP. Age at AP did not 
show any associations that would have warranted follow-up (Figure 6.19).  
 
 
 
Figure 6.17. Manhattan and Q-Q plots for peak height velocity in infancy (PHV1) from a 
meta-analysis of singletons. 
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Figure 6.18. Manhattan and Q-Q plots for peak weight velocity in infancy (PWV1) from a 
meta-analysis of singletons. 
 
 
 
Figure 6.19. Manhattan and Q-Q plots for age at infant adiposity peak (AP) from a meta-
analysis of singletons. 
 
Two interesting signals were identified for BMI at AP (Figures 6.20 and 6.21). The most strongly 
associated cluster of SNPs in chromosome 1 (top SNP rs9436303, p = 6.2x10
-8
) was located 
near the leptin receptor gene (LEPR). It is known that certain monogenic forms of obesity are due 
to rare mutations in this gene (412). The leptin hormone, which acts through LEPR, regulates 
adipose tissue mass through its effects on satiety and energy expenditure. Therefore, this gene 
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could be considered as a candidate gene for finding common variants that play a part in the 
common forms of obesity. Although slight heterogeneity between studies was observed for this 
association (pQ = 0.032, pRandom = 0.029), this was not considered to be a major problem since 
it was due to one small study showing non-significant association in the opposite direction (LISA 
study, N=380).   
 
The second biologically interesting signal for BMI at AP was in chromosome 5 (top SNP 
rs10515235, p = 1.2x10
-6
). This signal was very close to the PCSK1 gene, whose rare mutations 
have also been associated with extreme forms of obesity (413). Furthermore, some of its 
common variants have been associated with common forms of obesity (255).  
 
The top SNPs from both signals were chosen for replication in other cohorts. To allow for 
genotyping failure of the top SNPs, proxy SNPs were chosen based on LD (measured by r
2
) with 
the top SNP and statistical significance in the current analysis. The proxy SNP chosen for the 
rs9436303 was rs9436301 (r
2 
= 1, p = 6.4x10
-8
). Two proxy SNPs were chosen for the 
rs10515235: rs13158163 (r
2 
= 1, p = 3.4x10
-6
) and rs13153770 (r
2 
= 0.961, p = 1.3x10
-6
).  
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Figure 6.20. Manhattan plot for BMI at infant adiposity peak (AP) from a meta-analysis of 
singletons. 
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Figure 6.21. Q-Q plot for BMI at infant adiposity peak (AP) from a meta-analysis of 
singletons. 
 
Childhood 
 
GWA data on childhood growth parameters, age and BMI at AR, were available in the 
NFBC1966, HBCS and RAINE cohorts (N=6,051). There was a large cluster of 31 SNPs in the 
well-studied obesity gene FTO in chromosome 16 associated with age at AR at p < 10
-6
 level 
(Figures 6.22 and 6.23). The SNP showing the strongest association was rs1421085 (p = 6.1x10
-
8
). The commonly studied SNP rs9939609 (see 6.4.2) was also strongly associated with age at 
AR (p = 1.6x10
-7
). The top SNP (rs1421085) was chosen for replication, and rs9939609 could be 
used as a proxy SNP in case genotyping of rs1421085 failed. There was a cluster of five SNPs in 
chromosome 5 associated with age at AR at p = 6.7-8.6x10
-8
 significance level. This locus is 
intergenic between RANBP3L and SLC1A3 and has not been associated with adiposity related 
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traits before, but the top SNP from this signal was taken forward for replication based on p-value. 
There were no more associations with age at AR at p < 10
-7
 level to replicate, based on p-value 
alone.  
 
Four potential signals in or near candidate genes for adiposity related traits were observed at p < 
10
-5
 significance level. One of these was in chromosome 11 near the matrix metalloproteinase 13 
(MMP13) gene (top SNP p = 5.4x10
-7
). This association was largely driven by the HBCS. There 
was only a weak association in the NFBC1966 and no association at all in RAINE (heterogeneity 
p = 0.0095). However, the MMP13 gene is a potential candidate for obesity-related traits. Proteins 
of the matrix metalloproteinase (MMP) family are involved in the breakdown of extracellular matrix 
in normal physiological processes, e.g. tissue remodelling, and in disease processes, such as 
arthritis and metastasis. In Kawasaki disease, the MMP13 gene promoter has been shown to 
associate with coronary artery lesions (414). The MMP13 promoter polymorphism has been 
associated with atherosclerosis in the abdominal aorta in young black males (415). Furthermore, 
expression of MMP13 has been observed to increase in response to leptin stimulation (416).  
 
Another signal observed at p < 10
-5
 significance level for age at AR was in a potential candidate 
gene (Table 2.5), TFAP2B, chromosome 6, top SNP p = 3.0x10
-6
). A study in Japanese and UK 
populations suggests that polymorphisms in TFAP2B are associated with an increased risk of 
T2D (417). This association may operate through regulation of adipocytokine gene expression 
(418). Recently, a GWAS meta-analysis identified an association between a common variant 
(rs987237) in TFAP2B and waist circumference (WC) (274). According to the HapMap CEU 
reference, the distance between rs987237 and the top SNP from the present study, which is just 
outside of TFAP2B, is only 10KB but the LD is low (r
2 
= 0.044). Nevertheless, the WC increasing 
allele (G) of rs987237 was associated with earlier AR (p = 3.5x10
-4
), which is in the expected 
direction. Similarly, the SNP rs2206277 which had a nearly significant association with WC-GLUC 
in the meta-analysis presented earlier (p = 1.3x10
-7
; chapter 6.5.1, Table 6.17), was associated 
with age at AR in the expected direction (p = 3.2x10
-4
). This SNP is at 14KB distance from the top 
SNP and it is also in weak LD with it (r
2
 = 0.046). This observation suggests there might be two 
independent signals associated with age at AR in this locus. 
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Figure 6.22. Manhattan plot for age at adiposity rebound (AR) from a meta-analysis of 
singletons.  
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Figure 6.23. Q-Q plot for age at adiposity rebound (AR) from a meta-analysis of singletons.  
 
For BMI at AR, no associations at p < 10
-7
 significance level were identified (Figures 6.24 and 
6.25) and therefore no SNPs were taken for replication based on p-value alone. There were 
several signals at p < 10
-5
 level, which consisted of 135 SNPs. Ten SNPs with the lowest p-value 
(≤ 5x10
-7
) belonged to a cluster in the DLG2 gene in chromosome 11 (top SNP p = 1.4x10
-7
). 
Variation at the DLG2 locus may contribute to maintenance of glucose homeostasis through 
regulation of insulin sensitivity and beta-cell function according to a study by Palmer et al. (2010) 
(419). Therefore this gene could be considered as a candidate gene for metabolic traits such as 
BMI. However, it has to be noted that the top SNP identified in the present analysis is not in the 
same region of the gene that was identified in Palmer et al. (2010) (419). 
 
In addition, two previously discovered candidate genes for child and adult obesity, FTO and 
GNPDA2, were associated with BMI at AR (top SNPs rs17817964 p = 9.7x10
-7
 and rs12641981 p 
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= 3.1x10
-6
, respectively). For age at AR, an FTO SNP was already chosen for replication, and the 
same SNP will also be used for BMI at AR. The most strongly associated SNP (top SNP) with 
BMI at AR in the GNPDA2 gene was rs12641981 (p = 3.1x10
-6
). However, since the previously 
published SNP, rs10938397 (399), was in a perfect LD with the top SNP (r2 = 1), and had an 
association of a similar magnitude with BMI at AR (p = 5.4x10
-6
), it was chosen for replication (the 
top SNP was chosen as the best proxy SNP). The signals in chromosomes 2 and 14 (p = 6.2x10
-7
 
and p = 2.1x10
-7
, respectively) did not point to any potential candidate genes and therefore were 
not considered for follow-up. 
 
 
Figure 6.24. Manhattan plot for BMI at adiposity rebound (AR) from a meta-analysis of 
singletons. 
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Figure 6.25. Q-Q plot for BMI at adiposity rebound (AR) from a meta-analysis of singletons. 
 
Although the meta-analysis of multiple GWAS did not identify any genome-wide significant or 
biologically interesting signals for PHV1 even at p < 10
-5
 level, it was of interest to further examine 
the associations between the known adult height SNPs and PHV1 in the meta-analysis setting 
and see if these results align with the results from the analysis of directly genotyped SNPs in 
NFBC1966 alone (327). All 48 adult height SNPs (imputed or genotyped) were included in the 
meta-analysis of GWAS. Ten SNPs in/near genes SF3B4/SV2A, UQCC, C6orf173, CDK6, 
PLAG1, PXMP3/PKIA, EFEMP1, ADAMTS17 and HHIP were associated with PHV1 at nominal 
significance level (p < 0.05), all of these in the expected direction. Three of them (SF3B4/SV2A, 
UQCC and HHIP) were the same as observed in NFBC1966 alone. Besides offering support for a 
true effect, the overlap could partly be explained by the fact that the proportion of NFBC1966 
subjects in the data included in the meta-analysis was as high as 43%. Additionally, the DLEU7 
and HIST1H1D associations identified in the NFBC1966 were borderline-significant in the meta-
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analysis (p = 0.055 and p = 0.061, respectively) and the ADAMTS17 association identified in the 
meta-analysis was borderline-significant in the earlier NFBC1966 analysis (p = 0.072). The 
strongest of these associations in both meta-analysis and in the NFBC1966 was with 
SF3B4/SV2A (meta-analysis p = 2.7x10
-5
). The differing results between the two analyses 
regarding the SNPs in/near C6orf173, CDK6, PLAG1, PXMP3/PKIA, EFEMP1 and LCORL are 
probably largely due to inadequate statistical power, particularly in the NFBC1966 analysis 
(N=3,538). Also, the failure to identify associations with the 38 remaining adult height SNPs in the 
meta-analysis can be partly attributed to limited power. Although the power to identify 
associations in the meta-analysis was generally higher (90% to detect per allele effect size of 6% 
SD assuming MAF = 0.31, p < 0.05 significance threshold and additive genetic model), even in 
the sample of N=6,933 the power to detect modest but typical effect sizes (magnitude of 4% SD) 
with these assumptions was only 60%. For SNPs with smaller than average MAF (< 0.31), 
statistical power would have been even lower. However, it is also possible that some of the adult 
height SNPs only operate at a later stage of growth and do not associate with PHV1 at all, or 
have only a negligible effect. For example, in the meta-analysis of PHV1, the SOCS2 SNP 
(rs11107116) showed a null effect (p = 0.56) similarly to the earlier NFBC1966 analysis (p = 
0.43), which is consistent with the suggestion of a potentially age-dependent genetic effect. 
 
To summarise, several potential signals were identified in this first meta-analysis of GWAS on 
weight and BMI growth parameters in infancy and childhood (N=6,051-7,215). Variants in two 
biological candidate genes for obesity, LEPR and PCSK1, had nearly genome-wide significant 
associations with BMI at AP. There was also a suggestive association between a variant in a 
known BMI-associated gene (TMEM18) and PWV1. Loci that have previously been reported in 
GWAS on BMI or other adiposity traits (FTO, GNPDA2, TFAP2B) were associated with age 
and/or BMI at AR, and additionally, potential novel associations between these traits and variants 
in/near DLG2 and RANBP3L/SLC1A3 were identified. Replication of these signals needs to be 
confirmed before publication of the results. Follow-up will be requested for eight signals which are 
summarised in Table 6.21 (rs numbers cannot be given before replication and publication). 
Additionally, the MMP13 signal, which raised heterogeneity concerns, may be replicated in the 
NFBC1986 before asking other groups to genotype it.  
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Table 6.21. Signals selected for replication from meta-analysis of GWAS on growth 
parameters. 
 
Phenotype Nearest gene Top SNP p-value Justification for follow-up 
PWV1 TMEM18 5.9 x 10
-5
 Biology (399) 
BMI at AP LEPR 6.2 x 10
-8
 Low p-value and biology (412) 
BMI at AP PCSK1 1.2 x 10
-6
 Biology (413) 
Age at AR 
(BMI at AR) 
FTO 6.1 x 10
-8
 Low p-value and biology (27) 
Age at AR RANBP3L/SLC1A3 6.7 x 10
-8
 Low p-value 
Age at AR TFAP2B 3.0 x 10
-6
 Biology (274) 
BMI at AR DLG2 1.4 x 10
-7
 Biology (419) 
BMI at AR GNPDA2 3.1 x 10
-6
 Biology (399) 
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7. General discussion 
 
This thesis reviewed methods and strategies for analysing genetic associations in general 
population-based studies (2.1). The analytic strategies chosen for the genetic analyses of this 
thesis included 1) the study of “statistical” candidate variants identified in previous GWAS meta-
analyses in relation to growth phenotypes in the NFBC1966 and other longitudinal data sets (5.5 
and 6.4), and 2) meta-analyses of GWAS on birth measures, growth parameters and adult 
metabolic and anthropometric phenotypes (5.6 and 6.5). Different growth modelling methods 
were also reviewed (2.2). Parametric, biologically motivated growth curve models were chosen 
for application in the prospective NFBC1966 (5.2). Growth parameters derived from these models 
were subsequently used as outcomes in GWAS and their meta-analyses (5.6.3 and 6.5.3). 
Additionally, maternal and environmental determinants of early growth and associations between 
early growth and adult metabolic and anthropometric phenotypes were assessed (5.3 and 6.3). 
The results were placed in the context of existing literature on genetics of growth (2.3) and 
metabolic phenotypes (2.4), and the DOHaD framework (2.5). Study-specific discussions can be 
found in chapter 6. The contribution of the results to the DOHaD research is discussed in this 
chapter (7.2). This chapter also includes discussion on growth modelling and genetic analysis 
methodologies (7.1), strengths (7.3) and limitations (7.4) of this thesis, and discussion on the 
problem of unexplained heritability, as well as new strategies for identifying genetic causes of 
complex diseases (7.5). Finally, suggestions for future work are given (7.6). 
 
7.1. Discussion of methodology 
 
7.1.1. Growth modelling and choice of methods 
 
The NFBC1966 is an ideal resource for growth modelling purposes, since it contains frequent 
growth measurements from birth to adulthood of a large number of subjects born in the same 
year in a defined geographical area, and the subjects were followed up prospectively. The sub-
sample of the NFBC1966 used for growth modelling and for genetic analysis in this thesis is 
adequately representative of the original cohort and hence the population of Northern Finland in 
that specific era. Representativeness was evaluated in detail in the context of analysing 
predictors of infant height growth velocity, and the published height SNPs in relation to infant and 
pubertal height growth velocities (chapters 5.3.1 and 5.5.1). 
 
Frequent measurements of height and weight from birth to adulthood are rarely available in large 
population-based studies, which makes replication of the results challenging. Fitting similar 
models and deriving similar phenotypes across study populations is required to ensure 
 208 
comparability of results. This is, however, impossible without dense measurement points. One 
possibility is to combine several smaller studies with dense growth measurements for replication 
and meta-analysis. Another possibility is to gather growth data from different studies with 
availability of data at varying ages, and maximise the use of data at each age window of interest. 
In this thesis, this was done for the analysis of the FTO locus in relation to BMI growth throughout 
childhood (chapters 5.5.2 and 6.4.2). 
 
A standard parametric approach was chosen to model longitudinal growth. This has the 
advantage of natural biological interpretability of the parameters obtained from the fitted models 
(190), and these models appeared to fit the NFBC1966 data well. Subsequently, similar models 
were successfully fitted to other data sets, and used in the collaborative efforts reported in this 
thesis. There are a number of alternative approaches, for instance smoothing splines; these are 
easy to fit but the interpretation of parameters poses challenges, as does the selection of the 
degree of smoothness to be enforced. These approaches are better suited for visual description 
of the data than for its analysis (193). I attempted to fit models based on cubic smoothing splines 
(420) to these data, but found the results difficult to interpret and sensitive to the number and 
location of knots selected. Therefore, only results for the parametric growth models are presented 
in this thesis. Furthermore, the simplicity and interpretability of the growth parameters from 
parametric models enables their use as phenotypes in GWAS in a straightforward way. Meta-
analysis of GWAS on these parameters is easy to implement, as long as collaborating groups are 
willing and able to either provide growth data to be modelled centrally, or to fit growth models to 
their data and extract the phenotypes for GWAS by themselves. Analysis of more complex 
phenotypes on a genome-wide scale would have been computationally intensive and hardly 
feasible using current methodology, software and computational capacity. 
 
The parameters derived from different growth models showed a high internal quality, based on 
their associations with each other and with observed birth and adult anthropometric measures in 
the NFBC1966 (Table 6.2). However, some assumptions had to be made to account for random 
variation associated with the derived parameters. The weighting of the SNP association analyses 
by the number of measurements per person within the age period in question assumes that the 
reliability of the growth data has a proportional relationship with the frequency of measurements 
taken within the age period, and that the measurement accuracy does not depend on the 
frequency of the measurements taken. Although these seem reasonable assumptions, they are 
difficult to verify using this data alone. Ideally, the analyses would be weighted by the inverse of 
the variance attached to the phenotypes derived from the growth models. However, the variances 
for the derived outcomes could not be directly estimated from the models, and therefore 
weighting by the number of measurements was used as a proxy. Weighting was used for 
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candidate SNP association analyses but was not applied in GWAS due to restrictions in the 
GWAS software (weighted regression was not implemented in SNPTEST). Exclusion of 
individuals with less than three observations within the age window in question was applied in all 
analyses. The estimated curves for individuals with only few growth measurements would mainly 
reflect the population curve, since their individual data would not be dense enough to capture the 
shape of the curve and accurately estimate the departure of their individual curve from the 
population curve. One limitation of this approach is that it does not take into account the timing of 
the growth measurements and the distance between them. For example, for estimating BMI curve 
in infancy, a person with two measurements at 3 months and 9 months would be excluded, 
whereas a person with three measurements at 1, 2 and 3 months would be included. One could 
argue that the former person has more relevant data available for estimating BMI at AP than the 
latter, despite having one less measurement point. However, the average frequency of 
measurements in the NFBC1966 at any age window was much higher and therefore this kind of 
scenario would have been rare. 
 
The results of the model comparison in the NFBC1966 for infant height and weight were 
consistent with the model comparison on early weight growth in another study in Congolese 
infants (197), where the Reed1 model showed the best fit. Similar, published model comparisons 
for early height growth could not be found. For the whole period of height growth from birth into 
adulthood, the superiority of the JPPS model over slightly simpler parametric models, such as the 
Preece and Baines (PB1) and modified Shohoji and Sasaki (SSC) models, has been described 
elsewhere (201), and was not tested in the NFBC1966. As expected, JPA-2 (which is an 
extension of JPPS) fitted better than JPPS in the NFBC1966. The high correlation between ATO 
and age at PHV2 (Table 6.2) estimated from the JPA-2 model largely explains the similarities in 
the results between the two phenotypes. There was also a moderately high inverse correlation 
between PHV2 and age at PHV2. This may contribute to some overlap in the genetic association 
results, and must be acknowledged in the interpretation of the results. 
 
7.1.2. Strategy for the genetic analyses 
 
The strategy adopted for the genetic analyses presented in this thesis was a combination of 
candidate gene analyses (based on statistical candidate variants from published GWAS meta-
analyses) and GWAS including large-scale meta-analyses. In GWAS, a single-SNP analysis 
using an additive genetic model was applied genome-wide in a frequentist framework, followed by 
meta-analysis where applicable. The rationale for this approach is strongly tied with and justified 
by the timing of this PhD project, which has to be placed in the historical context of technological 
and methodological developments in genetic population studies. The project started at the dawn 
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of the large-scale GWAS era (in 2006) in which researchers had high hopes for the discovery of 
genetic variants underlying complex traits. This was shortly after repeated failures to identify 
these variants using the biological candidate gene approach. While waiting to receive GWA data 
for the NFBC1966 (funded through a large-scale effort by NIH / NHLBI / STAMPEED 
programme), this project focussed on replicating the first GWAS signals discovered in other 
studies, e.g. the association between the FTO locus and adult BMI (27), and on the analysis of 
growth phenotypes in relation to SNPs identified for adult anthropometric traits (see Sovio et al. 
(2009) (327) and Sovio* et al. PLoS Genet 2011 (in press)). These efforts led to interesting 
insights into the age-dependent nature of associations between common SNPs and growth 
(chapter 6.4). Subsequently, the focus shifted to the management and analysis of the NFBC1966 
GWA data (Sabatti et al. (2009) (324) and chapters 5.6.1 and 6.5.1), before starting collaborative 
efforts in large-scale meta-analyses of GWAS (Freathy* et al. (2010) (348) and Kraja* et al. 
Diabetes 2011 (in press)). The strategy adopted for this project was almost inevitable, due to the 
timing of this project (2006-2010), which coincided with global efforts in conducting GWAS and 
their meta-analyses. Therefore, opportunities to explore different approaches were limited. 
Fortunately, the adopted approach turned out to be fruitful, measured by the number of resulting 
articles from this work that were published in reputable journals (see the list of publications at the 
beginning of this thesis). However, disappointingly, the GWAS strategy has still not been able to 
explain a high proportion of the variability of any given phenotype by these genetic discoveries 
(39) which has led to a frantic quest to find the sources of unexplained or ―missing‖ heritability of 
the phenotypes (chapter 7.4). Another disappointment has been the inability to identify the causal 
variants that affect the trait. Nearly all of the real culprits are still hiding among highly correlated 
associated variants that have no functional role (32, 421). In the following, I will briefly discuss 
strengths and limitations of the GWAS approach combined with meta-analysis. 
 
One of the strengths of the GWAS approach is that it is ―agnostic‖, i.e. it interrogates the whole 
genome and does not depend on the availability of prior biological information (hypothesis-free 
approach). Therefore it is less prone to bias than candidate-based methods (33). Genotyping a 
population-based cohort of individuals with DNA available (marker-based approach) gives the 
advantage of analysing several phenotypes with conventional methods, and the possibility of 
analysing continuous traits. This is not possible for GWAS limited to a case-control design, which 
is better suited for the analysis of disease endpoints, especially when the disease is uncommon 
in the population. 
 
A limitation of the GWAS approach that clearly affected this PhD project was the slowness of the 
process of obtaining the GWAS data. This was due to genotyping failures, problems in genotype 
calling, various stages of QC and imputation. Although genotyping was already underway at the 
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start of this PhD, it took 18 months to obtain a ―nearly complete‖ release of the data that could be 
used in this thesis. Imputation of the final release was not yet finished by the time analyses were 
completed for this thesis. The ―nearly complete‖ release was only inferior to the final release in 
the sense that it contained a smaller sample of cohort members (N=639 fewer members, which is 
12% less than in the final release), not in terms of data quality. 
 
The GWAS approach rarely yields robust associations in a single population due a low statistical 
power to identify genome-wide significant (p < 5x10
-8
) associations. Also, the NFBC1966 was not 
suited for analysing disease endpoints or extremes of a trait distribution (e.g. hypertension, 
hyperglycaemia, T2D) on its own, since these conditions are still rare at age 31 years. To tackle 
these limitations, power was increased by participating in consortia with similar research interests 
and availability of similar data. This led to a situation where 1) early growth phenotypes could be 
studied in a much larger sample and 2) metabolic phenotypes could be studied in a larger sample 
covering a wider age range.  
 
Work in consortia proved to be productive and yielded statistically robust results. However, 
production of the results was very slow for a number of reasons: agreement on the protocol and 
permissions to go ahead with analyses took more time than expected (permission for the growth 
parameter GWAS was only granted at the beginning of the 4
th
 year of the PhD due to competing 
interests); phenotypes had to be estimated from the growth models and transformations done in 
the same way in all studies; there were delays regarding individual studies due to holidays, sick 
leaves and failure in communication from study leaders to analysts; and results from individual 
studies needed to be meta-analysed and replicated in other data sets before submitting them for 
publication. On the other hand, work in consortia was very valuable in terms of learning, sharing 
knowledge, and establishing contacts with other researchers in the field.  
  
The single-SNP analysis using frequentist methods and the additive genetic model was a strategy 
that led to initial success. However, it should be considered only as the first step. For example, 
this approach ignores potential epistatic effects and the possibility of non-additive SNP effects 
(e.g. recessive effects). Suggestions for further work including the simultaneous analysis of 
multiple SNPs are given in chapter 7.6. 
 
7.2. Discussion of results in the DOHaD framework 
 
Study-specific discussions can be found in chapter 6. Overall, of the proposed mechanisms 
underlying the association between poor foetal growth and higher risk of adult disease outlined in 
chapter 2.5, it was possible to examine the foetal programming (2.5.2), growth acceleration 
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(2.5.5) and genetic susceptibillity (2.5.6) hypotheses using the data available for this PhD project. 
Instead of disease endpoints, adult anthropometric and metabolic traits were used as 
intermediate phenotypes in these investigations, due to the young age of the primary study 
population, the NFBC1966. Contributions of maternal stress and glucocorticoids (2.5.3) and 
epigenetic modifications (2.5.4) on these phenotypes could not be examined in this thesis, but 
these aspects should be considered in further studies. In Figure 7.1, the growth measurements 
and parameters as well as adult anthropometric and metabolic phenotypes included in this thesis 
are placed within the DOHaD framework (see also Figure 2.5). The arrows represent associations 
between genotypes, environmental factors, growth and metabolic phenotypes from gestation to 
adulthood. This is a simple conceptual graph, where details of the observed associations are 
omitted. In this thesis, the emphasis was on studying genetic rather than environmental 
associations with the phenotypes. 
 
The finding that babies born shorter grow faster in length immediately after birth (6.3.1) supports 
the foetal programming hypothesis (2.5.2). This inverse association between BL and PHV1 was 
identified in both sexes in NFBC1966 and NFBC1986 but in the cohort born 20 years later, the 
association was stronger (Das* et al. (under review in Pediatrics)). In both cohorts, maternal pre-
eclampsia during pregnancy was also associated with a faster postnatal growth and this 
association seemed to be partly mediated by birth size and gestational age.  
 
 
 
Figure 7.1. Genetic and environmental effects on growth throughout childhood and on 
adult anthropometric and metabolic phenotypes (DOHaD framework). BW = birth weight, BL = 
birth length, PHV1 = peak height velocity in infancy, PWV1 = peak weight velocity in infancy, BMI = body mass index, AP 
= adiposity peak in infancy, AR = adiposity rebound in childhood, ATO = age at pubertal height growth spurt take-off, 
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PHV2 = peak height velocity in puberty, APHV2 = age at PHV2, WC = waist circumference, BP = blood pressure, GLUC = 
glucose, TG = triglyceride, HDLC = high density lipoprotein cholesterol, MetS = metabolic syndrome. 
 
On the contrary, a higher birth weight was associated with a faster immediate postnatal growth in 
weight (PWV1) in the NFBC1966 (Table 6.2 and Table A.6). This result is not in line with the 
foetal programming hypothesis. However, these associations were unadjusted. Therefore, a 
careful exploration of potential factors that may obscure the relationship between BW and PWV1, 
and subsequent adjusted analyses should be performed before drawing conclusions on these 
analyses. Additionally, the mediation of other predictors of PWV1 through BW could be examined 
using more complex statistical techniques (see 7.5). Due to time constraints these analyses could 
not be included in this thesis. 
 
Results from the NFBC1966 also indicate that a fast immediate postnatal growth (measured by 
PHV1 and PWV1), an early adiposity rebound (AR), and an early pubertal height growth spurt 
contribute to adult obesity and adverse metabolic profile (6.3.2). These associations remained 
after adjustments for other prior growth measures or parameters. For instance, the association 
between faster immediate postnatal growth and higher adult BP and WC persisted after an 
adjustment for BW, and early AR was strongly associated with a worse metabolic profile after 
adjustments for earlier growth (BW, PHV1, BMI at AP) and even after an adjustment for BMI at 
AR. These results give support to the growth acceleration hypothesis (2.5.5). Although the effect 
of poor intrauterine growth on adult metabolic phenotypes may partly mediate through faster 
postnatal growth, the studies included in this thesis suggest an effect of postnatal growth that is 
independent of prior growth, including birth size. 
 
However, the studies of growth parameters and metabolic traits discussed so far ignored the 
possibility of a genetic component that may play a part in the observed associations. In the meta-
analyses of GWAS, the association identified between the variant rs9883204 in ADCY5 and BW 
(6.5.2) suggests pleiotropic effects on foetal growth (possibly a direct effect of the foetal risk allele 
via reduced insulin secretion in utero) and adult glucose regulation and T2D. This finding is 
consistent with the foetal insulin hypothesis (45) (2.5.6). 
 
Another example of a potential pleiotropic effect is the TFAP2B. Variants in this gene have been 
found to be associated with adult adiposity, measured in WC (2.4.1). Another nearby SNP from 
this gene was identified for the WC-GLUC trait combination in Kraja* et al. Diabetes 2011 (in 
press) (6.5.1), and yet another SNP in the same gene was found to be associated with age at AR 
in the growth parameter GWAS meta-analysis (6.5.3). All effects were found to be in the logical 
direction, i.e. WC or WC-GLUC increasing alleles were associated with lower age at AR. The 
SNP associated with age at AR has a low LD with the WC-GLUC SNP and the published WC 
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SNP (r
2 
= 0.046 and r
2
 = 0.044, respectively), which suggests that there might be more than one 
independent signal in this locus. 
 
To conclude, the studies described in this thesis found evidence for each of the potential 
mechanisms underlying the DOHaD hypothesis that could be studied: foetal programming, 
growth acceleration, and genetic susceptibillity (2.5). Current literature along with this thesis 
suggest simultaneous contribution of different mechanisms. However, the relative explanatory 
power of each mechanism in the development of common diseases remains unclear. This is 
partly because the full extent of the contribution of pleiotropic genetic effects has not yet been 
assessed. Also, more research is needed on the role of epigenetic mechanisms before relative 
contributions of each mechanism on adult diseases can be considered. 
 
7.3. Strengths 
 
This thesis contains the largest published studies to date that examine parameters from fitted 
growth curves throughout childhood in relation to predictors of growth, genetic variants and 
anthropometric and metabolic phenotypes in adulthood. The prospectively followed up 
NFBC1966 was an ideal data set for these studies, since it contains diverse phenotypic 
information and frequent growth measurements from birth to adulthood, as well as GWA data. It 
is also a very homogenous cohort in terms of ethnicity, and has preserved a high 
representativeness of the source population throughout the follow-up. The meta-analysis of 
GWAS from multiple prospective, longitudinal birth cohorts was a statistically powerful and 
successful strategy for the identification of common genetic variants underlying early growth 
phenotypes. 
 
7.4. Limitations 
 
The clinical examination in the NFBC1966 at age 31 years was restricted to participants still living 
in the original study area or in the Helsinki area (N=8,463 out of 11,637 alive at age 31; 73%). 
However, demographic factors were fairly similar among persons attending the clinical 
examination (71% of the invited, N=6,007) and the remaining cohort members who were still alive 
(N=5,630) (329). Even less selection bias was observed when the sub-group with growth data 
and height SNP information (N=3,538) was compared with attendees of clinical examination who 
did not have this information available (N=2,469) (327).  
 
The NFBC1966 study design excluded the possibility to evaluate parent-of-origins effects and 
thus the epigenetics hypothesis, due to lack of parental DNA. However, these types of data are 
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rare and typically available only in small studies, except within the Icelandic population where 
parent-of-origin information is more widely available. In the NFBC1966, parental DNA is not 
available. However, there is a possibility to collect DNA from the children of the female members 
of the NFBC1966, which would enable the study of the epigenetics hypothesis. 
 
Phenotype inaccuracy turned out to be very problematic in one of the sub-studies of this thesis. 
The meta-analysis of GWAS on gestational age (GA) that failed to identify any associated genetic 
variants (5.6.2 and 6.5.2), included cohorts where GA was calculated from the last menstrual 
period. The NFBC1966 was one of these cohorts. Phenotype inaccuracy together with a limited 
statistical power may have contributed to the failure to identify associations at the genome-wide 
significance level (p < 5x10
-8
). Additionally, the effect of foetal genotype on GA may not be as 
important as the effect of maternal genotype on GA; however, in many cohorts, including the 
NFBC1966, maternal genotype information was not available. Furthermore, information on 
medically induced births was not available in some of the cohorts, including the NFBC1966. 
However, in 1966 this practice was still uncommon. Preliminary results from further analyses 
show that limiting the meta-analysis to cohorts with accurate phenotype information (i.e. GA 
based on ultrasound measurements) increases the chances of finding biologically plausible 
signals even when the sample size is considerably smaller. The statistical power is not 
necessarily smaller in this case, since the accuracy of the phenotype increases it (this aspect is 
still rarely taken into account in power calculations). 
 
7.5. Unexplained heritability and new strategies for identifying genetic causes of complex traits 
 
The GWAS approach has been successful in identifying hundreds of reproducible genotype-
phenotype associations. They have revealed some interesting biology in the genetics of common 
diseases, including pleiotropic effects. These findings have resulted to a vast amount of high-
impact publications and media interest. However, the proportion of the estimated heritability of the 
phenotype these replicated associations explain is disappointingly small, typically only 1-20% per 
trait (see Table 1 in Manolio et al. (2009) (39)), with an exception of age-related macular 
degeneration for which common variants of large effect in five loci explain 50% of heritability. 
Therefore, from the public health point of view these results are still of little value until more of the 
genetic architecture underlying common disease has been discovered, interpreted and translated 
into disease prevention and treatment strategies. 
 
One reason for the unexplained or ―missing‖ heritability could be the overestimation of trait 
heritability. New techniques for heritability estimation that account for potential confounding by 
unmeasured shared environment should result in more accurate heritability estimates (39). 
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Another reason could be inaccurate phenotyping which reduces observed effect sizes. One 
option is to use intermediate phenotypes (endophenotypes) instead of disease outcomes in 
GWAS (421). Sometimes this may result to cleaner phenotypes and a higher statistical power. 
For example, in young populations this may sometimes be the only option because disease 
prevalence at young ages is low. Analysing continuous metabolic traits instead of T2D or CVD 
outcomes is an example of this. Also, from a public health point of view the analysis of 
endophenotypes is feasible, since it may lead to an early identification of high-risk individuals for 
interventions. 
 
The commonly used threshold for statistical significance in GWAS (p < 5x10
-8
) controls the false 
positive rate adequately and most signals below this threshold are replicated successfully. 
However, using such a stringent threshold results in a high false negative rate, i.e. many true 
associations with a small effect size will be ignored as non-significant. There replicated 
associations with common variants with a moderate effect size are bound to be only a tip of an 
iceberg, and there should be a multitude of more common variants with smaller effect sizes yet to 
be discovered. Sebastiani et al. (2009) challenge researchers to re-analyse their data by using 
alternative techniques, e.g. Bayesian procedures, which give better control over the false 
negative rate (422). 
 
Evidence for the presence of a large number of small effects that together explain a considerable 
proportion (~45%) of the estimated heritability of height was recently published (423). This study 
was conducted in a population of Australian adults and adolescents of European descent. The 
authors of this paper argue that if the genetic architecture of other complex phenotypes matches 
that of height, these results could be generalised to these phenotypes. Therefore, larger meta-
analyses of GWAS would be needed to discover the remaining genetic variants with small effects. 
This paper also suggests that an imperfect LD between causal variants and genotyped SNPs 
might further contribute to the low proportion of explained variance in complex traits (423). Causal 
variants with a low MAF could only be detected by sequencing. 
 
Some of the genome-wide significant phenotype associations with common variants could be 
synthetic associations, which means that the effect of a rare variant is incorrectly attributed to a 
common variant (424). The effect size of this common variant is small or moderate as it 
represents a diluted signal coming from a rare causal variant with a large effect on the phenotype 
(421). Since the rare variant by which the association is driven can be even megabases away 
from the common variant that picked up the signal, follow-up sequencing should be extended 
beyond the LD block around the common variant in question (424). Low frequency and rare 
variants as well as structural variants are poorly detected by the currently available genotyping 
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arrays, but as soon as next-generation sequencing becomes more affordable, much research will 
be focused on the role of rare variants, including structural variants (e.g. CNVs), in common 
disease. Population isolates are more likely to be enriched in rare variants and therefore their role 
in this type of research may become pronounced (39). Initially, applying whole-exome sequencing 
on individuals at the extreme tails of phenotypic distribution could be used as a cost-saving 
approach. When affordable, whole-genome sequencing can be applied to entire populations. This 
reminds of the early use of the trait-based approach for GWAS before genotyping all study 
subjects became feasible. In addition, the recent GWAS meta-analyses based on imputed data 
have neglegted the study of the sex chromosomes. As the imputation methods for the variants in 
the X and Y chromosomes improve, more phenotype associations can be expected to be found 
from the sex chromosomes (39). 
 
Most GWAS to date have been conducted in populations of European ancestry. However, genetic 
variation is much greater in populations of recent African ancestry. Therefore, GWAS on these 
populations is likely to result in new discoveries, and this has already been demonstrated in some 
studies (39). One can draw an analogy from the classic epidemiological paper by Geoffrey Rose 
(425), which pointed out that when exposure levels are too homogenous within a population, the 
exposure-disease association is not fully captured by traditional methods. Similarly, in genetic 
epidemiology, if the LD is high, i.e. genetic variability is low, genotype-phenotype associations 
cannot fully be captured within a population. 
 
Undetected gene-gene (GxG) and gene-environment (GxE) interactions may exist but strictly 
speaking they are not part of the ―missing‖ heritability since these non-additive effects do not 
contribute to narrow-sense heritability (423). There are not many examples yet of strong GxG or 
GxE interactions in the literature (421). Inconsistencies in these findings can often be attributed to 
small sample sizes. For example, two out of four studies (N~700-5,500) identified a GxE 
interaction between physical activity (PA) and the FTO effect on BMI, suggesting PA attenuates 
the FTO-BMI association. Subsequently, a large population-based study (N~25,000) gave 
evidence for the same GxE interaction (426). 
 
Imprinting has been presented as yet another possibility for the unexplained heritability (421), 
although strictly speaking, epigenetic mechanisms only contribute to heritability if they persist on 
average for many generations (427). Due to lack of parental genetic information, most GWAS 
have treated the maternal and paternal alleles as exchangeable. An Icelandic study 
demonstrated effects with three traits including T2D, where parental origin of the allele made a 
difference (428). In this case, treating alleles as exchangeable can either lead to a diluted effect 
or no effect at all, since it is possible that the maternal and paternal alleles operate in opposite 
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directions (one increasing and the other decreasing the disease risk). If imprinting and epigenetic 
mechanisms in general play an essential role, it could be possible that the genotypes of the 
ancestors of individuals turn out to be better predictors of phenotypes than the individual‘s own 
genotype (429). However, evidence of transgenerational effects is still largely based on animal 
studies.  
 
In conclusion, there is no consensus at the moment among prominent geneticists on which of the 
possible sources of unexplained heritability to focus (39). Expert opinions strongly reflect the 
academic background and current research efforts of these experts (429). I personally consider it 
likely that larger meta-analysis collaborations including analyses of rare and low-frequency 
variants, including structural variants, will make the largest contribution in explaining the currently 
unexplained heritability of complex phenotypes.  
 
7.6. Suggestions for further work 
 
Studies on growth and metabolic phenotypes could be developed further by evaluating prenatal 
predictors of infant weight and BMI growth and their possible mediation through birth weight. A 
comprehensive model could be built encompassing pre- and postnatal growth, their predictors, 
adult anthropometric and metabolic phenotypes and selected lifestyle and environmental factors. 
This web of relationships could be modelled, for example, using a path analysis approach which 
estimates direct and indirect effects of exposures measured at various time points over the life 
course on the distal outcomes (for an application of this method, see Gamborg et al. (2009) 
(430)). Additionally, this analysis could include one or more SNPs, e.g. a small number of 
candidate variants. The analyses could be performed in a structural equation modelling (SEM) 
framework, e.g. by fitting growth mixture models (GMM).  
 
Also in the GWAS setting, growth trajectories could be modelled using different methods. For 
example, SEM could be used to classify growth patterns into a limited number of classes, and this 
classification could then be used as a phenotype in the GWAS. Another possibility would be to 
summarise trajectories by estimating best linear unbiased predictors (BLUPs) representing 
random effects slopes of individual trajectories. The BLUPs could then be analysed using GWAS. 
The idea of both of these methods is similar to the growth parameter estimation applied in this 
thesis: to use simple summary measures of individual trajectories as phenotypes in the GWAS. 
Work is already underway within the EGG/EAGLE Consortium to model growth in these ways, 
and it is planned to perform a meta-analysis of GWAS on the resulting summary phenotypes. In 
the future, when computational capacity increases and methods and software are developed 
further, it may become possible to model growth and conduct GWAS simultaneously in one step.  
 219 
 
Rather than analysing the effect of each SNP individually, a multiple SNP approach could be 
attempted, for example to study all variants selected for replication simultaneously in the follow-
up stage, in addition to SNP-by-SNP analyses. At this point, epistatic effects could also be 
explored. In case of a large number of SNPs, variable selection models or Bayesian shrinkage 
methods could be applied to reduce dimensionality. 
 
In the context of very large samples (over 50,000 to ensure adequate statistical power), epistasis 
and gene-environment interactions could be added to GWAS. This would require phenotype 
harmonisation across data sets (147), which is challenging, since phenotype availability, quality, 
measurement technique, coding practices (e.g. classification of variables), and age at 
measurement tend to vary between data sets. Additionally, alternatives to the commonly used 
additive genetic model (e.g. recessive model) could be explored in the GWAS. 
 
The transition from GWAS to new avenues is already in progress. Beside common SNPs, the 
contribution of different types of genetic variation, e.g. rare variants, including structural variants, 
could be analysed in relation to birth size, postnatal growth and metabolic phenotypes. This will 
become more feasible as the quality of the 1000 Genomes reference panel continues to improve, 
and even more when whole-genome sequencing becomes affordable.  
 
As our understanding of the genetic architecture of growth and metabolic phenotypes improves, it 
may be possible to build prediction models for adverse phenotypic profiles (e.g. metabolic 
profiles) including both genetic and environmental risk factors. These models can then be used to 
identify people at a high risk early in life, and to target interventions to these individuals. 
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8. Appendix 
 
Table A.1. Key concepts and definitions in genetic studies. 
 
Concept Explanation 
Additive genetic 
model 
A genetic model where one copy of disease allele causes n-fold 
increased risk and two copies 2n-fold increased risk. 
Allele A variation of DNA sequence (gene or marker) at a given locus. If there 
are two possible variations, the locus is called bi-allelic. 
Association study Association studies can be divided into family based and population 
based studies. The former detect linkage-based associations by using 
transmission disequilibrium tests (TDT). The latter are conducted in 
populations of apparently unrelated (distantly related) people. 
Differences between genetic markers can be tested in disease cases 
and their controls (case-control study) or the marker association with a 
continuous trait can be assessed in a population (e.g. cohort study). 
Autosome A chromosome that is not a sex chromosome. 
Block substitution A type of structural variation where a string of adjacent nucleotides 
varies between different genomes. 
Candidate gene 
study 
An association study of a gene that is suspected of causing a disease 
or influencing a trait, based on some prior biological evidence on its 
involvement. 
Chromosome A single microscopically visible macromolecule of DNA. Chromosomes 
carry the genetic material in the cell nucleus. Humans have 22 pairs of 
autosomes and one pair of sex chromosomes (XX for female, XY for 
male). 
Co-dominant 
genetic model 
A genetic model where increased risk caused by disease allele is not 
restricted to additivity or multiplicativity. This is also called ‗general 
genetic model‘. 
Common disease – 
common variant 
(CDCV) hypothesis 
Hypothesis that common variants with small or modest effects are the 
main contributors to common diseases. 
Common variant A variant with MAF ≥ 1% (to distinguish from a low frequency variant 
the threshold is sometimes set to MAF ≥ 5%).  
Complex trait A common trait believed to be attributed to genetic effects with low 
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Concept Explanation 
penetrance, environmental factors and gene-environment interactions. 
Copy number 
variant (CNV) 
A type of structural variant in which identical DNA sequences are 
repeated in some genomes but not in others.  
Crossing over See Recombination. 
Cryptic relatedness The unrecognized presence of close relatives in the study sample. 
Deep sequencing Determination of the DNA sequence with a deep coverage (see 
Sequence coverage). 
De novo 
genotyping 
Bespoke genotyping of a variant of interest. This is commonly done in 
replication data sets to follow up a signal from a GWA study.  
DNA Deoxyribonucleic acid molecule. It contains the instructions for the 
development and functioning of all living organisms. 
DNA methylation Attachment of a methyl group (CH3) to a cytosine base in the DNA. It is 
an epigenetic mechanism involved in silencing of genes and it plays an 
important role in cell differentiation. DNA methylation survives cell 
divisions without changing the underlying DNA sequence. Some DNA 
methylations can be used as biomarkers to predict disease. 
Dominant genetic 
model 
A genetic model where one copy of disease allele is enough to 
increase disease risk (two copies do not cause additional risk increase 
compared to one copy). 
Dominant allele An allele that masks an alternative allele. If the disease allele is 
dominant, both homozygous dominant and heterozygous genotypes 
lead to the disease phenotype. 
Dynamic complex 
trait (DCT) 
Complex trait that has been measured and changes over time, e.g. 
body height and weight. 
Endophenotype See Intermediate phenotype. 
Epigenetic changes Heritable changes in gene expression or phenotype, which are not due 
to changes in the DNA sequence. For example, epigenetic changes 
may be due to changes in the activation of certain genes. DNA 
methylation and histone modifications are examples of epigenetic 
changes. 
Epistasis Interaction between genetic variants (at different loci).  
Exon Segment of DNA with protein-coding sequences in a gene. 
Exome The part of the genome that consists of exons. The human exome 
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Concept Explanation 
covers only about 1% of the human genome but it is believed to be the 
most functionally relevant part of it. 
False discovery 
rate (FDR) 
The expected false positive rate. 
False positive rate Probability of falsely rejecting the null hypothesis in a particular 
statistical test (among all tests performed), also called type I error rate. 
Family-wise error 
rate (FWER) 
Probability that at least one of the statistical tests performed results in 
type I error. 
Fine mapping Genetic mapping of a constrained locus in order to refine the 
phenotype association signal and identify the causal variant. 
Functional mapping A framework in which parameters from mathematical functions 
describing trajectories of dynamic complex traits (DCTs) are estimated 
and studied in relation to genetic variants (and environmental factors).  
Gene Segment of DNA that corresponds to a unit of inheritance. 
Gene expression Translation of the information encoded in a gene into a functional gene 
product (RNA or protein). 
General genetic 
model 
A genetic model where increased risk caused by disease allele is not 
restricted to additivity or multiplicativity (see Co-dominant genetic 
model). 
Genetic mapping Localisation of genes underlying phenotypic traits based on statistical 
correlation with DNA variation. 
Genetic marker Genetic variant that can be linked to a trait or disease. 
Genetic variant A DNA sequence variant. These can be classified into single nucleotide 
variants and structural variants. The latter include insertion-deletions, 
block substitutions, inversions and copy number variants (CNVs). 
Genome See Human genome. 
Genomic control 
(GC) 
Correction of the genetic association test statistic for population 
stratification by using genomic inflation factor (λ). 
Genomic inflation 
factor (λ) 
Quantitative measure of inflation and excess false positive rate. λ = 
observed median of the distribution of the test statistic / expected 
median. 
Genotype Person‘s genetic makeup at a locus determined by the alleles. A SNP 
has three possible genotypes i.e. combinations of alleles, e.g. A/A, A/G 
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Concept Explanation 
and G/G.  
Genotype relative 
risk (GRR) 
The probability of disease for a particular genotype at a locus 
compared to another genotype. Defined separately for each genetic 
model. For example, for multiplicative model, GRR = p1/p0 = p2/p1, 
where px = probability of disease in the presence of x copies of disease 
allele, x = 0, 1, 2. 
Genome-wide 
association study 
(GWAS) 
Study of the association between common genetic variation and a 
phenotype (trait or disease) in a densely genotyped sample. 
Haplotype A sequence of alleles in a single chromosome that have been inherited 
as a unit. 
Hardy-Weinberg 
Equilibrium (HWE) 
The stable frequency distribution of genotypes. In a large, randomly 
mating population the genotype and allele frequencies remain stable 
over generations, and there is a fixed relationship between the two. 
Heritability The proportion of phenotypic variation in a population attributable to 
genetic variation between individuals. Narrow sense heritability only 
accounts for additive genetic effects, whereas broad sense heritability 
accounts for total genetic variance including non-additive genetic 
effects. 
Heterozygote Person who has two different alleles at a given locus. 
Histone A protein in eukaryotic cell nucleus. Histones are involved in packaging 
DNA into chromosomes, gene expression and chromosome 
stabilization. 
Histone 
modification 
Various types of modifications of histones (e.g. acetylation, 
methylation, phosphorylation) that can create epigenetic mechanisms 
to regulate disease-related processes, e.g. disease development, 
response to treatment and prognosis. 
Homozygote Person who has two identical alleles at a given locus. 
Human genome The sequence of all genetic material (DNA) in human chromosomes. A 
small fraction of DNA is located in the mitochondria.  
Identical by descent 
(IBD) 
Two alleles at a locus are identical by descent (IBD) if they are copies 
of the same ancestral allele. 
Imprinting The phenomenon where the gene expression depends on the parental 
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Concept Explanation 
origin of the allele. This is also called parent of origin effect. DNA 
methylation is the key mechanism through which silencing of genes 
according to parental origin operates. 
Imputation Filling in genotypes at SNPs not genotyped in the sample, based on LD 
relationships in the HapMap or another reference panel. 
Insertion-deletion 
(indel) 
A type of structural variation where one or more base pairs are present 
in some but absent in other genomes. 
In silico genotyping In silico means ―performed on computer or via computer simulation‖. In 
silico genotyping refers to imputing the genotype of interest from 
existing GWA data that does not contain the particular SNP in 
question. 
In silico replication Replication of (GWA) study findings in other (GWA) studies, with use of 
imputation if necessary (e.g. when the original and replication study 
have used different genotyping panels). 
Instrumental 
variable 
A variable (genetic variant) associated with a modifiable exposure. In a 
Mendelian randomisation study, the instrumental variable is used to 
assess the causality of the association between the exposure and the 
outcome. 
Intermediate 
phenotype 
A phenotype that increases the risk of a disease endpoint. For 
example, blood pressure and lipid levels can be seen as intermediate 
phenotypes for cardiovascular disease. 
Intron A non-coding segment that separates exons. 
Inversion A type of structural variant in which the order of base pairs is reversed 
in a certain section of the chromosome. 
Light sequencing Sequencing involving 1-3 reads at any place in the genome. 
Linkage Tendency of genes on the same chromosome to segregate together. 
Linkage 
disequilibrium (LD) 
The non-random association between two alleles in different loci on the 
same chromosome. A high LD reflects infrequent recombination. In 
association studies, LD is often measured by squared correlation 
coefficient between pairs of loci (r
2
). 
LD bin A group of highly correlated SNPs generally inherited together. 
Linkage study Linkage study aims to map genetic disease loci in a large, high-risk 
pedigree by identifying traits co-inherited with the genetic markers 
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Concept Explanation 
linked with the causative variant. 
Locus (pl. loci) A chromosomal location for gene or DNA sequence. 
Low frequency 
variant 
A variant with MAF between 0.5% and 5%. 
Marker-based (MB) 
approach  
Compares phenotype trait values between different marker genotypes. 
Major allele The more common allele of a polymorphism. 
Minor allele The rarer allele of a polymorphism.  
Minor allele 
frequency (MAF) 
The proportion of chromosomes in the population carrying the rarer 
allele, usually expressed in %. 
Mendelian disease 
or trait 
A monogenic, typically rare disease or trait attributed to a highly 
penetrant genetic effect. 
Mendelian 
randomisation 
Random assortment of genes from parents to offspring. It can be used 
to make inferences about environmentally modifiable causes of 
disease by examining genotype-disease associations. 
Microsatellite 
marker 
A tandemly organized repeat of a short (typically 2-6 nucleotides long) 
sequence. It is also called short tandem repeat (STR) or short 
sequence repeat (SSR). 
Minisatellite marker A tandemly organized repeat of a longer (typically 7-100 nucleotides 
long) sequence. Highly polymorphic minisatellites are called VNTRs. 
Multiplicative 
genetic model 
A genetic model where one copy of disease allele causes n-fold 
increased risk and two copies n
2
-fold increased risk. 
Multistage design In stage one a sub-sample is tested for a dense set of markers, and in 
later stage(s) an independent sample is tested on a subset of the most 
significant SNPs. 
Nonsynonymous 
SNP 
A SNP for which each allele codes for a different amino acid in the 
protein sequence. 
Nucleotide The DNA sequence consists of four types of nucleotide bases: adenine 
(A), cytosine (C), guanine (G) and thymine (T). 
Nutrigenomics The study of the interaction between different foods and genes in 
relation to complex disease risks. 
Parent of origin 
effect 
See Imprinting. 
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Concept Explanation 
Penetrance Probability of the phenotype given the genotype.  
Pharmacogenomics The study of how genetic variation affects the response to medications. 
Phenotype The clinical expression of genotype(s), environmental factors, or both, 
including traits (e.g. height) and diseases (e.g. diabetes). 
Pleiotropy The phenomenon whereby a single gene produces multiple, distinct, 
apparently unrelated phenotypic effects. 
Polymorphic locus A locus that has at least two alternative alleles. 
Polymorphism Synonymous with common variant (MAF ≥ 1%). 
Pooled sample A sample that contains blood (or DNA) from more than one disease 
case or control. 
Population 
admixture 
A mixture of two or more populations with different disease 
prevalences. 
Population 
(sub)structure or 
stratification 
A population includes subgroups of individuals more related to each 
other than to other individuals in the population. These ethnic groups 
may have different marker allele frequencies and disease prevalences. 
Positional cloning Identification of a disease gene using genetic mapping techniques, 
based on the knowledge of its position in the genome alone (without 
information on the biochemical basis of the disease). Also called 
reverse genetics as opposed to the traditional cloning approach that 
identifies the gene by using pre-identified gene products. 
Proxy A variant highly correlated to the variant of interest that is used as a 
substitute in an association study. 
Quantitative trait 
loci (QTL) 
Loci for a continuous phenotype. QTL mapping may have more power 
than disease mapping if the phenotype is well-defined and accurately 
measured. 
Rare variant A variant with MAF < 1% (to distinguish from a low frequency variant 
the threshold is sometimes set to MAF < 0.5%). 
Recessive genetic 
model 
A genetic model where two copies of disease allele are required for 
increased disease risk.  
Recessive allele An allele that is masked by an alternative allele. If the disease allele is 
recessive, the phenotype is expressed only in those who are 
homozygous for the disease allele. 
Recombination The exchange of fragments of genetic material between chromosomes 
 227 
Concept Explanation 
which results in the formation of new combinations of alleles in the 
offspring. It occurs naturally in meiosis, creating genetic diversity 
between generations. This is also called crossing over. 
Replication Examination of the discovered variant in other data sets using the 
same association analysis model (also called exact replication). 
Resequencing Determination of the DNA sequence using an established sequence as 
a reference (see also Whole genome sequencing). 
RNA Ribonucleic acid molecule. RNA is important in the protein synthesis. 
Rs number for SNP dbSNP accession ID. dbSNP is a public domain SNP database at 
National Center for Biotechnology Information (NCBI), USA. 
Sequence 
coverage 
Each base of the genome is sequenced a number of times, e.g. 40x is 
regarded as a deep and 2x as a low coverage (see Deep sequencing). 
Single nucleotide 
polymorphism 
(SNP) 
A common (MAF ≥ 1%) genetic variant that represents alteration in a 
single nucleotide base. 
Single nucleotide 
variant 
A genetic variant that represents alteration in a single nucleotide base. 
Includes SNPs as well as rare and novel variants of this type. 
Structural variants Genetic variants excluding single nucleotide variants. These include 
insertion-deletions, block substitutions, inversions and copy number 
variants (CNVs). 
Tag-SNP A representative SNP in a high LD region. Most of the genetic variation 
can be captured using a tag-SNP from each LD bin instead of 
genotyping all SNPs. 
Trait-based (TB) 
approach 
Tails of a phenotype distribution are genotyped and the most promising 
genetic markers are then genotyped in another population or in those 
in the middle of the distribution. 
Unphased 
genotype 
information 
Genotype information without knowledge on which parent each allele is 
inherited from, i.e. no information on parental genotypes. 
Variable number of 
tandem repeat 
(VNTR) 
Variable number of tandemly repeated sequences that vary in length 
and are highly polymorphic. They are highly polymorphic minisatellites 
(terms VNTR and minisatellite are often used synonymously) or 
sometimes microsatellites. 
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Concept Explanation 
Whole genome 
sequencing 
Determination of the DNA sequence (i.e. the order of the nucleotide 
bases) of a genome at a single time (see also Resequencing). 
Winner‘s curse Inflation of the estimated effect size of genotype-phenotype association 
in the data set in which the discovery was made. To assess the effect 
size more reliably, the association should be subsequently estimated in 
other data sets. The winner‘s curse is more prevalent in small studies 
since its magnitude is inversely related to the statistical power of the 
study.  
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Table A.2. Height in the NFBC1966 singletons by sex.  
 
  Males   Females   
Age range (y) Mean age (y) N Mean SD N Mean  SD 
0 0 2101 50.78 2.11 2089 50.01 2.02 
0.46-0.54 0.50 1051 69.00 2.49 1094 67.06 2.56 
0.92-1.08 1.00 1562 76.45 2.71 1586 74.92 2.71 
1.83-2.17 2.00 1012 87.24 3.42 1016 85.93 3.29 
2.75-3.25 3.01 965 95.25 3.87 1009 94.11 3.82 
3.75-4.25 4.01 907 102.43 4.17 1003 101.32 4.17 
4.75-5.25 5.01 799 109.02 4.52 906 108.09 4.75 
5.67-6.33 6.02 848 115.62 4.91 907 114.48 4.93 
6.67-7.33 6.98 1518 121.01 5.26 1515 119.86 5.20 
7.67-8.33 7.94 1116 125.94 5.57 1077 124.90 5.63 
8.58-9.42 8.96 909 131.81 5.88 888 130.90 5.95 
9.58-10.42 9.98 877 137.55 6.08 839 136.69 6.35 
10.58-11.42 11.00 1322 142.26 6.25 1339 142.66 7.01 
11.58-12.42 11.88 1334 146.76 6.68 1267 148.09 7.48 
12.58-13.42 12.96 928 153.92 8.18 873 155.25 7.30 
13.58-14.42 14.01 1174 161.40 8.71 1188 159.78 6.14 
14.58-15.42 14.88 1150 167.21 8.37 1067 161.78 6.11 
15.58-16.42 15.99 597 172.68 6.87 565 163.52 6.00 
16.58-17.42 16.97 694 175.77 6.52 702 164.01 6.03 
17.58-18.42 17.89 459 177.03 6.09 424 164.59 6.17 
30.31-32.40 31.14 2107 178.17 6.44 2106 164.62 6.20 
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Table A.3. Weight in the NFBC1966 singletons by sex. 
 
  Males   Females   
Age range (y) Mean age (y) N Mean SD N Mean  SD 
0 0 2116 3.57 0.52 2111 3.46 0.49 
0.46-0.54 0.50 1162 8.47 0.99 1094 7.83 0.90 
0.92-1.08 1.00 1616 10.56 1.99 1615 9.92 1.19 
1.83-2.17 2.00 1069 12.77 1.39 1084 12.25 1.41 
2.75-3.25 3.01 1026 14.70 1.62 1056 14.17 1.66 
3.75-4.25 4.01 929 16.57 1.92 1027 16.16 2.09 
4.75-5.25 5.01 819 18.51 2.25 921 18.07 2.40 
5.67-6.33 6.02 873 20.67 2.79 928 20.28 3.11 
6.67-7.33 6.98 1554 22.84 3.34 1543 22.46 3.72 
7.67-8.33 7.94 1131 25.31 3.82 1100 24.85 4.27 
8.58-9.42 8.95 920 28.46 4.61 896 28.09 5.19 
9.58-10.42 9.98 889 31.93 5.75 842 31.54 5.93 
10.58-11.42 11.00 1340 34.95 6.11 1341 35.70 7.23 
11.58-12.42 11.88 1339 38.15 6.94 1277 39.45 8.19 
12.58-13.42 12.96 936 43.79 8.87 877 45.62 9.11 
13.58-14.42 14.01 1181 49.70 9.50 1194 50.46 8.98 
14.58-15.42 14.88 1154 55.17 9.74 1092 52.83 8.63 
15.58-16.42 15.99 588 60.60 9.97 612 55.97 9.51 
16.58-17.42 16.97 688 64.38 8.76 763 56.23 8.05 
17.58-18.42 17.89 472 67.32 8.89 476 56.90 7.58 
30.31-32.40 31.14 2107 80.07 12.6 2096 65.65 13.19 
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Table A.4. BMI in the NFBC1966 singletons by sex. 
 
  Males   Females   
Age range (y) Mean age (y) N Mean SD N Mean  SD 
0 0 2101 13.80 1.32 2089 13.77 1.32 
0.46-0.54 0.50 1063 17.83 1.57 1108 17.41 1.56 
0.92-1.08 1.00 1573 18.01 1.55 1589 17.68 1.64 
1.83-2.17 2.00 1011 16.80 1.34 1029 16.66 1.43 
2.75-3.25 3.01 972 16.22 1.30 1010 16.02 1.34 
3.75-4.25 4.01 905 15.78 1.20 1006 15.72 1.39 
4.75-5.25 5.01 800 15.55 1.21 906 15.44 1.39 
5.67-6.33 6.02 852 15.46 1.38 909 15.43 1.61 
6.67-7.33 6.98 1535 15.54 1.46 1525 15.60 1.85 
7.67-8.33 7.94 1128 15.91 1.55 1083 15.88 1.89 
8.58-9.42 8.95 912 16.34 1.80 885 16.31 2.15 
9.58-10.42 9.98 877 16.83 2.12 835 16.82 2.32 
10.58-11.42 11.00 1328 17.20 2.14 1336 17.44 2.62 
11.58-12.42 11.88 1328 17.63 2.28 1269 17.85 2.66 
12.58-13.42 12.96 924 18.36 2.47 868 18.88 2.96 
13.58-14.42 14.01 1177 18.95 2.41 1183 19.72 3.06 
14.58-15.42 14.88 1147 19.62 2.47 1075 20.13 2.87 
15.58-16.42 15.99 585 20.25 2.67 597 20.96 3.24 
16.58-17.42 16.98 685 20.85 2.45 745 20.89 2.72 
17.58-18.42 17.89 462 21.47 2.57 458 21.01 2.59 
30.31-32.40 31.14 2107 25.20 3.56 2096 24.22 4.67 
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Table A.5. Mean (SD) [cm/year] and regression coefficient (% difference with 95% CI) of 
peak height velocity in infancy (PHV1) by sex-specific quintiles of birth length (BL) [cm] for 
NFBC1966 singletons. 
 
 Males Females 
BL quintile N Mean (SD) % difference 
(95% CI) 
N Mean (SD) % difference 
(95% CI) 
1 427 54.7 (3.3) Reference 351 51.3 (3.9) Reference 
2 408 54.6 (3.1) -0.1 (-0.9, 0.7) 313 50.9 (3.8) -0.3 (-1.4, 0.8) 
3 376 54.2 (3.3) -0.9 (-1.7, -0.1) 440 50.9 (3.8) -0.3 (-1.3, 0.8) 
4 326 54.5 (3.2) -0.5 (-1.4, 0.3) 390 51.1 (3.8) 0.1 (-1.0, 1.2) 
5 342 54.0 (3.6) -1.4 (-2.2, -0.6) 381 50.3 (3.9) -1.7 (-2.8, -0.7) 
 
Sex-specific quintile cut-offs for the NFBC1966:   
Males: 1: ≤ 49cm, 2: 50cm, 3: 51cm, 4: 52cm, 5: >52cm 
Females: 1: ≤ 48cm, 2: 49cm, 3: 50cm, 4: 51cm, 5: >51cm 
Individuals with less than 3 height measurements at 0-2 years have been excluded. Regression analysis for ln(PHV1) was 
weighted by the number of height measurements at 0-2 years. 
 
Table A.6. Mean (SD) [kg/year] and regression coefficient (% difference with 95% CI) of 
peak weight velocity in infancy (PWV1) by sex-specific quintiles of birth weight (BW) [kg] 
for NFBC1966 singletons.  
 
 Males Females 
BW quintile N Mean (SD) % difference 
(95% CI) 
N Mean (SD) % difference 
(95% CI) 
1 411 13.7 (4.3) Reference 408 11.8 (1.7) Reference 
2 399 13.5 (1.8) -0.3 (-2.2, 1.7)  419 12.0 (1.6) 2.1 (0.2, 4.0) 
3 427 13.6 (1.9) 0.1 (-1.8, 2.1) 401 12.2 (1.7) 4.0 (2.1, 6.0) 
4 371 13.8 (1.8) 1.7 (-0.4, 3.7) 424 12.3 (1.7) 4.8 (2.8, 6.8) 
5 399 14.1 (2.0) 3.2 (1.2, 5.3) 369 12.2 (1.8) 3.4 (1.4, 5.5) 
 
Sex-specific quintile cut-offs for the NFBC1966:   
Males: 1: ≤ 3150g, 2: >3150-3450g, 3: >3450-3700g, 4: >3700-3980g, 5: >3980g 
Females: 1: ≤ 3080g, 2: >3080-3350g, 3: >3350-3570g, 4: >3570-3850g, 5: >3850g 
Individuals with less than 3 weight measurements at 0-2 years have been excluded. Regression analysis for ln(PWV1) 
was weighted by the number of weight measurements at 0-2 years. 
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Figure A.1. Systolic blood pressure (SBP) [mmHg] at age 31 years stratified by birth weight 
(BW) and peak height velocity in infancy (PHV1) tertiles (BW: low, middle, high; PHV1: 
slow, average, fast) in the NFBC1966 singletons. Mean with 95% confidence interval (CI) is 
given. 
 
 
 
Figure A.2. Systolic blood pressure (SBP) [mmHg] at age 31 years stratified by birth weight 
(BW) and peak weight velocity in infancy (PWV1) tertiles (BW: low, middle, high; PWV1: 
slow, average, fast) in the NFBC1966 singletons. Mean with 95% confidence interval (CI) is 
given.  
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Figure A.3. Waist circumference [cm] at age 31 years stratified by birth weight (BW) and 
peak height velocity in infancy (PHV1) tertiles (BW: low, middle, high; PHV1: slow, 
average, fast) in the NFBC1966 singletons. Mean with 95% confidence interval (CI) is given. 
 
 
 
Figure A.4. Waist circumference [cm] at age 31 years stratified by birth weight (BW) and 
peak weight velocity in infancy (PWV1) tertiles (BW: low, middle, high; PWV1: slow, 
average, fast) in the NFBC1966 singletons. Mean with 95% confidence interval (CI) is given. 
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